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The protozoan parasite Trypanosoma brucei brucei causes nagana in cattle and is a widely used 
model for human sleeping sickness. The major lysosomal cysteine proteinases (trypanopains) of 
African trypanosomes may contribute to pathogenesis by degrading proteins in the mammalian 
bloodstream and also appear to be essential for the viability of T. cruzi and T. congolense. This 
study describes the first purification to electrophoretic homogeneity of trypanopain-Tb from 
T. b. brucei and the first reported characterisation of its enzymatic properties. Trypanopain-Tb 
was purified from bloodstream forms of T. b. brucei by a combination of three phase 
partitioning (between ammonium sulfate and tertiary butanol), and chromatography on 
quaternary amine or pepstatin A-Sepharose resins. 
Trypanopain-Tb was found to be a typical cysteine proteinase, in that it is inhibited by typical 
cysteine proteinase inhibitors and requires reducing agents for full activity. Trypanopain has 
cathepsin L-like specificity for synthetic substrates and readily degrades various proteins. 
In vitro analysis of the kinetics of trypanopain interaction with cystatins suggested that these are 
likely to inhibit any trypanopain released into the mammalian bloodstream. Furthermore, no 
trypanopain-like activity was detectable in the blood of infected hosts, so it appears that 
trypanopain is unlikely to contribute directly to pathogenesis by degrading bloodstream host 
proteins. 
Antibodies against a peptide corresponding to a region of the trypanopain active site were 
produced in rabbits and chickens. Both enzyme activity-enhancing and enzyme activity-
inhibiting antibodies were produced and these effects varied with the substrate tested. Thus, the 
in vivo effects of anti-trypanopain antibodies will only become clearly understood once the 
physiological substrates of trypanopain have been identified. 
Various cysteine proteinase inhibitors, including peptidyl diazomethylketones, killed cultured 
bloodstream forms of T. b. brucei. Use of biotinylated derivatives of peptidyl 
diazomethylketone and fluoromethylketone inhibitors suggested that trypanopain is the likely 
intracellular target of these inhibitors, indicating that the enzyme is essential for parasite 
viability. Furthermore, chalcones (a class of reversible cysteine proteinase inhibitors) killed in 
vitro cultured parasites and also prolonged the life of T. b. brucei-infected mice. Thus, 
trypanopain-Tb seems to be a possible target for new anti-trypanosomal drugs. 
v 
ACKNOWLEDGEMENTS 
I would like to express my appreciation to the following people and organisations for their 
indispensable assistance with this thesis: 
My first supervisor, Prof. John Lonsdale-Eccles for giving me a wonderful project and having 
enough trust in me to allow me the freedom to work independently and make my own mistakes, 
while still providing invaluable, challenging ideas and support when I most needed help. 
My second supervisor, Dr Theresa Coetzer, for her keen interest and tireless assistance, 
particularly with the writing up of this thesis and of scientific papers. 
My adopted supervisor, Dr Rob Pike, for teaching me what to consider before, during and after 
an experiment. 
The Alexandre Lorant Charitable and Educational Trust, the University of Natal, the Foundation 
for Research Development and Standard Bank for financial support. 
Dr Jim McKerrow, for broadening my horizons by enabling me to attend the 1997 Gordon 
Conference on Parasitism (held in Rhode Island, USA) and to visit his research group at the 
University of California (San Francisco). Additionally, to Fred Cohen and Xiaowu Chen for 
taking care of me during my visit, and for enabling me to participate in their exciting chalcone 
project. 
Ron BetTY, for contributions to my sanity in the face of twisted computer logic, instrument 
revolt and administrative blockages. 
Lesley Brown, for being such an amazingly efficient and pleasant part of our department. 
Nichola Scholfield, for her infectious enthusiasm which helped me persevere through the 
apparently reward less stages of this study and Rory Marty, for taking up Rob's place across the 
desk in a figurative as well as a literal sense. 
Vl 
Chris, for unparalleled integrity, love and insight; Gareth for faith, laughs, tears and ice creams, 
and my mother and entire family for their support. 
vii 
TABLE OF CONTENTS 
PREFACE ... .... ... .... ..... ..... .... ... .... .. .. ... .. .... ... ... ... ....... .. .... .. ..... ... ... ..... ... ..... ... ... ... .. ........ .. ... .... ..... ill 
ABSTRACT .. .. .. ... .. .. .. ...... .... ... .. ... ... ..... .... .. .. ... ... ..... ...... .... ..... ..... ...... .. .... ... .... .. .. ......... ... .... .. .... IV 
ACKNOWLEDGEMENTS ... .. ... ... ... .. .. .... ...... .. .. ..... .. .. .... .. ... ... ... .. .. ... ... ...... ....... ... ...... ... ... ..... .. V 
LIST OF TABLES ....... ..... ... .. .. .... .. ... ...... .... ... .. ... .... ... .... ..... .... ..... ... .... .. ..... .. ......... ...... ..... .... ... . xvi 
LIST OF FIGURES .... .... .. ..... .. ... ... ....... ..... .. ... ..... ... ... ........... ... ..... ..... .... .... .... .... .. .... ... .. ..... ... .... xviii 
ABBREVIATIONS ....... ... .... ... .. ......... ... .... .. ... .. ...... .............. .... ............ ....... .... ........ .. ..... ... ....... xxii 
CHAPTER 1 AFRICAN TRyPANOSOMIASIS ........................................ 1 
1.1 Introduction .... ... .. ... ...... ... .... .. ....... .... .. .. ..... ..... ..... ......... ......... .... .. ... .... ..... ..... ...... ...... ... .... 1 
1.2 Major African trypanosomiases ..... ... .. ....... .... .. .. ... .... .. ... ..... ..... ..... .. ... ...... ........ ...... ... ... .. 1 
1.2.1 Gambian sleeping sickness .... .... ...... .. .. ... ..... .. ........ ... ... ..... ...... ...... ........ .. ... .. .... 1 
1.2.2 Rhodesian sleeping sickness ..... ..... ... ... .. .. ..... ... .... ......... ... .. .... ............. .. .. .. .. ..... 2 
1.2.3 Cattle trypanosomiasis .. ... ... ........ ..... .. ......... ..... ..... ....... .. ............ .......... ............ 3 
1.4 Trypanosome morphology .. ... ... .......... .. ..... ......... ........ .... ... .. ..... ... .. ........ ...... .. .. .... ... .. .. .... 3 
1.5 Classification oftrypanosomes .. .... ........ ....... ... ... .......... ... ... ..... .......... .. ...... ... .... ... .... ... .. .. 4 
1.6 Life cycle of African trypanosomes ........ ..... .. .......... .. ... ..... ... ........ .. .. ..... ......... ... ... ........ . 8 
1.7 Symptoms of African trypanosomiasis ......... ...... ..... ... .... .. .. ... ............. ...... ...... .... .. .. ... .... 10 
1.8 Pathogenesis of trypanosomiasis .... .. ... ........ ... .. ........ ................ .... ... ......... .. ...... ..... .... ..... 11 
l.9 Diagnosis of African trypanosomiasis ... ... .... ... ....... ... .. ...... ... .. ..... .. ....... .......... ..... .. .. ....... 13 
1.10 Current prevention and treatment of trypanosomiasis .... ... .... ........ ... .. ...... ... .... .. ..... ... .... 14 
1.10.1 Control of tsetse fly .. ....... ... .. .... ....................... .................. ... ... .... ....... .... .. ...... .. 14 
1.10.2 Cun.ent treatment methods .............. ..... ... .... .. ..... .. .... .. ... ..... ... ...... ........... ... ... .. .. 15 





E. histolytica cysteine proteinase ... .... .. .. ...... ...... .. .. .. .... ..... ... .... ...... .. .. ... ... ........ 18 
Leishmania proteinases .... ... ............ ..... .... .. ... ..... ... ... .. .... ... ..... ...... .. ... .......... .. ... 18 
Schistosoma proteinases ..... .... ... ... ... ... ......... ........ ... ... ..... ........ .... .. ............ ....... 19 
Malarial proteinases ..... ..... ............. ..... ......... ....... .. .. .. .. .... ..... .. ... ... ...... .... .... .... .. 20 
1.12 Trypanopains .. ....... ....... ..... ... ... .......... .......... ..... .... ..... .... ... ... .. ...... ..... .. .. .... ...... ... .. .. ......... 20 
viii 
1.12.1 Correlation between disease resistance and production of 
anti-trypanopain-Tb IgG 1 antibodies ........ ... ............................................ .. ... .. 20 
1.12.2 Cysteine proteinase inhibitors kill live trypanosomes ........... .. ..... .. .... .. ........... 22 
1.12.3 General features of trypanopains ..................................................................... 22 
1.12.4 Primary sequence of trypanopains ................................................................... 23 
1.12.5 Catalytic mechanism of trypanopain .. .. .. .... .. ... .... ..... ............ .. ..... .. .................. 26 
1.12.6 Possible physiological functions of trypanopains .... ... ... ...... ........................ .. . 30 
1.13 Objectives of the present study .. ...... .. ....... ..... .... .. ........ ... .. ......... .. ................................... 31 
CHAPTER 2 GENERAL MATERIAL AND METHODS ........................ 33 
2.1 Materials ..... ................ .... ........ ........ .... ... ... ...... ... ....... ...... .................................. .. ............ 33 
2.2 Bicinchoninic acid (BCA) protein assay ........................................................................ 34 
2.2.1 Materials ...... ..... ..... ..... .. ................ ......... .... ...... .. .... ..... .............. ........... .... ..... .... 34 
2.2.2 Method ............................................................................................................. 35 
2.3 Concentration of proteins ............................................................................................... 35 
2.4 Tricine SDS-PAGE ......... ............... ................ ...... .................... ... ........ ...... .. ............... .... 36 
2.4.1 Materials ........... ............ ............. .. .... ...... .... ..................... ............. ........... .... ... ... 38 
2.4.2 Method .... .... ...... ..... ............... ... ................ ..... .. .... .. ...... .. .............. ......... ......... ... 38 
2.5 Substrate SDS-PAGE .............. .. ...... ........ .... ... ... .. .. ........................ ....... .. .. ....... ..... ...... .... 39 
2.5.1 Material .. .... ............... .. .... ... ..... .. ..... ..... .. .. ... ... .. ........... .. ............ ... ...... ... ............ 40 
2.5.2 Method ...................... .... ... ......... .......... ......... ... ........... .. ...... ...... .. ............. .... ..... 40 
2.6 Coomassie blue R-2S0 protein stain ................. ................ ......... .......... ... ...... .. ............ .... 41 
2.6.1 Materials .......... .. ......... ... .................................. .. .......... ..................................... 41 
2.6.2 Method ..... ............. ...... .. ............ .. .... ...... ... ................. ....... ......... ....................... 41 
2.7 Silver staining of proteins in polyacrylamide gels ... ... ........... .. ............. .... .. ........ ........... 42 
2.7.1 Materials ........................................................................................................... 42 
2.7.2 Method ............................................................................................................. 43 
2.8 Isolation of chicken antibodies from egg yolks .............................................................. 43 
IX 
2.8.1 Materials ................ ..... .. ....... .. ....... ...... .. .......... .... .. ............................................ 43 
2.8.2 Method .. ............ ...... ..... ...... ... ... .... ....... ...... ................... ................................... . 43 
2.9 Isolation of rabbit antibodies .......... ... ...... .... ... .... ... ........ .................. .................. ..... ........ 44 
2.9.1 Materials ......... .... .... ... ......... .. ... ... .... .. ......... ..... ...... .. .. ........... ...... ....... ........... ..... 44 
2.9.2 Method .......... ......... ............. ........... .. ... ...... .................... ....... ........ .................. .. 45 
2.10 Enzyme-linked immunosorbent assays (ELISAs) ........ ....... .............................. ..... .. .. ... 45 
2.10.1 Materials ..... .. ......... .. .... .. ...... ...... .. .... ... ...... ........ ......... .............. ..... .... ........... ..... 46 
2.10.2 Method .......... .................. ........ .. ........... .. ....... .. ............... ........ .. ........................ 46 
2.11 Western Blotting onto nitrocellulose membranes .... ................ .. .. ..... .... ...... .... ............... 47 
2.11.1 Materials .... ..... ....... ........ .. ............ ... .. ... ....... .. ....... .. ····· ·. · .. ··.··· ···· ······················· 48 
2.11.2 Method ........ .. ..... ..... ..... ................. ... ................. ... ......... .. ............ ........ .. .. ... .... .. 49 
CHAPTER 3 ISOLATION OF TRYPANOPAIN FROM 
T. b. brucei ................................................................................. 51 
3.1 Introduction ..... .. ....... .. ........... .... ........... ....... ...... ..... ... ......... .. .... .. ........ ..... ........................ 51 
3.2 Initial enzyme assay .. ............ ..... ............ ........ .......... .. ............ .. .... ....... ............................ 51 
3.2.1 Materials ... .... ....... ... .. ... ................. ..... .. .... ...... ..... ................................ .... ......... 52 
3.2.2 Method for standard enzyme assay ............ ..... ... ... ......................... .. ... .. ........... 53 
3.2.3 Method for enzyme micro-assays ..... .. ...... .. .................. .. ........ ........ ................. 53 
3.3 Growth and harvesting of trypanosomes ............ ........... .. .... ... .... .. .. .. ...... .... .... ...... .. ........ 53 
3.3.1 Materials .......... .... ... ..... ... ... .. .. ........... ... .. ........................................................... 54 
3.3.2 Method .... .... .... ... .... ....... .. .. .... ....... .... ... .... .. ............. .. ..... ..... .. ...... .... .............. .... 54 
3.4 Determination of active enzyme concentration by E-64 titration ........ .. .................... .. .. 55 
3.4.1 Materials ................ ............. .......... ... .. ................................. ..... ........ ..... ....... .. ... 56 
3.4.2 Method .... .. ........... .. .. ... .. ........................ ....................... ..... .... ... ..... ................. .. 57 
3.5 Rate of inactivation with E-64 ........ .. .. ................. .................. .. .. ... .. ............................. ... 57 
3.5.1 Materials .......... .... .. .. ................. .... ..... ... .... ................... ................................. .... 57 
3.5.2 Method ...................... ...... ... ............................................... .. .. ........................... 57 
3.6 Three-phase partitioning as an initial purification method ....................... .. ................... 57 
x 
3 6 1 Materl·a1s .............................. .. ............. ... .... .. ........ 58 . . . .. ................ .. ................ .. ..... . 
3 6 2 Method .......... .... ....... ... ..... ... .. .. ... ............. ... ....... ... ............... .. ............. .. ............ 58 .. 
3.7 Q-Sepharose chromatography ........................................................................................ 59 
3.7.1 Materials ............... .. .................... .... ..... ... .... ..... .... ...... ...... .. ..... .... ..... .... ......... .... 59 
3.7.2 Method ........... ... ..................... ............. ... .... ................... .... ..... .......................... 60 
3.8 Pepstatin A chromatography ... .... .............. ....... ... .... .. ............................... ......... ...... ....... 61 
3.8.1 Materials ........ .. ....... ... .. ..... ...... ... ..... ...... ... ...... ........... .... ........ ..................... ...... . 61 
3.8.2 Method ............................................................................................................ . 
3.9 Production of anti-trypanopain antibodies ..................................................................... 62 
3.10 ELISA evaluation of anti-trypanopain antibody production .......................................... 62 
3.10.1 Materials ........................................................................................................... 63 
3.10.2 Method ......... ................ ......... ................ ... .. .. ... ........ ... ... .. ... ... ........................... 63 
3.11 Evaluation of antibodies on a Western blot .................................... .......... ......... .... ... ..... 63 
3.11.1 Materials ........................................................................................................... 63 
3.11.2 Method ............................................................................................................. 63 
3.12 Results ............................................................................................................................. 64 
3.12.1 Rate of inactivation with E-64 ......................................................................... 64 
3.12.2 Isolation of trypanopain ...... .. ............... ....... .. .. .............. ............. .. .. ................ .. 64 
3.12.3 ELISA evaluation of anti-trypanopain antibodies ........................................... 72 
3.12.4 Western blot evaluation of anti-trypanopain antibodies .................................. 72 
3.13 Discussion ....................................................................................................................... 73 
CHAPTER 4: ENZYMATIC CHARACTERISATION 
OF TRYPANOPAIN-TB ........................................................ 80 
4.1 Effect of pH on trypanopain activity against Z-Phe-Arg-AMC ................ ............... ... .. 80 
4.1.1 Materials ... ....... ...... .............. ...... ...... .... ....... ..... ....... .... ......... .... ......................... 80 
4.1.2 Method ................... ... ......... ... ... ..... ... ......... ................... ... ...................... .... ....... 80 
4.2 Effect of pH on activity against 14C-gelatin ................................................................... 81 
Xl 
4.2.1 Materials ........ ......... .......... .. ................ .......... .... .... ......................................... .. . 81 
4.2.2 Methods ............................................................................................................ 81 
4.3 Effect of reducing agents on trypanopain activity against Z-Phe-Arg-AMC ................ 82 
4.3.1 Materials ... ... .... ... ... .. .. ..... .. ... .... .. ... .... ..... ........ ... .......... .... ... .... ................ ... .... ... . 82 
4.3.2 Method ..... ....... .. ......... .. ...... .... ............... ... .. ....... ......... .. ..... .... ........................... 82 
4.4 Optimal time of activation by cysteine ........................................................................... 83 
4.4.1 Materials .. ... ..... .... .. ... .. ... .... ......... ... ..... ... .. ..... .. .... ... .......... ......... .. ........ ..... ..... ... . 83 
4.4.2 Method .. ... ... ......... .. ....... ... ... ... .............. ..... ... ........ .. ....... .. ... ....... .. ...... .... .......... . 83 
4.5 Effect of pH on trypanopain stability ... ... ........ ....... .. ........ ............... ........... ... .......... ....... 83 
4.5.1 Materials ...... ............... ... ... .... ... .. ..... .............. .. ......... .. .......... .. ... .. ........ ... ........... 83 
4.5.2 Method ......... .. .... ..... ... .. .... ... ..... ............... ............. .... ... .... ........... ................ .. .... 84 
4.6 Specificity for synthetic substrates ... .... .......... ...... .... ............. .. ................. ... ................... 84 
4.6.1 Materials ... ........ ..... ........ .. .. ............ ... ............ .. ....... .. ... ... ...... .. ... ............. ........ ... 86 
5.1.2 Method ........ ............... .. ... ........... .......... ........ ..... ........ ........... ... ........... ...... ....... . 87 
4.7 Hydrolysis of proteins ...... .... ............... ...... .... ......... ....... ... .. ......... .. ...... ................ .... .... ... . 87 
4.7.1 Materials .......... ..... .. ..... ......... .. ... ........ .................. .. .. ....... .... ... .... .... ... ........ .. ...... 87 
4.7.2 Method ............................................................................................................. 88 
4.8 Results ... ..... .. ........ .. ....... ........ .... .... ............................. ...... .. ............ ...... ............. ..... .... .. ... 88 
4.8. 1 Effect of pH on trypanopain activity against Z-Phe-Arg-AMC. ... .. .... ........ .... 88 
4.8.2 Effect of pH on activity against 14C-gelatin .................. ....... ........... ....... ..... ..... 88 
4.8.3 Effect of reducing agents on trypanopain activity against 
Z-Phe-Arg-AMC ................ .......... ........................ ........... .......... ....................... 90 
4.8.4 Optimal activation time with cysteine .... ....... ........ .......... ... ...... ........ ............... 90 
4.8.5 Effect of pH on trypanopain stability .............................................................. 91 
4.8.6 Revised trypanopain assay buffers .................................................................. 91 
4.8.7 Hydrolysis of synthetic substrates ........ .. ... ......... .. .... .... ...... ..... ..... ........ .. ......... 92 
4.8.8 Hydrolysis of proteins ...... ............. .... ............... ......... ... .... .. ....... .... ........ .. ......... 94 
4.9 Discussion .. ........ ... .. .............. .... ..... ... ... ............ ................ ..... ... ... ..... ..... ........ ......... ....... .. 97 
CHAPTER 5 TRYPANOPAIN INTERACTIONS WITH 
INHIBITORS ........................................................................... 101 
Xli 
5.1 Inhibitor profIle ... ......... .. .. ... ....... ..... ......... ... ............. ....... ..................... .. ......................... 101 
5.1.1 Materials .... ... .... .. .. ...... .. .. ... .. .. .. ...... .. ........ ..... .. ... ........ ..... ... ... .. .. ... ......... .. .......... 102 
5.1.2 Method .. .. ........ ......... .... ..... ... ... .... .......... ..... .... .. ........... .... ...... .. ... ....... .. ..... ... .... . 103 
5.2 Association and inhibition rate constants of cystatins ....................... .. .. ..... .... ... .. ........... 104 
5.2.1 Materials ... ... ... .. .. .. ......... .... ...... .. ..... ..... .................................. ........................... 107 
5.2.2 Method ................. .... ..... ...... ................... ..... .... .... ... .... ... ..... ... ..... ..... ...... ... ....... . 108 
5.2.3 Calculation of Ki ................ ...... ...... ...... .. .... .... .. ... ...... .. .... ... .... .. ...... ... ... ....... ..... 109 
5.2.4 Calculation ofkass . ...... .. ... ... ..... . .. ........ ... ...... . ... . · .. · .. .. ... . . .. ..... . .............. .... ...... ... 109 
5.3 Associatio n with <XT macro glo bulin (<XT M) .. .. ..... .......... ...... ... .. ........ .................. ... ... ... .. 110 
5.3. 1 Materials ............. ..... .. ....... ... ...... ........... .. ...... ...... ... ...... .... .. ......... ......... .......... ... 111 
5.3.2 Method ..... ...... ... .. .... ...... .... .. ... ....... ... .... .... ...... .... .. ...... .. ...... ........ ... ....... ..... ....... 111 
5.4 Effect of enzyme inhibitors on Z-Phe-Arg-AMC hydrolysis by live T b. brucei ...... .. . 112 
5.4.1 Materials ..... ... ... ..... ... ... .. .. ..... ...... .... .. ... ... ..... ... ....... ....... ...... ... .. .. ..... .. .......... .... .. 113 
5.4.2 Method ........... ... .... ........ ...... ....... .... .... .......... ... ..... ... .... ...... .. .... .......... ....... ..... ... 113 
5.5 Is trypanopain active in the bloodstream of infected animals? .... ... ... ..... .. .... .. .. ......... .... 113 
5.5.1 Materials .. .... .. .... ......... ... ....... ............ .... ... .. ..... .. ... ....... ....... ... .................. ....... ... 114 
5.5.2 Method ... .... ..... .......... ... ..... .. ............... .... ..... .. .. .... ... .. .. .. .. ................. .............. .. . 114 
5.5 Detection of trypanopainlcystatin complexes in infected serum ... ..... ......... .................. 115 
5.6.1 Materials ... ... ....... ........ ....... ......... ...................... .. ...... .. .. .. .. ......... ....................... 115 
5.6.2 Method .. .... .. ... .... ............. ..... .. ... .... ....................... ... ...... .. .... ........ ... .............. .... 115 
5.7 Results ............... .. ..... .. ....... ................ ......... ... ...... ........... .......... .. ....... ... .. .. ... ... ...... ........ ... 116 
5.7.1 Inhibitor prof tile ... .. ... ..................................................... .. .................. .. ....... ... .. 116 
5.7.2 Kinetics of association between trypanopain and various cystatins ............... 116 
5.7.3 Association with <X2-M ....... ... .. .............. ... ..... .. ... ... ... .. ...... ... .. ........ .. ............... .. 119 
5.7.4 Effects of inhibitors on Z-Phe-Arg-AMC hydrolysis by live T b. brucei .. ... . 119 
5.7.5 Is trypanopain active in the blood of infected rats? ......... .................... ......... .. 121 
5.7.6 Detection oftrypanopainlcystatin complexes in infected serum ..... ........ ....... 122 
5.8 Discussion .... ......................... ...... .... ... ................. ...... ...... ........ .... .. .. ... .. .... .......... ............. 123 
CHAPTER 6: PRODUCTION AND EVALUATION OF ANTI-
PEPTIDE ANTIBODIES AGAINST A PEPTIDE 
X1l1 
FROM THE TRYPANOPAIN ACTIVE SITE ................... 128 
6.1 Introduction ....................................................... .. ........ .... ........... ............ ............ ... .... .. .. .. 128 
6.2 Choosing an immunogenic peptide .. ... ..... ... .. ......... ... ...... ...... .. ..... ............. ............ ... ...... 130 
6.3 Peptide conjugation ......................... .. .. .... ... ... .. ... .. ........ ... ..................... ................... ....... 134 
6.3.1 Materials ... ..... ....... .. ............. .. ............. .......... ... ........... ............... ......... ... .... .. ..... 134 
6.3.2 Method .. .......... .. ....................... .... ... .. .. ... .. ... .... ................. .... ... ......................... 135 
6.4 Immunisation of experimental animals ......................................... .......... .. ....... .... ......... . 137 
6.4.1 Rabbits ...................... .. .... ......... ......... ....... .. ...... ... ......... ......... ...... ........ .. ...... ..... . 137 
6.4.2 Chickens ..... ............... ....... ... ....... .. ..... ........ .. ....................... ... ......... .. ....... .. ...... . 138 
6.5 Assessment of antibody production and cross-reactivity with whole enzymes ............. 138 
6.5.1 Materials .... ...... ... ........ .... ... .. ... ......... ... ... ....... ............ .. .. ......... .. .. ....................... 139 
6.5.2 Method for ELISAs monitoring progression of antibody titre ... ........ .. ......... .. 139 
6.5.3 Method for ELISAs to determine recognition of whole trypanopain and 
cathepsin L by anti-peptide antibodies ........ ........ ......... .. ... ..... ........... ......... ..... 139 
6.6 Evaluation of antibodies with Western blots .................................................................. 140 
6.6.1 Materials ............... ... ... ...... ... .. .... ......... ..... ........ ... ........ ....... ... ......... ...... ......... ... . 140 
6.6.2 Method ........ ....... .. .. .. .. .. ... ....... ........ .. .. ....... .. ....... ............. ... ........ ... ... ........... .. ... 140 
6.7 Effect of anti-peptide antibodies on trypanopain activity against Z-Phe-Arg-AMC, 
14C-gelatin and FITC-albumin ......... ... .. .... ... ... ... .... ................. ............................. ... .. ... ... 141 
6.7.1 Materials ... ........ ................................................................................................ 141 
6.7.2 Method ........ ..... .. ....... ... ... ... .. .. ... .... .... ... ..... ............... ... .......... .... ... .................. .. 142 
6.8 Inhibition of antibody effect on enzyme activity by addition of free peptide ........ ........ 142 
6.8.1 Materials ........................................................................................................... 143 
6.8.2 Method .... ...... .... .... ......... .. .. ..... .... .. ........ ... ........ .. ..... .. ....... .............. ....... ........... 143 
6.9 Effects of antibodies on trypanopain activity against Z-Phe-Arg-AMC and 
14C 1· . 1 -ge atm m trypanosome ysates ........ .... .... ... ...... ............... ... ... .. .... ... .... ................ ... ... 143 
6.9.1 Materials ....... ............... .. ... .. ..... ............ ... .................. ..... ........... .. ...................... 143 
6.9.2 Method ........................ ...... ...... ....... .. .... .. .......................... .................... .. .......... 143 
6.10 Effect of antibodies on cathepsin L activity against Z-Phe-Arg-AMC and 




Materials .... ... .... ............................................................................................ ... . 143 
Method ............................... .............................................................................. 144 







Determination of antibody titre in rabbits and chickens .... .. ....... .. ...... ... ....... .. 144 
Recognition of whole trypanopain .................................... ... ...... ....... .. .... ......... 146 
Cross-reactivity with sheep cathepsin L. ............ .... ......................................... 147 
Western blots with anti-peptide antibodies ... .. .......... ..................... .. .......... ... ... 148 
Effect of antibodies on trypanopain activity against Z-Phe-Arg-AMC ...... .... 148 
Inhibition of antibody effect on Z-Phe-Arg-AMC hydrolysis by 
incubation with free peptide .... .. .... ... .......... ... ............ ... .......... .. .................... ... 151 
6.ll. 7 Effect of antisera on trypanopain activity against 14C-gelatin ..... ................. ... 153 
6.ll.8 Reduction of antibody effect on 14C-gelatin hydrolysis by 
pre-incubation with free peptide ........ ........... ...... ........................ .... : ................ 154 
6.11.9 Effect of anti-trypanopain antibodies on trypanopain digestion of 
FITC-albumin ..... .... ........................................................................ .... ..... ..... ... . 154 
6.1l.1O Effect of anti-trypanopain peptide antibodies on trypanopain hydrolysis of 
Z-Phe-Arg-AMC and 14C-gelatin in T b. brucei lysates .. ....... ..... ............... ... 155 
6.11 .11 Effect of anti-trypanopain antibodies on cathepsin L activity against 
Z-Phe-Arg-AMC and 14C-gelatin .......... .... .... .. ... ... ....... .. .......... .. .... ................. 156 
6.1l.12 Summary of results ..... ... ... ..... ..... ... .. ........................ ........ ...... .. ........................ 157 
6.12 Discussion ................................. ... ... ....... ....... ... .. ................. ... ............... .. .... .. .................. 158 
CHAPTER 7 EFFECT OF PROTEINASE INHIBITORS 
ON CULTURED T. b. brucei .................................................. 165 
7.1 Introduction ... ........... .. ....................... ...... .......... ...... ... .... .... .... .. .......................... ... ....... ... 165 
7.2 T b. brLlcei cell culture .. .... ............. .. ....................................................... .... .............. .... . 166 
7.2.1 Materials ... .. ... ... .... .................................................................. .... ..... .. .... ....... .. .. 166 
7.2.2 Method .. .... ..... ...... ... .......... ... ... ... ... ... .... ..... ............................. .. .......... .............. 167 
7.3 Effects of proteinase inhibitors on T b. brucei growth .......................... ....................... . 167 
xv 
7.3.1 Materials ........ ..... ...... .. .. ................................................ ....... ............. ................ 168 
7.3.2 Method ...... ............. .. ... .. ..... .. ....... .. ....... ................ .. ............................. .. ........... 168 
7.4 kass ofCMK, FMK and DMK .. .. ................ .... ........ ........................................................ 168 
7.4.1 Materials ........... .............. ... ..... ....... ... ... .. ................................ .. ......................... 171 
7.4.2 Method .. ................................ ..... ...... ................................................................ 171 
7.5 ICso ofCMK, DMK and FMK ... .............. .. ..... .. .......................................................... .. . 171 
7.5.1 Materials ..... ... .. .... .. ... ... .................................... ... .............. ..... ....... ...... ... ........... 172 
7.5 .2 Method ............. ... ............... .............. .. .................. .. ... ............... .. ............... ... .... 172 
7.6 Detection of biotinylated FMK and DMK ... ............. ............................................... .. ... . 172 
7.6.1 Materials .. ... ......... .. ... ................................................. ..... .. .. ... .... ........... ............ 172 
7.6.2 Method ... ........ .... ...... ........................................ .... ... ...... ... .. ... ............. ..... ...... ... 173 
7.7 Design ofcha1cones ... .. ......... ... .. ...................................................... ... .... ........................ 173 
7.8 Ki for chalcone interaction with trypanopain and cathepsin L. ... ........ ..... ...................... 176 
7.8.1 Materials ....... .... ... .. ........ ... ... .. ....... ... ... .... ................. .... .. ............. ..... .. ..... ..... ..... 176 
7.7.2 Method .... ... .... .. ........ ..................................................... ... ................ ..... ..... ..... . 176 
7.9 ICso for chalcones against cultured T. b. brucei ... .............. ... ... .. .. ....... ........................... 177 
7.9.1 Materials ......... ....... ............................................................. ...... .... ......... ... .... .... 177 
7.9.2 Method .. .. ..... .......... ........... ............................................. ..... ............................. 177 
7.10 In vivo testing of chalcones ...... ............ ... ... .. .... ......... ......... ... ... ... ............ ...... ... ..... .. ....... . 177 
7.10.1 Materials ........................ .. ..... ........ ... ... ...... ........... .............. ... ................ ............ 177 
7.10.2 Method .......................................................................... ...... ... ......... .. ..... .......... 177 
7.11 Results ... ... .. .. ... .. ..... ....... ........ ..... .. .. ... ......... ..... ........... ............. .......... .. .......................... .. 178 
7.11.1 Growth curve ... ........ ..... .. .. .... ..... .. .... .. ........ ......... .. ... ... ....... ... ................. .. .. .... .. 178 
7.11.2 Effect of proteinase inhibitors on growth of cultured T. b. brucei .. ..... .......... . 179 
7.11.3 kass ofCMK, DMK and FM ......... ...... .......... .......... .... .. .. .. ... ...... .......... .... .. ...... . 179 
7.11.4 ICso ofCMK, DMK and FMK ... .... ... ................................... .. ...... ....... .... ..... .. . 181 
7.11.5 Detection of biotinylated inhibitors ... .. ............... ...... ..... ....... .... ....... ................ 181 
7.l1.6 Ki for chalcone interaction with trypanopain and cathepsin L. ....................... 182 
7.11.7 ICso for chalcone activity against cultured T. b. brucei ................................... 182 
7.11.8 In vivo testing ofchalcones against T. b. brucei ............ ........................ ......... . 189 
7.12 Discussion .. ..... ... .... ............. ........... ........... .... ........ .. ........ ... ......... .... ... .................. ... ..... ... 190 
XVI 
CHAPTER 8 GENERAL DISCUSSION ...................................................... 199 
8.1 Introduction ... ................... ... .. ..... ... .. ... .. .. .. .. ..... .. ........... ... ... ..... ... .. .. ....... ... ..... ... .. ............. 199 
8.2 Enzymatic characterisation ... .. ... ... .. .. ... ...... .. .... .... .. ..... .... .. ... .. .. ........ ... .. .... .. ...... ... ... .... .. .. 200 
8.3 The control of trypanopain by inhibitors in the blooodstream ......... ... ..... ..... .. .. : ... ..... .... 202 
8.4 Trypanocidal activity of trypanopain inhibitors .... ....... ....... .... ..... .. ...... .... ........ .............. 204 
8.5 Future directions ...... .. ............ ...... ...... ... .... ............ ... ...... .. ..... .. ..... .......... ... ........... ........... 206 
CHAPTER 9 REFEREN CES ........................................................................ 208 
















LIST OF TABLES 
Degree of homology between trypanopain from T. b. bntcei and other 
cysteine proteinases ......... .... .. .... ......... .. ..... ................. ........ ... ... ..... ...... ..... ....... 25 
Preparation of two tricine SDS-PAGE gels for electrophoresis on 
the BioRad MiniProtean II electrophoresis cell ....... .. .... ..... ..... ... ..... .... .. .... ······ 39 
Comparison of purification of trypanopain from T. b. bntcei using 
Resource Q and pepstatin A-Sepharose chromatography ... ........... .... ......... ... . 71 
Comparison of immunisation protocols used to produce antibodies 
against various parasite cysteine proteinases ...... .. ..... ..... ... ..... ..... .... .... ..... .... ... 78 
Kinetic constants for trypanopain hydrolysis of various AMC substrates .... .. 93 
Kinetic constants for the hydrolysis of Z-Phe-Arg-AMC at various 
temperatures by human cathepsin L and the cathepsin L-like cysteine 
proteinases of various parasites ... ........ ... ... ...... .. .. ...... ...... .... .. ........... .... ....... .... 100 
Effects of various proteinase inhibitors on the activity of trypanosomal 
enzymes against Z-Phe-Arg -AM C .. .. ...... ..... ... ..... ........ .. ... ............. ... ... .. ....... .. 117 
Association, dissociation and inhibition rate constants for cystatin inhibition 
of trypanopain at 30°C ... .. .... ......... ... ..... ... .... ....... .... .. ............ ........ ........ ..... ... ... 118 
Half lives for association and dissociation of trypanopain an selected 
cystatins at physiological concentrations ... ....... .. ... .... .. ...... ... .......... ...... ........ ... 118 
Comparison of the inhibition of trypanopain, cathepsin L, cruzipain and 
papain by various cystatins .... .. ......... .. ..... ..... ... ... ................. .. ...... ............... ... .. 124 
Amino acid sequence homology between the chosen trypanopain peptide 
and the corresponding regions og other trypanosomal cysteine proteinases, 
human cathepsin L and papain .... ............. .. .. ....... ........ .... .......... ............ ... ...... .. 131 
Effect of free peptide on subsequent modulation of trypanopain hydrolysis 
of Z-Phe-Arg-AMC by activity-enhancing chicken anti-peptide 
antibodies .. .... ... ... ..... ..... .. .... ....... ..... .... ... .. ... ........ ... .. ... .. .... .................. ...... .... .. 151 
Effect of free peptide on subsequent modulation of trypanopain hydrolysis 
of Z-Phe-Arg-AMC by activity-inhibiting chicken anti-peptide 
antibodies .................... .... .... .. ......... .. ... ... ... .... ......... ........ .. ........................ ....... 152 
Effect of free peptide on subsequent modulation of trypanopain hydrolysis 
of Z-Phe-Arg-AMC by activity-enhancing rabbit anti-peptide 
antibodies .... ... .... .. .. .. ... ...... .... ........ ........ .... ..... ... .... ...... ... .. ..... ...... ...... ... ..... ...... 152 
XV111 
Table 15: Maximal effect of anti-trypanopain antibodies on trypanopain and 
cathepsin L activity against Z-Phe-Arg-AMC ... ..... ....... .. ..... ...................... .... 157 
Table 16: Effects of various antibodies on trypanopain digestion of synthetic and 
proteinaceous substrates ... .. ... .... ..... ........ ........ ......... ... .... ....................... .. .. ....... 158 
Table 17: Effects of CMK, FMK and DMK on cultured T. b. brucei and 
purified trypanopain ............ ... ... .. .. ........ ... .......... .. .. .. .. .. ....... .............. .. : ...... .... .. 180 
Table 18: Effects of chalcones on cultured T. b. brucei, trypanopain and 
cathepsin L ...... ....... .... .... ... .. .. ...... .... ... .... .... .... .... ....................... ... .. .... .. ... ... ... .. 183 
Table 19: Effects of hydrazide derivatives on cultured T. b. brucei, trypanopain and 
cathepsin L ... ... ............ .... ... ... .. ........ ..... .. ............................... ........... ............... 184 
Table 20 Effects of amide derivatives on cultured T. b. brucei, trypanopain and 
cathepsin L .. ...... ...... ... .. .. .... ... ...... .... .... ....... .. .... ....... ............ .. .............. ...... .. .. .. 186 
Table 21: Effects of acyl hydrazide derivatives on cultured T. b. brucei, trypanopain 
and cathepsin L ..... ... .. ...... .. ..... ....... .... .................... ..... ... .. ... .................. .... .. ... . 189 
Table 22: Effects of chalcones on murine model of T. b. brucei infection .. ...... ...... .. ... .. 190 
xix 
LIST OF FIGURES 
Figure 1: Diagrammatic representation of generalised T. b. brucei morphology ............. 6 
Figure 2: Schematic representation of T. b. brucei phylogenetic tree ...... ................. .... .... 7 
Figure 3: Life cycle of T. b. brucei showing morphological stages present in 
mammalian and tsetse fly hosts .......................................................................... 9 
Figure 4: Proposed catalytic mechanism of cysteine proteinases ................. .. .. ........ ........ 28 
Figure 5: Cartoon representation of cruzipain three-dimensional structure ...................... 29 
Figure 6: Complex formation between Cu+ and BCA .................... ............ ........ ..... ...... ... 34 
Figure 7: Polymerisation of acrylamide by Bis, TEMED and ammonium persulfate ...... 37 
Figure 8: Proposed mechanism for E-64 inactivation of cysteine proteinases ..... .. ......... . 56 
Figure 9: Rate of trypanopain inactivation by a molar excess of E-64 ............ .... ......... .... 64 
Figure 10: Optimisation of TPP for isolation of trypanopain from T. b. brucei ............. .. .. 65 
Figure 11: Chromatogram of HiLoad Q-Sepharose separation of trypanopain 
and OP-Tb from T. b. brucei ........ ... .............. ...... .. .. .... ................ .. ........ ......... ... 66 
Figure 12: Resource Q chromatography of trypanopain .... .......... ......... ..... ................ ..... ... 67 
Figure 13: Pepstatin A-Sepharose chromatography of trypanopain ...... ... ......... .... ............ 68 
Figure 14: SDS-PAGE of trypanopain after pepstatin A-Sepharose chromatography ... ... . 69 
Figure 15: Tricine SDS-PAGE gel of inactive trypanopain after Resource Q 
chromatography .................................................................................................. 69 
Figure 16: Gelatin-containing tricine SDS-PAGE of crude and purified trypanopain ... .... 70 
Figure 17 : ELISA monitoring antibody titre in chicken immunised with 
trypanopain .......... ... ..... ... .... .. ... ... .... .. ..... ...... .... .... .... .. .... ... .......... .... ................... . 72 
Figure 18: Western blots showing recognition of trypanopain by chicken 
anti-whole trypanopain IgY antibodies ....... ... ..... ....................... ... ...... ........... ... 73 
Figure 19: Schechter and Berger notation for proteinase subsites .. .... ...... ..... ... ... ..... .. ..... ... 85 
Figure 20: Effect of pH on trypanopain activity against Z-Phe-Arg-AMC ................... ..... 89 
Figure 21: Effect of pH on trypanopain activity against 14C_ gelatin ................................... 89 
Figure 22: Effect of reducing agents on trypanopain activity against 
Z-Phe-Arg-AMC ............................................................................................... 90 
Figure 23: Optimal time of trypanopain activation by 30 mM cysteine ............................ 91 
xx 
Figure 24: Effect of pH on the stability of trypanopain in the presence or absence 
of cysteine ................... ... ........ ... ...... .............. .. ..... ......... ... ................... ............. .. 92 
Figure 25: Calculation of Km and kcat values for trypanopain hydrolysis of 
Z-Phe-Arg-AMC ...... ... ............. .. ..... ................................................................... 94 
Figure 26: Trypanopain digestion of fibrinogen .......................................... .................... ... . 95 
Figure 27: Trypanopain digestion of BSA. ....... ...... .... ... .. ... .......... .. ..... .. ................. ; ........ .... 96 
Figure 28: Trypanopain digestion ofIgG .. ... .... .. , .... ............. .... ................ .. ...................... .. . 96 
Figure 29: Schematic representation of chicken egg white cystatin binding to a 
cysteine proteinase ............. ... ....... .... .... .. .. ........... .... .... ... ....... ..... ... .. ................... 106 
Figure 30: Association between trypanopain and arM ..... .... .. ...................................... .. ... 120 
Figure 31: Z-Phe-Arg-AMC activity in the sera of control and infected animals .... .. ........ 121 
Figure 32: Detection of trypanopainlcystatin complexes in the serum of 
T. b. brucei-infected rats .. .. ... ... ..... .... ........ ... ... .... ....... .... .. ...... .. .................. .. ...... 122 
Figure 33: Schematic representation of the three-dimensional structure of papain ............ 131 
Figure 34: Epitope prediction plots for regions of trypanopain ... ......... ..... ...... .. ................ 132 
Figure 35 : SDS-PAGE gel showing coupling of the trypanopain peptide to rabbit 
albumin and ovalbumin .............................................. ........... ...... .. ...... .... ........... 137 
Figure 36: Rabbit antibodies produced against the conjugated and free trypanopain 
peptide at various weeks post-immunisation .. .... ...... ...... ...... ..... ......... .. ....... ...... 145 
Figure 37: Chicken antibodies produced against the conjugated and free trypanopain 
peptide at various weeks post-immunisation ... ..... ..... ............. .... ...... ....... ........ .. 146 
Figure 38 : Recognition of whole trypanopain by rabbit anti-free peptide and 
anti-conjugated peptide antibodies in an ELISA ... .. ..... ..... .. .... .. ....... ............ ... .. 147 
Figure 39: Cross-reactivity between chicken and rabbit anti-trypanopain antibodies 
and sheep cathepsin L in an ELISA .......... ... ...... .. ......... ...... .. ..... ........................ 148 
Figure 40: Enhancement of trypanopain hydrolysis of Z-Phe-Arg-AMC by rabbit 
anti-trypanopain antibodies .... ............... ..... ..... ... .......... ....... ... ............ , ...... ... ..... 149 
Figure 41: Modulation oftrypanopain hydrolysis ofZ-Phe-Arg-AMC by chicken 
anti-free peptide antibodies ...... ... ........ ... ........ .. ........... ........... ... .... ... ...... .... ....... 150 
Figure 42: Effect of anti-peptide antibodies on trypanopain digestion of 14C-gelatin ... ..... 153 
Figure 43: Effect of anti-trypanopain peptide antibodies on trypanopain digestion 
of FITC-albumin .. ........... .................. .. .......... ...................... ...... ........ .. ................ 154 
XXI 
Figure 44: Effect of activity-enhancing chicken antibodies on trypanopain activity 
against Z-Phe-Arg-AMC n lysed T. b. brucei ..................... ....................... ... ... 156 
Figure 45: Postulated scheme for DMK inactivation of cysteine proteinases ............ .... .. .. 170 
Figure 46: Effect of proteinase inhibitors on growth of cultured T. b. brucei .................. .. 179 
Figure 47: Determination ofkass for Z-Lys-CMK inhibition oftrypanopain .............. ..... ... 180 
Figure 48: Determination ofICso for TPCK. ... ............ ....... .. ... ......... ............................ .. .. ... 181 































absorbance at x run 
az-macro glo bulin 
2,2-azino-di-[3-ethylbenzthiazoline sulfonate] 
angiotensin converting enzyme 
4-(2-aminoethyl)-benzenesulfonyl fluoride 






N, N' -methylenebisacrylamide 
butoxycarbonyl 





copy deoxyribonucleic acid 
chloro meth y lketone 
Complement factor I 
Complement factor 3 











































dithio threito 1 
extinction co-efficient 
electro spray mass spectroscopy 
L-trans-epoxysuccinyl-leucylamido( 4-guanidino) butane 
ethylenediaminetetra-acetic acid 
enzyme-linked immunosorbent assay 
initial enzyme concentration 
enzyme concentration 
fragment, antibody binding 
fragment, crystallisable 
fluorescein isothiocyanate 
fluoro methy lketo ne 
foetal calf serum 
N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
human immunodeficiency virus 





50% inhibitory concentration 
immunoglobulin G 
immunoglobulin G, subclass 1 
immunoglobulin M 
immunoglobulin Y 
International Laboratory for Research on Animal Diseases 
low molecular mass kininogen 
association rate constant 


































keyhole limpet haemocyanin 
equilibrium constant for inhibition 
Michaelis constant 
observed association rate constant 
dissociation rate constant 
length of the light path 
monoclonal antibodies 
methoxysuccinyl 
mass per volume 
m-maleimido benzoyl-N-hydroxysuccinimide ester 
Minimal Essential Medium 
acetate-2(N -morpho lino )ethanesulpho nic acid 
major histocompatability complex 
messenger ribonucleic acid 
N-ethylmaleimide 
amino terminal 
polyacrylamide gel electrophoresis 
isovaleryl-Val-Val-Statine-Ala-Statine 
phosphate buffered saline 








rat trypanopain modulator 
substrate concentration 
soybean trypsin inhibitor 




















Tris buffered saline 
trichloroacetic acid 
N, N, N', N'-tetramethyl ethylene diamine 
N -tosyl-L-phenylalanyl chloromethylketone 
N-tosyl-L-Iysyl chloromethylketone 
3,3' ,5,5' -tetramethyl benzidine 
three-phase partitioning 
2-amino-2-(hydroxymethyl)-1,3-propandiol 
University of Natal (Pietermaritzburg) 
initial velocity of an uninhibited enzyme reaction 
initial velocity of an inhibited enzyme reaction 
maximum velocity 
volume per volume 
variant surface glycoprotein 







Trypanosomes are protozoan parasites that infect a variety of animals including fish, 
amphibians, reptiles, birds 'and mammals (Chandler and Read, 1961 ; Hall, 1977). Almost all 
domestic animals and many wild animals can serve as hosts for one or more species of 
trypanosome, with the severity of infection and symptoms varying widely. The primary features 
of mammalian trypanosomiasis are intermittent fever, progressive anaemia and general loss of 
condition. Human African trypanosomiasis, which is also called African sleeping sickness, is 
often fatal if left untreated and cattle trypanosomiasis, also known as nagana, is of great 
economic importance in many parts of Africa. Cattle trypanosomiasis is "unique among 
diseases in that it is the only one which by itself has denied vast areas of land to all domestic 
animals other than poultry" (Hornby, 1950). About one quarter of Africa is completely 
unsuitable for livestock farming and at least one third of the continent is affected by 
trypanosomiasis to some degree. Most African trypanosomes complete part of their life cycle in 
the tsetse fly vector (Fripp, 1983) with the distribution of this vector thus limiting the general 
distribution of trypanosomiasis in Africa to some 11 million km2 between 14°N and 29°S 
(Kuzoe, 1993). African trypanosomiasis is thus a predominantly tropical disease (Hall, 1977). 
Approximately 55 million people in 36 countries are at risk of contracting African sleeping 
sickness [Kuzoe, 1993; International Laboratory for Research on Animal Diseases (ILRAD), 
1994], of which there are two forms: Gambian sleeping sickness occurring in West Africa and 
Rhodesian sleeping sickness occurring in East Africa. 
1.2 Major African trypanosomiases 
1.2.1 Gambian sleeping sickness 
Trypanosoma brucei gambiense causes Gambian sleeping sickness in humans. Initial symptoms 
include an intermittent fever, headaches, glandular enlargement and oedema (Chandler and 
Read, 1961; Fripp, 1983; see Section 1.7). Although the infection may spontaneously 
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disappear, the disease usually becomes chronic. When parasites enter the cerebrospinal fluid, 
neurological symptoms occur. Patients express a desire to sleep continuously, experience 
apathy, problems with co-ordination, tremors of the tongue and limbs, slow and mumbling 
speech and paralysis (Ukoli, 1984). Starvation, pyrexia and/or opportunistic diseases cause the 
patient to fall into a coma, which is followed by death. 
Before tsetse fly control was instituted, an epidemic in the Great Lakes region of Uganda 
reduced the population from 300 000 in 1901 to 100000 in 1908. Effective control measures 
were subsequently instituted, with the result that in the 1950's sleeping sickness was largely 
under control. Recent political upheavals in many areas of Afiica have led to relaxation of 
tsetse fly control and a resultant increase in the incidence of Gambian sleeping sickness in 
Congo, Cameroon, Sudan, Uganda, Tanzania, Angola, Malawi and Chad (Kuzoe, 1993; CDR 
News, 1994). In the late 1980's, some 5-10 000 cases were treated annually in Congo while in 
1994, 150000 cases were suspected. In some areas, up to 70% of the population is thought to 
be infected (CDR News, 1994), but poor medical surveillance complicates estimation of the 
true scope of the disease. 
T b. gambiense is transmitted between mammalian hosts by the tsetse flies Glossina palpa/is 
and G. tachinoides, which breed in wooded areas near lakes and rivers (Swellengrebel and 
Sterman, 1961). In areas where water supplies are limited and where man and the fly are 
dependent on the same water supplies, contact between man and fly is common and the disease 
easily transmitted. The disease is thus endemic in many areas, and while the prevalence is 
commonly less than 1 %, foci of higher transmission occur (Markell et a/., 1992). No animal 
reservoirs of the parasite are known. 
1.2.2 Rhodesian sleeping sickness 
Human infection with T b. rhodesiense causes Rhodesian sleeping sickness, which is a highly 
acute illness causing death within a few weeks or months of infection (Chandler and Read, 
1961; Hall, 1977; Tizard et a/., 1978; Fripp, 1983). Exceptionally high levels ofparasitaemia 
induce a high fever and rapid enlargement of the liver and spleen (see Section 1.7). The rapidity 
of disease progression prevents the development of neurological symptoms such as those seen 
in Gambian sleeping sickness (Ukoli, 1984). G. morsitans, the primary vector, differs from the 
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riverine G. palpalis in that it lives mainly in open woodland and so there is less contact between 
the vector and hosts. Despite its higher virulence, T. b. rhodesiense is thus less of a health 
problem than T. b. gambiense since outbreaks are sporadic and contained. In southern Africa, 
this disease still occurs in the Okavango Delta of Botswana, where wildlife such as antelope are 
asymptotically infected and serve as important reservoirs for the parasite. 
1.2.3 Cattle trypanosomiasis 
Cattle trypanosomiasis, also known as nagana, is by far the most economically important of the 
African trypanosomiases (Chandler and Read, 1961). Thirty percent of Africa's cattle and small 
ruminant population are at risk of contracting trypanosomiasis; with losses in meat production, 
milk yield and tractive power estimated to cost in the region of US$ 500 million per year. If 
lost potential in livestock and crop production is also considered, the disease costs Africa an 
estimated US$ 5 billion per year ~RAD, 1994). Some of the most potentially productive 
agricultural land in Africa is under-utilised because of the threat of nagana (ILRAD, 1992). 
Cattle trypanosomiasis is caused primarily by T. congolense, T. vivax' and T. brncei, which are 
transmitted between cattle by various Glossina species (Soulsby, 1982; Kaufinann, 1996). In 
addition to cattle, horses, camels, goats, chickens, dogs, cats and pigs can become infected with 
various species of trypanosome (Kaufinann, 1996). 
1.4 Trypanosome morphology 
. 
Trypanosomes have a variety of morphological stages, but the trypanosomal cell is 
characteristically elongated (15-40 11m long) and slender (11;2-31;2 11m wide), with a single 
flagellum extending along the length of the cell and beyond (Kreier and Baker, 1987). The 
flagellum arises from an intracellular basal body called the kinetosome and emerges through the 
flagellar pocket. Trypanosomes swim actively using this flagellum, which is attached to the cell 
by an undulating membrane (Ukoli, 1984). Most of the remaining trypanosomal cellular 
structures (e.g. nucleus, Golgi, endoplasmic reticulum) are similar to those found in higher 
organisms (Figure 1). Trypanosomes do, however, contain an unusually large amount of 
mitochondrial deoxyribonucleic acid (DNA) that is packaged into a body called the kinetoplast 
inside the single, large trypanosomal mitochondrion (Kreier and Baker, 1987). The kinetoplast 
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is as a small, rounded, nucleus-like body near the base of the flagellum (Kreier and Baker, 
1987). Its function is unclear. 
1.5 Classification of trypanosomes 
Members of the family Trypanosomatidae that spend their life partly in the blood or tissue of 
vertebrates and partly in the alimentary system of blood-sucking insects are known as 
haemoflagellates (Ukoli, 1984). This group includes the genera Trypanosoma and Leishmania, 
both of which are of medical and veterinary importance (Figure 2, Hoare, 1972; Markell et a/. , 
1992). The family is thought to have arisen from an ancestral insect parasite and some species 
(e.g. Leptomonas and Crithidia) are still exclusively insect parasites. Other than Trypanosoma, 
the only other genus of this family that parasitises humans is Leishmania. Both these species 
have two hosts during their life cycle, the one being an insect vector and the other a mammalian 
host. 
On the basis of their transmission by such insect vectors, mammalian-infecting trypanosomes 
may be divided into two main groups: salivarian and stercorial . The salivarian trypanosomes 
are transmitted from the salivary glands of infected insect vectors and are thus said to develop at 
the anterior station of the vector. Stercorial trypanosomes, on the other hand, are transmitted in 
the faeces of infected insect vectors and are thus said to develop at the posterior vector station 
(Hoare, 1972). African trypanosomes are salivarian parasites, while American trypanosomes 
are stercorial. 
South American trypanosomes differ most importantly from African trypanosomes in that they 
multiply intracellularly (most importantly, in cardiac muscle) and have as their vector a blood-
sucking insect of the family Reduviidae (Swellengrebel and Sterman, 1961; Soulsby, 1982; 
Fripp, 1983). Parasites develop in the hindgut ofthe vector and are transmitted to mammalian 
hosts when infected faeces are rubbed into a bite wound. Various domestic animals, especially 
dogs, serve as important reservoirs of the disease. The most important member of this group is 
T. cruzi, which causes Chagas' disease in humans. Up to 18 million people are thought to be 
affected by the disease, while millions more are at risk (Cazzulo et a/. , 1997). In some areas of 
Central and South America, the prevalence of this fatal disease may exceed 50%, with young 
children and infants most susceptible. The initial symptoms of infection include fever, 
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cardiomyopathy and enlargement of the colon. Interestingly, T. cruzi is thought to be the cause 
of the debilitating illness experienced by Charles Darwin for over half his life (Medawar, 1996). 
At the time, Darwin's doctors were baffled by his illness, suggesting that Darwin's symptoms 
were psychosomatic. T. cruzi was not identified until 27 years after Darwin's death, and 
modem authors have suggested that his symptoms fit those of Chaga's disease and postulate 
that Darwin's chances of escaping r cruzi infection during his travels in and around South 
America on the Beagle were negligible (Medawar, 1996). T. rangeli (also called T. ariari or 
T. guatemalensis) is another interesting South American trypanosome, that infects humans 
apparently asymptomatically. In Panama, approximately 75% of people under 16 years old are 
thought to be infected with this parasite (Markell et al., 1992). 
T. b. brucei , r b. gambiense and T. b. rhodesiense are morphologically indistinguishable and 
cannot be differentiated by serological means (Markell et aI1992). The three species differ only 
in host specificity and the severity of the disease they cause. The classification of this sub-group 
of parasites is thus controversial; with some authors proposing a division into three species and 
others into three sub-species (Ukoli, 1984). The latter is more widely accepted (Tait et al., 
1984), with the sub-species divided along geographical and host lines. r b. brucei is defined as 
being found throughout Afiica and infecting wildlife and domestic animals, but not man. 
[
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1.6 Life cycle of African trypanosomes 
African trypanosomes spend part of their complex life cycle (Figure 3) in a mammalian host and 
the rest in an insect vector, usually the tsetse fly (Chandler and Read, 1961; Swellengrebel and 
Sterman, 1961). The species of fly that serves as a vector varies with the genus of 
trypanosome. Cyclic transmission occurs when non-dividing metacyclic forms, present in the 
salivary glands or mouth parts of infected flies, infect susceptible mammals when the flies bite. 
Once inside the mammalian host, the metacyclic forms differentiate into bloodstream 
tryptomastigote forms that undergo rapid multiplication by binary fission in the bloodstream, 
lymphatics and cerebrospinal fluid (Markell et ai., 1992). The long and slender, rapidly dividing 
bloodstream forms stop dividing and become short and stumpy later in the infection. Some of 
the biochemical changes between the bloodstream forms suggest pre-adaptation for tsetse fly 
infection. Some trypanosome species, especially r b. brucei and r b. gambiense, are highly 
pleomorphic, with both morphological forms occurring simultaneously in the host. 
When a fly bites the infected mammal, it takes up trypanosomes in the bloodmeal. These 
parasites differentiate in the midgut of the tsetse fly into dividing procyclic forms before 
differentiating further into dividing epimastigote forms in the proboscis or salivary glands of the 
fly. The final stage of the 20-30 day life cycle is the differentiation of the epimastigote form into 
the non-dividing, mammalian-infective metacyclic form. 
The mechanism for the transformation from long, slender to short, stumpy forms is poorly 
understood. Various possibilities have been proposed, including that transformation is a 
programmed event in the cell cycle or that depletion of a key nutrient initiates transformation, 
but it seems most likely that a host-derived growth inhibitor triggers transformation into short, 





















Figure 3: Life cycle of T. b. brncei showing morphological stages present in mammalian and 
tsetse fly hosts. 
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1.7 Symptoms of African trypanosomiasis 
In the case of Gambian sleeping sickness, a bite by an infected insect is followed by an 
asymptomatic incubation period of a few days to several weeks, while onset of Rhodesian 
sleeping sickness is acute (Markell et al. 1992). The area of the bite may become ulcerated to 
form a painful "trypanosomal chancre", from which trypanosomes can be aspirated. At this 
stage, the infected person appears outwardly healthy, although trypanosomes can be detected in 
the bloodstream. This stage can persist for several months and the infection may disappear 
without the development of further symptoms (Markell et al. 1992). However, if the 
trypanosomes multiply and invade the lymphatic system, the patient begins experiencing fevers, 
headaches and joint pains, possibly accompanied by anorexia, generalised weakness, nausea and 
vomiting. An asymptomatic phase then follows, with the levels of trypanosomes in the 
bloodstream dropping. This is followed by further attacks of intermittent fever as the 
trypanosome population repeatedly rises and falls . Large numbers of trypanosomes are 
detectable in the bloodstream during periods of fever. 
Infection of the lymphoid system is particularly common in the early stages of the disease. 
While any lymph nodes may become infected, those in the posterior cervical region are 
particularly susceptible. Inflammation of these nodes is called "Winterbottom's Sign", and was 
used by slave traders to identifY potentially infected Africans. Proliferation of parasites in the 
lymphoid tissue causes generalised lymphoid hyperplasia. Anaemia, thrombocytopaenia, 
hypergammaglobulinaemia [especially of Immunoglobulin M (IgM)] and disseminated 
intravascular coaggulation are common symptoms. While congenital transmission IS 
uncommon, stillbirths and abortions are common during this stage of the disease. 
Neurological symptoms, such as lassitude, fatigue, confusion and apathy, develop later in the 
course of the infection when trypanosomes enter the brain (Markell et al 1992). Such 
symptoms are much more marked in Gambian than Rhodesian sleeping sickness. Motor 
changes include fibrillation of the muscles of the face, lips and fingers, and inco-ordination 
leading to slurred speech and an ataxic gait. Sensory changes are less marked, but pressure on 
the palms or ulnar nerve may be followed by severe pain a short time after pressure is removed 
(Kerandel's Sign). Neurological symptoms become severe in the final stages of the disease. 
11 
Convulsions, paraplegia or hemiplegia and incontinence are commonly experienced, with the 
patient eventually slipping into a coma. 
Cattle trypanosomiasis is characterised by similar symptoms to human trypanosomiasis. After a 
one to three week incubation period, infected cattle develop an intermittent fever, increased 
pulse rate and shallow respiration; after which emaciation, severe anaemia, lymph node 
enlargement, splenomegaly and oedema are experienced. Wasting of both body fat and muscle 
and impaired reproductive ability are important from an economic standpoint (Urquhart et ai. , 
1987; Kaufmann, 1996). Although the severity of the disease varies with the nutritional status 
and stress levels of an animal, the slow, progressive anaemia is often fatal . In very acute cases, 
death can occur within 1 week of infection. 
1.8 Pathogenesis of trypanosomiasis 
Trypanosome-infected individuals show a wide variety of clinical signs and since no obvious 
gross lesions are present, there has been some debate as to the pathogenesis of the disease 
(Tizard et ai. , 1978). Severe anaemia is a common characteristic of trypanosoma! infection and 
contributes to the fatigue and loss of condition experienced by infected hosts. Although multi-
factorial, anaemia is now thought to be caused primarily by extensive lysis of red blood cells. 
Although the mechanisms whereby haemolysis occurs are unclear, some possible contributory 
mechanisms are listed below (Boreham, 1974; Tabel et ai. , 1978; Tizard et ai., 1978; Murray 
and Dexter, 1988): 
• Soluble trypanosomal antigens may adsorb onto circulating erythrocytes, where they can 
become opsonised by circulating anti-trypanosome antibodies. Such surface-bound 
antibodies initiate antibody-dependent cytotoxic reactions against erythrocytes by recruiting 
Fe (fragment, crysta!lisable)-receptor bearing phagocytes and eosinophils and by triggering 
the classical complement pathway. 
• Trypanosoma! surface glycoproteins can also stimulate the classical complement pathway 
directly and so initiate erythrocyte lysis independently of circulating antibodies. 
• The presence of trypanosomes in the blood appears to damage capillary walls, leading to 
diffuse intravascular coagulation and the development of microthrombi in capillary beds. 
Passing erythrocytes are trapped and damaged by these micro thrombi and must 
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subsequently be removed from circulation. Such microangiopathic anaemia is thus a 
secondary feature of damage to capillary walls. 
• Trypanosoma! phospholipase A acts on phosphatidyl choline to release free fatty acids 
which may have detergent-like effects on erythrocyte membranes. 
• Trypanosomes release a 12 kiloDalton (kDa) protein that appears to directly mediate 
haemolysis. 
Once haemolysed, erythrocytes are thought to be removed from the bloodstream primarily by 
mononuclear phagocytes. Spleen enlargement is a common early feature of trypanosomiasis 
and is thought to be caused partly by increased sequestration of phagocytosed red blood cells. 
After prolonged stimulation by the massive parasite load, the expanded mononuclear phagocyte 
system is thought to remain active once trypanosomes have been eliminated from the blood. 
Non-specific phagocytosis of erythrocytes may thus continue, contributing to further anaemia 
(Murray and Dexter, 1988). 
Factors other than haemolysis are also thought to contribute to trypanosome-induced anaemia. 
For example, erythropoeisis and haemopoeisis seem to be inadequate in relation to the extent of 
anaemia (Murray and Dexter, 1988). Trapping of iron in reticuloendothelial cells is thought to 
exacerbate abnormal haemopoeisis, so administration of testosterone, cobalt or erythropoeitin 
has been suggested to increase iron release from storage sites in the body. 
In addition to inducing severe anaemia, trypanosome infection commonly causes disturbances in 
functioning of the host's immune system. Parasites endeavour to evade the host immune 
system by regularly changing their surface antigens, which are known as variable surface 
glycoproteins (VSG). A single trypanosome may have as many as 1 000 different VSG 
varieties (Hadjuk, 1984) and the persistent presence of new trypanosomal antigens in the blood 
results in the production of high levels of circulating antibodies, particularly IgM (Tizard et aI. , 
1978). Some of these antibodies are directed against trypanosomal antigens but many are 
directed against heterophils, antiglobulins and other self antigens, thus initiating autoimmune 
complications (Tizard et aI., 1978). Cross-reactivity between host and parasite proteins may 
also contribute to autoimmune reactions (Muller et aI. , 1993). Serum complement levels are 
depleted by trypanosome infection, with the early components such as complement factors I 
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(Cl) and 3 (C3) being most affected (Tizard et a!., 1978). The increase in antibody levels 
described above leads to an increase in the number of circulating immune complexes, which fix 
complement and so contribute to its depletion. Depletion of complement is thought to favour 
parasite survival by hampering complement-mediated lysis of parasites. 
Reports on the effects of trypanosomal infection on T-cell responses are varied. While some 
authors state that only susceptible cattle experience T-cell suppression (Longstaffe and Terry, 
1982), others conclude that there is no such correlation (Flynn and Sileghem, 1993). 
Trypanosome-infected hosts experience a wide variety of symptoms other than the anaemia and 
immune system malfunctioning discussed above. While T. congolense is found almost 
exclusively in the bloodstream T. b. rhodesiense, T. b. gambiense and T. b. brocei also infect 
tissues (Ukoli, 1984). These organisms thus also cause degeneration, necrosis and 
inflammation of tissues, producing a complex set of symptoms. Many of these symptoms are 
thought to be caused by toxic trypanosomal metabolites (Alafiatayo et aI. , 1993). For example, 
the neurological symptoms especially corn.Inon in Gambian sleeping sickness may be caused by 
transamination of tryptophan and other related indoles to produce tryptophol (indole-3-ethanol, 
Tizard et a!. , 1978). In experimental animals, tryptophol produces a comatose-like state, alters 
body temperature and initiates immunosuppression and is thus thought to be at least partially 
responsible for the "sleepiness" symptoms of Gambian sleeping sickness. The headache often 
experienced during the early stages of the disease may be caused by parasites blocking 
capillaries in the choroid plexus, which causes localised oedema and obstructs the flow of 
cerebrospinal fluid (Markell et a!. , 1992). 
1.9 Diagnosis of African trypanosomiasis 
Since the initial symptoms (e.g. fever, headaches, joint pains) of trypanosomiasis are fairly non-
specific, diagnosis of trypanosomiasis requires identification of parasites in the blood, lymphatic 
or cerebrospinal fluid (Chandler and Read, 1961 ; Tizard et aI. , 1978; Fripp, 1983). In cases 
where only a few parasites are present, blood can be centrifuged to concentrate the parasites in 
the buffY coat. 
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Diagnostic complement fixation and fluorescent antibody tests are also available, with extremely 
sensitive monoclonal antibody-based antigen-detection enzyme-linked immunosorbent assays 
(ELISAs), DNA hybridisation assays and polymerase chain reaction (PCR)-based techniques 
under development for future early diagnosis (ILRAD, 1994). Histological analyses show 
localised accumulation of trypanosomes in the micro-vasculature, accompanied by extensive 
endothelial damage. Inflammatory responses to this damage, such as localised infiltration of 
lymphocytes and phagocytes, are also seen. 
1.10 Current prevention and treatment of trypanosomiasis 
Most of the countries that regularly report cases of trypanosomiasis have an annual per capita 
health budget ofless than US$10 (De Raadt, 1989). It is thus clear that preventative measures 
and treatments for sleeping sickness must be cheap to be of any significance in the affected 
areas. 
1.10.1 Control of tsetse fly 
Prevention of trypanosomiasis has centred mainly on control of tsetse fly populations using 
insecticides such as dichlorodiphenyl trichloroethane (DDT), dieldrin and endosulfan (Hall, 
1977; Grosvenor, 1986). These are still used to control tsetse fly numbers despite their 
deleterious effects on the environment (Wooff and Phillemon-Motsu, 1993). Alternative 
methods for controlling tsetse fly such as clearing bush around human settlements and the use 
of cattle odour-baited tsetse targets and traps, have met with some success (Wooff and 
Phillemon-Motsu, 1993), but domestic animals should be frequently sprayed or dipped in 
insecticide and stables screened to prevent re-entry of the fly into the area (Grosvenor, 1986). 
Many wild animals serve as reservoir species for trypanosomes and food for Glossina species 
but elimination of entire populations of reservoir species is not ecologically acceptable. 
An alternative method of controlling the disease is to protect susceptible animals from infection 
by parasites, instead of from biting by the fly. The prophylactic drug pentamidine is relatively 
expensive and the period of protection decreases with successive use. Thus, none of the 
currently available prevention methods is cost effective or efficient enough to allow cattle 
farming in the tsetse fly belt of Africa without close supervision (ILRAD, 1993). 
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Some species of cattle, such as the N 'Dama (Bas taurus) are naturally more resistant to 
infection than others and are more suited to areas where trypanosomiasis is endemic. Resistant 
cattle seem able to recognise and mount an effective immune response against parasite factors 
contributing to pathogenesis and so control disease progress (Authie et aI. , 1993). While 
introduction of resistant N'Dama into tsetse-supporting areas is attractive, there are some 
drawbacks. For example, while meat production by N'Dama is good, they produce little milk 
and are generally too small for draught work. Also, their trypanotolerance is reduced when the 
animals are stressed (ll-RAD, 1992; 1993). 
1.10.2 Current treatment methods 
Highly toxic arsenic and antimony-based drugs were commonly used for treatment of 
trypanosomiases until the 1960' s but have now been largely replaced by less toxic alternatives 
(Chandler and Read, 1961; Swellengrebel and Sterman, 1961; Soulsby, 1982; Fripp, 1983). 
One arsenical, melarsoprol, is still commonly used to treat the later, neurological stages of 
sleeping sickness. While the mechanism of action remains unclear, enzymes involved in energy-
generation are thought to be primary targets (Gutteridge, 1985). 
Suramin is a sulfated naphthylamine first introduced in the 1920' s as a treatment for the early 
stages of Gambian and Rhodesian sleeping sickness (pepin, 1994). The drug is thought to exert 
its effect primarily through inhibition of essential trypanosomal glycolytic enzymes, but its exact 
mode of action remains unclear (Markell et aI., 1992). While the drug is taken up selectively by 
trypanosomes and not mammalian cells, suramin can be extremely toxic in certain patients. Side 
effects include loss of consciousness, seizures, renal failure, fever, hepatitis, rash, pruritis, 
oedema, pain, conjunctivitis and photophobia (Markell et aI. , 1992). The drug does not cross 
the blood-brain barrier and is thus ineffective against the neurological stages of the disease 
(Gutteridge, 1985). 
Pentamidine (Lomidine or 4-4' -diaminodiphen-oxypentane di-~-hydroxyethane sulfonate) is a 
diamine compound that is thought to kill trypanosomes by interacting specifically with 
kinetoplast DNA (reviewed by Pepin, 1994). Trypanosomes are thought to be more sensitive 
to pentamidine than mammalian cells because they possess a pentamidine transport system that 
raises the intracellular concentration of the drug several fold above the plasma concentration 
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(Gutteridge, 1985). The drug, which was introduced in the 1940's, is particularly effective as a 
treatment for the early, haemolytic stages of Gambian sleeping sickness (Markell et a!., 1992). 
The main advantage of pentamidine over suramin is that a full course of the drug can be given 
over 7-10 days, while suramin treatment takes several weeks (Gu~eridge, 1985). Pentamidine 
does not cross the blood-brain barrier, so is ineffective against the neurological stages of the 
disease (Gutteridge, 1985). There are relatively few side-effects to treatment, but light-
headedness, renal damage and pain at the site if injection have been reported. Berenil is an 
aromatic diamine similar to pentamidine, but is used only in livestock (Gutteridge, 1985; 
Kinabo, 1993). 
Melarsoprol is a trivalent arsenic-based compound that is thought to inhibit various sulfur-
containing trypanosomal enzymes. The drug is of particular use in the neurological stage of the 
disease since it can cross the blood-brain barrier (Markell et a!. , 1992). This advantage must be 
weighed against the often extreme toxicity of melarsoprol, with symptoms such as 
encephalopathy experienced in 5-10% of patients (Kuzoe, 1993). Certain strains of both T b. 
gambiense and T b. rhodesiense are resistant to melarsoprol (Kuzoe, 1993). 
DL-a-difluoromethylornithine (DFMO, eflornithine) is a highly effective treatment for both the 
early and late stages of trypanosomiasis. The compound is a potent inhibitor of ornithine 
decarboxylase, which is involved in polyamine (most importantly, trypanothione) biosynthesis 
(McCann et al., 1981; Bacchi et a!., 1983; Fairlamb et a!. , 1987). However, limited host 
toxicity has been observed. Additionally, the drug must be administered intravenously four 
times daily for 14 days, making it an expensive treatment (Kuzoe, 1993). Variants ofDFMO 
are being tested in the hope that they will prove to be more effective or easier to administer than 
the parent compound (Bitonti et a!. , 1985). , 
None of the currently available drugs is thus entirely satisfactory. Major limitations are a lack of 
oral activity, side-effects and an inability to treat all stages of the disease (Gutteridge, 1985). 
While there are few reports of drug resistant human trypanosomes, resistant cattle strains limit 
the veterinary efficacy of the current drugs. This, together with the time and cost involved in 
controlling tsetse fly popUlations, has led to a search for novel means of disease therapy and 
prevention. 
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1.11. Parasite proteinases 
Parasitic protozoa cause numerous important human and animal diseases, including malaria, 
leishmaniasis and amoebiasis. The proteinases of these pathogens are though to be essential for 
parasite viability and/or contribute to pathogenesis. They are thus the subject of intense study 
as potential chemotherapeutic targets (McKerrow, 1989; North et aI., 1990a). The discovery 
( or synthesis) of specific proteinase inhibitors has made it possible to consider proteinase 
inhibition as a new chemotherapeutic approach for treating various parasite infections 
(McKerrow, 1989; North et aI., 1990a). The cysteine proteinases of numerous parasites are 
under investigation as potentially contributing to pathogenesis or as possible targets for novel 
anti-parasite drugs. Some of the cysteine proteinases thus studied include those of the protozoa 
Leishmania (Hunter et aI., 1992); Plasmodium (Rosenthal et aI., 1993); Entamoeba histoiytica 
(Luaces and Barrett, 1988; Avila and Calderon, 1993); Theileria parva (Nene et aI., 1990), 
Trichomonas (North et aI., 1990b) and Cryptosporidium parvum (Nesterenko et aI., 1995) as 
well as the helminths Spirometra mansoni (Yong Song and Chappell, 1993), Trichinella 
spiralis (Todorova et al., 1995), Fasciola hepatica (Dowd et aI. , 1995), Necator americanus 
(Brown et al., 1995); the trematode Schistosoma (Dresden and Deelder, 1979; Klinkert et aI., 
1989) and the nematodes Haemonchus contortus (Cox et aI., 1990) and Caenorhabditis 
elegans (Ray and McKerrow, 1992). Various functions have been proposed for these 
proteinases, including: 
• parasite protein catabolism, including activation or degradation of parasite peptide 
honnones, enzymes or regulatory molecules 
• parasite remodelling during transition from one life cycle stage to another 
• invasion of host tissue by degradation of connective tissue 
• evasion of the host immune system by degradation or activation of various molecules of the 
immune system 
• disturbance of host honnonal system by degradation of host peptide honnones. 
While these proteinases have been shown to degrade vanous host proteins (including 
complement components, cell surface proteins, immunoglobulins and haemoglobin) in vitro, 
their in vivo role( s) and substrate( s) remain largely speculative. Compared with their 
mammalian counterparts, namely cathepsins B, H and L, protozoan cysteine proteinases are 
18 
often larger and more stable in alkaline conditions (North et aI. , 1990a). They are usually 
lysosomal and have similar substrate specificities to homologous mammalian enzymes. 
1.11.1 E. histolytica cysteine proteinase 
E. histolytica is the causative agent of amoebiasis, characterised by colitis, dysentery and 
amebic abscess. Two of the virulence factors identified are a metalloproteinase (Scholze and 
Schulte, 1990) and a cysteine proteinase [called histolysain (Luaces and Barrett, 1988)]. The 
major cysteine proteinase of the parasite has been identified as a cytotoxin by virtue of the fact 
that addition of purified proteinase to tissue cultured monolayers of host cells induces 
cytotoxicity (Keene et aI., 1986, Luaces and Barrett, 1988). Furthermore, specific irreversible 
inhibitors of the proteinase prevent this damage (Keene et aI. , 1990). A correlation also exists 
between the pathogenicity of field isolates and their level of proteinase secretion (Reed et aI. , 
1989). The purified enzyme (23-27 kDa) is a typical cysteine proteinase, being activated by 
reducing agents and inhibited by diagnostic cysteine proteinase inhibitors (Scholze and Schulte, 
1988). A similar enzyme has recently been identified in E. invadens (Sharma et aI., 1996) and 
fragments of a homologous gene have been found in non-pathogenic E. histolytica (also known 
as E. dispar) (Mirelman et aI. , 1996). E. histolytica additionally possesses a membrane-
associated metallocollagenase thought to be involved in host invasion (Luaces and Barrett, 
1988; Munoz et aI., 1990). 
1.11.2 Leishmania proteinases 
Leishmaniasis is classified by the World Health Organisation (WHO) as one of the six major 
parasitic diseases, with over 12 million people infected by species of the parasite. The disease is 
characterised by symptoms varying from self-healing cutaneous ulcers to non-resolving 
mucocutaneous lesions and hepatosplenomegaly leading to death. Promastigotes express a 
surface zinc metalloproteinase at high density (Bordier, 1987; Bouvier et aI. , 1985) which is not 
inhibited by any physiological inhibitors (including a2-macroglobulin) (Heumann et al., 1989). 
Use of this proteinase as a vaccine has met with varying success (Russell and Alexander, 1988; 
Handmann et al., 1990; Jaffe et aI., 1990; Lopez et aI., 1991). Additionally, Leishmania 
amastigotes have been shown to express several biochemically distinct cysteine proteinases 
encoded by at least 19 genes (Robertson and Coombs, 1992). Three main groups of cysteine 
proteinases have been identified in L. mexicana and L. pifanoi (reviewed in Robertson et aI. , 
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1996). Type I cysteine proteinases are cathepsin L-like enzymes encoded by developmentally 
regulated multi-copy genes (e.g. Imcpb in L. mexicana; lpcys2 in L. pifanoi) and contain the 
long C-tenninal extension seen in cruzipain and trypanopain-Tb (Robertson and Coombs, 
1990). Type II leishmanial cysteine proteinases are also cathepsin L-like, but are encoded by 
single copy genes (e.g. Imcpa in L. mexicana; Ipcys1 in L. pifanoi) and lack the C-tenninal 
extension found in Type I enzymes. Type III leishmanial cysteine proteinases are cathepsin B-
like enzymes encoded by single copy genes (e.g. Imcpc in L. mexicana). Cysteine proteinase 
inhibitors inhibit growth of L. mexicana in mouse macrophages by 95% (Coombs and Baxter, 
1984) and there is a correlation between the strain pathogenicity and the level of cysteine 
proteinase expression (Bonaldo et aI., 1991). Gene knockout of the Imcpb group of 
proteinases from L. mexicana has shown that these are not essential for viability, since double 
knockout mutants can be cultured in vitro (Mottram et aI., 1996). Knockouts were, however, 
less able to infect host cells, showing that the enzymes are virulence factors. The various 
isoenzymes in the Imcpb group differ in their ability to restore virulence to null mutants 
(Mottram et aI., 1997), indicating that they have different functions in the parasite. 
1.11.3 Schistosoma proteinases 
Schistosoma mansoni and S. japonicum contain a variety of cathepsin-like cysteine proteinases, 
including enzymes resembling cathepsin B (Sm31, Dresden and Deelder, 1979; Klinkert et aI., 
1989; Ghoneim and Klinkert, 1995; Dalton et aI., 1996), cathepsin L (Sm24, Smith et al., 1994; 
Michel et al., 1995; Dalton et aI., 1996), cathepsin D (Becker et aI. , 1995; Wong et aI. , 1997) 
and cathepsin C (Butler et aI. , 1995). A membrane-anchored serine proteinase has also been 
described (Ghendler et aI., 1996). Additionally, schistosomes encode an asparaginyl 
endopeptidase called Sm32, which cleaves on the carboxy (C-) terminal side of asparagine 
residues that are not at either of the two positions closest to the amino (N-) terminal and that 
are not glycosylated (Davis et al., 1987; Ishii, 1994, Becker et al., 1995). Sequence analysis 
has revealed that there are no known mammalian homologues of this enzyme (Davis et aI., 
1987), and if this enzyme is shown to be vital for parasite viability, it is a very attractive target 
for drug design. 
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1.11.4 Malarial proteinases 
Malaria is the most important protozoan infection worldwide, with about 1 million reported 
deaths annually (Walsh, 1989). Numerous studies have implicated both cysteine and serine 
proteinases in invasion and rupture of erythrocytes, as well as processing of proteins required 
for this process (reviewed in McKerrow et at., 1993). Additionally, aspartic and cysteine 
proteinases are thought to be involved in haemoglobin degradation, which is the major source 
of parasite amino acids. A P. jaIciparum aspartic proteinase has been shown to cleave native 
haemoglobin at a specific site on the a-chain, suggesting that it might initiate haemoglobin 
digestion (Goldberg et at. , 1991), with a cysteine proteinase thought to be responsible for 
further degradation (Rosenthal et at. , 1988). Incubation of parasites with proteinase inhibitors 
blocks parasite development (Rosenthal et at., 1988; Bailly et at. , 1992), suggesting that these 
enzymes might be suitable chemotherapeutic targets. In an animal model of malaria, 
morpholine urea-Phe-hPhe-fluoromethylketone (FMK) cured 80% of mice infected with murine 
malaria (P. vinckei) when administered subcutaneously for 4 days at 100 mg/kg body weight 
(Rosenthal et at. , 1993). 
1.12 Trypanopains 
At the outset of the present study in 1994, zymogram profiles of the proteolytic components of 
T b. brucei identified a 28 kDa cysteine proteinase (Robertson et at., 1990, Huet et at. , 1992). 
The copy DNA (cDNA) of this enzyme, named trypanopain-Th (referred to as trypanopain 
throughout this thesis) had been sequenced (Mottram et at. , 1989), but the enzyme had not 
been isolated or enzymatically characterised. The homologous enzymes from T cruzi and T 
congolense ( called cruzipain/ cruzain and trypanopain-T c respectively) had been more 
extensively studied, and various lines of evidence, outlined below, suggested these proteinases 
might have pathogenic relevance. 
1.12.1 Correlation between disease resistance and production of anti-trypanopain-Tb 
IgG 1 antibodies 
Different breeds of cattle have varying resistance to trypanosome infection. For example, 
N'Dama cattle are resistant to T congolense infection, while Boran cattle are susceptible. 
N'Dama cattle are termed trypanotolerant because they have the ability to control trypanosome 
infection, while susceptible Boran cannot. While parasite numbers in resistant and susceptible 
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cattle are comparable for the first 30-40 days post-infection, parasitaemia then drops in resistant 
cattle but continues to increase in susceptible cattle (Authie et al., 1993). While there are likely 
to be many differences between trypanotolerant and susceptible cattle, one difference between 
the breeds is in their responses to the major cysteine proteinase of T congolense, namely 
trypanopain-Tc. Authie et al. (1993) showed that while trypanotolerant cattle produce 
anti-trypanopain Immunoglobulin G subclass 1 (IgG 1), susceptible cattle do not. Also, Afiican 
buffalo, which are known to be trypanotolerant, produce high levels of anti-trypanopain-Tc 
immunoglobulins during primary infection. Both susceptible and resistant' cattle produce IgM, 
so the type of antibody elicited seems to be of significance. 
Trypanopain-Tc has been detected in the plasma of susceptible and resistant cattle (Authie et 
aI. , 1993) where it may contribute to pathogenesis by degrading various host proteins 
(Rautenberg et aI. , 1982; Mbawa et aI. , 1992). If active trypanopain exerts a pathogenic effect, 
then anti-trypanopain antibodies may conceivably be protective if they inhibit enzyme activity or 
target circulating enzyme for removal by phagocytic cells. Therefore, animals failing to mount 
an effective immune response against trypanopain may have higher levels of active enzyme in 
their plasma, which may increase pathogenesis in these animals (Authie et aI., 1993). 
Crosses between Boran and N'Dama cattle have intermediate resistance to trypanosomiasis. 
compared with the parent breeds, but even within a breed, individual animals have differing 
susceptibilitx to the disease. The breed-restricted nature of anti-trypanopain responses suggests 
that recognition of the enzyme is somehow genetically restricted (Authie et aI. , 1992). 
Trypanopain-Tc shares high homology with mammalian cathepsin L (Fish et aI. , 1995) and so, 
like cathepsin L, trypanopains may carry only a small number ofT cell epitopes (Authie et aI. , 
1992). Since T cell recognition is dependent on interaction with major histocompatability 
complex (MHC) molecules, T cell responses to the few T cell epitopes of trypanopains may be 
strongly genetically restricted. 
While differences in responses to trypanopain are unlikely to be the sole difference between 
resistant and susceptible cattle, the observations of Authie et al. (1993) do suggest that further 
investigation of the role of anti-trypanopain immunoglobulin G subclass 1 (IgG 1) in the control 
of trypanosomiasis is warranted. Promisingly, susceptible cattle repeatedly experimentally 
infected and cured of infection by drug intervention were found to develop high titres of 
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protective anti-trypanopain antibodies, suggesting that susceptible breeds can develop immunity 
against infection (Authie et ai. , 1993). 
1.12.2 Cysteine proteinase inhibitors kill live trypanosomes 
Live T congo tense are killed in vitro 24-48 h after incubation with rnicromolar concentrations 
of specific peptidyl diazomethylketones (DMK) (Mbawa et aI., 1992). The most trypanocidal 
inhibitors were those that best inhibit purified trypanopain-Tc. Similar results were obtained 
with live T cruzi treated with DMK and acyloxymethylketone inhibitors of the major T cruzi 
cysteine proteinase, cruzipain (Franke de Cazzulo et at., 1994). 
1.12.3 General features of trypanopains 
Trypanopain-Tc and cruzipain are located primarily in the trypanosomal lysosome (Lonsdale-
Eccles and Grab, 1987a; Bontempi et aI. , 1989; Murta et ai. , 1990; Mbawa et at., 1992), and 
the same is thought to be true oftrypanopain. Small amounts oftrypanopain-Tc and cruzipain 
are found on the surface of trypanosomes (e.g. the flagellar pocket) and in flagellar pocket-
associated vesicles, suggesting that the proteinases may be targeted for secretion (Murta et at., 
1990; Souto-Padr6n, 1990; Mbawa et at., 1991a). 
The molecular masses of trypanopain-Tc (32 kDa, Rautenberg et ai. , 1982) and trypanopain 
(27 to 30 kDa, L~nsdale-Eccles and Grab, 1987a; Pamer et ai., 1989; Boutignon et ai. , 1990) 
are similar to those of mammalian cysteine proteinases. Cruzipain, however, is an unusually 
large (60 kDa) two-chain proteinase (Rangel et ai., 1981: Murta et ai., 1990). The reason for 
its large size is unclear. 
Different amounts of trypanopain are present at different stages in the trypanosome life cycle 
(Lonsdale-Eccles and Mpimbaza, 1986; Murta et ai., 1990; Souto-Padron et ai. , 1990; Mbawa 
et ai. , 1991 b). Mammalian-infective forms have higher levels of active trypanopain than do 
insect-infective forms (Mbawa et ai., 1992). Additionally the differentiation of T b. brucei 
bloodstream forms from the long slender to short stumpy forms is accompanied by an 8-fold 
increase in trypanopain activity (pamer et at., 1989; Mbawa et ai., 1991b). The last insect 
stage, namely the metacyclic form, has increased enzyme activity over the other insect forms, 
possibly reflecting preparation for mammalian infection. Cruzipain and some of the Leishmania 
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cysteine proteinases are also expressed at different levels during the parasite life cycle 
(Carnpetella et al., 1990; Souza et aI. , 1992; Franke de Cazzulo et al., 1994; Tomas and Kelly, 
1994). 
These changes in trypanopain levels may reflect a change in the nutritional requirements of the 
parasite at different stages of its life cycle. As the differentiation from long slender to short 
stumpy forms is accompanied by many metabolic changes, it has been suggested that 
trypanopain activity increases to cope with the catabolism of obsolete proteins (pamer et aI. , 
1989). Alternatively, the enzyme could aid initial survival in the insect midgut (pamer et aI. , 
1989). 
1.12.4 Primary sequence of trypanopains 
On the basis of their primary sequence data (Mottram et aI., 1989) and their catalytic activity, 
trypanopains belong to the papain family (C1) of cysteine proteinases in the CA clan (Barrett 
and Rawlings, 1996). Most cysteine proteinase fit into this group, which also contains the 
mammalian lysosomal proteinases cathepsins L, B, S, C, K and H, the plant proteinases 
bromelain, ficin and actinidin and cysteine proteinases from numerous other parasites and 
bacteria (Fasciola, Schistosoma, Leishmania, Plasmodium, Theileria, Streptococcus, 
Lactococcus and Porphyromonas). 
Trypanopain is encoded as a pre-pro-enzyme by multicopy genes that are arranged in tandem 
arrays on one or more chromosomes (Mottram et aI. , 1989). More than 20 copies of the 
trypanopain gene are present in T. b. bmcei, while as many as 130 copies of the cruzipain gene 
are found on 2-4 different chromosomes in certain T. cntZi strains (Campetella et ai., 1992; 
Eakin et aI., 1992). 
Similarly, L. mexicana cysteine proteinases are encoded by 19 genes located in a tandem array 
on a single chromosome (Souza et al., 1992; Mottram et al., 1996). The reason for this 
multiplication is unclear and it is not known whether all copies of this gene are transcribed or if 
some are pseudogenes. Studies of cruzipain isoforms suggest that the genes may encode 
enzymes with slightly differing substrate specificity. For example, the isoform cruzipain-2 has 
the novel and potentially physiologically important ability to cleave bradykinin from kininogen 
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(Lima et a/. , 1994). Gene knockout has also shown that the various lmCPb enzymes of L. 
mexicana also differ in their substrate specificity (Mottram et a/., 1997). 
Trypanopain is synthesised as a 48 kDa precursor that is processed to a 28-31 kDa mature form 
(Mottram et a/., 1989). The transcript can be divided into a hydrophobic pre-region, a 
hydrophilic pro-region, a central catalytic domain and a C-terminal extension. The pre-pro, 
catalytic domain and C-terminal extension are 30, 60 and 70% homologous to the 
corresponding regions of cruzipain (Campetella et at., 1992). A SwissProt search (Bairoch and 
Boeckmann, 1994, accession number P14658) reveals that trypanopain shares highest sequence 
homology with cysteine proteinases of other Trypanosoma and protozoan parasites of the 
family Trypanosomatidae (i.e. Leishmania, Markell et at., 1992). Of the mammalian 
cathepsins, trypanopain is most similar to rat and mouse cathepsin L (Table 1). 
Trypanopain, trypanopain-Tc, cruzipain and the L. mexicana ImCPb cysteine proteinase have 
unusually large C-terminal extensions consisting of about 130 amino acid residues in cruzipain 
(Campetella et a/., 1992; Eakin et a/., 1992), 110 in trypanopain (Mottram et aI., 1989) and 
100 in L. mexicana (Souza et at., 1992). While there are no known equivalents of this 
extension in mammalian cysteine proteinases, a cold-induced messenger ribonucleic acid 
(mRNA) found in tomatoes shows 22% homology to the trypanosomal extension (Schaffer and 
Fischer, 1988). The sequences are most closely related in a region thought to function as a 
proteolytically-sensitive hinge between the extension and the central domain, where trypanopain 
and cruzipain have consecutive proline and threonine residues respectively (Aslund et a/. , 1991) 
and the tomato mRNA has a proline/serine string. From knowledge of the size of active 
trypanopains, it is predicted that about 50 residues of the extension remain in the mature 
enzyme. 
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Table 1: Degree of homology between trypanopain from T. b. brucei and other cysteine 
proteinases. 
Parent organism Enzyme 0/0 Reference 
Homology 
T. congolense trypanopain-T c 69 Fish et al. (1995) 
T. cruzi cruZlpam 60 Cazzulo et al. (1989) 
L. pifanoi cysteine proteinase A-2 22 Traub-Cseko et al. (1993) 
L. mexicana ImCPb (Type I) 21 Souza et al. (1992) 
L. mexicana ImCPa (Type II) 23 Mottram et al. (1992) 
L. pifanoi cysteine proteinase A-I 23 Traub-Cseko et al. (1993) 
Rattus norvegicus cathepsin L 11 Ishidoh et al. (1987) 
Mus musculus cathepsin L 11 Troen et al. (1987) 
Homo sapiens cathepsin L 11 Gal and Gottesman (1988) 
Ovis aries cathepsin L 9 Ritonja et al. (1996) 
P. jalciparum falcipain 9 Rosenthal et al. (1992) 
P. vivax falcipain 6 Rosenthal et al. (1994) 
P. vinckei falcipain 6 Rosenthal (1993) 
Carica papaya papam 11 Cohen et al. (1986) 
Since the extension has limited occurrence in distantly related proteins, North (1991) suggested 
that the extension arose in a distant ancestral enzyme where it served an unknown function that 
is obsolete in most modem cysteine proteinases. In enzymes where it remains, it may confer 
unusual and beneficial properties. Various functions have been proposed for the extensions 
including mediation of trypanopain targeting to the lysosome (Cazzulo et aI., 1990a; Martinez 
et al., 1991; McKerrow, 1991), interaction with membranes (Souto-Padron et al., 1990) or 
maintainance of trypanopains in a zymogen state until the mature proteinase is cleaved off 
(McKerrow, 1991). However, the extension has subsequently been shown to be unnecessary 
for the activity of a trypanopain homologue from T b. rhodesiense (pamer et al., 1991), 
cruzipain (Eakin et aI., 1993) and L. pifanoi (Duboise et aI., 1994). Additionally, Lpcys1 from 
L. pifanoi lacks the extension but is still correctly targeted within the cell (Duboise et aI., 1994) 
and L. mexicana ImCPb isoenzymes lacking the extension are also active and correctly targeted 
(Mottram et aI., 1997). 
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Cruzipain has been identified as one of the major antigens (called GP 57/51) recognised by 
humans infected with T. cruzi (Murta et at., 1990; Malchiodi et aI., 1993; Gonzruez et aI. , 
1996) and cruzipain's dominant B-cell epitopes are located primarily in the C-terminal extension 
of the enzyme. Binding of antibodies to this region does not affect enzyme activity, leading to 
the suggestion that cruzipain contains defined antigenic and catalytic domains, with the 
C-terminal extension acting as an immune decoy to protect cruzipain against host attack 
(Cazzulo and Fransch, 1992; Martinez et aI. , 1993). Trypanopain-Tc is known to be an 
important cattle antigen (Authie et at.; 1992) and it would be interesting to determine whether 
this enzymes shares a division into catalytic and antigenic domains. 
1.12.5 Catalytic mechanism oftrypanopain 
While the catalytic mechanism of trypanopain has not been directly investigated, sequence data 
places the enzyme firmly in the papain-like family of cysteine proteinases (Mottram et aI. , 
1989). The catalytic mechanism of this class has been the subject ofa number of review papers, 
including those by Brocklehurst (1987), Dunn (1989a), Storer and Menard (1994) and Turk et 
al. (1997). Cysteine proteinases contain, by definition, a reactive cysteine residue in their active 
sites, and they additionally contain a conserved reactive site histidine residue. The enzymes are 
only active when these residues are ionised, when they are said to fonn the thiolate-imidazolium 
Ion pair. 
All known papain-like cysteine proteinase (with the exception of cathepsin C) are monomers 
folded into two domains (called L- and R-), between which is the active site cleft that binds 
substrate at many points. The active site cysteine residue is located on the L-domain and the 
active site histidine on the opposite R-domain. Determination of the cruzipain crystal structure 
confinned that trypanosomal cysteine proteinases are folded according to this typical papain 
blueprint (Figure 4) (McGrath et aI., 1995). 
Substrate hydrolysis begins with non-covalent association of the enzyme and substrate to fonn 
the Michaelis complex. The thiolate group of the active site cysteine acts as a nucleophile and 
attacks the carbonyl carbon of the scissile bond to form a postulated transient tetrahedral 
intermediate (Figure 5). The active site histidine donates its proton to the amide nitrogen of the 
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scissile bond, promoting formation of the acyl-enzyme intermediate and release of the 
C-terminal portion of the substrate. The acyl-enzyme intermediate undergoes nucleophilic 
attack by a water molecule to release the free enzyme and the N-terminal portion of the 
substrate. 
Various other tetrahedral intermediates are postulated to form between the stages shown in 
Figure 5Figure, but they are thought to be too short-lived to have been directly detected 
(reviewed by Storer and Menard, 1996). The initial nucleophilic attack on the carbonyl carbon 
of the scissile bond is facilitated in part by binding of the carbonyl oxygen into the oxyanion hole 
formed by neighbouring cysteine and glutamine residues. While the oxyanion hole is crucial for 




Figure 4: Cartoon representations of cruzipain three-dimensional structure. 
A and B show space fill and ribbon models respectively of cruzipain, with catalytic residues highlighted in 
yellow. C shows a space fill model of cruzipain, with the catalytic residues in yellow, the ~ and S3 subsites in red 
and the SI ' subsite in blue. D shows a ribbon model of cruzipain, with a-helices in red and J3-pleated sheets in 
yellow. The orientation of all representations is such that the active site cysteine residue is on the upper portion of 
the active site and the histidine/aspartate active site residues on the lower portion. Figures were prepared by 
Xiaowu Chen of the Department of Pharmaceutical Chemistry at the University of California, San Francisco, 
using the co-ordinates of McGrath et 01. (1995). 
29 
Substrate 
Thiolate-Imidazolitnn ion pair 
rHis-159 --N-H-CH-C-NH-CH-C--
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Cys-25 S- --------- HN ~NH 
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Cys-25 S------- - HN . NH 
\ ,/ ~ 
--N-H-CH-C-NH-CH-C--
I I I II 
















F\ + HN,¥NH 
The active site cysteine residue attacks the carbonyl carbon of the scissile bond to fonn a tetrahedral 
intennediate that rearranges to fonn the acyl-enzyrne intennediate and release the first portion of the 
substrate. Nucleophilic attack on the acyl-enzyrne intennediate by H20 releases.the second portion of the 
substrate. After Dunn (1989a). 
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1.12.6 Possible physiological functions of trypanopains 
Although the functions of the trypanopains remain unclear, various possibilities have been 
proposed. The enzymes appear to be essential for parasite viability because specific cysteine 
proteinase inhibitors kill isolated parasites in vitro (Mbawa et al., 1992; Franke de Cazzulo et 
aI., 1994). Their lysosomal locations suggest that these enzymes are centrally ~nvolved in the 
catabolism of parasite proteins, but the enzymes are also thought to digest host proteins as a 
source of nutrition. Haemoglobin digestion is thought to be carried out by the cysteine 
proteinases of numerous parasites, e.g. S. mansoni (Dalton et al., 1995), P.falciparum 
(Rosenthal et aI. , 1988), and Haemonchus (Cox et aI., 1990). In S. mansoni, cysteine 
proteinase gene expression is controlled at a temporal and spacial level, being up-regulated in 
the gut during the feeding stages of the parasite life cycle (Ray and McKerrow, 1992). 
Trypanopains have been proposed to help the parasite evade the host immune system. 
Trypanopains appear to interact with various components of the host immune system and may 
protect parasites against immune system attack in various ways. Firstly, fluorescence 
microscopy indicates that surface-bound anti-VSG antibodies are endocytosed and apparently 
degraded by live T. brucei, as only small amounts of labelled antibody are present within 
parasites after VSG clearance (Russo et aI. , 1994). However, if a cocktail of proteinase 
inhibitors is added, larger amounts of antibody are detectable in intracellular organelles. This 
suggests that lysosomal proteinases, possibly trypanopam, are involved in degradation of host 
antibodies. If this were the case, then trypanopain would help the parasite escape the 
opsonising effects of antibodies. 
Cruzipain also has IgG-degrading properties (Bontempi and C azzul 0 , 1990). The enzyme 
extensively degrades the Fe region of human IgG at pH 5.0 in vitro, destroying complement-
activating and phagocyte-recruiting ability (Bontempi and Cazzulo, 1990). However, the F ab 
(fragment, antibody binding) region remains relatively undegraded and may still be able to bind 
to the relevant antigen, in effect protecting it from binding to other whole, opsonising antibodies 
(Bontempi and Cazzulo, 1990). Furthermore, trypanosome-specific T-cells are reportedly not 
primed following infection (paulnock et aI. , 1988) and it has been postulated that trypanopain 
interferes with T cell responses to trypanosomal infection (pamer et al. , 1991). 
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Anti-cruzipain F(ab)2 fragments and cruzipain inhibitors partially prevent T cruzi entry into 
mammalian cells (piras et aI., 1985; Souto-Padr6n et aI., 1990), suggesting that cruzipain plays 
a role in cell penetration. Since neither T b. brucei nor T congolense are intracellular, 
trypanopain and trypanopain-Tc cannot have similar functions. 
Parasite cysteine proteinases are thought be involved in the transition between morphologically 
distinct stages in the parasite life cycle. Inhibition of cruzipain prevents maturation of 
epirnastigotes to metacylic forms, as well as the maturation of tryptomastigotes to amastigotes 
(Mierelles et al. , 1992; Harth et aI. , 1993; Franke de Cazzulo et aI. , 1994). Cruzipain may be 
involved in remodelling of necessary cytoskeletal elements or catabolism of obsolete proteins 
from the previous stage. Addition of cysteine proteinase inhibitors also inhibits maturation of 
L. mexicana promastigotes to amastigotes (Coombs et al. , 1982)' 
Trypanopains may contribute to pathogenesis by degrading vanous host proteins. 
Trypanopains degrade haemoglobin, IgG, oxidised insulin A and B chains and serum albumin 
in vitro, but it is not known if these are substrates in vivo (Rautenberg et al., 1982; Raimondi 
et aI. , 1991; Mbawa et ai. , 1992). Proteinase activity, thought to be due to trypanopain, is 
released from isolated T brucei (Nwagwu et aI. , 1988) but it is not clear whether the enzyme is 
actively secreted by live parasites or merely released upon death of the parasites. Even if 
released in an active form, the effect of host proteinase inhibitors on the enzyme has not been 
reported. 
1.13 Objectives of the present study 
Enzymes essential for parasite survival or involved in disease progression are recelvmg 
increasing attention as possible irnmuno- and chemotherapy targets. Although the pathogenic 
function(s) oftrypanopain remain unclear, various studies suggest that inhibition of the enzyme 
may have therapeutic benefits. While trypanopain genomic DNA and cDNA have been 
sequenced, relatively little is known about the active enzyme. The aim of this study was to 
purifY trypanopain from T b. brucei to electrophoretic homogeneity (Chapter 3) and to 
investigate some of the enzyme's fundamental properties, such as its pH activity and stability, its 
response to inhibitors and reducing agents and its specificity for synthetic substrates (Chapter 
4). The interactions between trypanopain and various potential inhibitors [both natural cystatins 
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(Chapter 5) and anti-active site antibodies (Chapter 6)] were investigated to determine whether 
the enzyme is likely to be effectively inhibited should it be released into the host bloodstream. 
Additionally, the effects of synthetic trypanopain inhibitors on purified trypanopain and parasite 
viability were investigated to determine whether trypanopain is a potential target for novel 
anti-trypanosomal agents (Chapter 7). 
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Chapter 2 
General material and methods 
A variety of fundamental biochemical techniques were used throughout the study and are 
described here for convenience. More specific experimental procedures are described in 
their ~ppropriate chapters. The suppliers of all materials used in this study are listed 
below. 
2.1 Materials 
Buffer salts and other common chemicals were from BDH (UK), Merck (Germany), Riedel 
deHaen (Germany), UniLab (SA) or Boehringer Mannheim (Germany) and were of the 
highest purity available. Unless otherwise specified, distilled water was used throughout 
this study. HiLoad™ Q-Sepharose and Resource-QTM columns were from Pharmacia 
(Sweden). Acrylamide, bis-acrylamide, Triton X-I00 and bovine serum albumin (BSA) 
were from BDH Limited (UK). Papain, 4-(2-aminoethyl)-benzenesulfonyl fluoride 
(AEBSF) and 2,2 azino-di-[3-ethylbenzthiazoline sulphonate] (ABTS) were from 
Boehringer Mannheim (Germany). Percoll, m-maleimidobenzoyl-N-hydroxysuccinimide 
ester (MBS), Minimal Essential Medium (MEM), penicillin/streptomycin, bathocuproine 
disulfonate (BCDS), 3,3', 5,5' -tetramethyl benzidine (TMB), 5-bromo-4-chloro-3-indolyl 
phosphate/ nitroblue tetrazolium (BCIPINBT), goat anti-rabbit-alkaline phosphatase (AP), 
fluorescein isothiocyanate (FIT C)-albumin, commonly available enzyme inhibitors and 
fibrinogen were from Sigma Chemical Co. (USA). Dry dimethyl formamide (DMF) and 
di-isopropylfluorophosphate (DFP) were from Fluka (Switzerland). Nunc-Immuno 
MaxiSorp and PolySorp F96 ELISA plates were from Weil Organisation (SA). 
Chymostatin, leupeptin and antipain were from Cambridge Research Chemicals (UK). 
Freund ' s complete and incomplete adjuvants and gelatin were from Difco (USA). Rabbit 
anti-human high molecular weight (H-) kininogen antibodies were from CalBiochem 
(USA). Foetal calf serum (FCS) was from Delta BioProducts (SA). Sterile disposable cell 
culture plasticware and filters were from Corning (UK), Millipore (USA) and Bibby 
Sterilin (UK). Diethylaminoethyl (DEAE)-cellulose and Whatman No.1 filter paper were 
from Whatman International Ltd (UK). Lumax™ scintillation cocktail was from Lumac 
(Netherlands). 
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2.2 Bicinchoninic acid (BCA) protein assay 
The biuret protein assay is based on the reduction of alkaline Cu2+ to Cu + by the peptide 
bonds of a protein (or any other biuret-containing polymer) to form a concentration-
dependent blue complex. The Folin-Ciocalteau reagent (a phospho-
molybdic/phosphotungstic acid complex) is commonly used to enhance the sensitivity of 
the biuret assay (Lowry et a/. , 1951 ; Hartree, 1972). However, this reagent is unstable at 
the alkaline pH values required for Cu2+ reduction, necessitating careful timing of reagent 
addition. Smith et al. (1985) described the use of BCA as an alternative, more stable 
reagent to detect Cu + and so enhance the sensitivity of the biuret assay (Figure 6). BCA is 
a stable, water -soluble compound that forms purple complexes with Cu + in an alkaline 
environment. The BCA assay is more convenient than the Lowry assay in that it is 
completed in a single step, is less sensitive to interference by buffer salts and ionic or non-
ionic detergents and shows less protein-to-protein variation than the Lowry assay (Smith et 
aI. , 1985). Reducing agents and copper chelators do, however, interfere with the assay. 
-OOC COO , , , 
/ 
Cul+ 
, , , 
OOC COO-
Figure 6: Complex formation between Cu+ and BCA. 
The N atoms of two molecules of BCA interact with a Cu + ion in an alkaline environment to 
produce a stable, purple, H20-soluble complex that can be quantified by its absorbance at 562 nm. 
After Smith et al. (1985) . 
2.2.1 Materials 
Reagent A [1% mass per volume (m/v) Na-BCA, 2% (m/v) Na2C03, 0.16% (m/v) 
Na-tartrate, 0.4% (m/v) NaOH, 0.95% (m/v) NaHC03]. Sodium-BCA (1 g), Na2C03 
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(2 g), Na-tartrate (0.16 g), NaOH (0.4 g) and NaHC03 (0.95 g) were dissolved in 90 mI of 
H20, adjusted to pH 11 .25 with NaOH and made up to 100 mI. 
Reagent B [4% em/v) CuS04.5H20]. CUS04 (4 g) was dissolved in 90 mI of deionised 
H20 and made up to 100 mI. 
Standard working solution. Reagent A (100 volumes) was mixed with Reagent B 
(2 volumes) to produce an apple-green standard working solution that was stable for 
approximately 1 week. 
2.2.2 Method 
Protein samples (0.2-50 Ilg) were diluted to 50 III with a suitable buffer in 11h mI 
polyethylene microfuge tubes. Standard working reagent (1 mI) was added and the 
solution thoroughly mixed. Depending on the degree of sensitivity required, the mixture 
was incubated according to one of the following protocols: 
(i) Room temperature (RT) for 2 h (suitable for detecting 20-120 Ilg protein), 
(ii) 37°C for 30 min (intermediate sensitivity), or 
(iii) 60°C for 30 min (5-25 Ilg protein). 
After incubation, samples were cooled to RT and the absorbance at 562 nm (AS62) read. 
Buffer alone added to dye reagent served as an absorbance blank. A standard curve for 
each incubation protocol was prepared from quintiplicate assays carried out at 6 
concentrations of ovalbumin (5-120 Ilg protein). The protein concentrations of samples 
were calculated from equations generated by linear regression of the standard protein 
results . 
2.3 Concentration of proteins 
During enzyme purification, it was often necessary to concentrate dilute protein solutions 
[e.g. before sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-P AGE) or 
before further purification] . Samples were concentrated by dialysis against sucrose or 
polyethylene glycol (pEG, 20 kDa), with the sample placed inside a closed dialysis bag and 
surrounded by a layer of either dry sucrose or PEG (20 kDa) polymer at 4°C. Water 
moved along a concentration gradient from the dilute solution inside the membrane to the 
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concentrated polymer outside of the membrane. The pores of the dialysis membrane used 
were small enough to prevent loss of proteins greater than 12 kDa from the sample. 
Gloves were worn during handling of the dialysis membrane to prevent introduction of skin 
keratins into samples. These proteins are troublesome contaminants which cross-react 
non-specifically with many antibodies in Western blots and appear as contaminants at 
about 68 kDa on reducing SDS-PAGE (Ochs, 1983; Shapiro, 1987). Once 'a sample was 
sufficiently concentrated (usually 5-10 fold in 2-4 h), the membrane was briefly rinsed in 
H20 and the membrane cut open to release the sample. 
Pores in the dialysis membrane used (cut-off limit 12 kDa) were small enough to allow 
sucrose to enter the dialysis bag and mix with the sample. In cases where such 
contamination was unacceptable (e.g. prior to electrophoresis), samples were dialysed 
against PEG (20 kDa), which is too large to pass through the membrane and so does not 
contaminate the sample. PEG is, however, considerably more expensive than sucrose, so 
dialysis against PEG was only carried out during the final stages of enzyme purification. 
2.4 Tricine SDS-PAGE 
SDS-PAGE is an analytical technique used to evaluate the purity and molecular mass of 
protein samples (Laemmli, 1970). The method involves the separation of proteins on the 
basis of size during migration through a polyacrylamide gel placed in an electric field . The 
effects of a protein' s innate charge on its migration are counteracted by addition of the 
anionic detergent SDS to mask the protein' s innate charge. This reagent converts native, 
globular, amphoteric proteins into highly negatively charged rod-like complexes; the length 
of which is dependent on the molecular mass of the protein. Binding of SDS thus renders 
the charge to mass ratio of all proteins in the sample equal, allowing proteins to be 
separated on the basis of size alone. An inverse relationship exists between the log of a 
protein' s molecular weight and the distance it migrates from the cathode (starting point) 
(Dunn, 1989b), so SDS-P AGE is commonly used to estimate the molecular masses of 
sample proteins by comparing their migration to that of standard proteins of known 
molecular mass. 
Polyacrylamide gels are formed by the co-polymerisation of acrylamide monomers with a 
cross-linking agent, such as N, N' -methylenebisacrylamide (Bis) (Figure 7). Gel 
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polymerisation is initiated by agents such as N, N, N' , N' -tetramethylethylenediamine 
(TE11ED) and accelerated by agents such as ammonium persulfate (Dunn, 1989b). The 
pore size of the gel is dependent on the concentration of the total monomer (acrylamide 
plus Bis, %T) and on the concentration of the cross-linker, Bis (%C). The %T determines 
the effective separation range of the gel. 
Although tricine SDS-PAGE is a modification of the original SDS-PAGE method 
described by Laemmli (1970), it operates on the same fundamental principles. In contrast 
to the Laemmli system, different buffers are placed in the upper and lower buffer reservoirs 
to create a discontinuous buffer system. Once electrophoresis starts, proteins stack 
between the leading chloride ion and the trailing tricine ion (Schagger and von Jagow, 
1987). This concentrates samples into thin starting zones in the stacking gel and thus 
ensures good separation in the separating gel. Once the samples enter the separating gel, 
the decreased pore size of the separating gel "unstacks" the proteins, causing them to 
separate on the basis of size alone (Dunn, 1989b). The system has various advantages over 
the Laemmli system, such as increased resolution of smaller proteins (5-20 kDa) and 
uniformity of stacking and separating gel buffers. In addition, the gel buffer used is more 
stable than the Laemmli stacking gel buffer and so can be stored for longer periods of time 
(Schagger and von Jagow, 1987). The tricine SDS-PAGE method was routinely used for 
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Figure 7: Polymerisation of acrylamide by Bis, TE11ED and ammonium persulfate. 




Anode buffer [0.2 M 2-amino-2-ehydroxymethyl)-1,3-propandiol eTris)-Cl. pH 8.9]. Tris 
(24.22 g) was dissolved in 950 mI H20 , titrated to pH 8.9 with HCI and made up to 1 1. 
Cathode buffer [0.1 M Tris, 0.1 M tricine, 0.1 % em/v) SDS, pH 8.25]. Tris (12.2 g) and 
tricine (17.9 g) were dissolved in 950 mI of H20 and 10% (m/v) SDS stock solution 
(10 ml) added. The pH was adjusted to 8.25 and the buffer made up to 1 1. 
Gel buffer [3.0 M Tris-Cl. 0.3% em/v) SDS, pH 8.45]. Tris (72.7 g) and SDS (0.6 g) were 
dissolved in 150 ml of H20, titrated to pH 8.45 with HCI and made up to 200 mi. 
Monomer [49.5% em/v) acrylamide, 3% em/v) Bis]. Acrylamide (48 g) and Bis (3 g) were 
dissolved in 50 mI of H20 and the solution made up to 100 mi. 
10% em/v) Ammonium persulfate. Ammonium persulfate (0.1 g) was dissolved in H20 
(1 mI) just before use. 
Reducing sample buffer [125 mM Tris-CL 4% (m/v) SDS, 20% volume per volume (v/v) 
glycerol, 10% (v/v) B-mercaptoethanoL pH 6.8]. Gel buffer (2.5 mI), 10% SDS (4 mI), 
glycerol (2 mI) and ~-mercaptoethanol (1 ml) were made up to 10 ml with H20. 
~-Mercaptoethanol was added to the treatment buffer to reduce any disulfide bonds in the 
sample and thus allow unhindered binding of SDS to disulfide-bonded regions of sample 
proteins and to permit the dissociation of disulfide-linked subunits. 
Non-reducing sample buffer [125 mM Tris-Cl, 4% (m/v) SDS, 20% (v/v) glycerol, pH 6.8). 
Gel buffer (2.5 ml), 10% SDS (4 ml) and glycerol (2 ml) were made up to 10 ml with H20. 
2.4.2 Method 
Tricine SDS-PAGE was carried out as described by Schagger and von Jagow (1987) using a 
BioRad Mini-Protean® II electrophoresis cell, assembled as described in the manufacturer' s 
manual. F or gels that were to be silver stained, extra care was taken to clean the plates 
thoroughly before gel assembly by soaking them in nitric or chromic acid. Separating and 
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stacking gels were prepared as described in Table 2and allowed to polymerise for at least 2 h 
and a half hour respectively. 
Samples (containing at least 1-2 j..lg of protein per band for Coomassie staining or 100-300 ng 
of protein per band for silver staining) were mixed with either an equal volume of reducing 
sample buffer or a half volume of non-reducing sample buffer. More uniform binding of SDS 
to proteins was effected by boiling samples (90 s) to fully denature proteins. Bromophenol 
blue marker dye, which migrates at the buffer front, was added to each sample before loading to 
allow monitoring of protein migration through the gel. Gels were run at 70 V until the 
bromophenol blue tracker dye entered the separating gel, and then at 100 V until the 
bromophemol blue reached the bottom of the gel. Throughout this study, Pharmacia (Sweden) 
molecular mass markers were used. These are phosphorylase b (96 kDa), BSA (67 kDa), 
ovalbumin (43 kDa), carbonic anhydrase (30 kDa) and soybean trypsin inhibitor (20 kDa). 
Table 2: Preparation of two tricine SDS-PAGE gels for electrophoresis on the BioRad 
Mini-Protean® II electrophoresis cell. 
Type of gel Gel buffer Acrylamide (NH4)zSzOs TEMED HzO 
(ml) (ml) (~l) (~l) (rnl) 
Separating 6 3.6 60 6 8.4 
Stacking 1.5 0.5 30 12 4 
2.5 Substrate SDS-PAGE 
Heussen and Dowdle (1980) described a modification of SDS-PAGE that allows 
visualisation of proteinases after electrophoretic separation by incorporation of a suitable 
protein substrate into the separating gel prior to polymerisation. Following 
electrophoresis, gels are incubated in a relevant assay buffer to allow proteinases 
immobilised in the gel to digest the incorporated substrate. Areas of proteinase activity 
can be seen as clear bands of digestion against a dark staining protein background. 
Variations of this method have been successfully used to investigate the proteinases of 
various pathogens, including T. brucei (Robertson et a/., 1990), T. congolense (Mbawa et 
a/. , 1992), F hepatica (Smith et a/., 1993), T. spiralis (Todorova et a/., 1995), S. mansoni 
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(Smith et aI. , 1994; Dalton et aI. , 1996), L. mexicana (Robertson and Coombs, 1990; 
Hunter et aI. , 1992; Ilg et al., 1994) and E. histolytica (Sharma et a!. , 1996). Fibrinogen 
and gelatin have been successfully used as substrates for trypanopains (Lonsdale-Eccles 
and Grab, 1987a; Lonsdale-Eccles et aI. , 1995). 
The method should, however, not be relied upon for an accurate estimate ' of proteinase 
molecular mass. Hummel et al. (1996) reported that incorporation of a protein substrate 
into the SDS-P AGE gel can increase the apparent molecular mass of proteins by 15-20%, 
with the degree of increase differing for different proteins. They thus recommend that 
estimates of molecular mass made from substrate SDS-PAGE be viewed with caution. 
2.5.1 Materials 
Protein solution [1 % (rn/v) gelatin or fibrinogen in gel buffer]. Gelatin or fibrinogen 
(0.1 g) was dissolved in gel buffer (10 ml, Sections 2.4.1) with gentle heating. 
2.5% (v/v) Triton X-lOa. Triton X-lOa (5 ml) was diluted to 200 ml with H20 . 
Assay buffer [100 mM sodium acetate, 1 mM ethylenediaminetetra-acetic acid (EDTA), 
30 mM cysteine, 0.02% (rn/v) NaN3, pH 5.5]. Glacial acetic acid (5 .725 ml), 
Na2EDT A.2H20 (0.37 g) and NaN3 (0.2 g) were dissolved in 950 ml of deionised H20 , 
adjusted to pH 5.S with NaOH and made up to 1 I with deionised H20 . Cysteine (0.53 
gllOO ml assay buffer) was added just before use. 
0.1 % (rn/v) Amido black. Amido black (0.1 g) was dissolved in methanol:acetic acid :H20 
in a 30: 10:60 ratio (100 ml) and filtered through Whatman No. 1 filter paper. 
2.5.2 Method 
Separating gels were cast as per Section 2.4.2, except that the gel buffer (6 ml) was 
replaced by a mixture of the protein substrate solution [3 ml of 1 % (rn/v) gelatin or 
fibrinogen in gel buffer] and gel buffer (3 ml), giving a final concentration of 0.16% (rn/v) 
of protein in the separating gel. Stacking gels were cast as described in Section 2.4.2. To 
ensure that enzyme activity was maintained, samples were never boiled prior to 
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electrophoresis. After electrophoresis, the gels were soaked in two changes of 2.S% (v/v) 
Triton X-100 in 1 h to remove SDS and re-nature any proteinases present. Gels were 
incubated in assay buffer (3 h, 37°C) to allow digestion of the incorporated substrate and 
stained in amido black for 1 h. Gels were destained in several changes of methanol: acetic 
acid:H20 (30 : 10:60) until clear bands were visible against a dark background. 
2.6 Coomassie blue R-2S0 protein stain 
Coomassie Brilliant Blue R-2S0 is a non-polar, sulfated triphenylarnine dye used to visualise at 
least 1 Ilg of protein per band (Dunn, 1989b). This method provides a simple way of 
visualising proteins separated by SDS-PAGE. 
2.6.1 Materials 
Stain stock solution [1% em/v) Coomassie blue R-2S0]. Coomassie blue R-2S0 (1 g) was 
dissolved in 100 rnl of H20 and filtered through Whatman No. 1 filter paper. 
Staining solution [0.12S% em/v) Coomassie blue R-2S0, SO% ev/v) methanol, 10% (v/v) acetic 
acid]. Stain stock (62.S rnI) was mixed with methanol (2S0 rnI) and acetic acid (SO rnI) and 
made up to SOO rnl with H20 . 
Destaining solution I [SO% ev/v) methanol, 10% ev/v) acetic acid]. Methanol (SOO rnI) and 
acetic acid (100 rnI) were made up to 1 litre with H20 . 
Destaining solution n [7% ev/v) methanol, S% ev/v) acetic acid]. Methanol (SO rnI) and acetic 
acid (70 rnI) were made up to 1 litre with H20 . 
2.6.2 Method / 
After removal from the electrophoresis unit, gels were placed in stain solution for 4 h. The 
gels were rinsed in H20 and immersed in destain I (4 h), followed by destain n (until the 
background had cleared fully) . Gels were stored in polyethylene zip-seal bags and kept 
well hydrated until photographed. They were stable for long periods of time in this form. 
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2.7 Silver staining of proteins in polyacrylamide gels 
Silver staining is a highly sensitive method of detecting proteins in electrophoresis gels, 
based on the reduction of silver ions to metallic silver (Blum et aI., 1987). As little as 
100 ng of protein per band can be detected, making this technique second only to 
radioactive labelling in terms of sensitivity. The method described by Blum et al. (1987) 
differs from previous methods in that gels are pre-treated in a thiosulfate solution to 
increase sensitivity. Thiosulfate is also included in the developing solution to complex with 
insoluble silver salts and thus prevent their accumulation on the surface of the gels (Blum 
et ai., 1987). 
2.7.1 Materials 
Fixing solution [50% (v/v) methanol, 12% (v/v) acetic acid, 0.05% (v/v) 37% (v/v) 
formaldehyde]. Methanol (100 rnI), acetic acid (24 rnI) and formaldehyde [100 III of37% (v/v) 
solution] were made up to 200 rnl with H20 . 
Thiosulfate solution [0.02% (m/v) sodium thiosulfate]. Na2S203.5H20 (40 mg) was dissolved 
in H20 (200 rnI). 
Silver nitrate solution [0.2% (m/v) AgN03, 0.075% (v/v) 37% (v/v) formaldehyde]. AgN03 
(400 mg) was dissolved in 150 rnl of H20 , formaldehyde [150 III of a 37% (m/v) solution] 
added and the solution made up to 200 rnl with H20. 
Developing solution [6% (rn/v) NaC03, 0.05% (v/v) 37% formaldehyde, 0.0004% (rn/v) 
Na2.S&3). NaC03 (12 g) was dissolved in 150 rnl of H20, formaldehyde [0.1 rnl of37% (m/v) 
solution] and Na2S203.5H20 (4 rnl of thiosulfate solution above) added, and the solution made 
up to 200 rnl with H20 . 
Stopping solution (50% (v/v) methanol, 12% (v/v) acetic acid). Methanol (50 rnI) and 
12% (v/v) acetic acid (12 rnI) were diluted to 100 rnl with water. 
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2.7.2 Method 
For each step, 50 ml of reagent was required to immerse each gel. Deionised water was 
used throughout. Gels (1.5 mm thickness) were fixed for at least 1 h (preferably 
overnight) and stained according to the following protocol : 
(i) 50% (v/v) ethanol (3x20 min) 
(ii) thiosulfate solution (1 x30 min) 
(iii) H20 (3 x20 s) 
(iv) silver nitrate solution (20 min) 
(v) H20 (2x20s) 
(vi) developing solution (until bands were visible) 
(vii) H20 (until bands were fully developed) 
(viii) stop solution (at least 20 min). 
2.8 Isolation of chicken antibodies from egg yolks 
Immunoglobulin Y (lgY) was isolated from egg yolk by PEG precipitation, as described by 
Polson et al. (1980). The method is essentially a two-step procedure, with vitellin and fats 
removed in the first precipitation step and antibodies precipitated in the second. PEG is a 
water-soluble, high molecular weight polymer that concentrates proteins in the 
extra-polymer space by steric exclusion, until they exceed their solubility limit and 
precipitate. 
2.8.1 Materials 
100 mM Na-phosphate buffer, 0.02% em/v) NaN3, pH 7.6. NaH2P04.2H20 (15 .60 g) and 
NaN3 (0 .2 g) were dissolved in 950 ml of H20, titrated to pH 7.6 with NaOH and made up 
to 1 I with H20. 
2.8.2 Method 
Eggs produced by chickens immunised with identical antigens were kept separate to 
determine whether individual responses differed. Egg yolks were separated from the 
whites and gently washed under running tap water. The yolk membranes were pierced, the 
yolk contents collected and mixed with two volumes of sodium phosphate buffer. Solid 
PEG (6 kDa) was added to 3.5% (m/v) and dissolved with gentle stirring. The precipitated 
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vitellin fraction was removed by centrifugation (4 420xg, 30 min, RT) and the supernatant 
filtered through a plug of absorbent cotton wool in a glass funnel. 
The PEG concentration of the clear filtrate was increased to 12% (m/v) by adding 
8.5% (rn/v) solid PEG. The solution was centrifuged (12 OOOxg, 10 min, RT) and the 
antibody pellet re-dissolved in a volume of sodium phosphate buffer equivalent to that 
obtained after filtration . PEG was added to 12% (m/v) and the solution centrifuged 
(12000xg , 10 min, RT) . To ensure gentle re-suspension, the antibody pellet was 
dislodged from the walls of the centrifuge tube with a glass rod and left overnight to slowly 
re-suspend in sodium phosphate buffer of 1/6 the original yolk volume. The final antibody 
solution was centrifuged to remove undissolved material (27 OOO xg, 10 min, RT) and 
stored at 4°C with NaN3 [0.02% (m/v)] as a preservative. 
To determine the concentration of purified antibody, the equation A = ELc (Dawson et aI. , 
1968) was used, 
where: A represents absorbance at 280 nm ( arbitrary units), 
E, the extinction co-efficient (mg-I. cm-I.mr l ), 
L, the length of the light path (cm) and 
c, the concentration of the absorbing solution (M). 
For IgY, E is equal to 1.25 mg-I .cm-I .mr l (Coetzer, 1985). 
2.9 Isolation of rabbit antibodies 
A method similar to that used for IgY isolation from egg yolk was used for isolation of 
rabbit antibodies. PEG (6 kDa) was used to precipitate IgG from rabbit serum, using 
conditions optimised by Polson et al. (1964) in their studies on PEG precipitation of serum 
components. 
2.9.1 Materials 
Borate buffered saline (35 mM boric acid, 37 mM NaCI, 17.5 mM NaOH, 8 mM HCI, 
pH 8.6). Boric acid (2.16 g), NaCI (2.19 g), NaOH (0.7 g) and 37% (v/v) HCI (0.62 ml) 
were dissolved in about 950 ml of H20, titrated to pH 8.6 and made up to 1 I with H20. 
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2.9.2 Method 
One volume of serum was mixed with 2 volumes of borate buffered saline and solid PEG 
(6 kDa) added to 14% (m/v). After dissolving the PEG by gentle stirring, the mixture was 
centrifuged (12 OOO xg, 10 min, RT) and the supernatant discarded. The antibody-
containing pellet was re-suspended in the original serum volume of sodil,lm phosphate 
buffer and PEG added to 14% (m/v) as before. The solution was centrifuged (12 OOO xg, 
10 min, R T), the pellet resuspended in a volume of sodium phosphate buffer containing 
30% (m/v) glycerol equivalent to 1/2 the original serum volume and the preparation stored 
at -20°C with NaN3 [0.02% (m/v)] as preservative. To determine the concentration of 
purified antibody, the equation A = SLc was used as above, with S for IgG equal to 
1.43 mg-1.cm-1.mr1 (Hudson and Hay, 1980). 
2.10 Enzyme-linked immunosorbent assays (ELISAs) 
An ELISA is a technique exploiting the highly specific nature of the antigen/antibody 
interaction to detect or quantify either component in a test sample (Nakane et al. , 1966; 
Engvall and Perlmann, 1971). For example, an antigen can be imrnobilised on an inert 
plastic support (microtitre plate) and overlaid with test solution containing the 
complementary antibody. Antibody present in the test solution will only bind to the 
imrnobilised antigen, and the amount of bound antibody can be quantified. This is usually 
done using a second antibody directed specifically against the first, and conjugated to an 
enzyme that has a virtually colourless substrate and a coloured product that can be 
quantified spectrophotometrically. The absorbance of the final solution is a measure of the 
amount of antibody in the test solution. ELISAs were used in the present study to monitor 
antibody production in experimental animals and to evaluate the ability of anti-peptide 
antibodies to cross-react with whole trypanopain and cathepsin L. 
Horseradish-peroxidase (HRPO, 40 kDa) was used as the reporter enzyme in all cases. 
This enzyme catalyses the transfer of electrons from the substrate to peroxide, generating a 
coloured product (Kemeny and Chantler, 1988). HRPO and its chromogens are 
economical and offer a good combination of sensitivity and speed of reaction. The choice 
of HRPO substrate used depends on the sensitivity required for the assay (Kemeny and 
Chantler, 1988). ABTS generates a blue-green product, which is measured at 405 nm, and 
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is suitable for most routine ELISAs. For more sensitive assays, TMB is a more suitable 
substrate. TMB generates an initial blue reaction product that is converted into a yellow 
product (which is monitored at 450 nm) by addition of the acidic stop reagent (Josephy et 
aI., 1982). TMB is more quickly oxidised than other HRPO substrates, so colour 
development is faster. The increased sensitivity of this method can, however, lead to 
increased background, so the plate must be thoroughly washed between incubations. 
2.10.1 Materials 
50 rnM carbonate coating buffer. NaHC03 (0.21 g) was dissolved in 45 m1 of H20, 
titrated to pH 6.0 with HCI and made up to 50 m1 with H20 just before use. 
Phosphate buffered saline (PBS), pH 7.2. NaCI (8 g), KCI (0.2 g), Na2HP04.2H20 
(1.15 g) and KH2P04 (0.2 g) were dissolved in 950 ml of H20 and made up to 1 I with 
H20 . 
0.5% (m/v) Bovine serum albumin in PBS (BSA-PBS). BSA (0.5 g) was dissolved in 
90 m1 of PBS and made up to 100 m1 with PBS. 
0.1 % (v/v) Tween-20. Tween-20 (1 ml) was dissolved in 1 I of PBS. 
0.15 M Citrate-phosphate buffer, pH 5.0. An aqueous solution of citric acid (21 gil) was 
titrated with a solution ofNa2HP04.2H20 (35.6 gil) to pH 5.0. 
0.05% (m/v) ABTS and 0.0015% (m/v) H20 2 in 0.15 M citrate-phosphate buffer. ABTS 
(7.5 mg) was dissolved in 0.15 M citrate-phosphate buffer, pH 5.0 (15 ml) and H20 2 
(7.5 J.ll) added just before use. 
ABTS stopping buffer [0.15 M citrate-phosphate buffer containing 0.1% em/v) NaN3]. 
NaN3 (0.1 g) was dissolved in 100 ml of 0.15 M citrate-phosphate buffer, pH 5.0. 
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TMB . One TMB tablet was dissolved in 1 ml of dimethylsulfoxide (DMSO) and diluted to 
10 ml with 3 ml 0.15 M citrate-phosphate buffer (pH 5.0) and 6 ml H20 . H20 2 (2 Ill) was 
added just before use. 
TMB stopping solution (2 M H2S04). H2S04 (19.6 g) was diluted to 100 ml with H20. 
2.10.2 Method 
Plates were washed three times with 0.1% (v/v) Tween-20 between each stage of all 
ELISAs. The volume of reagents given applied unless otherwise stated. Test antigens 
(150 !lllwell) were coated to the wells of multi titre ELISA plates in carbonate buffer (16 h, 
4°C) and remaining sites in the wells blocked with BSA-PBS (200 !lllwell, 1 h, 37°C). 
Test primary antibodies (commonly titrated between 200 and 1 !lg/ml in BSA-PBS, 
100 !lllwell) were incubated in the wells (2 h, 37°C), followed by anti-species-HRPO 
secondary antibodies (120 !lllwell in BSA-PBS, 1 h, 37°C) and ABTSIH20 2 or TMBIH20 2 
substrate (150 !lllwell). Once colour had adequately developed, ABTS or TMB stop 
solution (50 Illlwell) was added and the absorbance at 405 nm or 450 nm respectively read 
on an EL 312 Bio-Kinetics Reader (Bio-Tek Instruments). 
2.11 Western Blotting onto nitrocellulose membranes 
Western blotting is a method devised to allow identification of electrophoretically 
separated bands using specific antibodies. To facilitate binding of antibodies to 
complementary antigens, the separated protein bands are transferred by an electric current 
from the SDS-PAGE gel in which they were separated to a supporting nitrocellulose 
membrane. The gel and nitrocellulose are placed adjacent to one another to form a 
"sandwich" which is arranged in the blotting apparatus so that the gel is placed on the 
cathode side and the nitrocellulose on the anode side. Negatively charged SDS-coated 
protein anions migrate from the negative cathode towards the positive anode. They 
migrate out of the polyacrylamide gel and bind to the adjacent nitrocellulose, maintaining 
the separation achieved in the SDS-PAGE step. Remaining unoccupied sites on the 
nitrocellulose are blocked with a protein solution to prevent non-specific adherence of 
antibodies (which are proteins themselves) to the nitrocellulose. Diagnostic primary 
antibodies are incubated with the blot and bind to any complementary antigens present on 
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the nitrocellulose. An enzyme-linked secondary antibody (also called the reporter 
antibody) is incubated with the blot to detect the bound primary antibodies, after which an 
appropriate substrate is used to visualise the bound secondary antibodies. 
Numerous stages of the procedure are open to optimisation. The composition of the 
blocking agent can be varied to achieve low levels of non-specific background colour. 
Gelatin, low fat milk powder and BSA are commonly used. The composition of the 
blotting buffer can be varied to maximise protein mobility or adherence to the 
nitrocellulose (Spinola and Gannon, 1985). The Towbin buffer (Towbin et ai., 1979) 
described below was routinely used in the present study, but the renaturing buffer 
described by Dunn (1986) was occasionally used (e.g. Section 6.6). HRPO and alkaline 
phosphatase (AP) detection systems were commonly used. HRPO conjugates and 
substrates (e.g. 4-chloro-1-naphthol) are economical, but are less sensitive and are 
susceptible to fading upon exposure to light. AP systems (e.g. BCIPINBT) are more 
sensitive and the precipitate does not fade . 
2.11.1 Materials 
Towbin blotting buffer [25 mM Tris, 192 mM glycine, 20% (v/v) methanoL 0.1% (m/v) 
SDS, pH 8.3]. Tris (9.08 g) and glycine (43.2 g) were dissolved in 2 1 of H20. Methanol 
(600 ml) and SDS (3 ml of a 10% solution) were added and the solution was made up to 
3 1 with H20 . The pH of this buffer should not be adjusted, since this increases buffer 
conductivity, resulting in a higher initial current and decreased initial resistance. The pH 
will vary between pH 8.1 and 8.5 depending on the quality of the reagents. This buffer 
should only be used once, since it loses its ability to maintain a stable pH during transfer. 
SDS and methanol increase protein mobility, but may also reduce protein binding to 
nitrocellulose. 
Tris-buffered saline (TBS, 25 mM Tris-Cl, 200 mM NaCI, pH 7.4). Tris (2.42 g) and 
NaCI were dissolved in 950 ml of H20 , adjusted to pH 7.4 with HCl and made up to I I 
with H20. 
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Ponceau S stain [0.1 % (m/v)]. Ponceau S (0.1 g) was dissolved in 1 % (v/v) glacial acetic 
acid in H20. 
Blocking reagent 1[0.5% (m/v) BSA-TBS]. BSA (0.5 g) was dissolved in 100 ml ofTBS. 
Blocking reagent II [5% (m/v) low-fat milk powder]. Low fat milk powder (5 g) was 
dissolved in TBS (90 ml) and made up to 100 ml with TBS. 
4-Chloro-l-naphthollH:&2. A stock solution of 0.3% (m/v) was prepared by dissolving 
4-chloro-1-naphthol (0.03 g) in methanol (10 ml). This was diluted to a working solution 
by diluting 2 ml to 10 ml with TB S. H20 2 (10 Ill) was added to the working solution. 
BCIPINBT. One BCIPINBT tablet was dissolved in H20 (10 ml). 
500 mM NaOH. NaOH (20 g) was dissolved in 900 ml of H20 and the solution made up 
to 11 with H20 . 
2.11.2 Method 
Gloves were worn throughout to prevent development of keratin bands on the blot (Ochs, 
1983 ; Shapiro, 1987). Nitrocellulose was cut to the approximate size of the gel and 
pre-soaked in blotting buffer for 15 min. After completion of electrophoresis, gels were 
removed from the electrophoresis apparatus and rinsed in blotting buffer. The Western 
blot "sandwich" apparatus was submerged in chilled blotting buffer. A fibre pad and three 
sheets of blotting paper were soaked in blotting buffer and placed on the anode side of the 
Western blot "sandwich" apparatus. Pre-soaked nitrocellulose was placed on top of the 
blotting paper, followed by the gel and three further sheets of wet blotting paper. The 
sandwich was closed and inserted into the blot apparatus (half filled with blotting buffer) 
with the gel facing towards the cathode side of the apparatus and the nitrocellulose 
towards the anode side of the apparatus. A stirrer bar was placed in the bottom of the 
apparatus to maintain uniform conductivity and temperature during blotting. The 
apparatus was attached to a cooling water bath to maintain a low temperature during 
blotting. Gels were either blotted for 2 h (200 rnA, unlimiting volts) or overnight (30 V, 
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unlimiting current). Overnight blotting was empirically determined to be most successful 
for trypanopain transfer. 
On completion of blotting, the sandwich was disassembled and the blot stained with 
Ponceau S (1 min) and washed in H20 to reveal the molecular mass markers. These were 
gently marked with a blunt pencil and the blot cut into smaller sections if required. The 
blot was destained by drop-wise addition of 500 mM NaOH to the H20. Free sites on the 
membrane were blocked using block I or II (1 h) and washed in TBS (5 min, 3 times) . 
Primary antibody in blocking reagent was applied (2h) and the blot washed in TBS (5 min, 
3 times) . Secondary antibody in blocking reagent was applied (1 h) and the blot washed in 
TBS (5 min, 3 times). Substrate was added, with 4-chloro-1-naphthol used for HRPO-
linked secondary antibodies and BCIPINBT used for AP linked secondary antibodies. 
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Chapter 3 
Isolation of trypanopain from T. b. brucei 
3.1 Introduction 
To obtain sufficient amounts of pure trypanopain for kinetic characterisation, large numbers of 
T. b. brncei were required. This chapter describes established techniques for expansion of 
cryo-preserved parasites in suitable mammalian hosts. Additionally, trypanopain had not been 
purified to electrophoretic homogeneity at the outset of this study, so this chapter describes the 
modified cathepsin L assay used to monitor initial trypanopain isolations, and the subsequent 
development of the first reported isolation protocol for trypanopain. 
3.2 Initial enzyme assay 
At the outset of this study, no optimised assay for trypanopain activity was available. To 
conveniently monitor the activity of proteolytic enzymes in vitro, synthetic substrates containing 
di- or tri-peptides linked to chromogenic or flu orogenic leaving groups are commonly used. 
The chemistry of the chromophore or fluorophore must be such that it only emits a strong 
signal once cleaved from the peptide portion, so that the light or fluorescence emitted is a 
measure of the amount of substrate hydrolysis (Knight, 1995). The peptide portion is designed 
with the substrate specificity of the target enzyme in mind, thereby conferring selectivity for a 
particular enzyme or group of enzymes. The leaving group occupies the proteinase sub site 
immediately C-terrninal of the scissile bond. These substrates are thus most effective for 
enzymes whose specificity is governed by the S sub sites (notation of Schechter and Berger, 
1967) which bind residues on the N-terrninal side of the peptide cleavage site, rather than the S' 
sub sites which bind residues on the C-terrninal side of the scissile bond (Knight, 1995). 
Para-nitroanilide (pNa)-based substrates are commonly used colourirnetric proteinase 
substrates, while many fluorometric proteinase substrates are based on 7 -amino-
4-methylcoumarin (AMC). AMC is an aromatic amine that fluoresces at different wavelengths 
depending on whether it is linked to an amino acid or not (Zimmerman et aI., 1976): It is 
regarded as a "sensitive, safe and convenient leaving group" for proteinase substrates (Barrett 
and Kirschke, 1981). Carbobenzoxy (Z)-Phe-Arg-AMC is commonly used as a simple and 
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sensitive assay for mammalian cathepsin L (Barrett and Kirschke, 1981), cruzipain (Murta et 
al., 1990; Lima et aI., 1992) and trypanopain-Tc (Mbawa et aI., 1992), so this substrate was 
chosen for initial monitoring oftrypanopain activity. 
3.2.1 Materials 
Assay buffer [340 roM sodium acetate, 60 roM acetic acid, 4 roM Na2EDTA 0.02% (m/v) 
NaN3, 4 roM dithiothreitol (DTT), pH 5.5]. Sodium acetate.3H20 (23.13 g), glacial acetic acid 
(1.72 ml), Na2EDTA.2H20 (1.49 g) and NaN3 (0.1 g) were dissolved in 450 rnl of H20, 
adjusted to pH 5.5 with NaOH and made up to 500 ml with H20 . DTT (6 mg) was added to 
10 rnl of buffer just before use. After purification and characterisation oftrypanopain, this assay 
buffer was modified to achieve increased sensitivity. The modified assay buffer is described in 
Section 4.8.6. 
Stock substrate solution (1 roM Z-Phe-Arg-AMC). Z-Phe-Arg-AMC (1 mg) was dissolved in 
DMSO (1.5 rnI) and stored at 4°C. 
Working substrate solution (20 11M Z-Phe-Arg-AMC). Stock substrate solution (100 )..11) was 
diluted to 5 rnl with H20. 
Brij-35 diluent [0.1 % (m/v)]. Brij-35 (0.1 g) was dissolved in 90 rnl of H20 and made up to 
100 ml with H20 . 
Stopping reagent (l00 roM monochloroacetate, 30 roM sodium acetate, 70 roM acetic acid, 
pH 4.3). Monochloroacetate (9.45 g), sodium acetate.3H20 (4.08 g) and glacial acetic acid 
(4 ml) were dissolved in 950 ml of H20 , titrated to pH 4.3 with NaOH and made up to 1 I with 
H20 . 
1 roM AMC standard. AMC (1.8 mg) was dissolved in DMSO (10 rnI). The standard was 
used at 0.5 )...lM working solution by diluting the stock solution (5 )J.J) in a 1: 1 mixture of the 
assay buffer and stopping reagent (10 rnI). 
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3.2.2 Method for standard enzyme assay 
For standard continuous assays, samples (containing approximately 1-5 ng trypanopain) were 
diluted with Brij-35 diluent (to 250 ~l) and equilibrated to 37°C in a temperature controlled cell 
and pre-warmed assay buffer (500 ~l) added. After 1 min activation in assay buffer, substrate 
(250 ~l of working solution) was added and product fluorescence monitored on a Hitachi 
F-2000 spectrofluorimeter (excitation 370 run, emission 460 nm). Standard stopped time 
assays were performed in the same manner, except that stop solution (1 ml) was added 
10 minutes after substrate addition and the fluorescence measured. 
3.2.3 Method for enzyme micro-assays 
When numerous samples were to be assayed, a modification of the above assay was performed 
using a 7600 Microplate Fluorimeter (Cambridge Technology, Inc.). This method proved to be 
of particular use for assaying column eluates, since many samples could be assayed 
simultaneously. Micro-continuous assays were performed by diluting trypanopain (1-5 ng) with 
Brij-35 (to 25 ~l) and activating the enzyme for 1 min in pre-warmed assay buffer (50 ~l, 
37°C). Substrate (25 ~l) was added and the fluorescent product monitored (excitation 370 run, 
emission 460 nm). Micro-stopped time assays were performed in the same manner, except that 
stop reagent (1 00 ~l) was added 10 min after substrate addition. Trypanopain activity was 
calibrated by quantifYing the moles of AMC released from the substrate using an AMC standard 
(50-250 pmol). A standard curve was prepared for each assay method, taking the different final 
volumes into account. Unless otherwise stated, trypanopain activity is expressed as picomoles 
of AMC produced per second. 
3.3 Growth and harvesting of trypanosomes 
Cryo-suspensions of neld-isolated trypanosomes can be kept indefinitely by freezirig the 
parasites in a cryo-protective solution in liquid nitrogen. Cryo-preserved parasite populations 
can be expanded when large numbers of parasites are required by injecting the cryo-suspension 
into suitable susceptible mammalian hosts such as rats. Parasites can be purified from the blood 
of the infected animals using Percoll gradients (Grab and Bwayo, 1982) and anion exchange 
chromatography on DEAE-cellulose (Lanham and Godfrey, 1970). 
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3.3.1 Materials 
Phosphate saline glucose (pSG) (57 mM NaH2P04, 57 mM Na2HP04, 46 mM NaCL 56 mM 
glucose, 0.1 mM hypoxanthine, pH 8.0). NaH2P04.2H20 (8.89 g), Na2HP04 (8.09 g), NaCI 
(2.68 g), glucose (10.08 g) and hypoxanthine (0.014 g) were dissolved in 950 ml of H20, 
adjusted to pH 8.0 with HCI and made up to 1 I with H20 . Hypoxanthine has. been found to 
help maintain the viability of parasites during the isolation procedure (Lonsdale-Eccles and 
Grab, 1987b). 
Sodium citrate anticoagulant [3% (m/v)]. Trisodium citrate.2H20 (6 g) was dissolved in PSG 
(200 ml) . 
Percoll solution [0.25 M sucrose, 2% (w/v) glucose in PercolL pH 7.4]. Sucrose (17.1 g) and 
glucose (4 g) were dissolved in 150 ml Percoll, adjusted to pH 7.4 with solid 
N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (Hepes) and made up to 200 ml with 
Percoll. 
Elution buffer [100 mM Na-acetate, 1 M NaCl, pH 5.0]. NaCI (58.44 g) was dissolved in 
900 ml of H20 and glacial acetic acid (5 .7 ml) added. The pH of the solution was adjusted to 
pH 5.0 with NaOH and the volume made up to 11. 
3.3.2 Method 
Cryo-suspensions of Trypanosoma brucei brucei (clone ll.,-Tat 1.1) were thawed from liquid 
nitrogen and diluted as required in PSG. The viability of the parasites was microscopically 
confirmed and the parasites injected intraperitoneally into adult Wistar rats. For T b. brucei, an 
inoculum of about 106 parasites per rat ensured the development of high parasitaemia in less 
than 1 week. Blood parasitaemia was monitored daily by microscopic examination (at 400x 
magnification) of blood taken from the tail vein and when high parasitaernia was evident, rats 
were sacrificed using ether and the infected blood collected into anticoagulant by cardiac 
puncture. 
Parasites were purified from blood components by a combination of isopycnic density 
centrifugation on a Percoll gradient (Grab and Bwayo, 1982) and anion exchange 
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chromatography on DEAE-cellulose (Lanham and Godfrey, 1970). Blood was mixed 1: 1 with 
Percoll and centrifuged (30 OOOxg, 30 min, 4°C). The opaque trypanosome layer was carefully 
aspirated, washed once with 3 volumes of cold PSG (3 OOOxg, 20 min, 4°C) and the 
trypanosome-containing pellet re-suspended in a minimum volume of PSG. Parasites were 
applied to DEAE-cellulose pre-equilibrated in a sintered glass funnel with cold PSG. The pH of 
the sample and the gel (PH 8.0) was found to be critical for effective separation, so solid Tris 
was added to the sample at this stage to re-establish the pH at 8.0, if necessary. A 4 to 5-fold 
excess of gel over blood ensured good separation, with trypanosomes passing through the gel 
unhindered and erythrocytes and other blood components binding to the gel (Lanham and 
Godfrey, 1970). The eluted parasites were concentrated by centrifugation (1 OOOxg, 10 min, 
4°C) and re-suspended in a small volume of PSG. Purified parasites were counted using a 
Neubauer haemocytometer and frozen at -70°C until required. Material bound to the 
DEAE-cellulose was eluted by washing the gel with 5 column volumes of PSG containing 1 M 
NaCl, followed by 5 column volumes of elution buffer. Regenerated resin was stored in 
1 % (m/v) thiomersal in PSG (with glucose omitted) between purifications. Cryo-suspensions 
of r b. brncei were prepared by mixing infected blood 1: 1 with PSG containing 20% (m/v) 
glycerol, and freezing the solution slowly in a polystrene container submerged in liquid nitrogen. 
3.4 Determination of active enzyme concentration by E-64 titration 
The concentration of active enzyme in a preparation can be determined by titration with an 
irreversible enzyme inhibitor that reacts only with active enzyme molecules in an equimolar 
manner. Since such an inhibitor binds covalently to the enzyme, the concentration of active 
enzyme present can be calculated from the minimum concentration of inhibitor required for full 
inhibition of the enzyme. L-trans-epoxysuccinyl-Ieucylamido (4-guanidino )butane (also known 
as E-64) is an irreversible inhibitor of most thiol proteinases and binds covalently to the active 
site cysteine residue of susceptible enzymes (Barrett et al. , 1982). Members of the papain 
superfamily of cysteine proteinases are particularly susceptible to E-64, facilitating the use of 
this reagent as an active site titrant for this family of enzymes. The reagent does not react with 
free reducing agents, non-active site cysteine residues or other classes of proteinases (Barrett et 
al. , 1982). 
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E-64 was first isolated by Hanada et al. (l978a) from a solid culture of Aspergillus japonicus, 
but various analogues ofE-64 (e.g. E-64c, E-64d, Ep-475, Ep-453 and Ep-459) containing the 
active L-trans-epoxysuccinic acid moiety have since been synthesised and characterised 
(Hanada et at., 1983). E-64c is of particular interest because it penetrates cells more readily 
than the parent molecule (Mason and Wilcox, 1992). The exact mechanism of E-64 
inactivation of cysteine proteinases is not understood, but the carboxylate groups of E-64 are 
thought to position and activate the epoxide of E-64, causing it to alkyl ate the active site 
cysteine residue (Figure 8) (Hanada et aI., 1978b; Meara and Rich, 1996). The E-64 
leucyl-isobutyl side chain may bind to the Sl ' or S2' enzyme subsite (Barrett et al., 1982; Rich, 
1986, nomenclature of Schechter and Berger, 1967). 
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Figure 8: Proposed mechanism for E-64 inactivation of cysteine proteinases. 
Rich (1986) proposes that the thiol of the active site cysteine residue (Cys-S) of the target proteinase 
attacks the C-3 carbon of the epoxysuccinyl group of E-64, allowing protonation of the E-64 epoxide 
oxygen by the active· site histidine (H-Irn-His). 
3.4.1 Materials 
As per Section 3.2.1. 
Stock E-64 (10 mM). E-64 (3 .8 mg) was dissolved in DMSO (100 /-ll) and diluted to 1 ml with 
H20 . This stock solution was diluted to a 3 !-lM working solution with H20 when required. 
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3.4.2 Method 
Trypanopain (2-10 ng, 25 Ill) was incubated with E-64 (25 III of a 1-10 11M solution) for 
30 min at 30°C in assay buffer (50 Ill). After 30 min, the mixture was diluted to 250 III with 
Brij-35 diluent and assayed in a stopped-time assay as described in Section 3.2.3 to determine 
residual enzyme activity. Linear regression was performed on a plot of trypanopain activity vs 
E-64 concentration. The minimum concentration of E-64 that completely inactivated all 
trypanopain activity was taken as the active concentration of the enzyme. 
3.5 Rate of inactivation with E-64 
Barrett et at. (1982) suggested that full inhibition of a target proteinase by E-64 occurs in 
30 min. The rate of trypanopain inactivation by E-64 was determined to confirm that this 
30 min incubation period was sufficient for full trypanopain inactivation and thus sufficient for 
accurate enzyme titration. 
3.5.1 Materials 
As per Section 3.4.1. 
3.5.2 Method 
A molar excess of E-64 (1 0 ~, 30 Ill) was incubated with trypanopain (150 nM, 30 Ill) in 
assay buffer (60 Ill) for various lengths of time before the enzyme was assayed against Z-Phe-
Arg-AMC in stopped-time assays as described in Section 3.2.2. Dilution into the substrate and 
assay buffer is sufficient to halt association of trypanopain and E-64 (Salvesen and Nagase, 
1989). 
3.6 Three-phase partitioning as an initial purification method 
No purification of trypanopain to electrophoretic homogeneity had been reported at the outset 
of the present study, so a new purification method was devised. Three-phase partitioning 
(TPP) was chosen for initial purification of the enzyme. TPP is a relatively crude fractionation 
procedure in which I-butanol [30% (v/v) of total mixture volume] is mixed with the sample 
solution and various percentages [ern/v) of the total mixture volume] of ammonium sulfate 
added. I-Butanol is infinitely miscible with pure water, but becomes increasingly less miscible 
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when salt is added. Consequently, addition of ammonium sulfate to a t-butanol-protein mixture 
causes precipitation of proteins as a concentrated, dehydrated button between the salt and 
butanol layers (pike and Dennison, 1989). Since different proteins precipitate out at different 
salt concentrations incremental addition of ammonium sulfate allows for crude fractionation of , 
protein mixtures. Compared with ammonium sulfate precipitation, greater purification may be 
obtained using TPP since lipids, pigments and other organic solvent-soluble materials remain in 
the butanol layer. The re-dissolved TPP pellet also contains low amounts of salt, enabling the 
resulting sample to be loaded onto ion exchange columns without prior desalting. 
3.6.1 Materials 
1% em/v) Triton X-I00. Triton X-lOO (1 g) was diluted to 100 rnl with H20. 
Zero NaCI buffer [20 mM sodium acetate, 1 mM Na2EDTA 0.02% em/v) NaN3, pH 5.5]. 
Glacial acetic acid (l.145 rnI), Na2EDT A.2H20 (0.37 g) and NaN3 (0.2 g) were dissolved in 
950 rnl of deionised H20 , adjusted to pH 5.5 with NaOH and made up to 1 I with deionised 
H20 . The buffer was filtered through a 0.22 11m filter before use. 
3.6.2 Method 
Lysis of T. b. brucei (approx. l x l08 cells) was effected by addition of Triton X-lOO to 
0.1 % (m/v) final concentration and the lysate diluted lO-fold in zero NaCI buffer. I-Butanol 
was added to 30% (v/v) of the total volume, i.e. 11 rnl t-butanol added per 25 rnl of sample. 
Increasing percentages of ammonium sulfate were added to optimise trypanopain isolation by 
sequential precipitation of trypanosomal proteins. The solution was centrifuged (10 OOOxg, 
10 min, RT) after each round of ammonium sulfate addition and the protein precipitates 
re-dissolved in zero NaCI buffer before being assayed against Z-Phe-Arg-AMC in stopped-time 
assays (Section 3.2.3). The Z-Phe-Arg-AMC-hydrolysing activity from T. b. brucei was shown 
to precipitate between 10 and 25% (m/v of the total volume) ammonium sulfate. 
F or subsequent large scale purification of trypanopain, trypanosomes (approximately 5.5 x l 09 
parasites) were lysed as described above. I-Butanol was added to 30% (v/v) of the total 
volume, i.e. 11 rnl t-butanol added per 25 rnl of sample. Ammonium sulfate was added to 
10% (m/v) (i.e. 3.6 g/25 rnl sample), the mixture centrifuged (10 OOOxg, 10 min, RT) and the 
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membranous pellet discarded. Further ammonium sulfate was added to the supernatant to give 
a final concentration of 25% (m/v), i.e. 5.4 g/25 m1 sample. The trypanopain-containing 
precipitate was collected by centrifugation (10 OOOxg, 10 min, RT) and re-suspended in a 
minimal volume of zero NaCI buffer. The final trypanopain-containing sample was centrifuged 
(15 OOOxg, 30 min, 4°C) to remove any insoluble material. 
3.7 Q-Sepharose chromatography 
Following the initial isolation with TPP, further trypanopain purification was effected using 
anion exchange chromatography on HiLoad™ quaternary amine (Q)-Sepharose® High 
Performance and Resource™ Q columns (both from Pharmacia, Sweden). The HiLoad™ 
Q-Sepharose® High Performance column was used in the initial chromatography step, since it 
combines excellent resolution, high flow rates (up to 100 cm/h) and a high protein-binding 
capacity (up to 30 mg of protein per m1 of medium). This step was followed by 
chromatography on Resource™ Q, which is more suited for removal of trace contaminants. 
The small volume of this polyetheretherketone-based column (1 rnI) allows for fine separation 
by enabling maintenance of a plateau in the salt gradient in response to elution of a protein. 
3.7.1 Materials 
All buffers were filtered through 0.22 ~m filters before use to prevent clogging of the high 
performance columns. All columns were run on the GradiFrac™ Chromatography System 
(pharmacia, Sweden), facilitating reproducible gradient formation . 
Q-Sepharose equilibration buffer [20 mM sodium acetate, 1 mM Na2EDTA 100 mM NaCl, 
0.02 % Cm/v) NaN3, pH 5.5]. Glacial acetic acid (1.145 ml), Na2EDTA.2H20 (0.37 g), NaN3 
(0.2 g) and NaCI (5.844 g) were dissolved in 950 ml of deionised H20, adjusted to pH 5.5 with 
NaOH and made up to 11 with deionised H20. 
Q-Sepharose elution buffer [20 mM sodium acetate, I mM Na2EDTA 1 M NaCL 0.02% (m/v) 
NaN3, pH 5.5]. Glacial acetic acid (1.145 ml), Na2EDTA.2H20 (0.37 g), NaN3 (0.2 g) and 
NaCI (46.752 g) were dissolved in 950 rnl of deionised H20, adjusted to pH 5.5 with NaOH 
and made up to 1 I with deionised H20 . 
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Z-Arg-Arg-AMC stock solution (1 mM). Z-Arg-Arg-AMC (1.2 mg) was dissolved in 2 ml of 
DMSO. 
Z-Arg-Arg-AMC working solution (20 11M). Stock Z-Arg-Arg-AMC (100 Ill) was diluted to 
5 ml with H20 . 
Oligopeptidase-Tb (OP-Tb) assay buffer [100 mM Tris-CL 10 mM DT!, pH 8.0]. Tris 
(12.11 g) was dissolved in 900 ml of H20 and the pH adjusted to pH 8.0 with HCI. DTT 
(15.4 mg/l0 ml) was added just before use. 
3.7.2 Method 
The trypanopain-containing sample from Section 3.6 was loaded onto HiLoad Q-Sepharose 
(dimensions 26x110 mm, flow rate 1 mlImin) pre-equilibrated in Q-Sepharose equilibration 
buffer. After elution of the unbound material, a gradient of 100 mM to 1 M NaCI in 
Q-Sepharose equilibration buffer was applied over 5 column volumes, followed by one column 
volume of Q-Sepharose elution buffer. The eluted fractions were assayed against Z-Phe-Arg-
AMC and Z-Arg-Arg-AMC in stopped-time assays as described in Section 3.2.3 . Fractions 
active against Z-Phe-Arg-AMC but not Z-Arg-Arg-AMC were identified as trypanopaiil, while 
fractions active against both substrates were identified as OP-Th. OP-Tb fractions were pooled 
for further purification (Troeberg et aI., 1996). 
Active trypanopain fractions were pooled, dialysed against zero NaCI buffer (2x45 min, 1 I 
each) and loaded onto Resource Q (dimensions 6.4x30 mm, flow rate 1 mlIl1}in) equilibrated in 
Q-Sepharose equilibration buffer. After elution of the unbound material, a NaCl gradient 
(0.1-0.5 Min Q-Sepharose equilibration buffer) was applied over 15 column volumes (15 ml) 
with the salt concentration held constant during the elution of each protein peak to enhance 
separation. Active fractions (determined from stopped-time assays against Z-Phe-Arg-AMC as 
described in Section 3.2.3) were dialysed against three changes of zero NaCI buffer (500 rnl 
each) overnight at 4°C to remove salt and against PEG (Section 2.3) to concentrate the sample. 
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3.8 Pepstatin A chromatography 
The Q-columns used in Section 3.7 were highly efficient, allowing purification oftrypanopain in 
three short steps. However, the Resource Q column proved to have a short life span, clogging 
irreparably after three or four runs despite efforts to prevent this (i.e. filtration of buffers and 
samples through 0.22 ~m filters, and the manufacturer's recommended cleaning procedures). 
At R2 000 per column, this highly effective purification step was not cost-ineffective, 
necessitating the search for an alternative chromatographic purification strategy. Chicken egg 
white cystatin affinity chromatography proved ineffective, since trypanopain failed to elute from 
the column in a variety of elution buffers. This is presumably because trypanopain binds too 
tightly to the immobilised inhibitor. Since pepstatin A was known to be a weak trypanopain 
inhibitor (pamer et at., 1989), pepstatin A-Sepharose was tested as an affinity matrix. 
3.8.1 Materials 
Pepstatin A-Sepharose. This resm was a gift from Dr Philip Fortgens, Department of 
Biochemistry, University of Natal, Pieterrnaritzburg (UNP). 
Pepstatin A-Sepharose equilibration buffer [20 mM sodium acetate, 1 mM Na2EDTA 500 mM 
NaCL 0.02 % em/v) NaN3, pH 5.5]. Glacial acetic acid (l.145 ml), Na2EDTA.2H20 (0.37 g), 
NaN3 (0.2 g) and NaCI (29.22 g) were dissolved in 950 ml of deionised H20, adjusted to 
pH 5.5 with NaOH and made up to II with deionised H20 . 
Pepstatin A-Sepharose elution buffer [20 mM sodium acetate, 1 mM Na2EDTA 500 mM 
NaCl, 5% em/v) Brij-35, 0.02 % em/v) NaN3, pH 5.5]. Glacial acetic acid (1.145 ml), 
Na2EDTA.2H20 (0.37 g), NaN3 (0.2 g), Brij-35 (50 g) and NaCI (29.22 g) were dissolved in 
950 ml of deionised H20 , adjusted to pH 5.5 with NaOH and made up to II with deionised 
H20. 
HiTrapTM Blue Sepharose equilibration buffer [50 mM Tris-CL 0.02 % em/v) NaN3, pH 8.0]. 
Tris (6.055 g) and NaN3 (0.2 g) were dissolved in 900 ml of water, adjusted to pH 8.0 with 
HCI and made up to II with H20 . 
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HiTrapTM Blue Sepharose elution buffer [50 roM Tris-Cl, 1 M NaCl, 0.02 % em/v) NaN3~ 
pH 8.0]. Tris (6.055 g), NaCI (58.44 g) and NaN3 (0.2 g) were dissolved in 900 rnl of water, 
adjusted to pH 8.0 with HCl and made up to 11 with H20 . 
3.8.2 Method 
The trypanopain fraction eluted from HiLoad Q-Sepharose was loaded onto pepstatin 
A-Sepharose (dimensions 13x l0 rom, flow rate 0.26 mlImin) pre-equilibrated in pepstatin 
A-Sepharose equilibration buffer. After elution of the unbound material, trypanopain bound to 
the column was eluted step-wise in pepstatin A-Sepharose elution buffer. Fractions active 
against Z-Phe-Arg-AMC (stopped-time assays conducted as described in Section 3.2.3) were 
pooled, dialysed against three changes of zero NaCI buffer (500 rnl each) overnight at 4°C to 
remove salt and concentrated using PEG (Section 2.3). Trace contamination with albumin was 
occasionally observed after pepstatin A-Sepharose chromatography. This was removed by 
passing the sample over HiTrap Blue Sepharose (dimensions 9x23 rom, flow rate 1 mlImin) 
equilibrated in HiTrap Blue Sepharose equilibration buffer. Trypanopain was recovered in the 
unbound fraction, with bound albumin subsequently removed from the column with HiTrap 
Blue Sepharose elution buffer. 
3.9 Production of anti-trypanopain antibodies 
After the purification of trypanopain, anti-trypanopain antibodies were produced, primarily as 
tools for evaluation of trypanopain presence in various samples (Section 5.5). The effects of 
these antibodies on enzyme activity were also evaluated. Because of the extremely limited 
amount of purified enzyme available, only one experimental animal could be immunised. A 
chicken was chosen for this task because of the ease with which large quantities of Ig Y can be 
isolated from the yolk, where Ig Y is concentrated to provide passive immunity for the 
developing chick (polson et aI. , 1980). 
Trypanopain (purified on Resource Q, Section 3.7.1) was triturated with adjuvant until a thick 
emulsion formed. A chicken was injected intramuscularly at 4 to 6 sites on either side of the 
sternum at weeks 0 (10 llg trypanopain), week 1 (10 ).lg), week 2 (5 ).lg) and week 6 (5 ).lg) and 
eggs collected from the start of the immunisation protocol. Freund's complete adjuvant was 
63 
used for the initial inoculation and Freund's incomplete adjuvant for subsequent inoculations 
(Freund and McDermott, 1942). 
3.10 ELISA evaluation of anti-trypanopain antibody production 
ELISAs were conducted to assess the progression of antibody production in the imrnunised 
chicken. Reagent volumes were reduced throughout the assay to minimise the amount of 
purified trypanopain required to complete the assay. 
3.10.1 Materials 
As per Section 2.10.1. 
3.10.2 Method 
Trypanopain (20 pmoVrnl, in 50 III carbonate coating buffer) was adsorbed to the wells of 
rnicrotitre plates (16 h, 4°C) and remaining sites blocked with BSA-PBS (200 Ill, 1 h, RT) . 
Plates were washed in PBS-Tween (3 times) and test primary antibodies (50 Ill, 1-200 Ilglrnl in 
BSA-PBS) incubated (2 h, 37°C). The plate was washed as before and incubated with rabbit 
anti-IgY-HRPO secondary antibodies (50 Ill, 1 h, 37°C). After washing of the plate, 
ABTSIH20 2 substrate was added, colour development stopped and the Aws monitored as 
described in Section 2.10.2. 
3.11 Evaluation of antibodies on a Western blot 
The ability of the anti-trypanopain antibodies to recognise denatured trypanopain on a Western 
blot was investigated using lysed T b. brncei satIlples. 
3.11.1 Materials. 
As per Sections 2.11.1 . 
3.11.2 Method 
Proteins separated by tricine SDS-PAGE were electroblotted onto nitrocellulose at 30Y for 
16 h and blocked with block II (Section 2.11.2). The nitrocellulose was incubated with IgY 
anti-trypanopain antibodies in block II (200 Ilglrnl, 2 h), followed by rabbit anti-IgY-HRPO 
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secondary antibodies m block IT (1/300 dilution, 45 min) and 4-chloro-1-naphthoVH20 2 
substrate. 
3.12 Results 
3.12.1 Rate of inactivation with E-64 
Trypanopain activity against Z-Phe-Arg-AMC decreased rapidly within the first minute of 
incubation with E-64 (Figure 9). After this, residual activity decreased slowly. The 30 min 
E-64 incubation period recommended by Barrett et al. (1982) was thus considered sufficient for 
accurate enzyme titration. 
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Figure 9: Rate oftrypanopain inactivation by a molar excess ofE-64. 
Trypanopain (150 nM) was pre-incubated for various lengths oftime in assay buffer with a molar excess 
of E-64 (10 flM). The residual enzyme concentration was determined from quintuplicate stopped-time 
assays againstZ-Phe-Arg-AMC (5 flM) as described in Section 3.2.2. 
3.12.2 Isolation of trypanopain 
Optimisation of TPP indicated that the Z-Phe-Arg-AMC-hydrolysing activity of T b. brucei 
precipitates between 10 and 25% (m/v) ammonium sulfate (Figure 10). 
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Figure 10: Optimisation ofTPP for the isolation oftrypanopain from T. b, brucei. 
65 
Increasing percentages of ammonium sulfate were sequentially added to triplicate samples of lysed 
T b. brucei containing I-butanol added to 30% (v/v) of the total volume. After centrifugation (10 OOOxg, 
10 min, RT), each protein precipitate was re-dissolved and assayed against Z-Phe-Arg-AMC in triplicate 
stopped-time assays (Section 3.2.3). 
The 10-25% ammonium sulfate cut from TPP was loaded onto HiLoad Q-Sepharose and 
eluted in a 5 column volume salt gradient. All fractions were assayed against both Z-Phe-Arg-
AMC (hydrolysed by trypanopain and the trypanosomal oligo peptidase OP-Tb) and Z-Arg-
Arg-AMC (hydrolysed only by OP-Tb) to monitor the separation of these two enzymes. 
OP-Tb eluted in the unbound fraction, while trypanopain eluted in the bound fraction 
(Figure 11), This chromatographic procedure thus allowed separation of these enzymes early in 
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Figure 11 : Chromatogram ofHiLoad Q-Sepharose separation of trypanopain and op-Th from 
T. b. brucei. 
The 10-25% (Nf4)zS04 cut of TPP was loaded onto HiLoad Q-Sepharose (dimensions 26x 11 0 mm, 
flow rate 1 mlImin) pre-equilibrated in Q-Sepharose equilibration buffer [100 mM NaCI in 20 mM 
Na-acetate, 1 mM Na2EDTA, 100 mM NaCI, 0.02 % (m/v) NaN3, pH 5.5] and the unbound material 
eluted. A NaCI gradient (0.1-1 M) was applied over 5 column volumes and the fractions (4 ml) assayed 
against Z-Phe-Arg-AMC (II) and Z-Arg-Arg-AMC (e ) in duplicate stopped time assays as described in 
Section 3.2.3. 
Active HiLoad Q-Sepharose fractions were dialysed and applied to a Resource Q column. The 
increased resolving power of the Resource Q column enabled separation of the HiLoad 
Q-Sepharose sample into 3 active peaks (Figure 12). Silver staining of these Resource Q peaks 
revealed that the middle active peak contained a single protein of 30 kDa. Gelatin-containing 
tricine SDS-PAGE showed that only the 30 kDa band contained in these peaks was 
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Figure 12: Resource Q chromatography of trypanopain. 
Active fractions from HiLoad Q-Sepharose were loaded onto Resource Q (dimensions 6.4x30 mm, flow 
rate 1 mlImin) pre-equilibrated in Q-Sepharose equilibration buffer [20 rnM Na-acetate, 1 rnM 
Na2EDTA, 100 rnM NaCI, 0.02 % (m/v) NaN3, pH 5.5]. After elution of the unbound material, a NaCI 
gradient (0.1-0.5 M) was applied, with the salt concentration held constant during the elution of each 
protein peak (at 0.17 M, 0.2 M and 0.25 M) to enhance separation. Active fractions (e ) were 
determined from duplicate stopped-time assays as described in Section 3.2.3. 
Trypanopain was thus effectively purified into three component parts by HiLoad and Resource 
Q chromatography. However, the crucial Resource Q column was not cost effective (Section 
3.8). Pepstatin A-Sepharose chromatography thus replaced this step in later trypanopain 
purifications. A single peak: ofZ-Phe-Arg-AMC activity eluted from the pepstatin A-Sepharose 
column. The elution of trypanopain could not be monitored using the A280 trace, since the 
Brij-35 in the elution buffer absorbs strongly at 280 nm and obscured the increase in A280 
occurring with elution of the enzyme (Figure 13). Trace albumin contamination was 
occasionally observed after this step. This was easily removed by passing the sample over 
HiTrap Blue Sepharose. SDS-PAGE showed that trypanopain was pure after HiTrap Blue 
Sepharose chromatography (Figure 14). 
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Trypanopain was found to be most stable if stored at -20°C in 50010 glycerol. However, even 
when stored in this manner, the enzyme lost activity over time. Irrespective of the purification 
protocol, non-reduced, boiled trypanopain had an apparent molecular mass of 30 kDa, in 
agreement with previous reports (Mottram et aI. , 1989). However, boiled, reduced enzyme 
had an apparent mass of35-39 kDa (Figure 14). It was noted that upon storage, the apparent 
molecular mass of trypanopain also increased in this manner, with the increase c~rrelating with 
loss of activity and age of the preparation. For example, trypanopain purified on Resource Q 
initially had an apparent molecular mass of 30 kDa, but when inactive enzyme was 
electrophoresed some months later, this same sample of purified enzyme had an apparent 
molecular mass of39 kDa (Figure 15). 
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Figure 13 : Pepstatin A-Sepharose chromatography of trypanopain. 
The bound trypanopain fraction from HiLoad Q-Sepharose was loaded onto pepstatin A-Sepharose 
(dimensions 13x lO mm, flow rate 0.26 mlImin) equilibrated in pepstatin A-Sepharose equilibration 
buffer [20 mM Na-acetate, 1 mM Na2EDTA, 500 mM NaCI, 0.02 % (mlv) NaN), pH 5.5]. After 
elution of the unbound material, trypanopain bound to the column was eluted in pepstatin A-Sepharose 
elution buffer [equilibration buffer plus 5% (mlv) Brij-35, applied from the position of the arrow]. 
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Figure 14: SDS-P AGE of trypanopain after pepstatin A-Sepharose chromatography. 
A: Trypanopain (300 ng, 30 kDa, lane 1) was mixed with an equal volume of non-reducing treatment 
buffer and boiled for 2 min prior to electrophoresis and silver stained after electrophoresis. Pharmacia 
molecular mass markers (Section 2.4) are shown in lane 2. 
B: Trypanopain (300 ng, 39 kDa, lane 3) was boiled in an equal volume of reducing treatment buffer for 
2 min prior to electrophoresis and silver stained after electrophoresis. Phamlacia molecular mass 







Figure 15: Tricine SDS-PAGE of inactive trypanopain after Resource Q chromatography. 
Inactive trypanopain (300 ng, 35 kDa, lane 1) was mixed with an equal volume of non-reducing 
treatment buffer and boiled for 2 min prior to tricine SOS-PAGE and silver stained after electrophoresis. 
Pharmacia molecular mass markers (Section 2.4) are shown in lane 2. 
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Gelatin zymogram analysis of trypanopain purified by either Resource Q or pepstatin 
A-Sepharose (Figure 16) chromatography also showed that trypanopain was the only 
proteinase present in purified samples, with a molecular mass of approximately 30 kDa. Many 
bands of activity were visible in lysed T. b. brucei, with molecular masses ranging from 
approximately 30 kDa to above 94 kDa. These may either represent many different proteinases 








Figure 16: Gelatin-containing tricine SDS-PAGE of crude and purified trypanopain. 
Tricine SDS-PAGE gels containing gelatin were prepared and electrophoresed as in Section 2.5 . After 
electrophoresis, the gels were soaked in Triton X-IOO to remove SDS and re-nature any proteinases 
present. Gels were incubated in assay buffer (3 h, 37°C, 100 mM Na-acetate, I mM Na2EDTA, 30 mM 
cysteine, 0.02% (mlv) NaN3, pH 5.5) to allow digestion of the incorporated substrate and stained as ill 
Section 2.5. Lane I shows Pharmacia molecular mass markers (Section 2.4). Lane 2 shows gelatin 
digestion by pepstatin A-Sepharose-purified trypanopain (30 kDa) and lane 3, digestion by lysed 
T. h. bnlcei . 
Table 3 compares the two methods used for trypanopain purification. OP-Tb readily cleaves 
Z-Phe-Arg-AMC (Km=O.73 flM; Kornblatt et ai., 1992; Troeberg et ai., 1996) and E-64 
titration showed that OP-Tb accounts for 50% of the Z-Phe-Arg-AMC-hydrolysing activity in 
samples taken from lysed T. b. brucei and following TPP (Troeberg et aI., 1996). Values given 
for trypanopain activity in lysed cells and after TPP are thus half of the total Z-Phe-Arg-AMC-
hydrolysing activity present in these samples. OP-Tb and trypanopain are separated on HiLoad 
Q-Sepharose, so trypanopain activity values given for this and subsequent steps are calculated 
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from the total Z-Phe-Arg-AMC-hydrolysing activity present in these samples. Table 3 shows 
that the two purification methods were comparable in terms of yield and purification. 
Table 3: Comparison of purification of trypanopain from T b. brucei using Resource Q 
and pepstatin A-Sepharose chromatography. 
Purification with Resource Q 
, 
Fraction Total Total activity Specific Purification Yield 
protein (pmol.s-1) activity (fold) (%) 
(mg) (pmol.s-1.mt1) 
Lysed cells 210 2400 11 1 100 
TPP 7 850 121 11 35 
H.iLoad Q-Sepharose 0.24 405 1688 153 17 
Resource Q 0.01 200 20000 1 818 8 
Purification with pepstatin A-Sepharose 
Fraction Total Total activity Specific Purification Yield 
protein (pmol. s-1) activity (fold) (%) 
(mg) (pmol.s-1.mt1) 
Lysed cells 213 2281 11 1 100 
TPP 9 572 64 6 25 
H.iLoad Q-Sepharose 0.2 397 1 985 180 17 
Pepstatin A-Sepharose 0.04 252 6300 573 11 
HiTrap Blue Sepharose 0.01 245 24500 2227 11 
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3.12.3 ELISA evaluation of anti-trypanopain antibodies 
High concentrations of anti-trypanopain IgY antibodies were produced in the immunised 
chicken against very low levels of immunogen (30 Jlg total over 4 weeks), showing that the 
enzyme is highly immunogenic in chickens. The highest titre antibodies were produced between 
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Figure 17: ELISA monitoring antibody titre in a chicken immunised with trypanopain. 
Trypanopain was coated onto ELISA plates (20 pmol/ml in Na-carbonate buffer, 50 Ill/well, 16 h, 4°C) 
and test primary chicken antibodies titrated between 200 and 1 Ilg/ml (in BSA-PBS, 50 Ill/well, 2 11, 
37°C). Rabbit anti-chicken-HRPO secondary antibodies (50 Ill/well in BSA-PBS, 1 h, 37°C) and 
ABTSIH20 2 substrate (100 Ill/well) were used as the detection system. Absorbance readings at 405 om 
of non-immune antibodies (e) and antibodies from week 3 (A), week 4 (11), week 5 ( • ) and week 6 (T) 
represent the average of duplicate experiments. 
3.12.4 Western blot evaluation of anti-trypanopain antibodies 
Anti-whole enzyme antibodies recognised both purified trypanopain and enzyme present in 
lysed cells (Figure 18). As expected, only one band was targeted in purified trypanopain 
samples. In lysed cells, however, the antibodies targeted 3 bands, at 30, 35 and 38 kDa. Pamer 
et al. (1991) have previously reported this pattern of recognition by anti-trypanopain antibodies 








Figure 18: Western blots showing recognition of trypanopain by chicken anti-whole 
trypanopain Jg Y antibodies. 
The tricine SDS-PAGE gel was electroblotted onto nitrocellulose (30 V, 16 h) and blocked with 5% 
(m/v) low-fat milk powder. The blot was incubated with chicken anti-trypanopain IgY (200 Ilg/ml, 2 h), 
followed by rabbit anti-IgY -HRPO secondary antibodies (1/300 dilution, 45 min) and 4-chloro-l-
naphthoIJI-h02 substrate. Lane 1 shows recognition of purified trypanopain (200 ng) and lane 2 of lysed 
T b. brucei (containing approximately 200 ng trypanopain). No proteins were recognised by no.11-
immune antibodies (results not shown). 
3.13 Discussion 
E-64 inhibited trypanopain fully within 4 '12 minutes, with most of the inhibition occurring in the 
first 30 seconds. The rate of association was too fast to enable calculation of the association 
rate constant, kass, without a stopped-flow apparatus. As expected, this shows that E-64 is a 
suitable titrant for trypanopain and that trypanopain is similar to cathepsins B, Hand L and 
papain in this respect (Barrett et aI., 1982). While 10 min pre-incubation with E-64 would 
probably have been sufficient for full inactivation, all titrations were carried out over 30 min as 
suggested by Barrett et al. (1982) to allow for direct comparison with the reported method and 
to compensate for the lower concentrations ofE-64 routinely used to titrate trypanopain. 
At the outset of this study, trypanopain had not previously been purified to electrophoretic 
homogeneity. Previous studies on this enzyme have used either partially purified enzyme (Huet 
et aI., 1992) or lysed T. b. brucei (Boutignon et aI., 1990; Robertson et aI., 1990). However, 
purification of trypanopain-Tc and cruzipain is well documented. Ammonium sulfate 
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precipitation is commonly used for crude fractionation of these enzymes (Murta et al., 1990; 
Lima et aI., 1992), while affinity chromatography procedures have been extensively used for 
further purification, with ligands including p-aminophenylmercuric-acetate (Rangel et al., 
1981), thiopropyl groups (Rautenberg et al., 1982; Mbawa et aI., 1992), cystatin (Mbawa et 
aI., 1991a) and monoclonal antibodies (Authie et al., 1993). Anion exchange chromatography 
on Q-resins (Cazzulo et aI., 1989) and molecular exclusion chromatography ·(Rangel et al., 
1981; Rautenberg et aI. , 1982; Mbawa et aI. , 1992) have also been employed for purification. 
In the pres~nt study, trypanopain was purified from T. b. brocei by TPP between tertiary 
butanol and ammonium sulfate (pike and Dennison, 1989), anion exchange chromatography on 
Q-resins and affinity chromatography on pepstatin A-Sepharose. No other group has reported 
the use ofTPP or pepstatin A-Sepharose chromatography for isolation oftrypanopains. 
TPP was an effective crude isolation procedure, successfully removing large amounts of 
contaminating protein (97% of the starting material). This step was also useful in that the 
re-dissolved TPP pellet contained low amounts of salt, enabling the trypanopain sample to be 
loaded onto Q-Sepharose columns without prior desalting. While the concomitant loss of 
enzyme activity (25-35% yield) was also high, similar losses were recorded using ammonium 
sulfate precipitation (results not shown), indicating that this would not have been a better initial 
step. Furthermore, the yield after this step was highly variable (20-60%) for apparently 
identical isolations. T. b. brocei undergoes various biochemical changes during its transition 
from the short to stumpy bloodstream fonn, and it is likely that the relative numbers of each 
form differed from preparation to preparation, depending on the immune response of the host 
animal, the number of parasites inoculated, etc. Thus the biochemical composition of the 
starting material probably varied between isolations, possibly accounting for the variable yield. 
The success of the purification reported here hinged on the fact that trypanopain adheres to 
quaternary amine resins at pH 5.5, while most other trypanosomal proteins do not. This implies 
either that the pI oftrypanopain is below pH 5.5, or that a particular domain of the enzyme is 
strongly negatively charged below the pI. SDS-PAGE showed that only trace contaminants 
remained after the first chromatography step. Additionally, this step enabled separation of 
trypanopain from op-Tb early in the purification protocol, allowing isolation of the two 
enzymes from the same starting material. This minimised the number of experimental animals 
killed and protected op-Tb from digestion by trypanopain. 
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The increased resolving power of the Resource Q column over the HiLoad Q column enabled 
purification of trypanopain from remaining trace contaminants. The small volume of this 
column (1 rnI) precluded its use as an initial chromatography step, but facilitated finer separation 
of trypanopain than was possible with the HiLoad column. This was done by maintaining 
constant salt concentrations in response to elution of a protein using the GradiFrac 
chromatography system. The single trypanopain peak from HiLoad Q-Sepharose was 
separated into three active peaks on Resource Q. Interestingly, cruzipain also separates into 
three active peaks on Mono Q columns (Cazzulo et at., 1989). No such separation was seen 
when eluting pepstatin A-Sepharose with a Brij-35 gradient, presumably due to the lower 
resolving power of this column. In the present study, only the middle trypanopain peak from 
Resource Q proved to be pure, with the other two peaks shown by SDS-P AGE to contain 
various contaminants in addition to the predominant 30 kDa trypanopain band. Separation is 
thought to have occurred because of the high resolution of the Resource Q column and the 
non-linear gradient applied. 
Trypanopain is encoded by many tandernly arranged genes (Mottram et aI. , 1989), as are the 
major cysteine proteinases of T cruzi (Campetella et aI. , 1992; Eakin et aI., 1992) and 
Leishmania (Souza et aI., 1992; Mottram et at., 1996). In the case of cruzipain, the different 
gene products vary slightly in their substrate specificity (Lima et aI. , 1994), possibly indicating 
that the gene products fulfil slightly different roles in the organism. Preliminary kinetic analysis 
of the three Resource Q peaks obtained in the present study revealed no such variation in 
trypanopain specificity, but a more comprehensive search using more substrates may reveal 
some differences. While the variation between the enzyme populations from Resource Q is 
likely to be slight, their separation must reflect some underlying variability in trypanopain. The 
enzyme may be differentially glycosylated in vivo or the enzyme population may consist of three 
different gene products. Further analysis of the translation of trypanopain-encoding genes is 
required to unravel the cause and significance of this chromatographic separation., as well as to 
understand why trypanopain is encoded by multiple genes. However, since no variation in 
kinetic behaviour could be detected for the three Resource Q peaks, no distinction was made 
between the use of the middle Resource (pure) Resource Q fraction and trypanopain (eluting as 
a single fraction) from pepstatin A-Sepharose in future kinetic experiments. 
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Despite filtering all buffers and samples through 0.22 !lm filters, two individual Resource Q 
columns became blocked after only three or four runs, so an alternative chromatographic step 
was sought. The high affinity with which cystatin B and chicken egg white cystatin inhibit 
trypanopain rendered these ligands unsuitable for affinity chromatography since trypanopain 
bound essentially irreversibly to these resins (results not shown). Chicken egg white cystatin 
has, however, been used as an effective ligand for one-step affinity chromatography purification 
ofcruzipain (Labroila et al., 1993) and trypanopain-Tc (Mbawa et a!. , 1991a), indicating that 
trypanopain has a higher affinity for this inhibitor than other trypanopains. While pepstatin A is 
traditionally considered an inhibitor of aspartic proteinases, it has been shown to inhibit 
trypanopain from T b. rhodesiense fairly weakly (pamer et a!. , 1989) and was thus considered 
a potentially suitable affinity chromatography ligand. Pepstatin A-Sepharose provided a highly 
effective chromatography step, removing all but a 68 kDa contaminant from the trypanopain 
preparation. Removal of this contaminant by HiTrap Blue Sepharose confirmed the suspicion 
that it was albumin. In preliminary studies, trypanopain was eluted from pepstatin A-Sepharose 
using a linear Brij-35 gradient of 0-10% (m/v) . Since the single peak eluted in this manner 
contained either only pure enzyme or enzyme contaminated with a small amount of albumin, a 
step gradient of 5% Brij was considered time-effective and sufficient for trypanopain elution 
from pepstatin A-Sepharose. In addition to its lower cost, the pepstatin A-Sepharose 
purification method was slightly more effective than the Resource Q method. The former gave 
an 11 % yield of enzyme, while the latter gave an 8% yield. While not particularly high, the final 
yield achieved compares favourably with isolation of other parasite cysteine proteinases 
(Cazzulo et a!. , 1989; Smith et al., 1993; Yong Song and Chappell, 1993). 
It was repeatedly observed during the course of this study that successful purification of 
trypanopain was only possible if the entire purification was completed in 1 day. The high flow 
rates possible with the GradiFrac system were thus essential, and the step gradient elution from 
pepstatin A-Sepharose additionally helpful. Attempts to utilise molecular exclusion 
chromatography were unsuccessful because all trypanopain activity was lost over the protracted 
time required for elution. All enzyme activity was also lost on hydrophobic columns (butyl- and 
phenyl-Sepharose). Similar low enzyme stability has been reported for the cathepsin L-like 
cysteine proteinase ofF hepatica (Smith et a!., 1993). 
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Substrate SDS-PAGE (Lonsdale-Eccles and Grab, 1987a) and primary sequence analysis 
(Mottram et al., 1989) suggest that trypanopain has a molecular mass of 28-31 kDa. In the 
present study, non-reduced, non-boiled trypanopain had an apparent molecular mass of30 kDa, 
while the boiled, reduced enzyme had an apparent mass of 35-39 kDa (Figures 14 and 15). 
Cruzipain has also been shown to migrate differently on SDS-P AGE depending on reduction 
and boiling prior to electrophoresis (Martinez and Cazzulo, 1992a,b). Amino -acid sequence 
data suggests the true size of cruzipain to be 36.3 kDa (Campetella et al., 1992), but reduction 
and boiling increase the apparent molecular mass from 33 to 55 kDa. Martinez and Cazzulo 
(1992a, b) suggested that N-glycosylation plays a minor role in this increase, since the enzyme 
contains only 3 potential N-glycosylation sites which should only account for a variation of 
about 5 kDa. They proposed that the increase in mass following reduction and boiling is due 
primarily to reduction of disulfide bridges in the enzyme and resultant altered binding of SDS. 
They noted that the apparent molecular mass of cruzipain in substrate SDS-P AGE gels is low 
(approximately 33 kDa) and suggest that this is a consequence of not boiling the enzyme rather 
than of substrate incorporation into the gel. 
The results of the present study suggest that trypanopain exhibits similar electrophoretic 
behaviour to cruzipain. Again, since mature trypanopain also only has three potential 
N-glycosylation sites (Mottram et al. , 1989), the variation in mass is more likely to be a 
function of reduction of disulfide binds than of increased glycosylation. Interestingly, old, 
completely inactive preparations of trypanopain showed a similar increase in molecular mass to 
that seen with reduced samples, suggesting that these disulfide bonds are essential for 
trypanopain activity. This suggests that oxidation of disulfide bonds, rather than auto-digestion, 
is the primary cause of the loss of activity in stored trypanopain. 
Only 30 Ilg of trypanopain over 4 injections was required to elicit high titre antibodies in a 
single immunised chicken. This is much less than is normally considered necessary to evoke an 
effective immune response. For example, Thorpe (1994) recommends that chickens be 
immunised with at least 30 Ilg of antigen per inoculation. The small amount of trypanopain 
available for immunisation prevented a statistically valid study of the immunisation protocol, but 
the result suggests that trypanopain is highly immunogenic in chickens, which is likely to be a 
function of the evolutionary distance between chickens and T b. brucei. Far less immunogen 
was used in the present study than has been used by other researchers to produce antibodies 
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against related parasite cysteine proteinases (Table 4). This suggests that antibodies can be 
successfully produced using smaller amounts of immunogen than are traditionally considered 
necessary. This is of particular significance where the required immunogen is unstable in its 
purified form or starting material is limited, as is commonly the case with parasite enzymes. 
Table 4: Comparison of immunisation protocols used to produce antibodies against 
various parasite cysteine proteinases. 
Parasite species 
T. b. brucei 1 
~ . 2 . manson[ 
L. mexicana 3 
T. congolense 4 
T. cruzi 5 
F hepatica 6 
Ancylostoma caninum 7 
nr Not reported. 
References: 
I Present study 
4 Mbawa et al. (1991a) 





used (Ilg) (weeks) 
30 6 chicken 
500 4 rabbit 
100 4 rabbit 
180 4 rabbit 
200 9 rabbit 
250 I nr rabbit 
200 6 rabbit 
2 Michel et al. (1995) 3 llg et al. (1994) 
5 Souto-Padron et al. (1990) 6 Smith et al. (1993) 
These antibodies produced against whole trypanopain recognised the enzyme in ELISAs and 
Western blots, paving the way for the use of these antibodies as tools for various studies. As 
previously reported for T. b. rhodesiense, (pamer et aI. , 1991), three bands were recognised by 
anti-trypanopain antibodies in lysed T. b. brucei. Pamer et al. (1991) suggest from analysis of 
the trypanopain gene coding region that these are likely to be processing intermediates of the 
enzyme. Pulse-chase studies are required to confirm this suggestion. 
While the cDNA of trypanopain from T. b. brucei and T. b. rhodesiense has been sequenced 
(Mottram et aI., 1989; Pamer et aI., 1990), the enzyme has not previously been purified to 
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electrophoretic homogeneity and hence little is known about trypanopain's basic enzymatic 
properties. To this end, the pH profile for the hydrolysis of synthetic and protein substrates, the 
effect of various reducing agents, and the enzyme's specificity for synthetic and protein 
substrates were investigated and are reported in the following chapters. 
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Chapter 4 
Enzymatic characterisation of trypanopain-Tb 
4.1 Effect of pH on trypanopain activity against Z-Phe-Arg-AMC 
When assessing the effect of pH on enzyme activity, it is important to maintain a constant ionic 
strength across the pH range investigated. Changes in ionic strength can affect ionisation of 
protein side chains and so, in turn, can affect enzyme activity independently of pH changes 
(Dehrmann et al. 1995; 1996). Maintenance ofa constant ionic strength across the range of pH 
values tested ensures that changes in activity can be ascribed to changes in pH alone (Ellis and 
Morrison, 1982). For this study, an acetate-2(N-morpholino )ethanesulphonic acid (MES)-Tris 
(AMT) buffer system with an ionic strength of 0.1 was chosen, covering the pH range from 4.0 
to 9.0 (Ellis and Morrison, 1982). 
Trypanopain-Tc is optimally active against Z-Phe-Arg-AMC between pH 5.5 to 6.0 (Lonsdale-
Eccles and Mpimbaza, 1986; Mbawa et al., 1992) while cruzipain is optimally active against 
this substrate between pH 5.0 and 7.0 (Murta et a!. , 1990)- Studies on partially purified 
trypanopain from T b. brucei indicated that the enzyme has a pH optimum against Z-Phe-Arg-
AMC of between 6.0 and 8.0 (Huet et al., 1992). 
4.1.1 Materials 
As per Section 3.2.1 . 
I AMT buffers (100 mM Na-acetate, 200 mM Tris-Cl, 100 mM MES, 6 mM DTT and 4 mM 
Na£DTA). Glacial acetic acid (1.72 rnI), MES (5.86 g), Tris (7.27 g) and Na2EDTA.2H20 
(0.37 g) were dissolved in H20 (200 rnI). This solution was divided into 10 aliquots (20 rnl 
each) which were titrated to pH values in the range 4.0 to 9.0 using HCI or NaOH and each 
diluted to 25 rnl with H20. DTT (6 mM, 1.4 mg/1. 5 rnI) was added just before use. 
4.1.2 Method 
Trypanopain (1.5 ng) hydrolysis ofZ-Phe-Arg-AMC at 37°C was measured using stopped-time 
) 
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assays as described in Section 3.2.3, except that assay buffer was replaced by AMT buffers in 
the pH range 4.0 to 9.0. 
4.2 Effect of pH on activity against 14C-gelatin 
For a more accurate estimate of trypanopain' s in vivo pH requirements, the optimal pH for 
digestion of a protein substrate by the enzyme was investigated. Zymogram analysis of lysed 
T. b. brucei suggests that trypanopain has a pH optimum of 5.0 to 6.0 for digestion of 
fibrinogen and collagen (Lonsdale-Eccles and Mpimbaza, 1986). Since only small amounts of 
purified trypanopain were available, a highly sensitive assay was required. Radio-labelled 
gelatin was found to be the most suitable of the potential substrates investigated, since 
preliminary studies showed that its sensitivity far surpassed that of other available methods 
e.g. azocasein (Barrett and Kirschke, 1981) and biotin- (Koritas and Atkinson, 1995) or 
fluorescein-labelled proteins (De Lumen and Tappel, 1970; Twining, 1984). 
4.2.1 Materials 
AMT buffers. As for Section 4.1 .1 
14C-Gelatin (1 mglml) was a gift from Dr Theresa Coetzer, Department of Biochemistry, UNP. 
Briefly, 14C_type IV collagen was prepared according to the method of Cawston and Barrett 
(1979) using [1_14C] acetic anhydride, which reacts primarily with the E-amino groups of lysine 
residues within the target protein. 14C_type IV collagen was converted to 14C-gelatin by 
incubation at 44°C for 2 h. 
Stop solution [15% (m/v) trichloroacetic acid (TCA), 0.75% (m/v) tannic acid]. TCA (1.5 g) 
and tannic acid (0.075 g) were dissolved in 7 ml of H20 and made up to 10 ml with H20. 
Scintillation cocktail [40% (v/v) Lumax in toluene]. Lumax (400 ml) was mixed with toluene 
(600 ml). 
4.1..2 Method 
Trypanopain (6 ng) was diluted to 375 /-L1 with 0.1 % (m/v) Brij-35 and incubated with AMT 
buffers in the pH range 4.0 to 9.0 (375 Ill, 10 min, 37°C). 14C-Gelatin (100 /-Ll) was added and 
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digestion allowed to proceed for 15 hat RT. Stop solution (100 Ill) was added and the mixture 
maintained on ice for 30 min. Following centrifugation (10000xg, 15 min, 25°C), the 
supernatant (500 Ill) was mixed with scintillation cocktail (5 rnI) and the counts per minute read 
in a Packard Tri-Carb Liquid Scintillation counter. 
4.3 EtTect of reducing agents on trypanopain activity against Z-Phe-Arg-AMC 
Since cysteine proteinase activity is dependent on reduction of the active site cysteine residue, 
these enzymes are usually pre-incubated with reducing agents before activity is measured 
(Dunn, 1989a). The effects of various concentrations of the reducing agents DTT, cysteine, 
~-mercaptoethanol and reduced glutathione on trypanopain hydrolysis of Z-Phe-Arg-AMC 
were investigated to determine which is the most effective activator oftrypanopain activity. 
4.3.1 Materials 
As for Section 3.2. 1, except that various reducing agents were used in the assay buffer. 
DTT (1 M). DTT (1.4 mg) was dissolved in H20 (200 Ill) on the day of use. 
Cysteine (1 M). Cysteine.HCl (0.035 g) was dissolved in H20 (200 Ill) on the day of use. 
B-mercaptoethanol (1 M). ~-mercaptoethanol (14 Ill) was diluted to 200 III with H20 on the 
day of use. 
Reduced glutathione (1 M). Reduced glutathione (0.064 g) was dissolved in H20 (200 I-ll) on 
the day of use. 
4.3.2 Method 
Trypanopain activity against Z-Phe-Arg-AMC was measured using stopped-time assays as 
described in Section 3.2.2, except that various reducing agents were used in the assay buffer. 
Trypanopain (1 .5 ng) was thus activated for 1 min with assay buffer containing DTT, cysteine, 
reduced glutathione or ~-mercaptoethanol (dilutions of stock solutions above giving 1-250 mM 
final concentration) before substrate addition. 
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4.4 Optimal time of activation by cysteine 
In order to reproducibly assay cysteine proteinases using stopped-time assays, the enzyme must 
be fully reduced when substrate is added so that total substrate hydrolysis during the assay is 
not Im:llted by time taken for enzyme activation. The optimal time required for activation of 
trypanopain by cysteine (at its optimal final concentration of30 mM, determined ,in Section 4.3) 
was thus investigated. 
4.4.1 Materials 
As for Section 3.2.1, except that the revised trypanopain synthetic substrate assay buffer 
[400 mM sodium phosphate, 60 rnM cysteine, 4 rnM Na2EDTA, 0.02% (m/v) NaN3, pH 7.0] 
described in Section 4.8.6 was used, giving a final cysteine concentration of30 rnM. 
4.4.2 Method 
Trypanopain (l.5 ng) was assayed as described in Section 3.2.2 except that the enzyme was 
pre-incubated in assay buffer for various lengths of time (0-7 min) before addition of 
Z-Phe-Arg-AMC. 
4.5 Effect of pH on trypanopain stability 
The stability of an enzyme is pH-dependent and the pH at which an enzyme is optimally stabile 
may differ from the pH at which it is optimally active. There are three main approaches to the 
study of pH stability. The enzyme under study can be pre-incubated at various pH values and 
then assayed at those values, which assesses a combination of pH stability and pH activity. 
Secondly, after pre-incubation at various pH values, the enzyme can be assayed at its optimal 
pH, giving a better reflection of the effect of pH on stability without the influence of pH on 
activity. Thirdly, hydrolysis of the substrate can be monitored continuously at various pH 
values with excess substrate and the decrease in velocity over time used to calculate the half-life 
of the enzyme at each pH. To assess the influence of pH on trypanopain stability alone, the 
second method was used. Trypanopain was thus incubated at different pH values in the range 
pH 4.0 to 9.0 and then assayed at pH ~ against Z-Phe-Arg-AMC. 
4.5.1 Materials 
AMT buffers. As per Section 4.1.1. 
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Assay buffer [400 ruM sodium phosphate, 60 ruM cysteine, 4 ruM Na2EDTA 0.02% (m/v) 
NaN3, pH 7.0]. As described in Section 4.8.6. 
4.5.2 Method 
To determine the pH stability of trypanopain in the absence of reducing agents, trypanopain 
(15 ng) was incubated in AMT buffers (100 mM, pH 4.0 to 9.0, 25 Ill) without cysteine for 1 h 
at 37°C. Assay buffer (50111) was added and residual trypanopain assayed using stopped-time 
assays as described in Section 3.2.3. The molarity of the second assay buffer (400 mM) was 
high enough to ensure that an optimum pH of 7.0 was maintained during this section of the 
assay. 
To determine pH stability in the presence of reducing agents, trypanopain (15 ng) was 
incubated in AMT buffers (100 mM, pH 4.0-9.0, 25 Ill) containing cysteine (30 mM final 
concentration) for 1 h at 37°C. The enzyme was assayed using stopped time assays as 
described in Section 3.2.3 . The assay buffer (50 Ill) subsequently added contained additional 
cysteine, maintaining a final cysteine concentration ono mM. 
4.6 Specificity for synthetic substrates 
At the outset of this study, no analysis of the specificity of trypanopain for synthetic substrates 
had been reported. However, since both trypanopain-Tc (Mbawa et aI., 1992) and cruzipain 
(Cazzulo et aI. , 1990b; Murta et aI. , 1990) are cathepsin L-like (Barrett and Kirschke, 1981), 
the same is likely to be true of trypanopain from T b. brncei. Once trypanopain had been 
purified to electrophoretic homogeneity, this hypothesis was tested by examining trypanop~n 
hydrolysis of a range of synthetic substrates. 
The active site of a proteinase can be divided into sub sites, each of which interacts with a single 
amino acid residue of the substrate (Schechter and Berger, 1967; Figure 19). Schechter and 
Berger (1967) devised a nomenclature system that is still widely used to describe these subsites. 
They proposed that the proteinase sub sites on the N-terminal side of the susceptible peptide 
bond be referred to as the Sl, S2 etc. sites and those on the C-terminal side of the susceptible 
bond as the S' 1, S' 2 etc. sites. The corresponding amino acid residues of the substrate are 
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referred to as Pi, P2, P'I, P' 2 etc. For papain-like cysteine proteinases, specificity is primarily 
governed by the S2 and SI' binding sites (reviewed in Turk et aI. , 1997). 
Cleavage point 
1 
S' 1 S' 2 
Figure 19: Schechter and Berger notation for proteinase subsites. 
This notation is used to describe subsites of a proteinase active site and the corresponding substrate 
amino acid residues. Amino acid residues on the N-tenninal side of the scissile bond are tenned PI, P2 
etc, while those on the C-terrninal side are denoted PI', P2' etc. The corresponding proteinase subsites are 
denotedS I, S2 ... SI ', S2' etc. After Schechter and Berger (1967). 
The steady-state kinetics of enzyme hydrolysis of a single substrate can be considered in terms 
of the Briggs and Haldane (1925) revision of the Michaelis-Menten equation, which states that 
the initial velocity (vo) of such a reaction is hyperbolically related to the initial substrate 




where Vo is the initial rate of substrate hydrolysis (M.S·I) 
V max is the maximum reaction velocity (M.S·I) 
[S] is the initial substrate concentration (M), and 
Kn, is the Michaelis constant (M). 
The reaction between a substrate and enzyme cin be described by the two kinetic constants 
V m:LX and Kro. Km is defined as the substrate concentration required to reach half V max and is a 
measure of the affinity between the enzyme and a particular substrate. kcat, the turnover 
number, is equal to V maJ[E]o where [E]o is the initial enzyme concentration (expressed in M). 
kcat (with units of S·I) represents the maximum number of substrate molecules that can be turned 
over by the enzyme per second. (pamer, 1981) Km and kcat can be determined experimentally 
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by measuring Vo at various [S] and fitting the data to a hyperbolic curve (price and Stevens, 
1989). Since it is mathematically easier to fit such experimental data to a straight line, various 
straight-line transformations of the Michaelis-Menten plot have been derived. These include the 
Lineweaver-Burk plot (Lineweaver and Burk, 1934), the Eadie-Hofstee plot (Eadie, 1942; 
Hofstee, 1952), the direct linear plot ofEisenthal & Cornish-Bowden (Eisenthal and Cornish-
Bowden, 1974; Cornish-Bowden and Eisenthal, 1974) and the Hanes plot (Hanes, 1932). 
While the Lineweaver-Burk is the most commonly used, it is the least statistically valid 
(Cornish-Bowden, 1995). For small values ofvo, small errors lead to large errors in I/vo, while 
for large va, these same small errors lead to small errors in lIvo. This transformation thus gives 
misleading impressions of experimental error. The Eadie-Hostee and Hanes plots also have 
various statistical limitations, albeit less marked than the Lineweaver-Burk plot 
(Cornish-Bowden, 1995). The direct linear plot is considered by many authors as the most 
reliable of the methods listed above. 
4.6.1 Materials 
The following peptide AMC substrates were all dissolved in DMSO to make 1 mM stock 
solutions: 
Arg-AMC HCI (Cambridge Research Chemicals); Benzoyl (Bz)-Arg-AMC HCI. Yz Hill 
(Bachem); Z-Arg-AMCHCI (Bachem); Z-Arg-Arg-AMC 2 AcOH (BacHem); Z-Ala-Arg-
Arg-AMC 2 acetate (Bachem); Z-Phe-Arg-AMC (Bacherri); Pro-Phe-A.rg-AMC 2 HCI. 
2~i} (Bachem); Glu-Gly-Arg-AMC (NovaBiochem); Z-Gly,Gly-Arg-AMCHCI 
(Cambridge Research Chemicals); Butoxycarbonyl (Boc)-Val-Gly-Arg-AMC HCI (Bachem); 
Boc-Leu-Gly-Arg-AMC HCI. 1 Yz Hill (NovaBiochem); Boc-TIe-Glu-Gly-Arg-AMC 
" 
(peninsula Laboratories); Z-Pro-Arg-AMC (Bachem); Bz-Phe-Val-Arg-AMC. 2 Hill 
(Bachem); D-Val-Leu-Lys-AMC 2 AcOR. 1.6 Hi} (Bachem); D-Ala-Leu-Lys-AMC lYz 
Hill (Bachem); Sl;lccinyl (Suc)-Ala-Phe-Lys-AMC 1 Yz TF A Hi} (Bachem); Ala-Phe-Lys-
AMC (Bachem); Ae---Ala-Ala-Pro-Ala-AMC (Bachem); Suc-Leu-Tyr-AMC (Sigma); Ac-Ala-
Ala-Tyr-AMC (Bachem); .Leu-AMC Hi} (Bachem); ,Gly-AMC HBr (Bachem); Z-Gly-Pro-
AMC (Bachem); ~ethoxysuccinyl (MeOSuc)-Asp-Tyr-Met-AMC (Bachem);v MeOSuc-Gly-
Leu-Phe-AMC (Bachem); MeOSuc-Gly-Trp-Met-AMC (Bachem); Suc-Ala-Ala-Phe-AMC 
(Sigma); Glu-Gly-Gly-Phe-AMC (Bachem). 
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4.6.2 Method 
The concentration of active trypanopain was determined by titration against E-64 as described 
in Section 3.4. Various concentrations of readily hydrolysed substrates (25-100)lM final 
concentration) were incubated with trypanopain (0.05 pmol, 1.5 ng) in stopped-time assays for 
10 minutes at 37°C as described in Section 3.2.3, while poorly hydrolysed substrates 
(25-100)lM final concentration) were incubated with trypanopain (0.05 pmol, 1.5 ng) in 
stopped-time assays as described in Section 3.2.3 for 4 h at 37°C to allow increased substrate 
hydrolysis. 
With excess substrate, the reaction velocity for the poorly hydrolysed substrates was assumed 
to be constant over the 4 h assay period and so stopped-time assays (Section 3.2.3) were 
considered adequate to approximate Vo. However, for the most rapidly hydrolysed substrates, 
Vo was determined more accurately from continuous assays performed over 10 min at each 
substrate concentration. Kinetic constants calculated for Z-Phe-Arg-AMC from continuous 
and stopped-time assays were compared to assess the validity of using stopped-time assays to 
calculate kinetic constants for other, less rapidly hydrolysed substrates. The software package 
Hyper 1.01 (© 1991-1992, Dr 1. S. Easterby, University of Liverpool, UK) was used to 
determine Km, V m.1X and kcat using the Hanes, Lineweaver-Burk, Michelis-Menten, 
Eadie-Hofstee and direct linear plots. 
4.7 Hydrolysis of proteins 
Since par.asitic cysteine proteinases have been postulated to contribute to pathogenesis by 
hydrolysing various host proteins (Rautenberg et al., 1982; Raimondi et al., 1991 ; Mbawa 
et aI. , 1992; Authie et a!. , 1994), trypanopain hydrolysis of albumin, fibrinogen and IgG was 
investigated. Trypanopain-Tc has been shown to degrade IgG, albumin and fibrinogen in vitro 
(Mbawa et aI., 1992), while cruzipain degrades gelatin (Tomas and Kelly, 1994), oxidised 
insulin A and B chains (Raimondi et a!. , 1991), casein, BSA, denatured haemoglobin (Bontempi 
et a!. , 1984) and IgG (Bontempi et a!., 1990) in vitro. 
4.7.1 Materials 
Test proteins. Fibrinogen (100 )lM, 34 mg), BSA (1 mM, 68 mg) and rabbit immunoglobulin 
(IgG, 100 )lM, 16 mg) were dissolved in O.l % (mlv) Brij-3 5 diluent (1 mI, Section 3.2.1). 
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Protein assay buffer. As per Section 4.8.6. 
4.7.2 Method 
Fibrinogen (8.8 JlM final concentration) was incubated with trypanopain (88 nM or 8.8 nM 
final concentration, to give 1: 100 and 1: 1000 molar ratios of enzyrne:fibrinogen respectively) in 
assay buffer (30 mM final cysteine concentration) at 37°C for 0, 15, 30 and 60 min. Aliquots 
were removed at the stated intervals and the reaction stopped by addition ofE-64 (1 mM final 
concentration). Samples were mixed with an equal volume of reducing treatment buffer, boiled 
for 90 sec and electrophoresed as per Section 2.4. 
BSA (100 JlM final concentration) was similarly incubated with trypanopain (1 JlM or 100 nM 
final concentration to give 1:500 and 1:1000 molar ratios of enzyme:BSA respectively). IgG 
(25 JlM final concentration) was similarly incubated with trypanopain (250 nM or 25 nM to 
give 1: 100 and 1: 1000 molar ratios of enzyme:IgG respectively). 
4.8 Results 
4.8.1 Effect of pH on trypanopain activity against Z-Phe-Arg-AMC 
Trypanopain activity against Z-Phe-Arg-AMC was optimal across a fairly wide plateau between 
pH 6.5 and 8.0 (Figure 20). Outside of this range, enzyme activity was substantially lower. All 
subsequent assays against Z-Phe-Arg-AMC were thus carried out at pH 7.0, in the optimal pH 
range, using 400 rnM NaH2P04 (see Section 4.8.6 for revised synthetic substrate assay buffer) 
4.8.2 Effect of pH on activity against 14C-gelatin 
Trypanopain activity against 14C-gelatin was optimal at pH 5.5, with activity dropping markedly 
on either side of this optimum (Figure 21). In contrast with activity against Z-Phe-Arg-AMC, 
trypanopain was thus active against 14C-gelatin across a narrower pH range and at more acidic 
pH values. Minimal activity was observed at physiological pH values. All subsequent assays 
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Figure 20: Effect of pH on trypanopain activity against Z-Phe-Arg-AMC. 
Trypanopain (1.5 ng) was assayed against Z-Phe-Arg-AMC at 37°C in quintuplicate stopped-time 
assays as described in Section 3.2.3, except that the assay buffer was replaced by AMT buffers (ionic 
strength 0.1 , 100 mM, pH 4.0 to 9.0) with DTT (6 mM) as reducing agent. 
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Figure 21 : Effect of pH on trypanopain activity against 14C-gelatin. 
Trypanopain (6 ng) was incubated with 14C-gelatin for 15 hat RT in quintuplicate stopped-time assays. 
Stop solution was added and the mixture maintained on ice for 30 min. Following centrifugation 
(4800 xg, 15 min, 25°C), the supernatant (500 Ill) was mixed with scintillation cocktail (5 ml) and the 
counts per minute read in a Packard Tri-Carb Liquid Scintillation counter. 
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4.8.3 Effect of reducing agents on trypanopain activity against Z-Phe-Arg-AMC 
Trypanopain was inactive against Z-Phe-Arg-AMC in the absence of reducing agents, while 
DTT, cysteine, ~-mercaptoethanol and reduced glutathione all enhanced trypanopain activity 
(Figure 22). This indicates that trypanopain displays typical cysteine proteinase latency. At low 
concentrations (up to 50 mM), cysteine was the most effective reducing agent, ~th an optimal 
concentration of 30 mM. While DTT was also most effective at low concentrations (20 mM 
optimal), ~-mercaptoethanol was more effective at higher concentrations (optimal at 250 mM, 
not shown). Reduced glutathione was a comparatively poor activator. Cysteine (30 mM final 
concentration) was thus used as reducing agent for all subsequent assays (see Section 4.8.6 for 
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Figure 22: Effect of reducing agents on trypanopain activity against Z-Phe-Arg-AMC. 
Trypanopain (1.5 ng) was assayed against Z-Phe-Arg-AMC at 37°C in quintuplicate 
stopped-time assays as described in Section 3.2.2, except that various concentrations of DTT 
(11), cysteine (A), ~-mercaptoethanol (T) or reduced glutathione (e) were used as reducing 
agents. 
4.8.4 Optimal activation time with cysteine 
Highest trypanopain activity was observed after 1 min pre-activation with cysteine (Figure 23). 
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Figure 23 : Optimal time oftrypanopain activation with 30 mM cysteine. 
Trypanopain (1.5 ng) hydrolysis of Z-Phe-Arg-AMC at 37°C was monitored usmg standard 
quintuplicate stopped-time assays (Section 3.2.2), except that the enzyme was activated with cysteine 
(30 mM) for 0-7 minutes before addition of Z-Phe-Arg-AMC. 
4.8.5 Effect of pH on trypanopain stability 
Below pH 7.5, trypanopain was slightly more stable in the absence of cysteine than in its 
presence (Figure 24). When pre-incubated without cysteine, trypanopain was relatively stable 
from pH 4.0 to 7.0, but above this pH the stability decreased sharply. In the presence of 
cysteine, tlypanopain was moderately stable between pH 4.0 and 8.0, above which decreased 
stability was observed (Figure 24). 
4.8.6 Revised trypanopain assay buffers 
The results in .Sections 4.8.1 to 4.8.4 necessitated modification of the cathepsin L assay buffer 
described in Section 3.2.1 for optimal assay of trypanopain activity. A Na-phosphate buffer of 
pH 7.0 was chosen as the synthetic substrate assay buffer. This buffer contained 400 mM 
NaH2P04.2H20 (62.4 gil), 4 mM Na2EDTA.2H20 (1.5 gil), 60 mM cysteine (10.51 gil) and 
0.02% (m1v) NaN3 (0.2 gil). Thus for standard assays against Z-Phe-Arg-AMC, trypanopain . 
. [diluted to 250 ~l in 0.1% (m1v) Brij-35] was pre-activated for 1 min in synthetic substrate 
assay buffer (500 ~l) before addition of Z-Phe-Arg-AMC (250 ~l of 20 ~ solution). After 
10 min, stop reagent (1 mJ) was added and the fluorescence read. For micro-assays, 1/10 
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volumes of the above reagents were used. 
F or subsequent experiments using 14C-gelatin as a substrate, a "protein assay buffer" of 
200 mM Na-acetate (11.45 ml acetic acidll), 1 mM Na2EDTA (0.37 gil), 68 rnM cysteine 
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Figure 24: Effect of pH on the stability of trypanopain in the presence or absence of cysteine. 
Trypanopain (15 ng) was incubated for 1 h at 37°C in AM[ buffers (100 mM, 0.1 ionic strength) over 
the pH range 4.0 to 9.0 (quintuplicate samples at each pH). Cysteine (30 mM) was either present (e) or 
absent (0) during pre-incubation. Residual enzyme activity against Z-Phe-Arg-AMC was determined 
using stopped-time assays as described in Section 3.2.3. 
4.8.7 Hydrolysis of synthetic substrates 
Of the synthetic substrates tested, Z-Phe-Arg-AMC was most readily cleaved by trypanopain, 
with a K.n of 1.2 11M and a kcat of 13.4 S-I, giving a kcatt'Krn of 11.3 S-I.I1Ml (Table 5). 
Pro-Phe-Arg-AMC was also readily hydrolysed with a K.n of 4.2 11M and a keat of 4.2 S-I, 
(kcatt'Krn of 1 S-I.I1M\ Table 5). Compared with these two substrates, other tested substrates 
were poorly hydrolysed. Generally, only substrates with Phe in P2 and Arg in PI were 
significantly cleaved (notation of Schechter and Berger, 1967). The cathepsin B substrate 
(Barrett and Kirschke, 1981) Z-Arg-Arg-AMC was comparatively poorly hydrolysed (keatt'Krn 
of 0.01 s-I.I1M
1 in 4 h assay). 
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As Z-Phe-Arg-AMC was by far the best of the substrates tested, a more accurate determination 
of its kinetic constants was undertaken, with Vo determined more accurately from continuous 
assays performed at a range of substrate concentrations (Figure 25). Km (0.93 ~M) and kcat 
(9.9 S-I) values calculated using this method were very similar to those calculated initially from 
10 minute stopped time assays (1.2 ~M and 13.4 S-1 respectively). This suggests that stopped 
time assays provide a reasonably accurate estimate of kinetic constants and that the values given 
below (Table 5) for the other substrates tested are thus reliable. 
Table 5: Kinetic constants for trypanopain hydrolysis of various AMC substrates. 
Values are calculated at 37°C from 10 minute or 4 h (*) quintuplicate stopped-time assays as described 
in Section 3.2.3, using various substrate concentrations (25-100 1lM). Results below represent the 
average of Km and ~ values determined using the Hanes, Lineweaver-Burk, Michaelis-Menten, Eadie-
Hofstee and direct linear plots. 
Substrate Km(~M) kcat (S-I) kcatlK.n( S-1 . IlM 1) 
*Z-Arg-Arg-AMC 12 0.126 0.01 
Z-Phe-Arg-AMC 1.2 13.4 11.3 
Pro-Phe-Arg-AMC 4.2 4.2 1 
Val-Leu-Lys-AMC 25 8.2 0.32 
Ala-Leu-Lys-AMC 27 6.5 0.24 
Suc-Ala-Phe-Lys-AMC 42 0.006 0.002 
Ala-Phe-Lys-AMC 28 5.2 0.19 
*Suc-Leu-Tyr-AMC 54 0.05 0.001 
*MeOSuc-Asp-Tyr-Met-AMC 68 0.09 0.00.1 
*MeOSuc-Gly-Trp-Met-AMC 4 0.04 '- 0.0105 
Note: Bz-Arg-AMC, Z-Arg-AMC, Z-Ala-Arg-Arg-AMC, Arg-AMC, Glu-Gly-Arg-AMC, Z-Gly-
Gly-Arg-AMC, Boc-Val-Gly-Arg-AMC, Boc-Leu-Gly-Arg-AMC, Boc-lle-Glu-Gly-Arg-AMC, 
Z-Pro-Arg-AMC, Ac-Ala-Ala-Pro-Ala-AMC, Ac-Ala-Ala-Tyr-AMC, Leu-AMC, Gly-AMC, Z-Gly-
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Figure 25 : Calculation ofKm and kcat values for trypanopain hydrolysis ofZ-Phe-Arg-AMC. 
a) Michaelis-Menten curve, (b) Lineweaver-Burk plot, (c) Eadie-Hofstee plot and (d) Hanes plot for 
trypanopain (0.05 pmol) hydrolysis of Z-Phe-Arg-AMC (O.1-to 11M) at 37°C. Initial velocities (vo in 
pmol AMC/s) were measured from quintuplicate continuous assays at different substrate concentrations, 
[S] in 11M. 
4.8.8 Hydrolysis of proteins 
Trypanopain readily degraded the a- (67 kDa) and ~-chains (56 kDa) of fibrinogen (Jakubke 
and Jeschkeit, 1983) within 15 min when incubated at a 1: 100 molar ratio of enzyme:fibrinogen 
(Figure 26). The y-chain (47 kDa), however, remained resistant for the full hour. By 
comparison, the entire fibrinogen molecule was resistant to degradation over 1 h at a 1: 1 000 
molar ratio of enzyme: fibrinogen. Trypanopain readily degraded BSA at 1 :500 and 1: 1 000 
molar ratios of enzyme:BSA (Figure 27), with more degradation observed at the higher enzyme 







substantial degradation was already evident after 15 min at both enzyme concentrations. 
Trypanopain readily degraded IgG at both a 1: 100 and 1: 1 000 molar ratio of enzyme:IgG 
(Figure 28). A similar degree of digestion was observed with both concentrations of enzyme, 
with only slightly greater degradation seen at the higher enzyme concentration. 
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Figure 26: Trypanopain digestion of fibrinogen. 
Fibrinogen was incubated with trypanopain in assay buffer at 37°C for 0, 15, 30 and 60 min. 
Aliquots were removed at the stated time intervals and the reaction stopped by addition ofE-64 
(1 mM final concentration). Samples were electrophoresed as per Section 2.4, using reducing 
treatment buffer. Trypanopain (88 nM) digestion of fibrinogen (8.8 11M, 1: 100 molar ratio of 
enzyme:fibrinogen) after 0 min (lane 1), 15 min (lane 2), 30 min (lane 3) and 60 min (lane 4), 
Pharmacia molecular mass markers (Section 2.4), and trypanopain (8.8 nM) digestion of 
fibrinogen (8.8 11M, 1: 1 000 molar ratio of enzyme:fibrinogen) after 0 min (lane 6), 15 min 
(lane 7),30 min (lane 8) and 60 min (lane 9) are shown. The molecular mass of the fibrinogen 
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Figure 27: Trypanopain digestion ofBSA. 
BSA was incubated with trypanopain in assay buffer at 37°C for 0, 15,30 and 60 min. Samples 
were prepared as in Figure 26. Trypanopain (100 nM) digestion ofBSA (100 )lM, 1: 1 000 
molar ratio of enzyme:BSA) after 0 min (lane 1), 15 min (lane 2), 30 min (lane 3) and 60 min 
(lane 4), Pharmacia molecular mass markers (lane 5, Section 2.4), and trypanopain (200 nM) 
digestion of BSA (100 )lM, 1:500 molar ratio of enzyme:BSA) after 0 min (lane 6), 15 min 
(lane 7), 30 min (lane 8) and 60 min (lane 9) are shown. 
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Figure 28: Trypanopain digestion ofIgG. 
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Trypanopain (250 nM) digestion ofIgG (8.8 )lM, 1:100 molar ratio ofenzyme:JgG) after 0 min (lane 1), 
15 min (lane 2), 30 min (lane 3) and 60 min (lane 4), Phannacia molecular mass markers (Section 2.4) 
and trypanopain (25 nM) digestion of IgG (8.8 )lM. 1: 1000 molar ratio of enzyme: IgG) after 0 min 
(lane 6), 15 inin (lane 7), 30 min (lane 8) and 60 min (lane 9) are shown. 
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4.9 Discussion 
Trypanopain was shown to be optimally active against Z-Phe-Arg-AMC between pH 6.5 and 
8.0. This is in agreement with previous studies carried out with partially purified trypanopain 
(Huet et aI. , 1992). By comparison, other trypanosomal cysteine proteinases are optimally 
active at slightly more acidic pH values, with trypanopain-Tc optimally active ~gainst Z-Phe-
Arg-AMC between pH 5.5 and 6.0 (Lonsdale-Eccles and Grab, 1987a; Mbawa et aI., 1992) 
and cruzipain optimally active between pH 5.0 and 7.0 (Murta et aI. , 1990; Stoka et al., 1995). 
A cysteine proteinase from the nematode Nippostrongylus brasiliensis is also optimally active 
against Z-Phe-Arg-AMC at pH 5.5 (Kamata et aI., 1995). Mammalian cathepsins are generally 
also optimally active at slightly more acidic values than trypanopain, with cathepsin H optimally 
active against Arg-AMC at pH 6.8 (Barrett and Kirschke, 1981) and cathepsin L against Z-Phe-
Arg-AMC at pH 6.5 (Dehrrnann et aI. , 1995). Cathepsin B, however, is optimally active 
against Z-Arg-Arg-AMC at pH 7.0-8.0 (Dehrrnann et aI., 1996). 
Trypanopain was optimally active against the proteinaceous substrate 14C-gelatin at pH 5.5, 
which is more in line with the acidic pH optimum expected for a lysosomal cysteine proteinase. 
These results confirm previous zymogram studies using lysed T. b. brucei, which suggested that 
trypanopain is optimally active against fibrinogen at pH 5.0 and against collagen at pH 6.0 
(Lonsdale-Eccles and Mpimbaza, 1986). Cruzipain is optimally active against IgG and gelatin 
between pH 5.0 and 7.5 (Murta et al ., 1990). Since a pH optimum determined using a 
proteinaceous substrate is more likely to be physiologically relevant than a pH optimum 
determined using a synthetic substrate, it is considered likely that the pH optimum of 
trypanopain against its natural substrates is approximately pH 5.5. 
Trypanopain displays typical cysteine proteinase latency (North et aI. , 1990a), in that it is only 
active in the presence of reducing agents. Such latency has been reported for trypanopain-Tc, 
cruzipain and crude trypanopain-Tb (Rautenberg et aI. , 1982; Lonsdale-Eccles and Grab, 
1987a; Murta et aI. , 1990). DTT (4-5 mM) and ~-mercaptoethanol (10 mM) are commonly 
used for activation oftrypanopain-Tc (Mbawa et aI., 1992) and cruzipain (Cazzulo et aI., 1989; 
Lima et aI. , 1992). Compared with these enzymes, it appears that trypanopain requires slightly 
higher concentrations of reducing agents for maximal activation. 
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To ensure a constant maximum reaction rate during a stopped-time assay of a cysteine 
proteinase, it is necessary to fully reduce the active site cysteine residue before addition of the 
substrate. Trypanopain was shown to require 1 min pre-activation in assay buffer before 
maximum levels of activity were reached. Decreased levels of activity were seen if the enzyme 
was activated for longer than 1 min. For example, less than half the activity present after 1 min 
activation remained if trypanopain was activated for 7 min. This suggests that the active 
enzyme may undergo substantial autocatalysis in the absence of an added substrate. 
Continuous assays against Z-Phe-Arg-AMC indicated that the reaction velocity over 20 min 
was unchanged, suggesting that trypanopain does not undergo any appreciable autocatalysis 
when in the presence of substrates such as Z-Phe-Arg-AMC. Autocatalysis thus appears to 
occur only when active trypanopain has no potential substrate present other than neighbouring 
trypanopain molecules. For this reason, reducing agents were omitted from all buffers used 
during purification of trypanopain. However, sufficient endogenously activated enzyme and 
reducing agents are likely to have been present in the lysed parasites to cause some 
autocatalysis of trypanopain. Since the lysed parasites contain many potential trypanopain 
substrates, this effect is likely to have been minor initially, but would have increased with 
increasing enzyme purity. 
Across the pH range tested, trypanopain was more stable in the absence of cysteine than in its 
presence, supporting the contention that the active enzyme undergoes autocatalysis. 
Approximately 17% less enzyme was present after the 1 h incubation period if cysteine was 
present. Compared with the activation experiment discussed above, the lower percentage of 
autocatalysis over a longer time period is thought to be a function of the higher concentration of 
enzyme (and thus potential proteinaceous substrate for remaining active enzyme molecules) 
used. In both the presence and absence of cysteine, sharp decreases in stability were only 
observed at alkaline pH values, suggesting that trypanopain undergoes denaturation in alkaline 
conditions but is fairly stable in acidic environments. Trypanopain is both stable and active at 
the pH chosen for the assay of synthetic peptide or protein substrates (PH 7.0 and pH 5.5 
respectively). Cruzipain is very similar to trypanopain in this respect, being optimally stable 
between pH 4.5 and 9.5 (Stoka et aI. , 1995). 
As expected, trypanopain has cathepsin L-like specificity for synthetic substrates. 




substrates with more than one amino acid residue were cleaved by trypanopain, suggesting that 
the S2 site must be occupied by an amino acid for hydrolysis to proceed. Hydrophobic residues 
such as Phe, Leu, Tyr and Trp were accepted in the P2 position while basic (Arg) and small, 
uncharged (Ala, Gly) residues were not accepted. Further information about trypanopain's P2 
preferences was gained from comparisons of the kinetic parameters determined for the 
hydrolysis of various substrates with Lys instead of Arg in Pl . Since these substrates were 
poorly cleaved, requiring 4 h incubation periods to generate kinetic constants, the differences 
observed between the rates of hydrolysis of these substrates should be viewed with caution. 
Nevertheless, comparison of Ala-Leu-Lys-AMC and Ala-Phe-Lys-AMC suggests that 
substrates with Leu in P2 might be as good as, or slightly better than, those with Phe in P2. 
Unfortunately, Z-Leu-Arg-AMC is not commercially available and this hypothesis was 
therefore not tested. 
Comparison ofVal-Leu-Lys-AMC and Ala-Leu-Lys-AMC suggests that hydrophobic residues 
(e.g. Val) in P3 are slightly preferred over small, uncharged residues (e.g. Ala). Thus 
trypanopain is fairly specific in its catalysis of synthetic substrates. It acts most readily on 
substrates with basic residues (Arg, Lys in order of preference) in PI and hydrophobic residues 
in P2 (e.g. Leu, Phe) and P3 (e.g. Val) and non-acidic residues in P4. Similar specificity has been 
reported for trypanopain-Tc (Mbawa et aI., 1992), cruzipain (Cazzulo et aI. , 1990a), 
mammalian cathepsin L (Barrett and Kirschke, 1981; Dufour and Ribadeau-Dumas, 1988) and 
papain (Menard, 1993) (Table 6). Since the determinations were made at different 
temperatures, direct comparison of the kinetic constants is not possible. Nevertheless, 
trypanopain-Tc and cathepsin L appear to catalyse the hydrolysis of Z-Phe-Arg-AMC most 
rapidly, as they have the highest kcat values (17 S·l) even though analysed at lower temperatures. 
Trypanopain-Tb has the lowest Km for Z-Phe-Arg-AMC, indicating that trypanopain has 
comparatively high affinity for this substrate. 
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Table 6 : Kinetic constants for the hydrolysis of Z-Phe-Arg-AMC at various temperatures by 
human cathepsin L and the cathepsin L-like cysteine proteinases of various 
parasites. 
kcat (S-I) Km (/lM) Temperature Reference 
Parasite 
caC) 
F hepatica nd 15 37 Smith et-al. (1993) 
T. b. rhodesiense nd 0.85 nd Pamer et al. (1991) 
T. congolense 17 4.4 25 Mbawa et al. (1992) 
T. cruzi 3.1 10 37 Murta et al. (1990) 
T. cruzi 0.88 2.4 37 Lima et al. (1992) 
T. cruzi nd 1.8 30 Serveau et al. (1996) 
Human cathepsin L 17 2.4 30 Mason et al. (1985) 
T. b. brucei 13.4 1.2 37 Present study . . 
Note: nd not determined 
This study shows that trypanopain hydrolyses the cathepsin B substrate Z-Arg-Arg-AMC 
poorly. While trypanopain-Tc and trypanopain from T. b. rhodesiense do not hydrolyse Z-Arg-
Arg-AMC (pamer et al. , 1991; Mbawa et al., 1992), cruzipain does so readily (Cazzulo et al., 
1990a; Lima et al., 1992). 
Trypanopain readily degrades BSA, fibrinogen and IgG. It is, however, very difficult to suggest 
a physiological substrate for trypanopain and the enzyme's ability to degrade these proteins in 
vitro does not imply that they are physiological substrates. It does, however, confirm that 
mammalian proteins are potential substrates. 
Once the basic enzymatic properties of trypanopain had been elucidated, the interactions of the 
enzyme with various synthetic and naturally occurring host proteinase inhibitors were 
investigated. The results of these experiments are presented in the following chapter. 
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Chapter 5 
Trypanopain interactions with inhibitors 
5.1 Inhibitor profile 
Proteinases can be divided into four classes (namely, cysteine, serine, aspartic and 
metalloproteinases) on the basis of the amino acid residues in their active sites that are 
responsible for substrate catalysis. Most generally used low molecular mass proteinase 
inhibitors are specific for one class of proteinase, with the result that a proteinase can be 
assigned to one of the four main classes of proteinases (Hartley, 1960) on the basis of its 
sensitivity to these diagnostic inhibitors. 
Cysteine proteinases are specifically and irreversibly inhibited by epoxides (e.g. E-64), 
peptide diazomethylketones and alkylating agents [e.g. iodoacetate (lAA), iodoacetamide 
(IAN) and N-ethylmaleimide (NEM)]. Peptide diazomethylkettones will be discussed in 
more detail in Chapter 7. E-64 is the classical diagnostic inhibitor of cysteine proteinases 
that was first isolated from Aspergillus japonicus (Section 3.4). The alkylating agents 
react preferentially with active site cysteine residues, but also show some reactivity 
towards free thiols (Salvesen and Nagase, 1989). These inhibitors can be inactivated by an 
excess of reducing agent, so care must be taken when using them in cysteine proteinase 
assay buffers that contain reducing agents to activate the proteinase under study. The final 
concentration of reducing agent is minimised in such cases by pre-activating the enzyme in 
a small volume of concentrated reducing agent before addition of the inhibitor in a buffer 
free of reducing agents. 
• 
Serine proteinases are specifically and irreversibly inhibited by organophosphates 
[e.g. diisopropylphosphofluoridate (DFP)], sulfonyl fluorides [e.g. phenylmethylsulfonyl 
fluoride (PMSF) and 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF)] and coumarins 
[e.g. 3, 4-dichloroisocoumarin (DCI)] and reversibly by soybean trypsin inhibitor (SBTI, 
Salvesen and Nagase, 1989) and the arginine analogue, benzamidine (Powers and Harper, 
1986). 
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Metalloproteinases are inhibited by zinc chelators such as 1, 10-phenanthroline and EDT A 
(Salvesen and Nagase, 1989). Aspartic proteinases are characteristically inhibited by 
isovaleryl-Val-Val-statine-Ala-statine (pepstatin A), a pentapeptide-like compound 
secreted by Streptomyces species, which has two residues of the unusual ~-amino acid 
statine [(3S, 4S)-4-amino-3-hydroxy-6-methylheptanoic acid] (Salvesen and Nagase, 
1989). The statine residues enable pepstatin A to act as a transition state analogue for 
aspartic proteinases (Kay et al., 1983). 
Some inhibitors react with more than one class of proteinase. For example, the peptide 
aldehydes leupeptin and antipain inhibit both cysteine and serine proteinases (Rich, 1986; 
Salvesen and Nagase, 1989). In place of the normal a-carboxylate present in the backbone 
of a peptide chain, these reversible inhibitors contain an aldehyde moiety that reacts with 
the active site residues of proteinases. These inhibitors mimic the tetrahedral intermediate 
formed during peptide bond hydrolysis and are the only transition-state analogue inhibitors 
identified for cysteine proteinases to date (Rich, 1986). Peptidyl chloromethylketones 
[e.g. N-tosyl-L-lysyl chloromethylketone (TLCK) and N-tosyl-phenylalanyl 
chloromethylketone (TPCK)] are irreversible inhibitors of cysteine and serine proteinases. 
They bind the target enzyme in a substrate-like manner, and then alkylate the active site 
histidine of serine proteinases or the active site cysteine of cysteine proteinases. These 
inhibitors will be discussed in more detail in Chapter 7. 
Although trypanopain has not been previously isolated, preliminary inhibitor studies on crude 
lysed T b. bntcei suggest that the enzyme is a typical cysteine proteinase (Lonsdale-Eccles and 
Mpimbaza, 1986). Purified trypanopain-Tc and cruzipain are completely inhibited by E-64, 
mercurial compounds and cystatins and thus display typical cysteine proteinase inhibitor 
profiles. 
5.1.1 Materials 
As per Section 3.2.1, with the assay buffer of Section 4.8.6. 
The following inhibitors were dissolved in H20 (1 ml) on the day of use: 
IAA (100 roM, 20 mg), 
NEM (10 roM, l.3 mg), 
IAN (10 roM, l.9 mg), 
Leupeptin (1 roM, O.S mg), 
Antipain (1 roM, 0.6 mg) and 
EDTA (100 roM, 37 mg). 
The following inhibitors were dissolved in methanol (1 rnI) on the day of use: 
PMSF (100 roM, 17 mg) and 
TPCK (10 roM, 3S mg). 
The following inhibitors were dissolved in DMSO (1 ml) on the day of use: 
Pepstatin A (1 roM, 0.7 mg), 
E-64 (0.2 roM, 1 mg/1S ml), 
AEBSF (S roM, 1 mg) and 
Chymostatin (10 roM, 6 mg). 
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SBTI (10 11M; 1 mg/S ml) was dissolved in assay buffer (Section 4.8.6) on the day of use. 
TLCK (1 roM, 1.1 mg) was dissolved in 1 roM HCI (3 ml) on the day of use. 
DFP (100 roM). Extreme care was taken in the preparation of this highly toxic inhibitor. 
Stock DFP (5.43 M) was diluted in assay buffer (Section 4.8.6) to 100 mM and used 
immediately. All residual material, including pipette tips and glassware, was soaked in 2 M 
NaOH to neutralise the inhibitor. 
5.1.2 Method 
The activity of trypanopain in the presence of various inhibitors was investigated by 
incubating the enzyme (2 ng, 150 Ill) with each inhibitor (1-10 roM, 100 Ill) in assay buffer 
(500 Ill) for 15 min at 37°C before assaying residual activity against Z-Phe-Arg-AMC 
(2S0 Ill) in stopped-time assays as described in Section 3.2.3. Activity was compared to 
the appropriate solvent-containing control in all cases. Since chloromethylketones and 
alkylating agents are inactivated by reducing agents, care was taken to minimise the 
relative amount of reducing agents used with these inhibitors. Concentrated enzymes were 
thus pre-activated (10 min at 37°C in 30 roM cysteine) and then diluted to the required 
working concentration in assay buffer minus reducing agent (final reducing agent 
104 
concentration of 3 roM cysteine). Activity was compared to controls assayed under the 
same conditions with the same concentration of reducing agent. 
For pepstatin A, the reversibility of inhibition was investigated by pre-incubating 
trypanopain (2 ng, 5 Ill) with assay buffer (250 Ill) and pepstatin A [various 
concentrations, diluted to 245 III in 0.1 % (m/v) Brij-35] for 15 min at 37~C. Controls 
were incubated with 0.1 % (m/v) Brij-35 alone. Aliquots of these inhibited and control 
enzyme mixtures were diluted 10-fold and 100-fold in 0.1% (m/v) Brij-35, giving three 
concentrations of inhibited and control enzyme. Samples (250 Ill) of each of these 
mixtures were diluted into assay buffer (500 Ill) and assayed against Z-Phe-Arg-AMC 
(250 Ill) in continuous assays as described in Section 3.2.2. If the percentage of active 
enzyme at each dilution was the same, then inhibition was diagnosed as irreversible. If, 
however, the percentage of active enzyme increased with dilution, then inhibition was 
diagnosed as reversible. 
For reversible inhibitors, control and inhibited Km and V max values (calculated as in Section 
4.6) were then compared to further diagnose the class of inhibition. K was determined 
from the equation (Salvesen and Nagase. 1989) 
Ki = .J!L/1 + .@l 
Vo -1 Kill 
Vi 
where Ki is the equilibrium constant for inhibition (M), 
[S] is the substrate concentration (M), 
[1] is the inhibitor concentration (M), 
V a is the initial velocity of the uninhibited reaction (arbitrary units), 
Vi is the initial velocity of the inhibited reaction (arbitrary units), and 
Km is the Michaelis constant for the substrate used (M) . 
5.2 Association and inhibition rate constants of cystatins 
Trypanopain has been postulated to contribute to pathogenesis by digestion of various host 
proteins (reviewed in Chapter 1). However in mammals, host and pathogen cysteine 
proteinases are usually kept under tight control by a variety of endogenous proteinase 
inhibitors. The most common of these belong to the cystatin superfamily. The interaction 
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between trypanopain and vanous cystatins was investigated to determine whether 
trypanopain is likely to be active in vivo or whether it is likely to be effectively controlled 
by these inhibitors . At the time this project was undertaken, no kinetic study of 
trypanosomal cysteine proteinase interaction with cystatins had been reported, although 
cruzipain interactions have been subsequently investigated (Stoka et al., 1995). 
Cystatins are tight-binding, reversible, competitive cysteine proteinases inhibitors, that are 
currently divided into three families on the basis of structure (Barrett et ai., 1986; Salvesen 
and Nagase, 1989; Abrahamson, 1993). New cystatins are, however, being discovered 
annually and await classification into families (Watanabe et ai., 1991; Misaka et ai., 1996; 
Yamashita and Konagaya, 1996; Gruden et ai., 1997). Family 1 cystatins (e.g. human 
cystatin A and B) are single chain, acidic polypeptides of 11-12 kDa with no intrachain 
disulfide bridges. The family is largely intracellular, with cystatin B being widespread in 
the cytoplasm of many cell types, and cystatin A found primarily in the skin and some 
white blood cells (Turk and Bode, 1993). Family 2 cystatins (e.g. cystatins C, D, S, SN 
and SA) are also of low molecular mass (13-14 kDa) but have two intrachain disulfide 
bridges and are found mostly in secretions like saliva and seminal plasma (Abrahamson, 
1993). Family 3 cystatins, or kininogens, are complex high molecular mass (60-120 kDa) 
glycoproteins with various multi-functional domains (Barrett et ai. , 1986). The two most 
common are high (H-) and low (L-) molecular mass kininogen, which are also parent 
molecules for the vasoactive kinins. Kallikreins cleave both L- and H-kininogen to liberate 
vasoactive kinins, thereby converting the parent kininogens into two-chain molecules 
joined by a single disulfide bond. L- and H-kininogen have identical heavy chains, but the 
light chain of H-kininogen is larger than that of L-kininogen (reviewed by Turk et al.. 
1997). The heavy chains consist of three tandemly repeated cystatin-like domains (D 1, D2 
and D3), two of which (D2 and D3) are inhibitory for cysteine proteinases. Each 
L-kininogen molecule has two binding sites for cysteine proteinases, one tight-binding site 
on domain 3 and the other of 7 to 18-fold lower affinity on domain 2 (Turk et ai., 1995) . 
Turk et al. (1995) stated, however, that the lower affinity site is likely to remain 
unoccupied under normal experimental conditions and need not be corrected for when 
calculating Ki for association with L-kininogen, provided that there is at least a 10-fold 
molar excess of inhibitor over enzyme. Since a 20-fold molar excess of L-kininogen was 
used in the present study, association with the weaker binding site was safely ignored. 
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Chicken egg white cystatin was the first cystatin to be crystallised (Bode et al., 1988) and, 
since cystatins are well conserved, provided much of our understanding of the manner in 
which cystatins inhibit cysteine proteinases. Cystatins are folded into a five-stranded 
anti-parallel ~-sheet surrounding a five-turn a-helix. The N-terminal section (Shibuya et 
aI., 1995) and two hairpin loops that connect adjacent strands of the ~-sheet (Stubbs et al., 
1990) are thought to be crucial for hydrophobic interaction with the active site of the 
target enzyme (Figure 29). 
Figure 29: 
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Schematic representation of chicken egg white cystatin binding to a cysteine 
proteinase. 
Conserved residues of the cystatin bind to the active site of a target proteinase in a substrate-like 
manner, but the conformation of the cystatin prevents it being cleaved. The N-terminal (yellow) 
cystatin region interacts with proteinase subsites S], S2 and S3, while two cystatin hairpin loops (red 
and blue) connecting adjacent J3-sheets interact with the S/ and S3' proteinase subsites. After 
Abrahamson (1993). 
The interaction between an enzyme and a reversible inhibitor can be described (Bieth, 
1980) by the simplified scheme 
kass 
E+I, ... EI 
kdiss 
where E is the initial enzyme concentration (M), 
I is the initial inhibitor concentration (M), 
EI is the concentration of the enzyme/inhibitor complex (M
2
) , 
kass is the association rate constant (M-I .S-I ) and 
kmss is the dissociation rate constant (S-I ). 
K the equilibrium constant for inhibition, is defined (Bieth, 1980) as 
I, 
K




To investigate the possible physiological effects of cystatins on trypanopain activity, Ki and 
kass for trypanopain association with human recombinant cystatin A, human L-kininogen, 
human L-kininogen domain 3, sheep cystatin B and human cystatin C were determined. 
The interaction between an enzyme and a reversible competitive inhibitor such as a cystatin 
can be investigated under either first or second order conditions (Salvesen and Nagase, 
1989). Under first order conditions, the inhibitor is in excess over the enzyme (at least a 
20-fold molar excess) and so the rate of reaction is essentially independent of enzyme 
concentration. Conversely, under second order conditions enzyme and inhibitor are at 
similar concentrations and the rate of reaction is dependent on the concentrations of both 
reactants . First order conditions were employed in this study, with inhibitors at a 20-fold 
molar excess over enzyme. 
5.2.1 Materials 
Papain assay buffer [350 mM KH2P04, 50 mM Na2HP04, 4 mM Na2EDTA, 40 mM 
cysteine, 0.02% em/v) NaN), pH 6.0]. KH2P04 (49.9 g), Na2HP04.2H20 (8.90 g), 
Na2EDT A.2H20 (1.49 g) and NaN3 (0.2 g) were dissolved in about 950 ml of H20, 
adjusted to 6.0 with KOH and made up to 1 I with H20 . Cysteine (200 ~l of 1 M solution) 
was added to 5 ml of assay buffer just before use. 
Cystatins were donated by the following researchers: Human recombinant cystatin A: 
Dr Ingemar Bjork (Department of Veterinary Medical Chemistry, Swedish University of 
Agricultural Sciences, Uppsala Biomedical Centre, Uppsala, Sweden); Human 
L-kininogen: Dr Rob Pike (Department of Biochemistry and Molecular Biology, Monash 
University, Victoria, Australia); Sheep cystatin B : Dr Theresa Coetzer (Department of 
Biochemistry, UNP); Human L-kininogen domain 3: Dr Ennes Auerswald (Abteilung fur 
Klinische Chemie und Klinische Biochemie in der Chirurgischen Klinik und Poliklinik, 
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Klinikum Innenstadt, Ludwig-Maximilians-Universitat Munchen, Germany); Human 
cystatin C: Dr Magnus Abrahamson (Department of Clinical Chemistry, University of 
Lund, Malmo General Hospital, Malmo, Sweden). 
5.2.2 Methods 
The active concentration of commercial papain was determined by titration against E-64 as 
described in Section 3.4, except that the pH 6.0 assay buffer described in Section 5.2.1 was 
used. Each inhibitor was then titrated against papain as described in Section 3.4 to 
determine the active concentration of the inhibitor. 
Trypanopain reaction velocity in the presence (v,) and absence (va) of inhibitor was 
determined using a modification of the standard continuous assay described in Section 
4.8.6. Trypanopain (0.05 nM final active concentration, 10 Ill) was incubated with Brij-35 
diluent (240 /-LI) and trypanopain assay buffer (500 /-Ll) for 1 min at 30°e. The assay was 
performed at 30°C because association at 37°C was too fast for accurate measurement. 
Z-Phe-Arg-AMC (250 /-Ll , 5 /-LM final concentration) was added and the reaction allowed 
to proceed until a steady-state velocity (va) was achieved. Inhibitor (1-5 nM final 
concentration, giving first order conditions) was then added and the reaction further 
monitored to determine Vi (Salvesen and Nagase, 1989). To ensure accuracy, the assay 
was repeated at various inhibitor concentrations (1-5 nM). 
F or data generated in this manner to be valid, linearity of the assay over the time period 
used was confirmed, as it is essential that any decrease in reaction velocity is due only to 
the addition of inhibitor and not to other factors such as enzyme instability or substrate 
depletion (Salvesen and Nagase, 1989). As a general rule, to ensure that reaction velocity 
does not change over the period of an assay due to substrate depletion, no more than 5% 
of the substrate present must be hydrolysed. Additionally, to ensure that first order 
conditions are maintained and that the rate of inhibition is independent of enzyme 
concentration, there must be at least a 20-fold molar excess of inhibitor over enzyme 
(Salvesen and Nagase, 1989). All of these conditions were satisfied in the present study. 
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5.2.3 Calculation of Ki 
For tight-binding inhibitors, it is inappropriate to use variations of the Lineweaver-Burk or 
Dixon plots to analyse inhibition data, since these assume that the concentration of 
enzyme-complexed inhibitor is negligible compared to the total inhibitor concentration. 
This assumption does not hold if a substantial degree of inhibition is seen at approximately 
equimolar concentrations of enzyme and inhibitor, which is the case with tight-binding 
inhibitors (Bieth, 1995) such as cystatins. Ki should then be calculated from the equation 
(Henderson, 1972; Salvesen and Nagase, 1989; Abrahamson, 1994): 
where: [I] is the inhibitor concentration (M), 
Va is the reaction velocity without inhibitor present (arbitrary units), 
Vi is the reaction velocity with inhibitor present (arbitrary units) , 
[S] is the substrate concentration (M) and 
Km is the Michaelis constant for the substrate used (M). 
This equation is valid when the enzyme concentration used is of the same magnitude as the 
calculated Ki and the inhibitor is sufficiently in excess so that it is not appreciably depleted 
during the assay (Abrahamson, 1994). Foran inhibitor to be considered physiologically 
relevant, its in vivo concentration must be at least 10 times Ki (Bieth, 1980). 
5.2.4 Calculation of kass 
kass, which gives a measure of how fast an inhibitor associates with an enzyme, can be 
calculated from pre-steady state experiments, by measuring the rate at which enzyme 
activity decreases when inhibitor is added (Lenarcic et at., 1996). This is done by plotting 
the natural log of residual enzyme activity against time. The gradient of the linear portion 
of this curve gives the observed (or pseudo-first order) association rate constant, -kobs, and 
the true association rate constant, kass, can then be calculated from the equation (Salvesen 
and Nagase, 1989): 
k - kobs 1 [S] ass - . + 
[I] Km 
where: [S] is the substrate concentration (M), 
[J] is the inhibitor concentration (M) and 
Km the Michaelis constant for the substrate used (M). 
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~ is the half life of association (s), 
kass is the association rate constant (M"I.S"I) and 
[J] is the in vivo inhibitor concentration (M"I) . 
If the enzyme is considered to be effectively inhibited after 5 half lives, then the delay time 
of inhibition in vivo can be considered as 5 times the halflife (Bieth, 1980). 
kass can also be used to calculate both a predicted dissociation rate constant (kJiss = Kixkass; 
Bieth, 1980) and thus the half life for dissociation for the enzyme-inhibitor complex, using 
the equation (Bieth, 1980): 
where: 
0.693 
tl / 2 = ---
4. is the halflife of dissociation (s) and 
kd 1SS is the dissociation rate constant (S"I ). 
5.3 Association with u2-macroglobulin (u2-M) 
U2-M is a non-specific proteinase inhibitor, reacting with all four classes of proteinases in 
an equimolar manner (Barrett and Starkey, 1973). The inhibitor is one of the major human 
plasma proteins and is structurally homologous to some of the complement proteins that 
contain internal thioester bonds. Proteinase cleavage of the exposed "bait-region" of U2-M 
induces a conformational change in the inhibitor that physically entraps the proteinase 
(Barrett and Starkey, 1973). The change in conformation of the U2-M molecule causes the 
U2-M and its entrapped proteinase to be rapidly cleared from the circulation through the 
multiligand U2-M receptor on monocytes (Ashcom et aI., 1990; Strickland et al., 1990; 
Moestrup et aI., 1992). Due to the physical constraints of the entrapment, the trapped 
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enzyme retains full activity against small peptides and inhibitors of less than 10 kDa in size 
(Barrett, 1981). Thus, while the enzyme is inactive against physiological protein 
substrates, it remains active against synthetic substrates commonly used to monitor enzyme 
activity (Harpel, 1976). Only small changes in Km and V max for synthetic substrates are 
observed when an enzyme is bound to a2-M. To test whether a proteinase is inhibited by 
a2-M, the purified enzyme is mixed with the inhibitor and subjected to' gel filtration 
chromatography. If the enzyme is inhibited by a 2-M, it will elute from the column as a 
high molecular mass complex and the increase in apparent molecular mass can be 
visualised as a shift in the elution position of activity against the enzyme's synthetic 
substrate. To confirm that the a 2-Mlproteinase complex was inactive against protein 
substrates, hydrolysis of fluorescein isothiocyanate (FITC)-albumin was investigated (De 
Lumen and TappeU, 1974; Twining, 1984). 
5.3.1 Materials 
Chromatography buffer [50 mM Tris-Cl, 1 mM DTT, 0.02% (m/v) NaN3, pH 8.0]. Tris 
(6 .055 g), DTT (0.15 g) and NaN3 (0.2 g) were dissolved in 900 ml of H20 , adjusted to 
pH 8.0 with HCI and made up to 1 I with H20. 
FITC-albumin (5 mg/rnl). FITC-albumin (5 mg) was dissolved in 1 rnl of 0.5% (rn/v) Brij-35 . 
Stop solution [5% ern/v) TCA]. TCA (5 g) was dissolved in 90 rnl of H20 and made up to 
100 rnl with H20 . 
FITC diluent (500 mM Tris-Cl, pH 8.5). Tris (6 g) was dissolved in 60 rnl of H20, adjusted to 
pH 8.5 and made up to 100 rnl with H20 . 
5.3.2 Method 
The active concentration of trypanopain was determined by titration against E-64 (with 
Z-Phe-Arg-AMC as the substrate), while the active concentration of a2-M was determined 
by titration against E-64-titrated papain [with azocasein as the substrate (Barrett and 
Kirschke, 1981)]. Trypanopain and a 2-M were individually applied to a Sephacryl S-100 
column (10 cm/h, 15 x300 mm) equilibrated in chromatography buffer and the elution 
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position of the individual components determined (by appearance of the A280 peak for 
arM and Z-Phe-Arg-AMC hydrolysis for trypanopain) . Trypanopain (10 pmol, 300 ng) 
was incubated with an equimolar amount of arM in trypanopain protein assay buffer 
(Section 4.8.6) allowing complete association (1 h, 37°C). The mixture was then applied 
to the Sephacryl S-100 column and the A280 profile and Z-Phe-Arg-AMC activity of the 
eluate monitored. 
To investigate whether the a2-MJproteinase complex was active against proteins, digestion of 
FITC-albumin was investigated. Control and a2-M-complexed samples (10 ng trypanopain, 
20 !il) were activated in trypanopain protein assay buffer (Section 4.8.6, 20 !il) and 
FITC-albumin (20 !il) added (24 h at 37°C). Stop solution was added (120 !iI, 1 h, RT) and the 
solution centrifuged (10 OOO xg, 10 min, RT). An aliquot (60 !il) was diluted with 1 rnl ofFITC 
diluent and the fluorescence read on a Hitachi F-2000 spectrofluorometer (excitation 490 nm, 
emmision 525 nm). Fluorescence of control, uninhibited samples was compared with that of 
arM-complexed samples. 
5.4 Effect of enzyme inhibitors on Z-Phe-Arg-AMC hydrolysis by live 
T. b. brucei 
Zymogram analyses of the proteinases of T b. brucei and T congolense have shown that 
the molecular masses of the proteinases from different parasite preparations can be highly 
variable. This variation is thought to be due, in part. to the effects of unknown 
components of mammalian serum on the proteinases (Lonsdale-Eccles and Mpimbaza, 
1986; Lonsdale-Eccles and Grab, 1987a). Preliminary work by colleagues in this 
laboratory showed that trypanopain can associate with a kininogen-like molecule (called 
rat trypanopain-modulator, rTM) to produce additional bands of higher molecular mass 
proteolytic activity on zymograms. The effects of L-kininogen on trypanopain hydrolysis 
of Z-Phe-Arg-AMC in live T b. brucei were investigated as part of a collaborative study 
investigating the in vivo significance of these novel, active complexes more directly 
(Lonsdale-Eccles et aI., 1995). However, since both trypanopain and the trypanosomal 
oligopeptidase OP-Tb hydrolyse Z-Phe-Arg-AMC, E-64 (which inhibits trypanopain) and 
leupeptin (which inhibits both trypanopain and OP-Tb) were first added to live T b. brucei 
to estimate what percentage of the total Z-Phe-Arg-AMC hydrolysis occurring in live 
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parasites was contributed by each enzyme. Once this was known, the effects of 
L-kininogen on trypanopain activity alone could be investigated. 
5.4.1 Materials 
As per Section 3.3 and Section 3.2.1. 
Inhibitors . Leupeptin (1 mg), E-64 (1 mg) and L-kininogen (1 mg) were dissolved in a 
50:50 mixture ofH20:DMSO (1 ml) on the day of use. 
5.4.2 Method 
Live T b. brucei (1.8 x 106 parasites/ml, kept on ice until required) were equilibrated to 
25°C or 37°C in pH 7.4 PSG (Section 3.3). Z-Phe-Arg-AMC was then added and the 
increase in fluorescence monitored continuously as in Section 3.2.2. E-64, leupeptin or 
L-kininogen (100 Ill, 0.1 mg/ml final concentration) were added to replicates of the above 
experiment to assess their effects on T b. brucei hydrolysis ofZ-Phe-Arg-AMC. 
5.5 Is trypanopain active in the bloodstream of infected animals? 
Studies in Section 5.2 suggest that trypanopain is likely to be effectively controlled in the 
bloodstream of infected mammals by endogenous cystatins. To test this prediction 
directly, the blood of experimentally infected rats and naturally infected cattle was tested 
for trypanopain activity. As controls, samples were also assayed for the presence of 
OP-Tb and endogenous mammalian kallikrein. Since all three enzymes hydrolyse Z-Phe-
Arg-AMC, combinations of inhibitors were used to discriminate between the two serine 
proteinases (OP-Tb and kallikrein) and the cysteine proteinase, trypanopain. OP-Tb is not 
inhibited by large proteinaceous serine proteinase inhibitors such as SBTI (Troeberg et ai., 
1996). This fact was used to discriminate between OP-Tb and SBTI-sensitive kallikrein 
activity. Z-Phe-Arg-AMC hydrolysis at pH 8.0 in the presence of SBTI (inhibits kallikrein) 
and E-64 (inhibits trypanopain) thus indicates the presence of active OP-Tb in infected 
sera, while similar hydrolysis at pH 7.0 in the presence of SBTI (inhibits kallikrein) and 
AEBSF (inhibits kallikrein and OP-Tb) indicates trypanopain activity in the test sera. 
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5.5.1 Materials 
Inhibitors (120 blM SBTl, 12 mM E-64 and 12 mM AEBSF). SBTI (3 .6 mgl1.5 ml), E-64 
(6.4 mgl1.5 ml) and AEBSF (4 mgl1.5 ml) were dissolved in DMSO on the day of use. 
Experimentally infected rat serum. Two adult rats were infected with r b. brucei as in 
Section 3.3, while a control rat was injected with PSG alone. Infected rats were sacrificed 
at peak parasitaemia and the control rat sacrificed at the same time. Blood was left to 
stand at RT to allow complete coagulation and centrifuged (1 OOOxg, 10 min, 4°C) to 
remove fibrin clots and parasites. The supernatant was microscopically confirmed to 
contain no parasites. 
Naturally infected cattle serum. Serum from cattle infected with r b. brucei was a gift 
from Dr Olivier Matthee (Department of Protozoology, Onderstepoort Veterinary School). 
Control, uninfected cattle serum was obtained from the local abattoir. 
Trypanopain synthetic substrate assay buffer. As per Section 4.8.6. 
OP-Tb assay buffer (1 50 mM Tris-Cl, 0.45 M NaCI, 30 mM OTT, pH 8.0). Tris (0.9 g) 
and NaCI (0.46 g) were dissolved in 45 ml of H20 , adjusted to pH 8.0 with HCl and made 
up to 50 ml with H20 . DTT (4.6 mglml) was added just before use. 
Kallikrein assay buffer (150 mM Tris-Cl, 0.45 M NaCI, pH 8.0). Tris (0.9 g) and NaCI 
(0.46 g) were dissolved in 45 ml of H20 , adjusted to 8.0 with Hel and made up to 50 ml 
with H20 . 
5.5.2 Method 
Replicates of infected or control serum (25 Ill) were incubated with each assay buffer for 
10 min at 37°C. Inhibitors (25 Ill) were then added and the mixture incubated for a further 
10 min at 37°C. Following addition of Z-Phe-Arg-AMC, fluorescence was monitored in 
stopped-time assays as described in Section 3.2.3. 
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5.6 Detection of trypanopain/cystatin complexes in infected serum 
Sandwich ELISAs were conducted to determine whether trypanopain is present in the 
serum of infected ' animals in the form of inactive trypanopainlcystatin complexes. 
Detection of such complexes implies that trypanopain released from dying trypanosomes 
becomes tightly bound to endogenous cystatins. Test sera from experimentally infected 
rats were applied to ELISA plates pre-coated with anti-cystatin B or anti-kininogen 
antibodies . Both free and trypanopain-complexed cystatins or kininogens were expected to 
bind to these antibodies. Anti-trypanopain antibodies were then applied to determine 
whether any of the inhibitors captured on the ELISA plate were also bound to trypanopain. 
5.6.1 Materials 
As per Section 2.11 .1 
Antibodies. Rabbit anti-cystatin B IgG was a gift from Nicola Scholfield (Department of 
Biochemistry, UNP) and rabbit anti-human H-kininogen IgG was from CalBiochem 
(La Jolla, CA, USA). 
5.6.2 Method 
A variation on the ELISA described by Takeda et al. (1992) to detect cathepsinlkininogen 
complexes was devised . Rabbit anti-human H-kininogen IgG or rabbit anti-cystatin B IgG 
(25 Ilg/ml in 100 III PBS per well, 4°C, 16 h) was adsorbed to the well of Nunc 
Immunosorb microtitre plates and remaining sites blocked with 0.5% (m/v) BSA-PBS 
(200 Ill/well, 1 h, 37°C). Infected rat or cattle serum was incubated (100 III of various 
dilutions per well, 2 h, 37°C). Chicken anti-trypanopain IgY [75 Ilglrnl in 120 III per well 
of 0.5% (m/v) BSA-PBS, 2 h, 37°C] was applied as the second antibody layer and rabbit 
anti-IgY-HRPO as the detection antibody (150 Ill/well, 1 h, 37°C). ABTSIH20 2 




5.7.1 Inhibitor profile 
In terms of inhibitor sensitivity, trypanopain was shown to be a fairly typical cysteine 
proteinase. Typical cysteine proteinase inhibitors (including E-64 and IAA, IAN and 
NEM) inhibited trypanopain completely, while typical serine and metalloproteinases 
inhibitors (such as DFP and EDT A, respectively) had no effect on enzyme activity. Of the 
alkylating agents, IAA was the most effective, inhibiting trypanopain activity by 100% at 
0.1 mM. By comparison, IAN was only 36% effective at this concentration, while NEM 
was ineffective (Table 7) . Leupeptin, antipain and chymostatin were all effective inhibitors 
of trypanopain (99-100% inhibition) . Data from previous studies for the related enzymes 
trypanopain-Tc and cruzipain are given for comparison. 
Interestingly, the aspartic proteinase inhibitor pepstatin A also inhibited trypanopain ( by 
22%). Pepstatin A inhibition of trypanopain was further investigated by calculating the 
apparent Km and V max in the presence of the inhibitor. Km was substantially increased (by 
approximately 50%) while Vmax remained unchanged, indicating that pepstatin A is a 
competitive trypanopain inhibitor (price and Stevens, 1989) with a K; of207±51 11M. 
5.7.2 Kinetics of association between trypanopain and various cystatins 
kass and predicted koff values for trypanopain association with various cystatins were in the 
107 _108 M-1 .s-1 and 10-4 S-I range respectively, while K; values were in the 10-11 M range 
(Table 8). Of the inhibitors tested, L-kininogen domain 3 and cystatin C associated fastest 
with trypanopain (108 M-1 .s-1). The slowest dissociation was observed for L-kininogen 
(8 .8x 1 05 S-I). 
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Table 7: Effects of vanous proteinase inhibitors on the activity of trypanosomal 
enzymes against Z-Phe-Arg-AMC. 
Trypanopain from T. b. brucei (2 ng) was incubated with each of the inhibitors below (15 min, 
37°C) and residual activity against Z-Phe-Arg-AMC measured in quintuplicate stopped-time assays 
as described in Section 3.2.3. Activity was compared to the appropriate solvent-containing controls 
in all cases . Data from previous studies for trypanopain-Tc (from T. congolense) and cruzipain 
(from T. cruzi) are given for comparison. 
Inhibitor Proteinases Concentration 
Trypanopain Trypanopain-Tc2 Cruzipain2 
inhibited I (mM) activity 
I 
I (% of control) 
E-64 C 0.001 0 I + + 
IAN C 10 0 + + 
IAA C 0.1 0 + -i-
NEM C 10 0 nd + 
; 
TLCK S&C I 1 0 I nd T + 
I 
TPCK S&C 1 0 nd + 
Leupeptin S&C 0.1 I 0 I + + I I 
Chymostatin S&C 0.1 1 I + I + 
Antipain S&C 0.1 0 
I 
+ + 
AEBSF I S 0.5 100 i nd I nd I I 
DFP S 10 100 nd nd 
PMSF S 10 100 + 0 
I 
SBTI S 0.01 100 + I 0 
EDTA I M 10 100 nd nd 
Pepstatin A A 0.1 78 + 0 
Note 1. C cysteine proteinase S serine proteinase 
A aspartic proteinase M metalloproteinase 
2. + inhibited 
0 unaffected 
nd not done 
Data from Steiger et al. (1979); Rautenberg et al. (1982); Lonsdale-Eccles and Mpimbaza 
(1986); Lonsdale-Eccles and Grab (1987a); Cazzulo et al. (1989); Murta et al. (1990); Healy et 
al. (1992); Mbawa et al. (1992). 
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Table 8: Association, dissociation and inhibition rate constants for cystatin inhibition of 
trypanopain (0.05 nM) at 30°C. 
Inhibitor Ki kass Predicted kolT 
(nM) (MIS-I) (S-I) 
Cystatin A 0.045 2.13x107 9.6x 10-4 
Sheep cystatin B 0.004 6.9x 107 2.8x l0-4 
Cystatin C 0.001 1.7x 108 1.7x lO-4 
L-kininogen 0.0035 2.5x 107 8.8 x 10-5 
L-kininogen domain 3 0.0044 1.1 x 108 4.8 x 10-4 
Note: 1. Cystatin C and L-kininogen domain 3 association with trypanopain was too rapid for 
accurate measurement without stopped-flow apparatus and the value given is thus only 
an estimate. 
2. Results represent the average of quintuplicate at each of four different inhibitor 
concentrations assays. 
As L-kininogen and cystatin C are the most abundant cystatins in blood (Abrahamson, 
1993), the half-lives of association and dissociation were calculated for these inhibitors. 
These calculations, using physiological concentrations of inhibitors cited by Abrahamson et 
al. (1986), showed that trypanopain associates with both L-kininogen and cystatin C 
within fractions of a second and that the inhibitor-enzyme complex dissociates fairly slowly 
(over a period of approximately 1-2 hours, as shown in Table 9). Thus trypanopain is 
likely to be inhibited effectively by cystatin C and (especially) L-kininogen in vivo. 
Table 9: Halflives for association and dissociation oftrypanopain and selected cystatins 
at physiological concentrations. 
Inhibitor Physiological Half life of association Half life of 
concentration (s) dissociation (min) 
L-kininogen 7.5 /-lM 0.006 131 
Cystatin C 80nM 0.08 68 
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5.7.3 Association with 0.2-M 
a2-M alone eluted from Sephacryl S-IOO in the void volume, while trypanopain alone 
eluted in the included volume. Following incubation with arM, trypanopain eluted in the 
void volume, indicating that the enzyme had associated with a2-M (Figure 30). The arM-
complexed enzyme was inactive against FITC-albumin, showing that inhibitio~ of proteinase 
activity had occurred. 
5.7.4 Effects ofinhibitors on Z-Phe-Arg-AMC hydrolysis by live T. b. brucei 
Leupeptin (which inhibits both trypanopain and OP-Tb) consistently inhibited Z-Phe-Arg-
AMC hydrolysis by nearly 100% at both 25°C and 37°C, while E-64 (inhibits only 
trypanopain) inhibited hydrolysis by approx. 50%. This indicates that approximately half 
of the Z-Phe-Arg-AMC hydrolysis by live T b. brucei can be ascribed to trypanopain. In 
the presence of L-kininogen, a 10-20% increase in the rate of hydrolysis of Z-Phe-Arg-
AMC was observed. This suggests that trypanopain activity was increased by 20-40%, 
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<l2-M alone (A) eluted in the void volume of Sephacryl S-100, while trypanopain alone (B) eluted in 
the included volume. After pre-incubation with <l2-M, trypanopain activity against Z-Phe-Arg-
AMC eluted in the void volume (C), indicating that it had associated with <l2-M. 
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5.7.5 Is trypanopain active in the blood of infected rats? 
Very low levels of Z-Phe-Arg-AMC hydrolysis were detected in the serum of control, 
uninfected animals, while high levels of activity against Z-Phe-Arg-AMC were detected in 
infected rats (Figure 31) and cattle. This activity was insensitive to E-64 and SBTI, but 
entirely eliminated by AEBSF. This indicates, firstly, that op-Tb was predominantly 
responsible for the hydrolysis observed and that it is present in an active form in the 
bloodstream of infected animals. Secondly, this study suggests that trypanopain is 
effectively controlled in the mammalian bloodstream, supporting the conclusion arrived at 
from in vitro studies with the purified enzyme and purified serum cystatins. Zymogram 
analyses of infected samples supported the results of this experiment, with no proteolytic 
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Figure 31: Z-Phe-Arg-AMC activity in the sera of control and infected animals. 
Infected rat (II) and cattle (II) serum or control, uninfected serum (II) (25 f!l) was incubated with 
assay buffer for 10 min at 37°C. Inhibitors (25 f!l) were then added and the mixture incubated for 
a further 10 min at 37°C. Following addition of Z-Phe-Arg-AMC, fluorescence was monitored in a 
microplate fluorimeter. Results represent the average of quintuplicate assays. 
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5.7.6 Detection of trypanopain/cystatin complexes in infected serum 
Sandwich ELISAs showed that trypanopainlcystatin Band trypanopainIH-kininogen 
complexes are present in the serum of infected rats (Figure 32) and cattle. This implies 
that trypanopain released from dying trypanosomes is tightly bound to cystatins in the 
bloodstream. Slightly higher levels ofR-kininogen complexes were detected. 
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Figure 32: Detection of trypanopainlcystatin complexes in the serum of T b. brucei 
infected rats. 
Rabbit anti-human H-kininogen IgG (A) and rabbit anti-cystatin B IgG (B) (25 Ilg/ml) were coated 
as the first antibody layer and infected rat serum (various dilutions) applied as the antigen layer, 
followed by IgY anti-trypanopain (75 Ilg/rnl) as the second antibody layer. Rabbit anti-IgY-HRPO 
and ABTSIH20 2 were used as the detection system. Absorbance readings at 405 nm of serum from 
infected rats (e and .A.), uninfected control animals (- ) and non-immune antibodies (0) represent 
the average of duplicate determinations. 
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5.8 Discussion 
Trypanopain has a fairly typical cysteine proteinase inhibitor profile, in agreement with the 
inhibitor profiles oftrypanopain-Tc and cruzipain. Trypanopain is sensitive to E-64, cystatins 
and alkylating agents, but insensitive to typical serine and metalloproteinase inhibitors (such 
DFP and EDT A respectively). Interestingly, the aspartic proteinase inhibitor pepstatin inhibited 
trypanopain to some extent, as has been previously reported for partially purified trypanopain 
from T b rhodesiense (pamer et a!. . 1989) and trypanopain-Tc (Mbawa et a!., 1992). 
Pepstatin A does not, however, inhibit cruzipain (Cazzulo et a!. , 1989). The inhibitor was 
found to increase trypanopain's apparent Km for Z-Phe-Arg-AMC (by approx. 50%) while Vma.x 
remained unchanged, indicating that pepstatin A is a competitive inhibitor of trypanopain (Ki 
calculated to be 207±51 ~M) . The competitive nature of its inhibition suggests that this 
pentapeptide-like compound (Salvesen and Nagase, 1989; Kay et a!.. 1983) acts as a 
pseudo-substrate for trypanopain. It may bind into the trypanopain active site differently 
from its mode of binding with aspartic proteinases. 
Trypanopain was shown to associate with 0'2-M, suggesting that this inhibitor would inhibit 
any trypanopain present in the mammalian bloodstream. At the time this study was 
undertaken, this was the first report of 0'2-M association with a trypanosomai proteinase 
(Troeberg et a!., 1996). Recently however, Morrot et a!. (1997) showed that cruzipain is 
also effectively inhibited by 0'2-M. They further showed that cruzipaini0'2-M complexes 
are effectively taken up by monocytes through the multiligand 0'2-M receptor, resulting in 
enhanced presentation of cruzipain-derived peptides to CD4 + T -cells. This indicates that 
binding of o'rM to cruzipain enhances immune responses against the enzyme. It is likely 
that the same is true in African trypanosomiasis. where trypanopain-Tc is reportedly one of 
the major antigens recognised in cattle (Authie et a!. , 1992). 
This study also showed that trypanopain is similar to cathepsin L (Barrett et a!. , 1986) and 
papain (Abrahamson, 1993) in its interactions with cystatins in vitro (Table 10). Later 
studies showed that cruzipain is also similar to these enzymes in its association with 
cystatins (Stoka et a!. , 1995). All four enzymes have very similar Ki and kass values for the 
various cystatins. In all three cases, association is very fast and the resultant complexes 
dissociate very slowly. 
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The time required for association and dissociation of a tight-binding, reversible inhibitor 
with an enzyme is partially dependent on the concentration of the inhibitor. When 
assessing the possible physiological effects of cystatins on an enzyme, the physiological 
concentrations of the cystatins must thus be considered. Cystatin C and L-kininogen are 
the most abundant cystatins in blood, with in vivo concentrations of 80 nM and 7.5 11M 
respectively (Abrahamson et a!., 1986). For an inhibitor to be considered physiologically 
relevant, its in vivo concentration must be at least 10 times Ki (Bieth, 1980). Clearly, this 
holds for cystatin C and L-kininogen and so these inhibitors are likely to effectively inhibit 
trypanopain in the bloodstream of T. b. brucei-infected animals. Since cystatins are 
relatively conserved between species (Barrett et a!., 1986) and the trypanosomal cysteine 
proteinases sequenced to date are highly homologous (Mottram et a!., 1989; Pamer et aI. , 
1990; Eakin et a!., 1992; Fish et a!. , 1995), the present study suggests that trypanopains 
from various trypanosome species are likely to be effectively inhibited by cystatins in a 
variety of mammalian hosts. 
Table 10: Comparison of the inhibition of trypanopain, cathepsin L. cruzipain and papain 
by various cystatins. 
I 
Cystatin A Cystatin B Cystatin C L ki . I L-kininogen - nmogen 
I domain 3 
i 
Ki (nM) 
Cathepsin L i 1.3 I 0.23 I 0.005 ! 0.0017 0.005 
i I I 
Papain ! 0 .019 0.12 0.005 I 0.0015 0.0030 I 
Trypanopain 0.045 0.004 0.001 0.0035 0.0044 
kass (M-I . S-I) 
Cathepsin L 3.8x 107 2.2xl07 nd 1 x 107 1 x 108 
Papain 4.31 x l06 2.2xl07 1.1xl07 2 x 107 3x 107 
Cruzipain 3.4x 106 3 x 107 7.9x 107 l.8x 107 nd 
Trypanopain 2.13xl07 6.9x 107 1.7x108 2.5x 107 l.1 x 108 
Note: 1. nd not detennined 
2. Data from Barrett et al. (1986), Abrahamson (1993), Turk et al. (1995), Stoka et al. 
(1995), Lenarcic et al. (1996) and the present study. 
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The blood of experimentally infected rats was assayed for trypanopain activity to test this 
prediction. High levels of op-Tb activity were detectable, as had been predicted from in 
vitro studies with serpins (Troeberg et aI. , 1996). However, as expected, no trypanopain-
like activity was detectable in any of the tested samples. Furthermore, sandwich ELISAs 
carried out on infected rat serum showed that detectable levels of trypanopainlcystatin and 
trypanopainlkininogen complexes are present in infected serum, but that these were 
inactive against Z-Phe-Arg-AMC. This suggests that trypanopain is effectively controlled 
in the mammalian bloodstream by association with cystatins. A previous study ofNwagwu 
et a!. (1988) possibly supports this conclusion. In their study, isolated live parasites were 
shown to release two proteinases active against BSA: one which is active at pH 5.4 
(thought to be trypanopain) and a second which is active at pH 8.0. However, when rat 
plasma was added to the isolated parasites, the trypanopain-like activity at pH 5.4 was not 
observed, suggesting that host plasma cysteine proteinase inhibitors, possible cystatins, 
effectively inhibited the released trypanopain. 
However, a kininogen-like molecule from rat serum reportedly enhances trypanopain 
activity in fibrinogen zymograms of lysed T b. brucei (Lonsdale-Eccles et a!. , 1995). This 
molecule, rTM, cross-reacts to some extent with anti-human kininogen antibodies. rTM 
has many other features in common with kininogens, such as its size (68 kDa), its acid and 
heat stability, and the presence of 15 kDa proteinase-sensitive domains. Additionally, 
L-kininogen was shown to enhance trypanopain activity on fibrinogen zymograms in a 
similar manner to rTM and so Lonsdale-Eccles et at. (1995) conclude that kininogen-like 
molecules have the potential to enhance trypanopain activity. The present study showed 
that leupeptin inhibited Z-Phe-Arg-AMC hydrolysis by live T brucei by 100%, while E-64 
inhibited activity by 50%. This suggests that about half of the Z-Phe-Arg-AMC hydrolysis 
by live T brucei is contributed by trypanopain and the other half by op-Tb (Kornblatt et 
a!. , 1992). L-kininogen was shown in the present study to mediate a 10 to 20% increase in 
Z-Phe-Arg-AMC hydrolysis, which suggests that it increased trypanopain activity by 
20-40%. The present study, however, clearly indicates that purified human L-kininogen is 
an effective inhibitor of purified trypanopain with a Ki of 0.0035 nM. Pike et al. (1992) 
reported a similar apparent contradiction in the interaction between mammalian cathepsin 
Land cystatin B. While purified cystatin B inhibited purified cathepsin L as expected, 
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abnormally active covalent complexes of the enzyme and inhibitor were shown to form 
in vivo . An unidentified factor, which may be absent in in vitro studies using purified 
components, may contribute to the formation of these active complexes in vivo (Dr Robert 
Pike, Department of Biochemistry and Molecular Biology, Monash University and 
Dr Theresa Coetzer, Department of Biochemistry, UNP, personal communication). It is 
possible that this putative additional factor modifies the interaction between trypanopain 
within live trypanosomes and L-kininogen in vivo, resulting in the formation of active 
complexes as reported by Lonsdale-Eccles et at. (1995). 
There are thus two apparently contradictory bodies of evidence concerning the effects of 
cystatins on trypanopain in the mammalian bloodstream. Firstly, trypanopain is effectively 
inhibited in vitro by all tested cystatins, no trypanopain-like activity is detectable in the 
blood of infected animals and in vivo-formed cystatinitrypanopain complexes are inactive 
against Z-Phe-Arg-AMC. On the other hand, L-kininogen enhances trypanopain-like Z-
Phe-Arg-AMC hydrolysis by live T. b. brucei and also enhances trypanopain-like 
hydrolysis of fibrinogen by lysed T. b. brucei on zymograms. The most convincing and 
apparently irrefutable piece of data is that no trypanopain activity is detectable in the 
bloodstream of infected animals. The assay used was shown to be sensitive enough to 
detect the presence in the bloodstream of another trypanosomal proteinase, OP-Tb, which 
contributes 50% of the Z-Phe-Arg-AMC hydrolysis by live parasites, so it is unlikely that 
the assay is not sensitive enough to detect trypanopain. 
If L-kininogen does activate the enzyme, why is no activity detectable in the bloodstream? 
It was considered possible that L-kininogen does enhance trypanopain activity in vivo, but 
that the enzyme is effectively inhibited by another proteinase inhibitor, e.g. a 2-M. 
However, sandwich ELlSAs showed that cystatin B/trypanopain and 
kininogenltrypanopain complexes formed in vivo are not active against Z-Phe-Arg-AMC. 
Alternatively, L-kininogen may activate trypanopain in live T. b. brucei, but not once the 
enzyme is outside of the trypanosome, in the bloodstream. A trypanosomal component 
may alter the interaction between trypanopain and L-kininogen in the parasite, but be 
ineffective in the bloodstream. It is considered most likely that the enhancement of 
trypanopain activity seen in zymograms is an artifact of the method used. Michaud et al. 
(1996) reported that cystatinlcysteine proteinase complexes with Ki values above 10 nM 
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are likely to dissociate during electrophoresis, while those with Ki values below 10 nM 
remain intact. However, the authors reported that papain! chicken egg white cystatin 
complexes (Ki of 5 pM) dissociate during electrophoresis, enabling the enzyme to regain its 
activity on zymograms. This suggests that the active trypanopain!kininogen complexes 
reported by Lonsdale-Eccles et al. (1995) and in the present study may be the result of 
dissociation of inhibitory complexes during electrophoresis. The high ' sensitivity of 
zymogram assays may have additionally inflated the apparent amount of activity seen at 
higher molecular weights. It is interesting that Michaud et al. (1996) only report activity at 
the molecular mass of the studied proteinase, while Lonsdale-Eccles et al. (1995) and the 
present study report additional activity at increased molecular masses. Whether this occurs 
only with Trypanosoma and Leishmania remains to be investigated. 
In summary, the majority of available evidence suggests that trypanopain is inactive in the 
mammalian bloodstream. Most convincingly, all in vivo data shows no enzyme activity. It 
is thus considered most likely that trypanopain is indeed effectively inhibited in the 
mammalian bloodstream by cystatins and ar M . However, the possibility that active 
trypanopain!cystatin complexes form under certain as yet undefined conditions cannot be 
excluded. 
Following investigation of the effects of mammalian proteinase inhibitors on trypanopain 
activity, the effects of anti-trypanopain antibodies on enzyme activity were investigated . 
The following chapter describes the production of antibodies against a peptide from the 
active site of trypanopain and evaluation of their effects on trypanopain activity against a 
variety of substrates. 
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Chapter 6 
Production and evaluation of anti-peptide antibodies against a peptide from 
the trypanopain active site 
6.1 Introduction 
Trypanopain-Tc and cruzipain have been identified as major antigens recognised by cattle and 
humans in T. congolense and T. crnzi infections respectively (de Souza et ai. , 1990; Murta et 
al. , 1990; Authie et ai. , 1993; Gonzalez et al., 1996), while cysteine proteinases of the helminth 
Spirometra mansoni (Kong et ai. , 1997) and the nematode Nippostrongylus brasiliensis 
(Kamata et al., 1995) are also major antigens recognised by infected hosts. It is thus likely that 
trypanopain from T. b. brncei is also highly immunogenic in natural infections. Authie et ai. 
(1993) report that production of anti-trypanopain-Tc antibodies correlates with resistance to 
trypanosomiasis in cattle, suggesting that immuno-targeting of trypanopain is beneficial to the 
infected host. Various authors have suggested that parasite cysteine proteinases may contribute 
to disease pathogenesis by degrading host proteins (McKerrow, 1993 ; McKerrow et ai., 1993 ; 
Robertson et ai., 1996), so it is tempting to speculate that immuno-targeting of trypanopain 
plays a role in disease resistance, possibly by antibody inhibition of trypanopain activity. 
Binding of anti-enzyme antibodies to enzymes reportedly has varied effects, with inhibition or 
enhancement of activity, as well as no alteration in enzyme activity being observed (Richmond, 
1977). The possible inhibitory effects of anti-trypanopain antibodies were investigated in the 
present study by producing and evaluating antibodies directed against a peptide corresponding 
to a portion of the trypanopain active site. The active site was targeted because of the increased 
likelihood that anti-active site antibodies would modulate enzyme activity compared with 
antibodies directed against other regions of the enzyme. 
Production of antibodies against a protein of interest can be accomplished in various ways, to 
produce antibodies with different properties. The method chosen is thus dependent on 
experimental requirements. For the purposes of this study, a versa~ile yet specific antibody 
preparation was required to recognise the enzyme in its native form (to assess the effects of the 
antibodies on enzyme activity) and preferably also in its denatured form (for use in ELISAs, 
Western Blots and immunocytochemical labelling). The most common method of raising 
antibodies is immunisation of an experimental animal with a whole protein (to produce 
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polyclonal anti-protein antibodies), but production of anti-peptide (to produce polyclonal 
anti-peptide antibodies) or monoclonal antibodies is also possible. Each of these methods was 
evaluated in the context of the experimental requirements of the present study. 
Since a whole protein contains many epitopes, immunisation of an experimental animal with 
such an antigen stimulates several B cell clones and results in the production of antibodies of 
many different specificities. The heterogeneity of such polyclonal antisera makes them 
unsuitable for applications that require antibodies of a single specificity, as only a fraction of the 
antibodies elicited are directed against anyone part of the protein. Immunisation with the 
whole enzyme was not considered suitable for this study since antibodies exclusively 
recognising the active site were required. 
A homogenous antibody population of single and known specificity can be produced from a 
single B-cell clone and these are thus termed monoclonal antibodies (mAbs) (Kohler and 
Milstein, 1975). Such clones are generated by fusing a single primed B-cell with an immortal 
cancerous cell to produce an immortal B-cell hybridoma. While the absolute specificity of 
mAbs is attractive, they are expensive and time-consuming to produce. Their specificity can 
also limit the applications of these antibodies, because they only recognise a single conformation 
of the antigen and are thus not sufficiently versatile for some of the applications required for this 
study. 
An animal immunised with a single perJtide from a target protein produces what are known as 
anti-peptide antibodies. In addition to recognising the free peptide, these antibodies cross-react 
with the target protein, provided that some of the conformations adopted by the peptide in 
solution mimic those adopted in the corresponding region in the target protein. Since several 
B-cell clones are stimulated by the peptide, the antibodies are polyclonal, but because they are 
all directed against the selected peptide, they have specificity more similar to mAbs than to 
anti-protein polyclonal antibodies (Lerner, 1984). The specificity of such anti-peptide 
antibodies for the target protein arises from the fact that a sequence of ten or more residues is 
likely to be unique to a particular protein. In addition to their specificity, anti-peptide antibodies 
are versatile because they recognise the target sequence in many different conformations and all 
have different "reading frames" in that they bind to different, overlapping regions of th~ peptide. 
This versatility presented an advantage for this study, since it increased the likelihood that the 
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antiserum would recognise whole trypanopain in both its native and denatured forms. This 
versatility of anti-peptide antibodies is their greatest advantage over mAbs. The combined 
versatility and specificity of anti-peptide antibodies thus resulted in the decision to produce 
anti-trypanopain antibodies by immunising experimental animals with a peptide from the active 
site of trypanopain. 
6.2 Choosing an immunogenic peptide 
The choice of an immunogenic peptide was based on a number of factors. A peptide from the 
active site region was chosen because antibodies against this region were considered more likely 
to modulate trypanopain activity than antibodies directed against other regions of the enzyme. 
In addition, the peptide had to be immunogenic, i.e. able to stimulate B-cells in the experimental 
animal to produce antibodies. Most methods of predicting antibody-eliciting B-cell epitopes are 
based on the premise that such epitopes are usually located on the surfaces of proteins, where 
they can interact with antibodies. The three-dimensional structure of the protein can be studied 
to identify surface regions or, where such structural data is unavailable, there are various 
methods for predicting stretches of surface-located amino acids from the primary sequence of 
the protein. Most of these methods assign each amino acid a numerical value on a scale, which 
is then applied to the primary sequence of a protein whose three-dimensional structure is 
unknown. Some of the methods are listed below: 
• Hopp (1985) constructed an acrophilicity scale based on the frequency with which each 
amino acid appeared on the surface of proteins of known three-dimensional structure. 
• Surface residues are usually more mobile and flexible than internal residues and 
crystallographic measurement of this mobility has been used to assign atomic temperature 
factors (also known as B-factors, or Debye-Waller factors) to the various amino acids. 
Karplus and Schulz (1985) devised an epitope prediction method based on B-factors, which 
Van Regenmortel (1986) suggests is the most reliable of the presently available prediction 
methods. 
• Hydrophobic amino acid residues are typically buried within the protein core to minimise 
interactions with the polar environment, while hydrophilic side chains are usually located on 
the surface to maximise interactions with water. Stretches of hydrophilic residues are thus 
more likely to be surface-located and accessible to antibodies (Hopp and Woods, 1981; 
Kyte and Doolittle, 1982). In some cases, hydrophilicity peaks of stretches of polypeptide 
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chains have been shown to correspond with known protein epitopes (Hopp, 1986), 
although Hopp and Woods (1981) caution that "not all antigenic determinants are 
associated with high points of hydrophilicity and not all high points are associated with 
antigenic determinants" . Nevertheless, they maintain that one determinant is always located 
at the highest point ofhydrophilicity. 
The three-dimensional structure of trypanopain is not yet known, which precluded a direct 
search for surface-located regions. Trypanopain is, however, 38% similar to papain (Mottram 
et at. , 1989), the three-dimensional structure of which is known (Drenth et at. , 1971 ; 
Figure 33), thus allowing consideration of the papain structure for the prediction oftrypanopain 
epitopes. To increase the likelihood of success, epitope prediction algorithms, such as those 
listed above, were also used. Such a combination of methods has been successful for choosing 
an immunogenic peptide from the homologous enzyme, cathepsin L, where antibodies 
produced against the chosen active site peptide cross-reacted well with the native enzyme 
(Coetzer et at. , 1991). In light of the success of this previous study, a peptide analogous to that 
chosen from cathepsin L by Coetzer et at. (1991) was used in the present study. The 
16-residue peptide chosen corresponds with residues 274 to 289 in the primary sequence of 
trypanopain (Mottram et at. , 1989) and includes the active site histidine residue, increasing the 
likelihood that antibodies would inhibit enzyme activity if this histidine residue is exposed in the 
native enzyme. The sequence of the chosen peptide (residues 274-289) in trypanopain is 
IL TSCTSKQLDHGVL 
where H represents the active site histidine. Some modifications to the original sequence were 
made in the synthesis of the peptide, namely 
• an N-terrninal cysteine was added to allow thioether coupling to a carrier molecule, 
• the internal cysteine residue was synthesised as an a-amino butyric acid residue to prevent 
dimerisation of peptides via disulfide bonds (Muller, 1988), and 
• the C-terrninal end was synthesised as an amide, mimicking an uncharged peptide bond and 
hopefully increasing cross-reactivity with whole trypanopain. 
The peptide (1461.93 Da) was synthesised by the Peptide Synthesis Core Facility at the 
University of Georgia, Athens, USA. The chosen peptide was expected to be immunogenic as 
it is greater than ten residues in length; is exposed in the parent protein and contains a local peak 
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of flexibility, mobility, accessibility and hydrophilicity (Figure 34). The trypanopain peptide 
chosen shows high sequence homology with corresponding regions of other trypanosomal 
cysteine proteinases, papain and mammalian cathepsin L. This is particularly marked 
immediately adjacent to the active site histidine residue (shown in bold in Table 11). 
Figure 33: Schematic representation of the three-dimensional structure of papain. 
The region corresponding to the chosen trypanopain peptide is shown in green. After Drenth et al. 
(1971). 
Table 11: Amino acid sequence homology between the chosen trypanopain peptide and 
corresponding regions of other trypanosomal cysteine proteinases, human 
cathepsin L and papain. 
Enzyme Sequence Reference 
Trypanopain IL-TSCTSKQLDHGVL Mottram et al. (1989) 
Trypanopain-Tc VL-TSCISKGLDBDVL Fish et al. (1995) 
Cruzipain VM-TSCVSEQLDHGVL Cazzulo et al. (1989) 
Human cathepsin L IYFEPDCSSEDMDHGVL Gal and Gottesman (1988) 
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Figure 34: Epitope prediction plots for regions of trypanopain. 
Plot A shows epitope prediction plots for residues 250 to 290 of trypanopain and Plot B shows epitope 
prediction plots for the peptide sequence (trypanopain residues 274-289) selected for anti-peptide 
antibody production. The Y-axis has arbitrary units of hydropbilicity (- ), accessibility (- ), flexibility 
(- ) and antigenicity (-). A software package, Predict7 (Cannenes et ai. , 1989}'was used to generate 
the data. 
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6.3 Peptide conjugation 
Although peptides of 10 residues or longer are considered immunogenic by some authors 
(Harlow and Lane, 1988), peptides are usually coupled to carrier proteins before immunisation, 
increasing their immunogenicity up to 1000-fold (Mariani et al., 1987). The selected peptide 
was conjugated to carrier proteins using the coupling reagent meta-mal~irnidobenzoyl 
N-hydroxysuccinirnide ester (MBS) as described by Kitagawa and Aikawa (1976), using the 
modifications ofLiu et al. (1979). This heterobifunctional reagent acylates amino groups via its 
active ester and also forms thioether bonds with sulfhydryl groups (Kitagawa and Aikawa, 
1976). In this study, MBS was used to link peptides to carrier proteins by the acylation of 
amino groups on the carrier protein and subsequent formation of thioether bonds with the 
N-terrninal cysteine of the peptide. Due to the heterobifunctional nature ofMBS, conjugation 
must be carried out in two distinct steps, which serendipitously prevents the formation of carrier 
or peptide dirners. A 30-50% yield of conjugate is usually obtained using MBS (Muller, 1988). 
Glutaraldehyde conjugation was unsuitable for the peptide used in this study because exclusive 
conjugation of the peptide to the carrier by the N-terrninus would be prevented by the presence 
of the E-arnino group on the lysine residue of the peptide (Avrameas and Ternynck, 1969). 
Ovalbumin was used as a carrier protein for immunisation into rabbits and rabbit albumin for 
chickens. These carriers were used instead of keyhole limpet haemocyanin (KLH), which is 
extremely immunogenic in experimental animals (polson et ai. , 1980) and elicits antibodies that 
have been found to react non-specifically in Western blots (Coetzer et ai. , 1991). 
6.3.1 Materials 
50 mM sodium phosphate buffer, pH 7.0. NaH2P04. 2H20 (0.69 g) was dissolved in 90 ml of 
H20 , titrated to pH 7.0 with NaOH and made up to 100 ml with H20 . 
Ellman' s reagent [10 mM .5,S'-dithiobis(2-nitrobenzoic acid), (DTNB) in 50 mM sodium 
phosphate buffer, pH 7.0, 10% (v/v) methanol]. DTNB (40 mg) was dissolved in methanol 
(100 Ill) and diluted to 10 ml with the sonium phosphate buffer described above. 
MBS (16 mM). MBS (5 mg) was dissolved in dimethylformarnide (DMF, 1 ml). DMF must 
be amine-free and "dry" to prevent undesired side reactions. 
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Reducing buffer [l00 mM Tris-Cl, 1 mM Na2EDTA 0.02% em/v) NaN3, pH 8.0]. Tris 
(1.21 g), Na2EDTA.2H20 (0.037 g) and NaN3 (0.02 g) were dissolved in 90 ml of H20, titrated 
to pH 8.0 with HCI and made up to 100 ml with H20 . 
10 mM DTT in reducing buffer. DTT (7.71 mg) was dissolved in 5 ml of reducing buffer just 
before use. 
Chromatography buffer [100 mM sodium phosphate buffer, 0.02% NaN3, pH 7.0]. 
NaH2P04.2H20 (6.9 g) and NaN3 (0.1 g) were dissolved in 450 ml of H20 , titrated to pH 7.0 
with NaOH and made up to 500 ml with H20 . 
6.3.2 Method 
Carrier protein (0.089 /lmol, equivalent to 4.16 mg ovalbumin or 6.20 mg rabbit albumin) was 
dissolved in phosphate buffer (2 ml). MBS (279 /ll, 3.56 /lmol, giving a 1:40 molar ratio of 
carrier:MBS) was added and stirred slowly into the carrier protein solution and acylation of the 
carrier allowed to proceed at RT for 30 min. Unreacted MBS was removed by 
chromatography on Sephadex G-25 (1.5 x 11.5 cm) pre-equilibrated in chromatography buffer 
at a flow rate of 10 cm/h. The A2so of the eluate was monitored and the activated carrier 
collected as the first peak. The subsequent peak, representing unreacted MBS was discarded. 
Peptide (5 mg, 3.4 /lmol, giving a molar ratio of peptide to activated carrier of 40:1) was 
dissolved in reducing buffer (1 ml). DTT (1 ml) was added and reduction of the peptide 
allowed to proceed for I 1f2 h at 37°C. Reduced peptide was separated from excess DTT by 
chromatography on Sephadex G-IO (l xl2 cm, pre-equilibrated at RT in chromatography buffer 
at 10 cm/h). Fractions (500 /ll) were collected manually in Eppendorftubes and 10 III of each 
fraction mixed with an equal volume of Ellman's reagent to construct the elution profile. This 
reagent produces a yellow product after reaction with reducing agents, with a light yellow 
colour marking the elution of the reduced peptide and an intensely yellow colour marking the 
elution of excess DTT. 
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The reduced peptide was immediately mixed with activated carrier and incubated for 3 h at R T. 
Carrier activation and peptide reduction should ideally proceed at the same time so that they are 
mixed immediately after preparation but, in practice, the time of elution of each is difficult to 
control exactly. Where necessary, the activated carrier, rather than the reduced peptide, was 
allowed to stand before the final reaction commenced, as Muller (1988) states that coupling 
yield is strongly dependent on the availability of sulfhydryl groups. Unbound peptide was 
removed by dialysis against 4 changes of sodium phosphate buffer over 16 h at 4°C. 
Estimating the efficiency of coupling proved difficult. Kitagawa and Aikawa (1976) titrated the 
maleimide groups on the carrier using a sulfydryl reagent (such as ~-mercaptoethanol, which 
binds to MBS) and Ellman's reagent. By determining the maleimide content of the carrier 
before and after conjugation, the efficiency of both carrier activation and coupling were 
estimated. In the present study, irreproducible results were obtained using this method, so three 
alternative methods of estimating coupling efficiency were investigated. The carrier-conjugated 
peptide (called the conjugated peptide throughout) and the free carrier were scanned between 
185 and 900 nm, but no marked differences in their spectra were noted. However, both the 
free, unmodified carrier and MBS-modified carrier gave sharp single bands on a silver stained 
SDS-PAGE gel, while the conjugates gave a large number of bands of greater size (Figure 35). 
The increased molecular mass indicates that successful conjugation to the carrier had occurred. 
Finally, electrospray mass spectroscopy (ES-MS), kindly performed by Ron Berry and Andrew 
Howes from this department while at the University of Stellenbosch, showed that numerous 
higher molecular weight species were present in conjugated peptide preparations but not in 
unmodified albumin (results not shown), suggesting that coupling was successful. However, 
the complexity of the ES-MS profile did not allow determination of the percentage of peptide 
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Figure 35 : SDS-P AGE gel showing coupling of the trypanopain peptide to rabbit albumin and 
ovalbumin. 
Ovalbumin-MBS-peptide (lane I), ovalbumin-MBS (lane 2) and unmodified ovalbumin (45 kDa, 
lane 3), rabbit albumin-MBS-peptide (lane 4), rabbit albumin-MBS (lane 5) and unmodified rabbit 
albumin (66 kDa, lane 6) are shown. Pharmacia molecular mass markers (Section 2.4) were used. 
6.4 Immunisation of experimental animals 
Because different species may respond differently to an immunogen (Harlow and Lane, 1988), 
both rabbits and chickens were immunised with the trypanopain peptide. Parallel experiments 
were conducted with the free and conjugated peptide to assess their relative immunogenicity. 
6.4.1 Rabbits 
Two young rabbits were each immunised with free peptide (200 jJ.g each, dissolved in 
heat-sterilised 100 mM sodium phosphate buffer, pH 6.0) and two with peptide-ovalbumin 
conjugate (about 200 jJ.g each of peptide). Since the exact efficiency of peptide-carrier coupling 
could not be calculated (see Section 6.3 .2), 40% coupling efficiency was assumed (Muller, 
1988) to calculate the required dose of conjugated peptide. Immunogens were triturated with 
an equal volume of Freund's adjuvant until a thick emulsion formed (Freund and McDermott, 
1942). Freund's complete adjuvant was used for all immunisations with free peptide and for 
initial immunisations with conjugated peptide. Freund's incomplete adjuvant was used for 
subsequent immunisations with the conjugated peptide. Rabbits were injected subcutaneously 
at 4-6 sites on either side of the spine (Chase, 1977) at weeks 0,2,6 and 10. 
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Blood was collected 3, 8 and 12 weeks after the first immunisation. The area surrounding the 
central ear vein was shaved and cleaned with alcohol. A needle was inserted into the ear vein 
and blood collected into dry test tubes. Clots were carefully loosened from the walls of the 
collection tubes with a sealed Pasteur pipette and blood was stored for 16 h at 4°C to allow 
complete clotting. The serum was aspirated and centrifuged (l500xg, 10 min, RT) to remove 
any remaining erythrocytes. 
6.4.2 Chickens 
Chickens are excellent animals for experimental antibody production, since large quantities of 
antibody are concentrated in the egg yolk to provide passive immunity for the developing chick . 
(polson et at., 1980). These antibodies are termed IgY, where the Y refers to their location in 
the egg yolk. Since antibodies produced throughout the immunisation protocol can be obtained 
by collecting the eggs, no bleeding of the chicken is necessary. Two chickens were immunised 
with free peptide (200 j.lg each, prepared as in Section 6.4.1) and two with peptide-rabbit 
albumin conjugate (about 200 j.lg peptide each, calculated as in Section 6.4.1). The immunogen 
was triturated with adjuvant until a thick emulsion formed. Because chickens respond 
unfavourably to repeated doses of Freund's complete adjuvant (Dr Theresa Coetzer, 
Department of Biochemistry, UNP, personal communication), the free peptide was alternately 
administered in Freund's complete and incomplete adjuvant. Conjugated peptide was 
administered in complete adjuvant for the first immunisation and subsequently in incomplete 
adjuvant. Birds were injected intramuscularly at 4 to 6 sites on either side of the sternum at 
weeks 0, 1, 2,6 and 10 and eggs collected from the start of the immunisation protocol. 
6.S Assessment of antibody production and cross-reactivity with whole enzymes 
Following isolation of chicken (Section 2.8) and rabbit (Section 2.9) antibodies, ELISAs were 
used to monitor antibody production in experimental animals by titrating test antibodies against 
the free peptide, coated as antigen (Section 2.10). The titre of each antibody is defined as the 
lowest antibody concentration that gives an absorbance value higher than the controls. Once 
the highest titre anti-peptide antibodies produced by each animal were identified, the ability of 
these antibodies to recognise whole trypanopain and cathepsin L was investigated. Only some 
of the anti-peptide antibodies were expected to cross-react with whole trypanopain (or 
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cathepsin L) since the free peptide used as antigen can adopt many conformations, only some of 
which mimic the naturally occurring conformations in the corresponding constrained region of 
the target protein. Hence only some of the elicited antibodies are directed against peptide 
conformations normally occurring in the parent enzyme. 
6.5.1 Materials 
As per Section 2.10.1. 
6.5.2 Method for ELISAs monitoring progression of antibody titre 
For ELISAs monitoring the production of anti-peptide antibodies in chickens and rabbits, the 
free peptide was coated as antigen (5 )..I.glrnl in PBS, 150)..1.1 per well, 16 h, 4°C) and remaining 
sites blocked with BSA-PBS (200 )..1.1, 1 h, 37°C). Test antibodies were then titrated (between 
250 and 2 )..I.glrnl in BSA-PBS, 100 )..1.1 per well, 2 h, 37°C) and the HRPO-linked secondary 
antibody added (120 )..1.1 per well in BSA-PBS, 1 h, 37°C). ABTSIH20 2 (150 )..1.1 per well) was 
used as the substrate and absorbance monitored at 405 nm. 
6.5,3 Method for ELISAs to determine recognition of whole trypanopain and 
cathepsin L by anti-peptide antibodies 
To investigate the cross-reactivity between anti-peptide antibodies and whole trypanopain, 
various steps were taken to increase the sensitivity over that achieved in Section 2.10. Whole 
trypanopain was coated directly onto Nunc "PolyS orb" ELISA plates (serial two-fold dilutions 
from 1 Ilglrnl in pH 6.0 sodium carbonate buffer, 150 III per well, 16 h, 4°C), which have 
superior antigen coating ability and lower background than the routinely used "MaxiSorb" 
plates. Coating was done in carbonate buffer, since this has been shown to improve recognition 
of whole cathepsin-like enzymes by anti-peptide antibodies (Coetzer, 1992). Remaining sites 
were blocked with BSA-PBS and primary antibody (fixed concentration of 50 )..I.glrnl in 
BSA-PBS) applied. Tween-20 [0.1% (v/v)] was added to this BSA-PBS to reduce non-
specific protein-protein interactions and so reduce background. The secondary antibody was 
applied as in Section 6.5.2, but a more sensitive HRPO substrate, namely TMB (150 III per 
well) was used to increase the signal generated by the HRPO. 
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ELISAs to determine whether the anti-peptide trypanopain antibodies recogruse whole 
cathepsin L were conducted as for the trypanopain ELISA above, with sheep cathepsin L 
coated as antigen [serial doubling dilutions from 1 Ilg/rnl in pH 6.0 sodium carbonate buffer 
(Coetzer, 1992), 16 h, 4°C]. 
6.6 Evaluation of antibodies with Western blots 
Following evaluation of anti-peptide antibodies by ELISA, the antibodies were evaluated by 
Western blots. Electroblotting denatures the antigen to a larger extent than occurs in an 
ELISA, so this method evaluates antibody recognition of fully denatured antigen. When initial 
experiments showed no recognition of fully denatured trypanopain by these antibodies, the 
renaturing buffer system of Dunn (1986) was used, in the hope that the partially renatured 
trypanopain would be successfully recognised. 
6.6.1 Materials 
As per Section 2.11 .1. 
Renaturing solution [50 mM Tris-Cl, 20% em/v) glycerol, pH 7.4]. Tris (6.055 g) was 
dissolved in 700 rnl of H20 and glycerol (200 g) added. The solution was adjusted to pH 7.4 
with HCI and made up to 11 with H20 . 
Dunn carbonate transfer buffer [10 mM NaHC03, 3 mM Na2C03, 20% ev/v) methanol, 
pH 9.9]. NaHC03 (l.6802 g) and Na2C03 (0.63594 g) were dissolved in 1.4 I, methanol 
(400 rnI) added and the solution made up to 2 I. The pH of this buffer should not be adjusted 
(see Section 2.11.1). 
6.6.2 Method 
For initial Western blots evaluating anti-peptide antibodies, the gel was electroblotted at 200 V 
for l lh h and blocked with block II (Section 2.11 .1). In separate experiments, various IgY and 
rabbit anti-peptide antibody preparations were applied at 500 Ilg/rnl and 250 Ilg/rnl respectively 
(3 h), followed by rabbit anti-IgY-AP or goat anti-rabbit-AP secondary antibodies 
(manufacturer's recommended dilutions, 1 h) and BCIPINBT substrate. 
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When these blots were unsuccessful, various steps were taken to improve on the initial method. 
Following tricine SDS-PAGE, gels were soaked in renaturing solution to promote renaturation 
of antigens (Dunn, 1986) and gels then blotted using the high pH transfer buffer. Primary 
antibodies were incubated with these blots for 31h h. 
6.7 Effect of anti-peptide antibodies on trypanopain activity agains,t Z-Phe-Arg-
AMC, 14C-gelatin and FITC-albumin 
Antibodies can activate, inhibit or have no effect at all on an enzyme's activity, depending on 
factors such as the epitopes targeted by the antibodies, antibody concentration and the substrate 
used (Richmond, 1977). Antibody-mediated inhibition is thought to be due either to occlusion 
of the active site or induction of an inactive conformation (Oppenheim and Nachbar, 1977). 
Since activity against large substrates is often completely or largely inhibited, while hydrolysis of 
small substrates is affected less, the former mechanism is thought to predominate. On the other 
hand, antibody-mediated enhancement of enzyme activity is thought to result from stabilising of 
an active enzyme conformation. 
Since the effect of an anti-enzyme antibody on the enzyme's activity is in part dependent on the 
substrate used to assess the effect (Richmond, 1977), three trypanopain substrates were used in 
these studies. Because the size of the substrate is often an important factor, large protein 
substrates C4C-gelatin and fluorescein isothiocyanate (FITC)-albumin (Lumen and Tappell, 
1974; Twining, 1984)] and a small synthetic substrate (Z-Phe-Arg-AMC) were chosen. 
6.7.1 Materials 
As per Sections 4.2 and 4.8.6. 
Antibody diluting buffer [100 roM Na-acetate, 1 roM Na2EDTA 0.02% em/v) NaN3, 0.1% 
(v/v) Tween-20, pH 8.0]. Glacial acetic acid (5 .7 rnI), Na2EDT A.2H20 (0.37 g) and NaN3 
(0.2 g) were dissolved in 900 rnl of H20 and Tween-20 (1 rnI) added. The solution was 
adjusted to pH 8.0 with NaOH and made up to II with H20 . 
FITC-albumin (5 mg/rnl). FITC-albumin (5 mg) was dissolved in 1 rnl of 0.5% (m/v) Brij-35. 
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Stop solution [5% em/v) TCA]. TCA (5 g) was dissolved in 90 ml of H20 and made up to 
100 ml with H20 . 
FITC diluent (500 roM Tris-CL pH 8.5). Tris (6 g) was dissolved in 60 ml of H20 , adjusted to 
pH 8.5 with HCl and made up to 100 ml with H20 . 
6.7.2 Method 
Trypanopain (l.5 ng for hydrolysis ofZ-Phe-Arg-AMC, 5.5 ng for hydrolysis of 14C-gelatin and 
FITC-albumin) was diluted to 250 )ll with 0.1 % (m/v) Brij-35. The antibody under study was 
diluted as required (final concentration of 31.25-1000 )lglml) with antibody dilution buffer 
(diluted volume 250 Ill) and the mixture incubated for 15 min at 30°e. An aliquot (250 )ll for 
Z-Phe-Arg-AMC hydrolysis; 150)l1 for 14C-gelatin hydrolysis) was assayed as usual against 
Z-Phe-Arg-AMC (Section 3.2.2) or 14C-gelatin (Section 4.2 and 4.8.6) at 37°e. Aliquots 
(50 Ill) to be assayed against FITC-albumin were added to this substrate (20 Ill) and incubated 
for 24 h at 37°e. Stop solution was added (1 20 Ill, 1 h, R T) and the solution centrifuged 
(10000 xg, 10 min, RT). An aliquot (60 Ill) was diluted with 1 ml of FITC diluent and the 
fluorescence read on a Hitachi F-2000 spectrofluorometer (excitation 490 nm, emrnision 
525 nm). Since the addition of non-immune antibodies slightly reduced enzyme activity against 
all three substrates, enhancement or inhibition of enzyme activity is expressed as a percentage of 
the activity detected after incubation with the same concentration of non-immune antibody. 
6.8 Inhibition of antibody effect on enzyme activity by addition of free peptide 
Interactions between trypanopain and anti-trypanopain antibodies were measured relative to 
interactions with non-immune antibodies so the results obtained from experiments described in 
Section 6.7 point to specific recognition of the enzyme by anti-trypanopain antibodies. To 
further confirm the specificity of the interaction, experiments in Section 6.7 were repeated in the 
presence of the free trypanopain peptide. Specific anti-peptide antibodies are expected to bind 
to the free peptide, leaving less free antibody to modulate trypanopain activity. If the antibody 
effect arises from specific recognition of the peptide region in trypanopain, then addition of free 
peptide should reduce the effect of antibodies on enzyme activity. 
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6.8.1 Materials 
As in Section 6.7.1. 
6.8.2 Method 
The trypanopain peptide was dissolved in 0.1 % (m/v) Brij 35 to give 10 000: 1 to 1: 1 molar 
ratios of peptide: enzyme. The peptide solution (100 Ill) was incubated with antibody (500 Jll, 
final concentration 500 Ilg/ml) for 15 min at 30°C to allow specific anti-peptide antibodies to 
bind to the peptide. The antibodies were then incubated with trypanopain as in Section 6.7.2. 
6.9 Effects of antibodies on trypanopain activity against Z-Phe-Arg-AMC and 
14C-gelatin in T. b. brucei Iysates 
6.9.1 Materials 
As per Section 6.7.1. 
6.9.2 Method 
As per Section 6.7.2, except that T b. brucei lysates were used instead of purified trypanopain. 
The concentration of trypanopain in these lysates was estimated by E-64 titration (Section 3.4) 
to be approximately 350 nM. 
6.10 Effect of antibodies on cathepsin L activity against Z-Phe-Arg-AMC and 
14C I . -ge atm 
Since trypanopain and sheep cathepsin L are 9% homologous (Mottram et al., 1989; Ritonja et 
al., 1996), some degree of cross-reactivity between anti-trypanopain antibodies and the 
mammalian enzyme was expected. Section 6.5.3 showed that anti-trypanopain anti-peptide 
antibodies recognised denatured cathepsin L in an ELISA. To determine whether these 
antibodies also recognise native cathepsin L, the effect of these antibodies on cathepsin L 
activity were determined. 
6.10.1 Materials 
As per Section 6.7.1, except with the following changes: 
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Cathepsin L assay buffer [340 mM sodium acetate, 60 mM acetic acid, 4 mM Na£DTA 
0.02% NaN3, 4 mM DTT, pH 5.5]. Sodium acetate.3H20 (23 .13 g), glacial acetic acid 
(l.72 ml), Na2EDTA.2H20 (0.75 g) and NaN3 (0.1 g) were dissolved in 450 ml of H20, 
adjusted to pH 5.5 with NaOH and made up to 500 ml with H20 . DTT (6.2 mg) was added to 
5 ml of buffer just before use. 
6.10.2 Method 
As per Section 6.7.2. 
6.11 Results 
6.11.1 Determination of antibody titre in rabbits and chickens 
Rabbits immunised with the conjugated peptide produced antibodies that recognised the free 
peptide effectively. Only minimal differences were observed between the responses of 
individual rabbits immunised with identical antigens, so the response of a single animal is shown 
(Figure 36A). Antibodies produced 3, 8 and 12 weeks post-immunisation all gave high signals 
compared to those generated by non-immune antibodies, with the antibody titre below 1 0 ~g 
antibody/ml for all weeks tested. 
Rabbits immunised with the free peptide also produced high titre antibodies, showing that the 
free peptide is immunogenic in rabbits. Only minimal differences were observed between the 
responses of individual rabbits immunised with identical antigens. Compared with the 
conjugated peptide, the free peptide appeared to be slightly less immunogenic (Figure 36B). 
While the titre of anti-(conjugated peptide) antibodies was high (below 10 jlglml) by 3 weeks 
post-immunisation, the titre of anti-(free peptide) antibodies was still low (below 100 jlg/ml) at 
this time. By weeks 8 and 12 post-immunisation, however, the titre of anti-(free peptide) and 
anti-(conjugated peptide) antibodies was comparable (below 10 jlg/ml), showing that the 
peptide ultimately elicited antibodies of similar strength irrespective of whether it was 
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Figure 36: Rabbit antibodies produced against the conjugated and free trypanopain peptide at 
various weeks post-immunisation. 
Peptide (5 ~ml) was coated for 16 h at 4°C in PBS. Antibodies produced against the conjugated (A) 
and free peptide (B) are shown. Absorbance values at 405 run represent the average of duplicate 
experiments. Non-immune antibodies (e) and antibodies from week 3 c-> week 8 (T) and week 12 (+) 
post-immunisation were titrated between 250 f..tg and 0.1 J.lg antibody/ml. Sheep anti-rabbit-HRPO was 
used as secondary antibody with ABTSIH20 2 as substrate. 
Only one of the chickens immunised with the conjugated peptide laid eggs, so comparison 
between individuals was not possible. Antibodies from weeks 3, 6, 8, 10 and 12 
post-immunisation all recognised the peptide well, with week 8 giving the highest signal (Figure 
37 A). Chickens immunised with the free peptide also produced high titre antibodies, showing 
that the free peptide was also immunogenic in chickens (Figure 37B). Antibodies from 6, 8 and 
12 weeks post-immunisation recognised the pe~tide well (titre below 10 J.lg antibody/mI), with 
week 8 giving the highest signal. Week 3 antibodies gave poor signals compared to the 
corresponding anti-( conjugated peptide) antibodies, showing that was the case with rabbits, 
chicken responses to the free peptide were slower than against the conjugate. Antibodies 






Production of anti-peptide antibodies was thus similar in rabbits and chickens, with respect to 
titre and timing of the immune response. Individuals immunised with identical immunogens 
responded similarly. The two species tested, namely rabbits and chickens, also responded 
comparably. High titre antibodies were produced faster against the conjugated peptide than 
against the free peptide, but by 8 weeks post-immunisation, titres of antibodies against the two 
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Figure 37: Chicken antibodies produced against the conjugated and free trypanopain peptide 
at various weeks post-immunisation. 
Peptide (5 f.1g!ml) was coated for 16 h at 4°C. Antibodies directed against the conjugated (A) and free 
(B) peptide are shown. Absorbance values at 405 nm represent the average of duplicate experiments. 
Non-immune antibodies (e) and antibodies from week 3 ~ week 8 (T) and week 12 (+) 
post-immunisation were titrated between 250 and 0.1 flg antibody/ml. Rabbit anti-chicken-HRPO was 
used as secondary antibody with ABTSIH20 2 as substrate. 
6.11.2 Recognition of whole trypanopain 
In addition to recognising the free trypanopain peptide, the anti-peptide antibodies recognised 
whole trypanopain in an ELISA. Rabbit responses are shown in Figure 38. Antibodies against 
both forms of the antigen (free and conjugated peptide) and from both species (rabbit and 
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Recognition of _ whole trypanopain by rabbit anti-(free peptide) and 
anti-( conjugated peptide) antibodies in an ELISA. 
Trypanopam (serial two-fold dilutions from 1 J.lg/ml) was coated for 16 h at ·4°C in pH 6.0 sodium 
carbonate buffer, after which a fixed concentration of test primary antibody (50 J.lg antibody/ml) was 
applied. Absorbance values at 450 nm of non-immune antibodies (0), anti-(free peptide) antibodies 
from rabbits I (~) and II (+) and anti-(conjugated peptide) antibodies from rabbits ill (-> and IV (T) 
represent the average of duplicate experiments. Sheep anti-rabbit-HRPO was used as secondary 
antibody with TMBIH20 2 as substrate. 
6.11.3 Cross-reactivity with sheep cathepsin L 
Since the trypanopain peptide sequence targeted is similar to the corresponding sequence in 
mammalian cathepsin L (Ritonja et at., 1988), cross-rea~ivity between anti-trypanopain 
antibodies and sheep cathepsin L was investigated in ELISAs performed in parallel with the 
trypanopain ELISA in Section 6.11.2. Both chicken and rabbit anti-(free peptide) and anti-
(conjugated peptide) antibodies recognised cathepsin L in an ELISA (Figure 39). Generally 
weaker signals were generated by cathepsin L than by trypanopain, showing that the antibodies 
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Figure 39: Cross reactivity between chicken and rabbit anti-trypanopain peptide antibodies 
and sheep cathepsin L in an ELISA. 
Sheep cathepsin L (serial two-fold dilutions from 1llglml) was coated for 16 h at 4°C in pH 6.0 sodium 
carbonate buffer. Absorbance values at 450 nm for rabbit non-immune antibodies (e), rabbit anti-(free 
peptide) (+) and anti-(conjugated peptide) antibodies (A), chicken non-immune antibodies (- ), chicken 
anti-(free peptide) (T) and anti-(conjugated peptide) antibodies (II) represent the average of duplicate 
experiments. Sheep anti-rabbit-HRPO or rabbit anti-chicken-HRPO secondary antibodies were used for 
detection and TMBIH20 2 was used as the substrate. 
6.11.4 Western blots with anti-peptide antibodies 
The anti-peptide antibodies did not recognise trypanopain on Western blots, whether purified 
enzyme or lysed T. b. brucei were used as antigen. Methods reported to increase recognition of 
antigens (Dunn, 1986) were unsuccessful. 
6.11.5 Effect of antibodies on trypanopain activity against Z-Phe-Arg-AMC 
Rabbit antibodies directed against both the free and conjugated peptide enhanced trypanopain 
hydrolysis of Z-Phe-Arg-AMC relative to non-immune antibodies (Figure 40). Antibodies 
directed against the free peptide activated the enzyme slightly more (by 64% at 500llg 
antibody/rnl) than those directed against the conjugated peptide (by 49% at 500 Ilg 
antib0 dy/rnl). The effects of antibodies from individual rabbits immunised with identical 
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antigens were comparable. Slightly greater enhancement was mediated by week 12 antibodies 
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Enhancement of trypanopain hydrolysis of Z-Phe-Arg-AMC by rabbit 
anti-trypanopain peptide antibodies. 
Trypanopain (1.5 ng) was incubated in triplicate with rabbit anti-peptide antibodies (31.25 to 1000 Ilg 
antibody/ml) at pH 8.0 (15 min, 37°C). Residual enzyme activity against Z-Phe-Arg-AMC was then 
detennined as described in Section 4.8.6. Effects of antibodies raised against the free peptide (e ) and the 
conjugated peptide ~ are shown. 
In contrast with rabbit antibodies, the effects of chicken antibodies on trypanopain hydrolysis of 
Z-Phe-Arg-AMC were more complex. Individual chickens produced both activity-enhancing 
and activity-inhibiting antibodies at different stages in their immune response. This effect was 
observed both in chickens immunised with the free peptide and those immunised with the 
conjugated peptide. In the case of the free peptide, antibodies produced 3, 6, 8 and 10 weeks 
after the first immunisation all enhanced trypanopain activity against Z-Phe-Arg-AMC, with 
enhancement increasing to an optimum at week 8 (Figure 41). Week 10 antibodies inhibited 
activity by 80%, while week 11 antibodies enhanced activity by 75% and week 12 inhibited by 
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Figure 41 : Modulation of trypanopain hydrolysis of Z-Phe-Arg-AMC by chicken anti-(free 
peptide) antibodies. 
Trypanopain (1.5 ng) was incubated in triplicate with chicken anti-(free peptide) antibodies (500 Ilg/ml) 
at pH 8.0 (15 min, 37 C). Residual enzyme activity against Z-Phe-Arg-AMC was then determined as 
described in Section 4.8.6. Activity is expressed relative to that observed after incubation with 
non-immune antibodies (500 Ilg/ml) with % enhancement of activity expressed as positive values and % 
inhibition of activity expressed as negative values. Chickens were immunised at weeks O. 1, 2, 6 and 10 
(arrows). 
Antibodies produced in chickens soon after immunisationlboosting with the free peptide appear 
to enhance activity while those produced a few weeks later appear inhibitory. Chicken 
responses to the conjugated peptide were similar to those against the free peptide. For 
example, antibodies produced 3, 6 and 8 weeks post-immunisation enhanced enzyme activity 
(by up to 46% at 500 Jlg/rnl) while those from weeks 10 and 12 inhibited activity (by up to 91 % 
at 500 Jlg/rnl) (results not shown). 
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Chicken anti-whole trypanopain antibodies (Chapter 3) inhibited trypanopain hydrolysis of 
Z-Phe-Arg-AMC by up to 60% at 1 mg/rnl (results not shown). 
6.11.6 Inhibition of antibody effect on Z-Phe-Arg-AMC hydrolysis by incubation 
with free peptide 
If the effects of the anti-peptide antibodies on trypanopain activity are specific, then pre-
incubation of the antibodies with the free peptide should substantially reduce the antibody 
effects on trypanopain activity. This was shown to be the case. For example, week 8 chicken 
antibodies raised against the free peptide enhanced trypanopain activity by 276% (Section 
6.1l.5) but after pre-incubation with the free peptide, this enhancement was greatly reduced. 
At a 10000: 1 molar ratio of peptide:enzyme, only 46% enhancement of trypanopain activity 
was observed (Table 12). The effects of the peptide on activation can thus be expressed as 
follows: 
'd ' d d ' f . . . 276 - x PeptI e - mduce % re uctIon 0 enzyme actIvltIon = % 
x 
where x represents enhancement of trypanopain activity by antibodies pre-incubated with the 
free peptide. Using this formula, the reduction in activity enhancement from 276% to 46% 
represents an 83% reduction of the antibody effect by pre-incubation with the peptide. 
Table 12: Effect of free peptide on subsequent modulation of trypanopain hydrolysis of 
Z-Phe-Arg-AMC by activity enhancing chicken anti-peptide antibodies. 
Peptide: enzyme % Enhancement % Reduction of 
molar ratio enhancement 
0 : 1 276 0 
1 : 1 113 59 
100 : 1 99 64 
1 000 : 1 73 74 
10000 : 1 46 83 
In contrast with week 8 chicken anti-(free peptide) antibodies, week 10 chicken anti-(free 
peptide) antibodies inhibited trypanopain activity by 80% (Section 6.1l.5). Pre-incubation of 
these antibodies with the free trypanopain peptide reduced the inhibition observed to the extent 
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that at 10 000:1 molar ratio of peptide:enzyme, no inhibition was seen (Table 13). This 
represents a 100% reduction in the antibody effect by addition offree peptide. 
Table 13: Effect of free peptide on subsequent modulation of trypanopain hydrolysis of 
Z-Phe-Arg-AMC by activity inhibiting chicken anti-peptide antibodies. 
Peptide:enzyme molar % Inhibition % Reduction of 
ratio inhibition 
0 : 1 80 a 
1 : 1 59 26 
10 : 1 58 28 
100 : 1 54 33 
1 000 : 1 56 31 
10 000 : 1 a 100 
In contrast with chicken anti-peptide antibodies, rabbit anti-peptide antibodies (all weeks) 
enhanced trypanopain activity against Z-Phe-Arg-AMC by up to 64% (for week 12 anti-(free 
peptide) antibodies at 500 Ilg antib0 dy/ml, Section 6.11.5). Pre-incubation of the antibodies 
with the free peptide reduced the enhancement of trypanopain activity substantially, to the 
extent that at ala 000:1 molar ratio of peptide: enzyme only 15% enhancement of activity was 
seen (Table 14) This decrease from 64% to 15% enhancement represents a 77% reduction in 
the antibody effect by addition of the free peptide. 
Table 14: Effect of free peptide on subsequent enhancement of trypanopain activity against 
Z-Phe-Arg-AMC by activity enhancing rabbit anti-peptide antibodies. 
Peptide:enzyme molar % Enhancement % reduction of 
ratio enhancement 
0: 1 64 a 
1 : 1 57 11 
10 : 1 50 22 
1 00 : 1 48 25 
1 000 : 1 28 56 
10 000 : 1 15 77 
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Addition of a non-related peptide should have no effect on binding of anti-trypanopain antibody 
to the enzyme. Poly-L-glutarnic acid was used to confinn that this occurred in the system under 
study. As expected, different molar excesses of poly-L-glutamate had no effect on anti-peptide 
antibody binding to trypanopain (results not shown) indicating that the peptide effect is specific. 
6.11.7 Effect of antibodies on trypanopain activity against 14C-gelatin 
All the tested anti-peptide antibodies activated trypanopain digestion of 14C-gelatin (Figure 42). 
The greatest level of enhancement was seen with chicken anti-(free peptide) antibodies (349% 
of non-immune activity at 250 Ilg/ml). Anti-whole trypanopain antibodies (Chapter 3) had no 
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Figure 42: Effect of anti-peptide antibodies on trypanopain digestion of 14C-gelatin. 
Trypanopain (5.5 ng) was activated with pH 5.5 assay buffer and incubated in quintuplicate with various 
concentrations (62.5 to 1000 Ilglml) of the antibody under study (30 rn.in, 37°C). 14C-gelatin was then 
added and digestion allowed to proceed at 37°C for 3Y2 h. Chicken anti-(free peptide) antibodies (II and 
.), chicken anti-(conjugated peptide) antibodies (T), rabbit anti-(free peptide) antibodies (+) and rabbit 
anti-(conjugated peptide) antibodies (A and -) from various weeks all enhanced trypanopain activity 
against 14C-gelatin relative to non-immune antibodies. 
6.11.8 
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Reduction of antibody effect on 14C-gelatin hydrolysis by pre-incubation with 
free peptide 
To test the specificity of anti-peptide antibody enhancement 14C-gelatin hydrolysis by 
trypanopain, the antibodies were pre-incubated with the free trypanopain peptide before 
incubation with trypanopain, as discussed in Section 6.11 .6. 
Pre-incubation of anti-peptide antibodies with the free trypanopain peptide reduced their 
subsequent enhancement of trypanopain activity against 14C-gelatin. Rabbit antibodies showed 
a complete abolition of enhancing activity when pre-incubated with the free peptide, while 
chicken antibodies showed up to 57% reduction in their enhancing activity (results not shown). 
6.11.9 Effect of anti-trypanopain antibodies on trypanopain digestion ofFITC-albumin 
All tested anti-peptide and anti-whole enzyme (Chapter 3) antibodies inhibited trypanopain 
digestion of FITC-albumin. Rabbit antibodies inhibited trypanopain activity poorly (14-18%), 
but chicken antibodies inhibited trypanopain activity by up to 40% (Figure 43). 
C 
50 .;; I 
. .0 i U 
J ro c 40 
·8 I 
0... 
30 j 0 C ro 
0... 
C I I ...... 
20 
I 
...... 1 0 
c I 
0 
10 1 . .0 :E 
:E 
I c 0 ..... 
~ 0 200 400 600 800 1000 
Antibody concentration (Ilg/ml) 
Figure 43: Effect of anti-trypanopain peptide antibodies on trypanopain digestion of 
FITC-albumin. 
Trypanopain (5 .5 ng) was incubated with vanous concentrations of anti-trypanopain peptide 
antibodies and hydrolysis of FITC-albumin measured in quintiplicate assays . Inhibition of 
trypanopain digestion of FITC-albumin by chicken anti-(free peptide) (e) and anti-(conjugated 
peptide) (_) antibodies is shown. 
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6.11.10 Effect of anti-trypanopain peptide antibodies on trypanopain hydrolysis of 
Z-Phe-Arg-AMC and 14C-gelatin in T. b. brucei Iysates 
The chicken antibodies [anti-(free peptide) week 8] that enhanced activity of purified 
trypanopain against Z-Phe-Arg-AMC (Section 6.1l.5) also enhanced hydrolysis of this 
substrate in crude lysates of T b. brucei (Figure 44). Comparable enhanceme~t of pure and 
crude lysate enzyme was observed at 1 and 0.5 mg antibody/mI. Below these concentrations, 
lower enhancement was seen in lysates than with the free enzyme at equal antibody 
concentrations. 
Chicken anti-(conjugated peptide) antibodies (week 10) that inhibited pure trypanopain also 
inhibited Z-Phe-Arg-AMC hydrolysis in lysed T b. brucei. For example, up to 82% inhibition 
was observed with the pure enzyme at 500 Ilg antibody/mI, while up to 70% inhibition was seen 
in lysates at the same antibody concentration (results not shown). 
Chicken anti-peptide antibodies thus modulated trypanopain activity In lysates at levels 
comparable to those seen for the purified enzyme. However, rabbit anti-(free peptide) and anti-
( conjugated peptide) antibodies that enhanced the activity of pure trypanopain, had no effect on 
trypanopain in lysates. Even at high concentrations of antibody (1 mg/mI) comparable activity 
was observed in trypanosome lysate samples incubated with non-immune and test antibody. 
Chicken and rabbit anti-peptide antibodies all enhanced digestion of 14C-gelatin by purified 
trypanopain (Section 6.11.7). However. in lysed T b. brucei, this effect was markedly reduced. 
so that little or no enhancement of activity was seen. 
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Figure 441 : Effect of activity-enhancing chicken antibodies on trypanopain activity against 
Z-Phe-Arg-AMC in lysed T ho brucei. 
The effects of week 8 chicken anti-(free peptide) antibodies (l 000 to 31.25 Ilg antibody/ml) on Z-Phe-
Arg-AMC hydrolysis in lysed T b. brucei (e) and by pure trypanopain (II) were investigated in 
triplicate assays . 
6.11.11 Effect of anti-trypanopain antibodies on cathepsin L activity against Z-Phe-
Arg-AMC and 14C-gelatin 
The tested anti-peptide trypanopain antibodies modulated cathepsin L activity against Z-Phe-
Arg-AMC and 14C-gelatin (Table 15). Most of the tested antibodies inhibited cathepsin L 
activity against Z-Phe-Arg-AMC. For example, anti-(free peptide) antibodies from chicken I 
(week 20) enhanced trypanopain activity against this substrate by up to 82%, but inhibited 
cathepsin L activity by 68%. 
Similarly, anti-(free peptide) antibodies from rabbit I (week 12) enhanced trypanopain activity 
against Z-Phe-Arg-AMC by 14%, but inhibited cathepsin L activity by 24% (Table 15). Thus, 
while anti-trypanopain antibodies do modulate cathepsin L activity against Z-Phe-Arg-AMC, 
the nature of the effect differs from that seen with trypanopain. Compared with their effects on 
trypanopain activity, the antibodies enhanced cathepsin L activity to a lesser extent, or inhibited 
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activity. No difference was seen between rabbit and chicken antibodies or between antibodies 
directed against the free or conjugated peptide. 
Table 15: Maximal effect of anti-trypanopain antibodies on trypanopain and cathepsin L 
activity against Z-Phe-Arg-AMC. 
Maximum effect on enZyme activity 
Antibody against 
Z-Phe-Arg-AMC 
Trypanopain Cathepsin L 
IgY anti-(free peptide) (chicken I, week 20) 82% enhancement 68% inhibition 
IgY anti-(conjugated peptide) (chicken n , week 10) 81 % inhibition 72% inhibition 
IgY anti-(conjugated peptide) (chicken In, week 6) 124% enhancement 55% enhancement 
IgG anti-(free peptide) (rabbit I, week 12) 14% enhancement 24% inhibition 
IgG anti-(free peptide) (rabbit n, week 12) I 64% enhancement 16% enhancement 
IgG anti-(conjugated peptide) (rabbit Ill, week 12) 27% enhancement 44% inhibition 
IgG (anti-conjugated peptide) (rabbit IV, week 12) 49% enhancement 53% inhibition 
The anti-trypanopain antibodies also modulated cathepsin L hydrolysis of 14C-gelatin. While 
these antibodies all activated trypanopain hydrolysis of this substrate, some enhanced cathepsin 
L activity, while others inhibited activity (results not shown). Generally, the effects on 
cathepsin L activity were substantially lower than was seen against trypanopain. 
6.11.12 Summary of results 





Table 16: Effects of vanous antibodies on trypanopain digestion of synthetic and 
proteinaceous substrates. 
Substrate Rabbit anti- Chicken anti- Chicken anti-
peptide IgG peptide IgY trypanopain IgY 
Z-Phe-Arg-AMC - +/- -
14C-gelatin 0 + +' 
FITC-albumin - - -
Note: +, activity enhanced; -, activity inhibited; 0, activity unaffected 
6.12 Discussion 
High titre antibodies were produced in rabbits and chickens against all the immunogens tested. 
Chickens proved to be far more convenient experimental animals than rabbits, both in terms of 
the higher total amount of antibody obtained and in obviating the need to bleed animals to 
obtain these antibodies. The major limitation of chicken antibodies is that they do not bind 
protein A (Larsson et aI. , 1993), so an additional mammalian linker antibody must be used in 
applications such as immuno-electron microscopy where gold probes are attached to protein A. 
This procedure was, however, beyond the scope of the present study, so this did not present a 
significant disadvantage. 
The trypanopain peptide was found to be immunogenic in rabbits and chickens, with antibody 
responses being of similar magnitude and timing in both species. Antibodies of comparable titre 
were produced against the conjugated and free peptides by 8 weeks post-immunisation. The 
only observed effect of conjugation of the peptide to a carrier molecule was to increase the titre 
of antibodies produced in the first 3 weeks after immunisation. Thus, while the conjugated 
peptide elicited high titre antibodies 3 weeks after the initial immunisation, the titre of anti-(free 
peptide) antibodies remained low at this time. While the free peptide is less immunogenic than 
the conjugate, the free peptide is still immunogenic in its own right. Similar immunogenicity ·has 
been reported for other small, unconjugated peptides. For example, Coetzer (1992) found that 
a similarly sized peptide corresponding to a region of the cathepsin L active site is immunogenic 
in its own right. 
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The free peptide was used as antigen instead of the conjugated peptide in all ELISAs 
monitoring antibody titre, because coupling chemistry creates epitopes unique to the conjugate, 
termed CAMOR (carrier modified residues) regions (Briand et aI., 1985). If the conjugated 
peptide (containing carrier and CAMOR regions) is used as an ELISA antigen, anti-carrier and 
anti-CAMOR antibodies cause false positive results. Use of the free peptide as the ELISA 
antigen obviates this problem, without having to remove anti-carrier and CAMOR antibodies 
from antisera. Some authors (Muller, 1988) maintain that peptides of 6-15 residues bind poorly 
to plastics, but successful binding of 10 to 20-residue peptides has been reported by others 
(Tanaka et aI., 1985; Davies et aI., 1987; Coetzer et aI., 1991; Moroder et at., 1992) and gave 
good results in the present study. 
In addition to recognising the free peptide, all anti-peptide antibodies tested recognised whole 
trypanopain in an ELISA. This shows that at least a proportion of the conformations adopted 
by the highly mobile peptide in solution mimic those that occur in the corresponding constrained 
region of the parent protein. A decreased signal was observed in ELISAs where trypanopain 
was used as antigen, compared with ELISAs using the free peptide as antigen. This is thought 
to be due to the fact that some of the anti-peptide antibodies bind only to conformations of the 
free peptide that have no equivalent in the parent protein and these antibodies are thus unable to 
recognise the whole protein. The concentration of antibodies effectively recognising the coated 
antigen is thus lower when trypanopain is used as the antigen. Conjugation of the peptide to a 
carrier protein had no discernible effect on the degree of cross-reactivity of the corresponding 
antibodies with trypanopain. Similar cross-reactivity between anti-peptide antibodies and their 
corresponding whole protein antigen has been previously reported for cathepsin Land D 
(Coetzer et aI., 1991) and cytochrome P-450IA2 (Edwards et aI. , 1990). 
Anti-trypanopain peptide antibodies not only recognised whole trypanopain in an ELISA, but 
were also shown to cross-react with whole sheep cathepsin L in an ELISA. This is thought to 
be a reflection of the homology between the peptide used in this study and the corresponding 
region of the cathepsin L active site (Ritonja et aI., 1988). 
None of the anti-peptide antibodies recognised trypanopain on a Western blot, despite attempts 
made to improve recognition. This indicates that the antibodies are unable to recognise their 
target sequence in fully denatured trypanopain. 
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Once the anti-peptide antibodies raised had been shown to recognise the intact enzyme, their 
effect on trypanopain activity was analysed. While the ELISAs discussed above show that the 
anti-peptide antibodies bind to whole, partially denatured trypanopain, the ability of these 
antibodies to modulate trypanopain substrate hydrolysis shows that they recognise and bind to 
the native enzyme in the form it is likely to be encountered in vivo. Various other enzymes, 
such as cathepsin D (Dingle et a!. , 1971), papain (Arnon and Shapira, 1967), human 
acetylcholinesterase (Olson et ai. , 1990), cathepsin L (Dennison and Pike, 1991) and 
cytochrome P-450lA2 (Edwards et a!. , 1990) are inhibited by their respective antibodies. In 
this study, the different anti-trypanopain peptide antibodies modulated trypanopain activity 
against Z-Phe-Arg-AMC, 14C-gelatin and FITC-albumin in different ways. 
All of the rabbit anti-(free peptide) and anti-( conjugated peptide) antibodies studied enhanced 
trypanopain hydrolysis of Z-Phe-Arg-AMC. Rabbit antibodies directed against the free peptide 
enhanced enzyme activity slightly more (64%) than those directed against conjugated peptide 
(49%), suggesting that the titre of antibodies recognising the native form of trypanopain is 
slightly higher in anti-(free peptide) antibody preparations than in those directed against the 
conjugated peptide. Immuno-enhancement of enzyme activity is thought to occur by antibody 
stabilisation of an active enzyme conformation (Richmond, 1977). Z-Phe-Arg-AMC is a small 
synthetic substrate, and is thought to be small enough to gain access to the antibody-occluded 
trypanopain active site. 
The effects of chicken antibodies on trypanopain were more complex, with individual chickens 
producing activity-enhancing and activity-inhibiting antibodies at different stages in their 
immune response. Antibodies produced shortly after each immunisation appeared to enhance 
trypanopain activity, while those produced a few weeks later appeared inhibitory. A polyclonal 
immune response, by definition, consists of a heterogeneous antibody population produced by 
numerous B-ceU clones and the properties of the antiserum are a balance of the individual 
properties of the various clones. Depending on the mode of binding, individual antibodies can 
either enhance or inhibit enzyme activity. The varied effect of antibodies on enzyme activity 
observed in this study could thus be a function of different B-cell clones being dominant at 
different stages in the immune response. A peptide can adopt numerous conformations in 
solution, some of which may elicit activity-enhancing antibodies and some of which elicit 
161 
inhibitory antibodies. Variation in the balance between these antibody populations may explain 
the result obtained in this study. Thus the B-cell clones that produce activity-enhancing 
antibodies may have been dominant at all tested stages of the rabbit immune response, while in 
chickens, B cell clones producing activity-enhancing antibodies may have been dominant soon 
after immunisation, followed later by B cell clones producing activity-inhibiting antibodies. 
Binding of antibodies to an enzyme active site is thought to have two primary effects on the 
enzyme. Firstly, the active site is occluded to some extent by the antibody, and , secondly, a 
conformational change is induced in the active site. The practical consequences of occlusion of 
the active site vary mainly with the size of a substrate used to assess enzyme activity 
(Richmond, 1977). Small substrates (e.g. Z-Phe-Arg-AMC) can often still gain access to the 
partially occluded active site, and occlusion will thus not appreciably inhibit activity against 
small substrates. Occlusion is more likely to lead to inhibition of larger substrates. 
Conformational changes in the enzyme active site may induce either a more or less active 
conformation. The nett effects of antibody binding on enzyme activity are thus a balance 
between the effects of occlusion and the effects of conformational changes. Since Z-Phe-Arg-
AMC is a small substrate, its hydrolysis is more likely to have been affected by antibody-
induced conformational changes than by occlusion effects. For larger protein substrates, 
occlusion effects are likely to predominate. 
The region of the trypanopain active site corresponding to the peptide immunogen used may be 
partially buried in the native trypanopain molecule. If this is the case, only portions of anti-
peptide antibodies may bind to this region. For example, antibody-induced conformational 
change and occlusion of the active site will differ depending upon whether all or some of the 6 
hypervariable regions of an antigen binding site of the antibody interact with the enzyme (Roitt, 
1991). Not all of these interactions are necessarily with the target peptide. 
The specificity of the antibody effects on trypanopain activity was investigated by 
pre-incubating antibodies with the free trypanopain peptide and with an unrelated peptide. 
Antibody modulation of trypanopain activity was substantially reduced when the antibodies 
were pre-incubated with the trypanopain peptide, whereas pre-incubation with an unrelated 
peptide (poly-L-glutamic acid) had no such effect. This implies that the specific peptide 
competes with trypanopain for binding to the antibodies and antibody binding to trypanopain is 
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thus thought to occur via the peptide sequence. The effects of the antibodies on trypanopain 
activity are thus unlikely to be due to non-specific interactions between the enzyme and the 
antibody. Absolute abolition of antibody binding to trypanopain was not always achieved by 
pre-incubation with the trypanopain peptide, but this is thought to be an unavoidable 
consequence of the assay design rather than a suggestion of non-specificity on the part of the 
antibody. The high sensitivity of the fluorometric assay used in this study necessitated the use 
of highly dilute enzyme, which, in turn., promotes dissociation of enzyme-antibody complexes. 
High concentrations of antibody are thus required for the formation of trypanopain-antibody 
complexes and to neutralise such high concentrations of antibody, vast molar excesses of 
peptide are required . It is thought that further increases in peptide concentration would reduce 
antibody binding to trypanopain almost entirely. This hypothesis was not tested experimentally 
because of the high cost of the synthetic peptide. 
The effects of anti-peptide antibodies on Z-Phe-Arg-AMC hydrolysis by trypanopain were thus 
complex. Richmond (1977) stated that the effect of antibodies on enzyme activity can vary 
with the substrate used, and since Z-Phe-Arg-AMC is not a potential physiological substrate, 
the results obtained using this substrate were not considered representative of the in vivo 
situation. Thus, to investigate the effect of these antibodies on trypanopain activity in vivo 
more directly, their effects on digestion of protein substrates were investigated. Since only 
small amounts of purified trypanopain were available, highly sensitive assays for trypanopain 
hydrolysis of proteins were developed, using 14C-gelatin and FITC-albumin. 
It was expected that binding of the anti-peptide antibodies to trypanopain would occlude the 
active site and thus inhibit digestion of protein substrates. However, all tested anti-peptide 
antibodies enhanced trypanopain hydrolysis of 14C-gelatin, while all antibodies inhibited 
hydrolysis ofFITC-albumin. While such variation in antibody activity with differing substrates 
is poorly understood, it has been well documented (Richmond, 1977). Pre-incubation of the 
anti-peptide antibodies with the free peptide reduced both these effects, showing that both are 
specific. In both cases, the antibodies are thought to bind specifically to the trypanopain active 
site, protecting the enzyme from autocatalysis during the 30 min pre-incubation period. While 
non-specific antibodies are also likely to prevent such autocatalysis by acting as alternative 
substrates, they are likely to do so less effectively than antibodies that specifically bind the active 
site. Interestingly, such a concentration-dependent enhancement of trypanopain activity against 
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14C-gelatin was seen in the presence of non-immune antibodies, presumably due to enzyme 
stabilisation. Following such postulated stabilisation of trypanopain during the pre-incubation 
phase of the experiment, either 14C-gelatin or FITC-albumin was added. Compared with non-
immune antibodies, activity against 14C-gelatin was enhanced, while activity against 
FITC-albumin was inhibited. 
A possible explanation for this result might be that the two substrates have different Km values 
for trypanopain. If 14C-gelatin has a higher affinity for trypanopain than do the anti-peptide 
antibodies, then it would displace these antibodies from the trypanopain active site when added, 
and the enhanced activity seen would then be a result of the increased stabilising ability of 
specific antibodies compared with non-immune antibodies. If on the other hand, FITC-albumin 
has a lower affinity for the trypanopain active site than do the anti-peptide antibodies, then it 
would be unable to displace these antibodies from the trypanopain active site and the inhibition 
of activity seen reflects continued antibody binding to the active site. To test this hypothesis. 
the Km values for trypanopain hydrolysis of 14C-gelatin and FITC-albumin would have to be 
determined, as well as the binding affinity of the various antibodies for trypanopain. However, 
the large amounts of trypanopain required for a statistically valid calculation of these constants 
(especially the binding affinity of the antibodies) precluded such a study. Additionally, the 
heterogeneous nature of the polyclonal antibodies raised in the present study is likely to 
complicate interpretation of such kinetic constants and may necessitate further purification of 
the antibodies or raising of monoclonal antibodies against the target peptide. It is, however, 
clear from the present results that the effects of anti-trypanopain antibodies on enzyme activity 
are largely dependent on the substrate in use. Without knowledge of the true in vivo substrates 
oftrypanopain, it is not possible to undertake a physiologically relevant study. 
The anti-peptide antibodies also modulated cathepsin L activity against 14C-gelatin. Compared 
with their effects on trypanopain activity against this substrate, the antibodies enhanced 
cathepsin L activity less or inhibited activity. This suggests that the antibodies bind differently 
to the cathepsin Land trypanopain active sites Since cathepsin L is unlikely to be remain active 
in the mammalian bloodstream, these antibodies are not likely to have a physiological effect. 
Anti-peptide antibodies were added to lysed T b. brocei to assess the potential effects of other 
trypanosomal factors on such antibodies. Chicken antibodies had the same effect in lysed cells 
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as was previously observed with the pure enzyme, that is, some antibodies mediated inhibition 
and others enhancement of trypanopain hydrolysis of Z-Phe-Arg-AMC. The 
enhancement/inhibition observed with the pure enzyme and in lysates was comparable, 
suggesting that trypanosome-derived factors do not interfere with the effects of these antibodies 
on trypanopain activity. In contrast, rabbit antibodies that substantially activated the pure 
enzyme, had no effect in lysed trypanosomes even at 1 mg antibody/mI. This suggests that the 
interaction between these antibodies and trypanopain is altered by some factor in trypanosome 
lysates that does not affect chicken antibodies. Nevertheless, it appears that anti-trypanopain 
antibodies may have the potential to modulate trypanopain activity in a specific manner. 
Trypanopain is likely to be effectively controlled in the mammalian bloodstream by cystatins, so 
the physiological relevance of the studies reported in this chapter are unclear. If trypanopain is 
not active in the bloodstream, then why does the production of anti-trypanopain antibodies 
correlate with disease resistance in cattle (Authie et al. , 1993)? If, as Lonsdale-Eccles et al. 
(1995) suggest, trypanopain interacts with kininogens in an unusual manner to produce an 
active complex, then it is feasible that trypanopain may contribute to pathogenesis in such cases 
and thus that inhibitory anti-trypanopain antibodies would be protective for the infected host. 
However, it is also possible that anti-trypanopain antibodies are not protective for the infected 
host, and that the correlation between anti-trypanopain antibody production and disease 
resistance is not meaningful. If this is true, then there would be no therapeutic advantage to 
eliciting anti-trypanopain antibodies. Since an evaluation of trypanopain as a potential target for 
novel anti-trypanosomal agents was the aim of this study, the anti-peptide antibody study was 




Effect of proteinase inhibitors on cultured T. b. bruce; 
7.1 Introduction 
Proteinases play important roles in the normal functioning of living systems as well as in 
various pathologies and disease processes. Proteinase inhibitors are thus being 
investigated as treatments for a wide variety of diseases, such as cancer (reviewed in De 
Clerk and Imren, 1994), arthritis (Esser et a!. , 1994), bone resorption (Delaisse et a!. , 
1980) emphysema, atherosclerosis, glomerulonephritis, septicaemia, periodontitis, 
coaggulation and complement cascade disorders (reviewed in Schnebli and Braun, 1986). 
In some cases, proteinase inhibitors have already proved to be effective drugs and are in 
clinical use. For example, inhibitors of angiotensin converting enzyme (ACE) are used in 
the treatment of hypertension, and inhibitors of the human immunodeficiency virus (HIV) 
aspartic proteinase are commonly used in the treatment of acquired immunodeficiency 
syndrome (AIDS) (reviewed by Scharpe et a!. , 1991). The cysteine proteinases of various 
pathogens have also received attention as potential targets for chemotherapeutic 
intervention. Cysteine proteinase inhibitors kill T cruzi (Ash all et a!. , 1990; Harth et a!., 
1993; Franke de Cazzulo et a!., 1994), T congolense (Mbawa et a!. , 1992) and 
Trichomonas vaginalis (Irvine et a!., 1997), and halt the development of S. mansoni 
(Wasilewski et a!., 1996), P. vinckei (Rosenthal et a!., 1993), P. jalciparum (Dluzewslci et 
a!. , 1986; Rosenthal et a!. , 1988; Rockett et a!., 1990; Rosenthal et a!., 1993; Bailly et a!. , 
1992; Gluzman et aI. , 1994) and Tritrichomonas foetus (Irvine et aI. , 1997). Additionally, 
inhibitors of the major cysteine proteinases of P. vinckei and S. mansoni have been shown 
to be effective against murine malaria and schistosomiasis in vivo (Rosenthal et aI., 1993 ; 
Wasilewski et a!., 1996). 
Since trypanopain is the major cysteine proteinase of T b. brucei, the effects of various 
cysteine proteinase inhibitors on the activity of purified trypanopain and on the growth of 
cultured bloodstream forms of T b. brucei were investigated. 
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7.2 T. b. brucei cell culture 
While culture of procyclic forms of trypanosomes is a well established technique (Tobie, 
1958; Cross and Manning, 1973 ; Brun and Schonenberger, 1973), the culture of 
mammalian bloodstream forms of trypanosomes has been more difficult to achieve. Hirumi 
et al. (1977) made the initial breakthrough in this field, culturing bloodstream 
trypanosomes using fibroblasts as a feeder cell layer. This method of culture has various 
drawbacks for metabolic studies, the greatest of which is the difficulty in discriminating 
between fibroblast and trypanosome metabolism. The discovery that reducing agents such 
as cysteine (Duszenko et al., 1985) or ~-mercaptoethanol (Baltz et aI. , 1985) are essential 
growth factors for trypanosomes paved the way for successful culturing of trypanosomes 
without feeder cells. However, copper ions present in the medium readily oxidise cysteine 
to cystine, which does not stimulate growth. This problem can be circumvented by 
addition of the copper-specific chelator bathocuproine sulfonate (BCDS) (Zak, 1958) to 
the culture medium (Duszenko et aI. , 1992; Hesse et aI. , 1995). 
Hesse et al. (1995) reported that trypanosomes cultured according to the protocol 
described below mimic a natural trypanosome infection in various ways. Most importantly, 
cultured trypanosomes undergo the oscillations in population size characteristic of natural 
populations during an infection . 
7.2.1 Materials 
Antibiotic solution. Lyophilised penicillin/streptomycin mix was reconstituted in 10 ml of 
autoclave-sterilised deionised H20 according to the manufacturer' s instructions, giving 
10 000 units of penicillin and 10 mg of streptomycin per mI. 
BCDS/cysteine stock (1 mM BCDS, 25 mM cysteine). BCDS (0.028 g) and cysteine 
(0.2195 g) were dissolved in 50 ml of deionised H20 and filter-sterilised through a 
0.22 ~m syringe filter. 
Foetal calf serum (FCS). Complement was heat-inactivated by incubation of the serum at 
56°C for 1 h. 
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Minimal essential medium (MEM) with Earle's salts, 0.25 mM cysteine and 0.01 mM 
BCDS, 15% (v/v) FCS. MEM was prepared as described by Hesse et al. (1995). MEM 
powder with Earle's salts (4.8 g) and NaHC03 (1.1 g) were dissolved in 405 ml of 
deionised water and the medium filter-sterilised through a 0.45 ~m pre-filter and a 0.22 ~m 
filter unit into an autoclave-sterilised glass bottle. FCS (75 ml) was added aseptically. For 
each 100 ml of medium, 1 ml each of BCDS/cysteine stock and antibiotic 'solution were 
added aseptically. 
7.2.2 Method 
Aseptic technique was maintained throughout (Adams, 1990). All work was carried out in 
a laminar flow hood equipped with 0.22 ~m air filters and an ultraviolet light, using 
autoclaved glassware and pipette tips, and commercially sterilised plastic pipettes (10 ml 
and 1 ml), culture flasks (with vented cap containing 0.2 ~m filters) and petri dishes 
(50 mm diameter). All items were liberally sprayed with 70% (v/v) isopropanol before 
introduction into the hood. Culture flasks were used for initial population growth 
experiments and petri dishes for subsequent proteinase inhibitor experiments. 
Medium was warmed to 37°C and ali quoted into flasks (5 ml of medium) or petri dishes 
(2 .5 ml of medium) using sterile plastic pipettes. Any test-specific reagents were added to 
the flask or dish, followed by the addition of approximately 7.5 x l 05 trypanosomes, thawed 
from stabilates in liquid nitrogen. Flasks or petri dishes were placed in a CO2 incubator at 
37°C and 5% (v/v) CO2 . Trypanosome growth was assessed using a haemocytometer to 
count the number of visibly motile trypanosomes. 
7.3 Effects of proteinase inhibitors on T. b. brucei growth 
Inhibitors of various classes of proteinases were added to cultured T b. brucei to 
determine which classes might be necessary for parasite viability. Experiments with similar 
inhibitors have been conducted on cultured bone tissue (Delaisse et aI. , 1980), various 
mammalian cell lines (Wilcox and Mason, 1992) and P. Jalciparum (Dluzewski et aI., 
1986; Rosenthal et al., 1988; Bailly et al. , 1992). 
7.3.1 Materials 
EDTA (100 mM). Na2EDTA.2H20 (37 mg) was dissolved in 1 ml ofDMSO. 
IAN (100 mM). IAN (18 mg) was dissolved in 1 mlofDMSO. 
Pepstatin A (loa mM). Pepstatin A (3.4 mg) was dissolved in 50 III ofDMSO. 
PM SF (loa mM). PMSF (17.4 mg) was dissolved in 1 ml ofDMSO. 
E-64 (100 mM). E-64 (4 mg) was dissolved in 111 IllofDMSO. 
TLCK (loa mM). TLCK (36 mg) was dissolved in 1 mlofDMSO. 
SBTI (4 mM). SBTI (40 mg) was dissolved in 500 III ofDMSO. 
Leupeptin (loa mM). Leupeptin (2.9 mg) was dissolved in 61 IllofDMSO. 
Aprotinin (6.8 mM). Aprotinin (4.4 mg) was dissolved in 100 III ofDMSO. 
NEM (loa mM). NEM (6 mg) was dissolved in 500 III ofDMSO. 
IAA (loa mM). IAA (10 mg) was dissolved in 500 III ofDMSO. 
7.3.2 Method 
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Petri dishes were set up as described in Section 7.2.2. Inhibitors (25 Ill, 100 mM) were 
added to MEM (2.5 ml) to give a final concentration of 1 mM. SBTI and aprotinin were 
tested at 40 ~M and 68 ~M respectively because of limitations on the amount of inhibitor 
available. DMSO [25 Ill, giving 1 % (v/v) DMSO] was added to solvent control 
experiments containing no inhibitors. The number of visibly motile trypanosomes present 
after 24 h was counted using a haemocytometer. 
7.4 ka~s ofCMK, FMK and DMK 
Peptidyl chloromethylketones (CMK) are synthetic, irreversible inhibitors of cysteine and 
serine proteinases. The peptidyl portion of the inhibitor is designed with the substrate 
specificity of the target enzyme in mind, so that the resulting inhibitors are able to 
discriminate between proteinases to some extent (Kurachi et ai. , 1973; Coggins et ai. , 
1974; Kettner and Shaw, 1981) . Following targeting of the inhibitor to a proteinase active 
site via the peptide sequence, the reactive CMK moiety binds covalently to the active site 
cysteine of cysteine proteinases (Whitaker and Perez-Villasenor, 1968) or the active site 
histidine of serine proteinases (Schoellmann and Shaw, 1963; Ong et al., 1965; Glover and 
Shaw, 1971), thereby irreversibly inactivating the respective enzymes. 
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Several other classes of peptidyl inhibitors have been designed based on the CMK theme. 
These newer inhibitors [e.g. peptidyl diazomethylketones (DMK) and fluoromethylketones 
(FMK)] are generally less reactive than the CMK, making them more specific for the target 
proteinase. FMK bind covalently with the active site histidine of serine proteinases and the 
active site cysteine of cysteine proteinases (Rauber et ai. , 1986; Angliker et aI., 1987). 
Given the same peptide moeities, FMK are less reactive than CMK, due to the fact that 
chlorine is a stronger nucleophile than fluorine (Rasnick, 1985). While FMK are only 2% 
as reactive as CMK against serine proteinases (Rauber et ai. , 1986), they are 35-40% as 
reactive as CMK against cysteine proteinases (Rasnick, 1985). Thus FMKs react more 
readily with cysteine than serine proteinases but, as they are irreversible inhibitors, this 
does not imply that they are specific for cysteine proteinases. Of the ketone family of 
inhibitors, FMK have been used most extensively in vivo, with much success. For 
example, FMK are active against murine malaria (Rosenthal et ai. , 1993) and S. mansoni 
(Wasilewski et a/., 1996) in vivo. 
DMK are considered specific for cysteine proteinases (Green and Shaw, 1981 ; Shaw, 
1994; Rasnick, 1996), although isolated cases of inhibition of serine proteinases have been 
reported (Rasnick, 1996). The DMK moiety has low reactivity with thiols (Brocklehurst 
and Malthouse, 1978) and reacts only with the active site cysteine residue following 
positioning of the inhibitor by the peptide portion of the D.MK (Leary et a!. , 1977). The 
positioning role of the peptide moiety enables the synthesis of D.MK with some degree of 
selectivity for various cysteine proteinases (Crawford et a!. , 1988). 
Since these inhibitors have low reactivity with thiols, they are stable in the presence of 
reducing agents in cysteine proteinase assay buffers (Leary et a!., 1977). The active site 
cysteine residue of the target enzyme is thought to protonate the diazo methyl carbon atom 
of D.MK, forming a diazonium salt. The C[ carbon of the diazonium salt undergoes a 
nucleophilic attack by the sulfhydryl anion of the enzyme, releasing N2 and alkylating the 
active site cysteine residue (Leary et a!. , 1977; Figure 45). More complicated reaction 
mechanisms, involving the formation of thiohemiketal intermediates, have also been 
proposed (Brocklehurst and Malthouse, 1978). 
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Figure 45 : Postulated scheme for DMK inactivation of cysteine proteinases. 
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The active site cysteine residue is thought to protonate the diazomethyl carbon atom, forming a 
diazonium salt. The C1 carbon of the diazonium salt then undergoes a nucleophilic attack by the 
sulfhydryl anion of the enzyme, releasing N2 and alkylating the active site cysteine residue. After 
French et ai . (1963) and Leary et ai. (1977) . 
The rate of association (kass) between an irreversible inhibitor and its target enzyme may be 
determined using either first- or second-order conditions, depending on the expected rate 
of association (Salvesen and Nagase, 1989). Since, based on preliminary studies, kass for 
trypanopain inactivation by DMK, FMK and CMK was suspected to be greater than 
105 M-1s-1, second order conditions were employed in the present study. For enzyme and 
inhibitor to be combined in equimolar amounts, the active concentrations of both reactants 
are determined and the two then combined in assay buffer (Kirschke and Shaw, 1981). 
Aliquots are removed at timed intervals and residual enzyme activity determined. A 
ten-fold dilution of enzyme and inhibitor in the assay mixture is sufficient to prevent further 
association of enzyme and inhibitor (Salvesen and Nagase, 1989) kass can be determined 
from the equation (Salvesen and Nagase, 1989) 
_1_ = _1 + kosso t 
[E] [E]o 
where [E] is the enzyme concentration (M) at time, t, 
[E]o is the initial enzyme concentration (M), 
kass is the association rate constant (M-1 .s-1), and 
t is the time of incubation (s) . 
A plot of time of incubation versus 1/[E] has a slope of kass and a Y -intercept of 1/[E]o. 
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7.4.1 Materials 
Sheep cathepsin L was a gift from Dr Theresa Coetzer, Department of Biochemistry, UNP. 
Inhibitor stock solutions (100 mM) These were prepared by dissolving the following mass 
of each inhibitor in 100 III ofDMSO: 


























The active concentrations of sheep cathepsin Land trypanopain were determined by E-64 
titration (Section 3.4) . CMK, FMK and DMK were titrated against cathepsin L to 
determine the active concentration of each inhibitor. All inhibitors were found to be 100% 
active (results not shown). Trypanopain (10 nM, 250 Ill) was activated in 500 III of 
pH 7.0 assay buffer (5 min, 37°C) and inhibitor (10 nM, 250 Ill) added. Aliquots (40 Ill) 
were removed from the mixture at timed intervals and assayed against Z-Phe-Arg-AMC 
for 10 min at 37°C as described previously (Section 3.2.2). Values for kass and [E]o were 
determined from plots of time of incubation versus 1/[E]. 
7.5 ICso of CMK, DMK and FMK 
Initial experiments in this laboratory showed that CMK, DMK and FMK kill cultured 
T. b. brucei. To quantify this trypanocidal effect, the ICso of each inhibitor was calculated, 
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where the 50% inhibitory concentration (ICso) is defined as the concentration of inhibitor 
required to inhibit trypanosome population growth by 50% compared to control 
populations after 24 h. 
7.5.1 Materials 
As per Section 7.3 .1. 
7.5.2 Method 
Various concentrations of each inhibitor (2.5 III in DMSO) were added to trypanosomes 
(7.5 x 1 OS parasites) in MEM (2.5 ml) in petri dishes and the dishes incubated as described 
in Section 7.2.2. The number of motile trypanosomes was counted after 24 h using a 
haemocytometer. Control flasks were incubated with 2.5 III DMSO (0.001% DMSO) . 
Plots of inhibitor concentration versus the number of live trypanosomes were prepared and 
ICso values determined. 
7.6 Detection of biotinylated FMK and DMK 
Killing of trypanosomes by cysteine-proteinase specific DMK suggests that a cysteine 
proteinase is essential for T. b. brucei viability. To identify the targeted proteinase(s) more 
directly, biotinylated inhibitors were added to live and lysed T. b. brucei. After 
electrophoresis and electroblotting, a streptavidin-alkaline phosphatase conjugate was used 
to detect the biotinylated inhibitors and thereby determine the molecular mass of the 
targeted proteinase(s) . Such biotinylated versions of CMK and DMK have been used to 
detect cathepsin B (Cullen et aI. , 1992; Walker et aI. , 1992) and chymotrypsin- and 
trypsin-like serine proteinases (Kay et aI. , 1992). 
7.6.1 Materials 
As per Section 2.11 . 
Biotinylated inhibitors. Biotin-Phe-Ala-DMK was purchased from BioSyn (The Queen's 
University of Belfast, UK) and biotin-Phe-Ala-FMK was a gift from Dr James McKerrow 
(University of California, San Francisco, USA). 
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7.6.2 Method 
Live and lysed T. b. brucei (containing 21 pmol trypanopain, as estimated by E-64 
titration) were incubated with biotin-Phe-Ala-FMK (420 pmol, 24 h, 37°C) and biotin-Phe-
Ala-DMK (420 pmol, 1 h, 37°C) respectively. Samples were electrophoresed on reducing 
tricine SDS-PAGE gels (Section 2.4) and electroblotted onto nitrocellulose, (30 V, 16 h, 
Section 2.11). After blocking with BSA-TBS, the blot was incubated with ExtrAvidin®-
alkaline phosphatase in BSA-TBS (3 h) and results visualised using BCIPINBT substrate. 
7.7 Design of chalcones 
Most enzyme inhibitors and antiparasitic drugs have been discovered in large, random 
screens (Kuntz, 1992) and their specificity and reactivity subsequently modified by 
chemical manipulation. While this method has worked well, it is time consuming and 
labour intensive. International funding for anti-parasite research is limited and major 
pharmaceutical companies have little interest in the "small profit and high cost of 
development" of antiparasite drugs (McKerrow et aI. , 1995). Any means of reducing the 
total cost and time required for the development of a new antiparasite drug would thus be 
welcomed. Once the mechanism of action and three-dimensional shape of an enzyme are 
known, it becomes possible to design molecules with high affinity for the enzyme active 
site. Such a method, known as rational drug design, is potentially a rapid method of drug 
development. Rational design of enzyme inhibitors has gained momentum in recent years, 
with the two most successful and well-known examples being the design of inhibitors of 
ACE and the mv proteinase. 
ACE acts on a number of physiologically important substrates (angiotensin I, neurotensin, 
enkephalins, bradykinin, substance P, cholecystokinin), producing a variety of 
physiological effector molecules (reviewed by Scharpe et aI. , 1991). While ACE had not 
been crystallised, primary sequence data shows that it is very similar to pancreatic 
carboxypeptidase A, the three-dimensional structure of which is known. Specific and 
potent ACE inhibitors were thus designed based on the structure of carboxypeptidase A, 
taking the known differences in specificity of the two enzymes into account in designing a 
model of the ACE active site (Ondetti et aI. , 1977). Orally active, peptide-based ACE 
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inhibitors designed in this manner are now clinically used to control hypertension (Scharpe 
et al., 1991). 
The gag and pol genes of HIV are expressed as polyproteins (Pr55 gag and Pr 160gag-pol) that 
are proteolytically processed to generate the virion core structural proteins (p 17, p24 and 
p7) and various essential enzymes (reverse transcriptase, ribonuclease H and endonuclease) 
(reviewed by Dreyer et al., 1989). This processing is done by a viral aspartic proteinase 
that cleaves at a consensus sequence occurring at various positions along the polyproteins. 
Since mv proteinase mutants are non-infectious and show altered morphology (Kohl et 
al., 1988), the proteinase was considered a potential target for drug therapy. The known 
consensus sequence for enzyme cleavage of its natural polypeptide substrate was used as a 
basis for rationally designed inhibitors using various peptidyl mimics of aspartic proteinase 
transition state analogues (Dreyer et al., 1989; Roberts et al., 1990). These inhibitors 
were found to competitively inhibit the HIV-1 and HIV-2 proteinases (Dreyer et al., 1989, 
Roberts et al., 1990) and also to have anti-retroviral activity (McQuade et aI., 1990; Meek 
et al., 1990) and now form part of the drug cocktail commonly used to treat AIDS 
patients. 
Rational design of novel drugs is increasingly benefiting from advances in computer 
technology. For example, potential enzyme inhibitors can be predicted using the computer 
programme DOCK, which assesses the complementarity and energy interactions between 
two molecules (Kuntz, 1992). The programme can be used to scan a database of available 
small molecules to predict those that will bind strongly to a target enzyme. The starting 
point for such a search is a three-dimensional structure of the target enzyme, from which 
the programme identifies grooves and invaginations on the enzyme surface, amongst which 
will be the enzyme active site. The three-dimensional structures of molecules in a database 
are evaluated in various orientations and conformations for their complementarity to the 
target enzyme. Once the programme has identified suitable lead compounds, the top 100 
to 200 can be individually examined using graphics programmes. The best 10-50 of these 
are tested in vitro for inhibition of the enzyme. Databases of 100 000 compounds can be 
evaluated in less than a week using DOCK, with about 2-20% of identified compounds 
inhibiting the target enzyme at micromolar concentrations (Kuntz, 1992). 
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While it is optimal to have a high resolution X-ray crystallographic structure of the target 
enzyme for DOCK searches, models can be used in cases where the three-dimensional 
structure is not known. Considering that X-ray crystallography remains a slow process, 
application of DOCK to model structures has obvious advantages. Such models can be 
constructed using the primary sequence of the target enzyme and the three-dimensional 
structures of homologous enzymes. The quality of the model generated in this manner is 
directly dependent on the degree of homology between the target enzyme and the 
homologous enzymes (Ring et aI., 1993). DOCK has identified successful inhibitors using 
models constructed from enzymes showing 20-30% homology with the target enzyme 
(Ring et aI., 1993) . 
Li et al. (1995) used DOCK to search for inhibitors of the P. jalciparum cysteine 
proteinase (falcipain). While the three-dimensional structure offalcipain is not yet known, 
the primary structure of the enzyme is approximately 33% homologous to cruzipain, the 
three-dimensional structure of which is known (McGrath et aI., 1995). A falcipain model, 
built using the primary sequence of falcipain and the three-dimensional structure of 
cruzipain (Li et aI., 1994), was used in a DOCK search of a chemical database. Chalcones 
(1 , 3-diphenyl-2-propen-l-one) were identified by this search as potential lead compounds. 
Interestingly, an independent research group published their finding that a chalcone-related 
molecule (lipochalcone A) isolated from licorice roots has anti-malarial activity (Chen et 
aI. , 1994). Li et al. (1995) synthesised a variety of chalcone derivatives, and showed that 
the molecules do indeed reversibly inhibit falcipain and also kill cultured P. jalciparum. 
Chalcones were also shown to inhibit cruzipain (Li et aI., 1995). 
Since trypanopain is 6-9% homologous to falcipain (Rosenthal et al., 1992; Rosenthal, 
1993; Rosenthal et aI., 1994) and 60% homologous to cruzipain (Cazzulo et aI., 1989), it 
was considered likely that the chalcones designed and synthesised by Li et al. (1995) 
would inhibit trypanopain and may have trypanocidal activity. In collaboration with Cohen 
and co-workers, the effects of chalcones on trypanopain and cultured T. b. brucei were 
investigated. To evaluate the potential toxicity of these compounds in mammals, the 
effects of chalcones on mammalian cathepsin L were also investigated. 
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7.8 Ki for chalcone interaction with trypanopain and cathepsin L 
Preliminary studies in our laboratory showed that chalcones are effective inhibitors of both 
trypanopain and cathepsin L. The interaction between chalcones and trypanopain or 
cathepsin L was quantitatively investigated by calculating Ki values for the interaction of 
the inhibitors with the enzymes. Inhibition was shown to be reversible by dilution of 
enzyme/inhibitor complexes (as described in Section 5.1.2). Ki values were calculated 
from the ratio between steady-state inhibited (Vi) and uninhibited (va) reaction velocities, as 
described in Section 5.2.3. 
7.8.1 Materials 
As per Section 4.8.6, 6.10.1 and 7.4. 
Chalcones. Chalcones were designed and synthesised by the research group of Professor 
Fred Cohen at the Departments of Pharmaceutical Chemistry and Medicine of the 
University of San Francisco, California, USA. 
7.8.2 Method 
Dilution of chalcone/enzyme mixtures reduced the percentage of inhibition, showing that 
chalcones are reversible inhibitors of trypanopain and cathepsin L (Section 5.1.2). Ki was 
calculated from continuous assays (Section 3.2.2) by comparing the rates of Z-Phe-Arg-
AMC hydrolysis in the absence and presence of chalcones (Section 5.2.3). Enzyme (3 ng, 
0.1 pmol, 240 Ill) was activated in pre-warmed assay buffer (25°C, 5 min, 500 Ill), Z-Phe-
Arg-AMC (250 Ill, 5 11M) added and the initial rate of substrate hydrolysis (va) determined. 
Inhibitor (0.1-10 nmol in 10 III DMSO, 0.1-100 11M final concentration) was added at 
several thousand-fold molar excess over the enzyme (first order conditions, Salvesen and 
Nagase, 1989) and the inhibited reaction rate (Vi) determined. Ki was calculated from the 
equation (Section 5.1 .2) 
Ki = [I] /1 + [S] 
VO -1 Km 
Vi 
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Since chalcones are competitive inhibitors, both [S] and [I] were considered. The affinity 
between substrate and enzyme was accounted for by inclusion of the Michaelis constant for 
hydrolysis of Z-Phe-Arg-AMC (Km), which is 1.2 ~M for trypanopain-Tb (Troeberg et ai. , 
1996) and 6.81 ~M for sheep cathepsin L (Dehrmann et aI., 1995). 
7.9 ICso for chalcones against cultured T. b. brucei 
Once chalcones were shown to be effective inhibitors of purified trypanopain, their effect 
on cultured T. b. brucei was investigated as described in Section 7.5. 
7.9.1 Materials 
As per Section 7.5.1. 
7.9.2 Method 
As described in Section 7.5.2, various concentrations of each tested chalcone (2.5 ~l in 
DMSO, usually 0.8-20 ~M final concentration) were added to T. b. brucei in MEM 
(2.5 rnI) in duplicate petri dishes and the number of motile trypanosomes counted (twice 
from each petri dish) after 24 h using a haemocytometer. Plots of inhibitor concentration 
versus the number of live trypanosomes were prepared and ICso values calculated. 
7.10 In vivo testing of chalcones 
Chalcones were shown to be highly trypanocidal in in vitro cell culture assays, suggesting 
that they might be effective anti-trypanosomal agents in vivo. The effects of the most 
trypanocidal chalcones on experimental T. b. brucei infection in mice were thus tested. 
7.10.1 Materials 
As per Sections 3.3.1 and 7.5. 
7.10.2 Method 
The chalcone most effective against purified trypanopain (ZLIII43A) and two of the most 
trypanocidal chalcones (ZLIII44A and MC161) in vitro were chosen for testing in mice. 
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The toxicity of chalcones was evaluated by injecting adult Balb/c mice intraperitoneally 
with 100 III of phosphate/saline/glucose (PSG) and 25 III of DMSO containing 2 mg of 
chalcone. The effect of chalcones on experimental T. b. bruce; infection was examined 
first by injecting mice intraperitoneally with 100 III of trypanosomes (5 000 trypanosomes 
total) in PSG and immediately afterwards with 25 III of chalcone (0.5 mg) in DMSO. 
Control mice were injected with 100 III trypanosomes (5 000 trypanosomes) and 25 III of 
DMSO alone. The effects of a delayed injection of chalcones on T. b. brucei infection 
were investigated by injecting mice intraperitoneally with 100 III of trypanosomes 
(5 000 trypanosomes total) in PSG and 3 h later with one of the three tested chalcones 
(0.5 mg in 25 III DMSO). Control mice were injected with 100 III trypanosomes 
(5 000 trypanosomes) and 3 h later with 25 III of DMSO alone. Parasitaemia was 
monitored in both cases by microscopic examination of blood taken from the tail vein 
(Section 3.3). 
7.11 Results 
7.11.1 Growth curve 
Assessment of trypanosome population growth was done by counting the numbers of 
visibly motile trypanosomes using a haemocytometer. Usually only a few non-motile 
trypanosomes were visible. These were assumed to be dead and were thus not counted. It 
appears that dead trypanosomes rapidly succumb to osmotic stress and burst. This 
serendipitously simplifies counting oflive trypanosomes. Ashall et at. (1990) reported that 
such counting methods give the same results as dye (e.g. eosin) exclusion methods. 
Growth characteristics similar to those described by Hesse et al. (1995) were seen in this 
laboratory. Following inoculation into the culture medium, about 20% of the population 
died. After about 2 h, the population size began increasing as the trypanosomes entered 
the logarithmic phase of their growth. After about 20 h, the stationary phase of growth 
was entered, followed by the decline phase. This occurred even if the medium was 
changed every 6 h. No active trypanopain was detectable in the supernatant of culture 
flasks . This was not unexpected, since FCS contains cystatins, which were shown in 
Chapter 6 to effectively inhibit trypanopain. 
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7.11.2 Effect of proteinase inhibitors on growth of cultured T. b. brucei 
The alkylating agents IAN, lAA and NEM were highly effective trypanocidal agents, 
killing all trypanosomes within 24 h (Figure 46). TLCK and SBTI were effective to a 
lesser extent, killing 54% and 40% of trypanosomes respectively in 24 h. All other 
inhibitors tested did not alter trypanosome population numbers relative to the, controls. 
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Figure 46: Effect of proteinase inhibitors on growth of cultured T b. brucei. 
Trypanosomes (approximately 7.5 x l 05 cells) were placed in duplicate petri dishes in MEM 
(2 .5 ml) with various proteinase inhibitors [in 25 III DMSO, 100 mM, except for SBTI (40 IlM) 
and aprotinin (68 IlM)] . DMSO [25 Ill, 1 % (v/v) DMSO] was added to duplicate control 
experiments . Petri dishes were placed in a CO2 incubator at 37°C and the number of visibly motile 
trypanosomes in the 0.1 III haemocytometer chamber count,ed (twice from each dish) after 24 h 
using a haemocytometer. 
7.11.3 kass of CMK, DMK and FMK 
Most of the tested inhibitors effectively inhibited purified trypanopain (Table 17, 
Figure 47). Z-Phe-Phe-CMK had the highest kass of the tested inhibitors 
(2.16x l06 M-1. S 1), followed by Z-Phe-Ala-FMK (1.53 x l06 M-1 .s-1) and Z-Phe-Ala-CMK 
(1. 1x106 Ml.S-l) . MeOSuc-Ala-Ala-Pro-Val-CMK had the lowest kass (5 .6x l04 Ml .S-l) . 
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Figure 47 : Determination ofkass for Z-Lys-CMK inhibition oftrypanopain. 
Trypanopain (10 nM, 250 f.11) was activated in pH 5.5 assay buffer (500 f.11, 5 min, 37°C) and 
Z-Lys-CMK (10 nM, 250 f.11) added. Duplicate aliquots (40 f.11) were removed from the mixture at 
timed intervals and assayed against Z-Phe-Arg-AMC in stopped-time assays for 10 min at 37°C. 
Data was plotted as time of incubation versus l/[Enzyme], with the gradient of the line equal to k a.'is 
I 
Table 17: Effects of CMK, FMK and DMK on purified trypanopain and cultures of live 
T b. brucei. 
Inhibitor kass xlOs (M-I .S-I) ICso (IlM) 
Z-Phe-Phe-CMK 21.6 ± 1.6 3.6 
Z-Phe-Ala-FMK 15.3 ± 0.6 31 
Z-Phe-Ala-CMK 11.3 ± 1.4 21 
Z-Phe-Ala-DMK 6.5 ± 0.4 6.1 
Phe-Pro-Arg-CMK 5.0 ± 0.5 >75 
Z-Phe-CMK 3.7 ± 0.4 20 
Z-Lys-CMK 3.4 ± 0.2 65 
TLCK 2.7 ± 0.2 48 
Z-Phe-Phe-DMK 2.4 ± 0.2 4.8 
TPCK 1.7 ± 0.2 14 
Z-Gly-Leu-Phe-CMK 1.3 ± 0.1 33 
MeOSuc-Ala-Ala-Pro-Val-CMK 0.6 ± 0.1 >75 
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7.11.4 ICso ofCMK, DMK and FMK 
Trypanosomes treated with micromolar concentrations of CMK, DMK and FMK inhibitors 
either died, or grew more slowly than controls. The morphology of some of the 
trypanosomes remaining in inhibitor treated dishes was noticeably altered, with the 
normally long and slender trypanosomes becoming short and round. The inhibitors can be 
divided into three groups on the basis of their effectiveness, namely the highly effective 
inhibitors (Z-Phe-Phe-CMK; Z-Phe-Phe-DMK and Z-Phe-Ala-DMK) with ICso values of 
approx. 5 ~M; the least effective inhibitors (phe-Pro-Arg-CMK and MeOSuc-Ala-Ala-
Pro-Val-CMK) with ICso values greater than 75 ~M; and an intermediate group 
(remainder) (Table 17). Figure 48 shows an example of one such ICso calculation. 
7.11.5 Detection of biotinylated inhibitors 
Biotin-Phe-Ala-FMK and biotin-Phe-Ala-DMK strongly labelled a single band of 
approximately 30 kDa in live and lysed r b. brucei respectively (Figure 49). This 
corresponds to the reported molecular mass of trypanopain (Lonsdale-Eccles and Grab, 
1987a; Pamer et aI. , 1989; Boutignon et aI., 1990; Troeberg et aI., 1996). 
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Figure 48: Determination of ICso for TPCK. 
Trypanosomes (7.S X 105 cells) were grown in duplicate petri dishes in MEM with vanous 
concentrations (10 -75 flM) of TPCK. The number of viable trypanosomes was counted (twice 
from each dish) after 24 h using a haemacytometer. The ICso was determined to be 14 flM. 















A: Live T. b. brucei (containing 21 pmol trypanopain) were incubated with biotin-Phe-Ala-FMK 
(0.42 nmol, 24 h) . B: Lysed T. b. brucei (21 pmol trypanopain) were incubated with with 
biotin-Phe-Ala-DMK (0.42 nmol, 24 h) . Both samples were electrophoresed as in Section 2.4 and 
electroblotted as in Section 2.11 (30 V, 16 h). After blocking with BSA-TBS, the nitrocellulose 
blot was incubated with ExtrAvidin®-alkaline phosphatase BSA-TBS (3 h) and results visualised 
using BCIPINBT substrate. 
7.11.6 Ki for chalcone interaction with trypanopain and cathepsin L 
Chalcones inhibited trypanopain and sheep cathepsin L, with low micromolar or high 
nanomolar Ki values (Tables 18-21). The rate of association (kass) between the enzymes 
and chalcones was too fast for accurate determination without a stopped-flow apparatus. 
Against trypanopain, ZLIII43A had 10-fold lower Ki (27 nM) than any of the other tested 
inhibitors. MC23A24, HH27A 13 , HH27A44 and TF-I-56 all had Ki values of approx. 
0.20 JlM. MC1S3, MC13S, MClS9, MC161 , BG21AII, HH29A43 and HH2SA43 did 
not inhibit trypanopain at all at 100 JlM. Against cathepsin L, ZUll lISA was most 
effective (Ki = 0.90 JlM), with ZLlll1ISA, MC36IA, MC96A41 and TF-I-60 also having 
low Ki values. HH29A 13 , HH29A14, HH26A13, BG2lAII and BG3lA02 were least 
effective against cathepsin L. 
7.11. 7 ICso for chalcone activity against cultured T. b. brucei 
The tested chalcones inhibited growth of cultured T. b. brucei substantially, with ICso 
values in the low micromolar and high nanomolar range (Table 18-21). MC161 had the 
lowest ICso value (0.24 JlM), with ZLIII44A, MC357 and TF-I-S2 also having ICso values 
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below 1 flM. MC24A24 had the highest ICso value (28 .56 flM), while MC96A41 and 
lllI29A13 also had ICso values above 23 flM. 
Table 18: Effects of chalcones on cultured T. b. brucei, trypanopain & cathepsin L. 
o 
A~B 
Chalcone A B T. h. brucei Trypanopain 
ICso (flM) Ki (flM) 
OX 
CI 
I /- '(xCI 
MC131b ~ N I 13 .80 0.37±0.06 
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Table 19: Effects of hydrazide derivatives on cultured T. b. brucei and purified 
trypanopain and cathepsin L. 
Chalcone A 
OH 
MC357 ifH ~I 
1# 
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Table 19 continued ..... 
Chalcone A B T. b. brucei Trypanopain Cathepsin L 
ICso (~M) Ki (~M) Ki (~M) 
NH OH 
O-Z ~ TF-I-53 ~ # 2.70 2.74±0.44 3.39±0.31 ~I , 
OH 
TF-I-54 BfJ:)- ~ 2.34 3.45±0.27 3.18±0.48 ~I 
eccC1 OH ~ TF-1-55 




TF-1-56 7' I 0 ~ 1.66 0.22±0.06 1.90±0.10 Bf ~ ~I 
OH 





~ 2.14 1.38±0.14 3.81±0.59 18 "",I 
HlCyO OH 
TF-1-60 N ~ 1.02 0.39±0.12 1.35±0.2 1 O-'Z ~ # "",I 
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Table 20: Effects of amide derivatives on cultured T. b. brucei and purified trypanopain 
and cathepsin L. 
Name T. b. brucei Trypanopain Cathepsin L 
, 
A B LDso (IlM) Ki (IlM) Ki (IlM) 





. ~ I 13 .50 0.66±0.11 13.01±1.49 
.fY 
OCH3 
MC23A13 ~OCH' 12.39 2.95±0.39 11.21±1.00 




fY ~ 25 .00 2.09±0.27 8.34±0.55 ~I C] 
MC24A41 
BrLY 
~ s ~l ~I 






~ OCH) 18 .28 6.20±0.77 21.69±3 .04 
Br~ CI 
MC24A22 





~ CI 28.56 0.61±0.09 11.52±1.38 
~lli MC24A31 Br---Q- ~I 12.94 9.69±1.33 5.33±1.25 
~ s r 
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Table 20 continued ... 
Chalcone A B T. b. bruce; Trypanopain Cathepsin L 
IC50 (11M) Ki (11M) Ki (11M) 
0 
~I 




BG31A02 Jy 1.82 0.50±0.08 52. 17±3.43 ~ F 
tr ~OCH' BG21All ~I 4.44 No inhibition 61.07±7.54 N I OCH) '" 
CY N Al 
HH25A43 N-NH 4.72 No inhibition 49.70±11.32 
HH26A13 0 





~ I 0 i:lOCH' 7.46 0.26±0.04 4.77±1.00 ~ Ii 
Br 
~ 
~' I 0 HH27A14 ~ ~'y 10.23 1.51±0.24 2.35±1.00 
OCH) 
BC'CLo-- ~OCH' 




~ I 0 ~:H 4.40 1.4<j)±0.24 16.09±3 .94 
~ Ii 
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Table 20 continued ... 
Chalcone A B T. b. brucei Trypanopain Cathepsin L 
ICso (11M) Ki (11M) Ki (11M) 
Br 
~ NySCH3 I ~ Oy HH27A44 :::,... ~:H 17.14 0.22±0.02 12.46±0.86 
, 




HH29A43 N-NH 4.40 No inhibition 20.49±1.87 
OCH) 
HH29A13 S ~OCH' 23 .77 9.08±2.80 60.0S±9.62 V 
HH29A14 s 
V 
~' 18 .19 13 .06±1.87 81.86±3 .1S 
OCH) 
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Table 21: Effects of acyl hydrazide derivatives on cultured T. b. brucei and purified 
trypanopain and cathepsin L. 
Name A B T. b. brucei Trypano'pain Cathepsin L 
ICso (11M) Ki (11M) Ki (11M) 
MC361A 2Y (CH3hN :::::,... I 1 :::::,...1 10.52 0.70±0.06 0.97±0.10 
OCH3 
MC361 2Y (H3ChN+ :::::,... I ~ :::::,...1 13 .55 25.56±2.82 No inhibition 
OCH3 
7.11.8 In vivo testing of chalcones against T. b. brucei 
An intraperitoneal dose of 2 mg of each of ZLIII43A, ZLIV44A and MC161 in DMSO 
was found to be non-lethal to adult Balb/c mice. Tested mice experienced slight side 
effects (appeared slightly bloated and photo-sensitive) only during the week following 
administration. Additionally, a dose of 5 000 trypanosomes (in 100 III PSG, 25 III DMSO) 
was shown to be lethal to adult Balb/c mice in 8-10 days. 
Control mice injected with T. b. brucei (5 000 trypanosomes) alone were compared with 
mice simultaneously injected with the same amount of parasite and 0.5 mg of chalcone. 
Control mice (n=8) died on day 7.2±1.3 . However, all mice (n=8) injected with ZLIII43A 
and MC 161 survived, with no parasites evident in the bloodstream 1 month after infection. 
Of the 8 mice injected with ZLIV44A, 3 died on day 5.3±0.6, and the remainder (n=5) 
survived, with no parasites evident in the bloodstream 1 month after infection. Control 
mice injected with T. b. brucei (5 000 trypanosomes) alone were compared to mice 
injected with 0.5 mg of chalcone 3 h after T. b. brucei infection. MC161 was very 
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effective, prolonging the life of infected mice by 48%, while ZLIV 44A prolonged life by 
18% and ZLIII43A was ineffective (Table 22). 
Table 22: Effects of cha1cones on murine model of T. b. brucei infection. 
Mice (n=8 in each group) were injected intraperitoneally with 100 III of trypanosomes 
(5 000 trypanosomes total) in PSG and chalcone (0.5 mg in 25 Ill) in DMSO injected 3 h later. 
Control mice (n=8) were injected with 100 III trypanosomes (5 000 trypanosomes) and 3 h later 
with 25 III ofDMSO alone. 
Drug Day of death % Increase in 
lifespan 
Control 4.4±1.1 -
ZLIV44A 5.2±0.8 18 
ZLIII43A 4.4±0.7 0 
MC161 6.5±1.1 48 
7.12 Discussion 
Of the proteinase inhibitors tested, the alkylating agents IAN, lAA and NEM were the 
most trypanocidal, killing all trypanosomes within 24 h. Since T. b. brucei growth is 
known to be dependent on the presence of free cysteine in the medium (Duszenko et a!. , 
1985; 1992), it is likely that these inhibitors are trypanocidal in part because they starve the 
parasite of this essential nutrient. TLCK was less effective, killing 54% of cultured 
trypanosomes within 24 h. TLCK inhibits serine and cysteine proteinases, so its 
trypanocidal action implies that such a proteinase is likely to be essential for T b. brucei 
viability. SBTI killed 40% of trypanosomes in 24 h, suggesting that a serine proteinase 
may be essential for viability. All other inhibitors tested did not alter trypanosome 
population numbers relative to the controls. Similar experiments have shown that 
leupeptin, chymostatin, pepstatin A and E-64 inhibit P. falciparum invasion of erythrocytes 
and haemoglobin digestion (Dluzewski et a!. , 1986; Rosenthal et a!., 1988; Bailly et a!. , 
1992) and that serine and metallo-proteinase inhibitors reduce basement membrane 
degradation by cancer cells (Stonelake et a!. , 1997). Some of the inhibitors are toxic to 
cells for reasons unrelated to proteinase inhibition (as is thought to be the case with the 
alkylating agents) and others do not readily enter cells [e.g E-64, Wilcox and Mason 
191 
(1992)]. Therefore, such tests with proteinase inhibitors can only be used as an initial 
guide to further experiments. The potential role of cysteine proteinases (including 
trypanopain) in T. b. brucei viability was thus further examined using DMK, CMK and 
FMK inhibitors. 
Most of the tested inhibitors inhibited purified trypanopain with kass values in the 
105 MI . sol range (Table 17). Reports of kass values for inhibition of other parasite and 
mammalian cysteine proteinases by CMK, DMK and FMK unfortunately show very little 
overlap, limiting the comparisons that may be made between the present and previous 
studies. Additionally, considerable differences are evident between the small number of 
repeat experiments reported. For example, Franke de Cazzulo et al. (1994) reported a kass 
of 3 x 1 03 M-l .s- l for the interaction of Z-Phe-Phe-DMK with cruzipain (the major cysteine 
proteinase of T. cruzi), while Mierelles et al. (1992) reported a 7-fold higher kass for the 
same inhibition (2x 1 04 M-l .s- l). The value determined in the present study for inhibition of 
trypanopain by this inhibitor is 2.44x105 M-l .s-\ which is 80-fold higher than the value 
reported by Franke de Cazzulo (1994) and 12-fold higher than the value reported by 
Mierelles et al. (1992), both for cruzipain. In light of the discrepancy between the 
reported cruzipain values, it is difficult to postulate whether the difference between 
cruzipain and trypanopain values represents a true difference between the inhibition of 
cruzipain and trypanopain or rather differences in the methods used to calculate kass. 
The majority of previous studies (Mbawa et aI. , 1992; Mierelles et aI., 1992; Franke de 
Cazzulo et al., 1994; Wasilewski et aI. , 1996) on the inhibition of parasite cysteine 
proteinases by CMK, DMK and FMK have been conducted under first-order conditions, 
with the inhibitor in excess over the enzyme under study. However, this is only 
appropriate in cases where kass is suspected to be less than 105 M-l .s-l (Salvesen and 
Nagase, 1989). Most studies on the inhibition of mammalian cysteine proteinases by 
CMK, DMK and FMK have been done on cathepsin L, with kass values above 105 M-l .s- l 
for all tested inhibitors (Shaw, 1994). With this in mind, second-order conditions were 
employed in the present study, with the resultant kass values determined to be above 
105 Ml .S-l (Table 17). These values are more in agreement with Shaw's values for 
cathepsin L than with those reported for cruzipain (Mierelles et aI., 1992; Franke de 
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Cazzulo et al., 1994). Reported kass values for ketone inhibition of the S. mansoni cysteine 
proteinase are in the 106 M-1.s-1 range (Wasilewski et ai., 1996), which are also in 
agreement with those obtained by Shaw (1994) and in the present study. However, 
irrespective of the actual kass values, most studies agree that derivatives of Phe-Phe and 
Phe-Ala are highly effective against these parasitic cysteine proteinases, reflecting their 
similarity to mammalian cathepsin L in terms of specificity. In light of 'trypanopain' s 
substrate specificity, it would have been optimal to test inhibitors with Arg in the PI 
position, but these were not commercially available at the time of the study. 
In addition to inhibiting purified trypanopain, micro molar concentrations of the tested 
DMK, CMK and FMK inhibitors were also trypanocidal for cultured bloodstream forms of 
T b. brucei. IC50 values were mostly in the 10-50 ~M range (Table 17). Previous studies 
have shown that cysteine proteinase inhibitors kill T cruzi (Ashall et al., 1990; Harth et ai. , 
1993 ; Franke de Cazzulo et ai., 1994), T congolense (Mbawa et ai., 1992) and 
T vaginalis (Irvine et ai., 1997), and halt the development of S. mansoni (Wasilewski et 
ai. , 1996), T foetus (Irvine et ai., 1997), P. vinckei (Rosenthal et ai. , 1993) and 
P. falciparum (Rockett et ai. , 1990; Rosenthal et ai., 1990). No IC50 values were reported 
in these studies, so the relative effectiveness of the inhibitors cannot be assessed. 
An absolute correlation between trypanocidal activity and inhibition oftrypanopain was not 
observed. This can, however, be ascribed to the differing properties of the inhibitors in a 
cell culture system. For example, Z-Phe-Ala-FMK was a highly effective inhibitor of the 
enzyme but only moderately effective against the parasite, possibly because it penetrates 
living cells less readily than CMK and DMK. On the other hand, TPCK was very effective 
against the parasite but only moderately effective against the enzyme. TPCK is, however, 
a broad spectrum inhibitor and its trypanocidal effect could be due to inhibition of enzymes 
other than trypanopain-Tb. To the author's knowledge, no evaluation of the relative 
toxicities of CMK, DMK and FMK for mammalian cells or trypanosomes has been 
published, but the two DMK inhibitors tested had two of the three lowest IC50 values, 
suggesting that DMK may be more toxic to parasite cells than CMK or FMK. Since 
factors (e.g . membrane permeability, general toxicity) other than inhibition of the target 
enzyme are likely to affect the relative trypanocidal efficacy of inhibitors in a cell culture 
system, it is not unexpected that there is not an absolute correlation between IC50 and kass 
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values. However, Z-Phe-Phe-CMK was the most effective inhibitor against both the 
purified enzyme and the cultured parasite, and MeOSuc-Ala-Ala-Pro-Val-CMK was least 
effective in both cases. 
The in vitro trypanocidal activity of the cysteine proteinase-specific DMK inhibitors 
suggests that a cysteine proteinase is required for T. b. brncei viability.' Biotinylated 
derivatives of two inhibitors (biotin-Phe-Ala-FMK and biotin-Phe-Ala-DMK) were thus 
incubated with live and lysed T. b. brucei respectively to visualise the population of 
enzyme(s) binding to these inhibitors. A single band of 30 kDa (corresponding to the 
molecular mass of trypanopain) was strongly labelled in both experiments, suggesting that 
trypanopain is a major intracellular target for these inhibitors. Since FMK react with 
cysteine and serine proteinases, the specificity of labelling in live trypanosomes by biotin-
Phe-Ala-FMK strengthens the likelihood that trypanopain (and no other serine or cysteine 
proteinase with this specificity) is essential for parasite viability. Studies previously 
conducted on other parasites using FMK, CMK and DMK showed that cysteine 
proteinases are essential for the viability of T. cruzi (Ashall et aI., 1990; Mierelles et aI. , 
1992; Franke de Cazzulo et ai., 1994), T. congolense (Mbawa et aI. , 1992), P. Jalciparum 
(Rosenthal et aI., 1988; Rockett et ai. , 1990), P. vinckei (Rosenthal et al., 1993) and 
S. mansoni (Wasilewski et aI. , 1996). Ketone derivatives of Phe-Ala and Phe-Phe were 
also highly effective in many of these studies, suggesting that a cathepsin L-like proteinase 
is targeted by these inhibitors. 
While FMK, CMK and cysteine proteinase-specific DMK inhibitors are active against 
various parasites in vitro, it is necessary to demonstrate their action in vivo. CMK, 
however, have not been extensively tested in vivo, since they react with various cellular 
components other than serine or cysteine proteinases (Rossman et ai. , 1974; Pong et aI. , 
1975). DMK are unstable at low pH and thus unsuitable for oral administration, and are 
reportedly also mutagenic (Rasnick, 1996). DMK and CMK have thus been used primarily 
as research tools. On the other hand, while various toxic FMK metabolites are produced 
in vivo, making high concentrations of FMK toxic and unsuitable for human use (Rasnick, 
1996), FMK have been extensively tested in animals. The LDso for FMK in rats is 
300-400 mg/kg (Smith et aI., 1988). Mice are cured of murine malaria (caused by 
P. vinckei) by morpho line urea-Phe-homophenylalanine-FMK (Rosenthal et aI., 1993), 
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which strongly inhibits the haemoglobin-degrading cysteine proteinase of P. vinckei in 
vitro and is active against murine malaria in vivo. Only moderate adverse side effects were 
seen in the treated mice, possibly due to cross-reactivity with host proteinases 
(e.g. cathepsins) which could be reduced by careful inhibitor selection (Rosenthal et al. , 
1993). Additionally, this inhibitor was effective in treating mice infected with S. mansoni, 
reducing the number of adult worms (by approx. 50%), egg production by ' adult worms, 
and hepatomegaly when administered at 1 mg twice daily intraperitonealy (Wasilewski et 
al. , 1996). The effects of morpholine urea-Phe-homophenylalanine-FMK and related 
inhibitors on experimental trypanosome infection should be determined. Insufficient FMK 
was available for in vivo testing against T. b. brucei, so the in vivo trypanocidal activity of 
FMK could not be evaluated. 
In addition to their toxicity, peptide-based compounds such as DMK, CMK and FMK have 
various disadvantages as potential drugs, the greatest of which are their short half lives in 
vivo and their limited oral bioavailability (Kuntz, 1992). Various steps have been taken to 
counteract these problems. In vivo hydrolysis can be reduced by inclusion of unusual or 
D-amino acids, backbone modifications and peptide cyclisation. Non-invasive alternatives 
to oral delivery (e.g. inhalation, nasal absorption, electroporation) are also being 
investigated (Kuntz, 1992). Such investigations were beyond the scope of the present 
study, so more bio-stable, non-peptide inhibitors of cysteine proteinases were sought for in 
vivo testing. Reports by Li et al. (1995) suggested that chalcones might be appropriate 
and, in collaboration with Fred Cohen and his co-workers (Departments of Pharmaceutical 
Chemistry and Medicine of the University of San Francisco, California, USA), the 
trypanocidal effects of this new group of reversible cysteine proteinase inhibitors were 
evaluated. Most the tested chalcones and chalcone derivatives effectively inhibited purified 
trypanopain as well as mammalian cathepsin L. DOCK modelling suggests that chalcones 
bind into the S2, S 1 and S l' sites of falcipain (Li et ar, 1995), and the same is likely to be 
true of trypanopain. 
The chalcones were fairly effective cathepsin L inhibitors. The chalcones series, which 
contains quinolinyl A rings, were almost all poor inhibitors of trypanopain (Table 18). 
Only those with substituents [CI or (CH3)2N) on their quinolinyl A rings (MC131b, MC143 
and MC 151) were effective against trypanopain at less than 10 11M. All of these 
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compounds were, however, effective against cathepsin L at approx 10 IlM or less. This 
suggests that the trypanopain active site is less able to tolerate substituted and 
unsubstituted quinolinyl A rings than is cathepsin L. However, the hydrazide derivative 
series contains three effective inhibitors with quinolinyl rings (TF-1-59, TF-1-55 and 
TF -1-51) suggesting that it is the combination of the chalcone linker with the quinolinyl A 
ring that is unfavourable for trypanopain. Of the various substitutions made, it appears 
that substitution of the B ring with F atoms is least favourable . 
The hydrazide derivatives were highly effective trypanopain inhibitors, with all Ki values 
falling below 5 IlM (Table 19). In addition, this group contained the most effective 
trypanopain inhibitor, ZLIII43A. Hydrazides with bulky non-quinolinyl A groups were 
generally more effective against trypanopain. This group was also effective cathepsin L 
inhibitors, with all Ki values below 2 IlM. While no direct comparison was made, it 
appears that acylation of the hydrazide linker had no effect on the efficacy of these 
inhibitors (Table 21). For example, MC361A is approx. as effective as ZLIII115A as an 
inhibitor of both trypanopain and cathepsin L. The effects of substitution on the A and B 
groups was most extensively studied in the group of amide derivatives (Table 20). 
Addition of Br to the A (5-membered S-ring) of I-ll-I29A13 (i.e. MC2A13) lowers the 
trypanopain Ki from 9.08 IlM to 2.95 IlM and the cathepsin L Ki from 17.35 IlM to 
3.24 IlM. Comparison of MC24A24 and MC24A22 suggests that trypanopain favours CI 
groups in positions 3 and 4 on the B phenyl ring rather than in positions 3 and 5, while the 
opposite is true for cathepsin L. Methyl groups are favoured in positions 3 and 5 
(I-ll-I29A13, Ki = 9.08 IlM) on the B ring rather than 2 and 5 (I-ll-I29A14, Ki = 13 .06 IlM) 
by both trypanopain and cathepsin L. Additionally, both enzymes favour CI substitutents 
on the B group over methyl groups (compare MC24A24 and MC24A12, Table 20). 
Methyl substitution on the B ring seems to be particularly unfavourable for cathepsin L. 
All of the tested chalcones were trypanocidal against cultured T. b. brucei. The chalcone 
MC161 had the lowest LD50 value (0.24 IlM), with the hydrazides ZLIII44A, MC357 and 
TF-I-52 also having LD50 values below 1 IlM. It thus seems that the hydrazide linker is 
best suited to crossing membranes. The amides MC24A24, MC96A4I and I-ll-I29A13 had 
the highest LD50 value (above 23 IlM), suggesting that this linker crosses T. b. brucei 
membranes poorly. 
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There was not an absolute correlation between inhibition of purified trypanopain and 
trypanocidal activity. This is not unexpected since trypanocidal activity requires additional 
properties (e.g. membrane solubility) not relevant to inhibition of trypanopain directly. 
Thus, some poor trypanopain inhibitors were highly trypanocidal (MC161 and MCI59), 
and some excellent enzyme inhibitors fared less favourably against the parasite (MC96A4I, 
MC24A24 and HH27 A44). 
The most effective trypanopain inhibitor ZLIII43A and two of the most trypanocidal 
chalcones (ZLIII44A and MC161) were tested in mice. When chalcones were injected 
simultaneously with T. b. brucei, all mice injected with ZLIII43A and MC161 and 63% of 
mice injected with ZLIV 44A survived. When chalcones were administered 3 h after 
T. b. brucei infection, ZLIV44A prolonged life by 18%, MC161 prolonged life by 48% and 
ZLIII43A was ineffective. The decreased effectiveness observed in the second study is 
thought to indicate that the effective concentration of chalcone trypanosomes were 
exposed to was higher in the first experiment. Chalcones are poorly water soluble, and it is 
likely that once injected into the body they will precipitate, so that only a small fraction of 
the administered dose remains available. When chalcones are co-administered with 
parasites, their concentration in the peritoneum appears to have been sufficient to kill 
enough parasites to prevent the establishment of an infection. However, when chalcones 
were injected 3 h after infection, the majority of parasites are likely to have migrated from 
the peritoneum, and the concentration of chalcone outside the peritoneum does not appear 
to have been sufficient to prevent completely the establishment of an infection. 
MC 161 was the most effective of the chalcones in in vitro cell culture experiments and in 
vivo mouse experiments. This chalcone is, however, a poor trypanopain inhibitor, with no 
inhibition evident at 100 11M. The low water solubility of the compound prevents its 
analysis at higher concentrations. The highly trypanocidal nature of this inhibitor may 
suggest that it is more able to cross parasite cell membranes than ZLIII43A or ZLIV44A. 
Alternatively, its intracellular target may not be trypanopain. ZLIII43A and ZLIV44A 
were effective trypanopain inhibitors and also highly effective trypanocidal agents in in 
vitro cell culture experiments. While these chalcones were less effective than MC161 in 
vivo, the current results suggest that increased doses of these inhibitors (especially 
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ZLIV 44A) are likely to give better results. Experiments are currently under way in our 
laboratory to assess the effects of repeated administration of chalcones on T. b. brucei 
infection. The low water solubility of the agents is likely to be a problem, with DMSO 
toxicity predicted to occur with multiple administrations. Potential ways to improve the 
water solubility of chalcones are being considered. 
The three chalcones were shown to be non-lethal to adult Balb/c mice, with only slight side 
effects seen in the first week after administration. Since all of these compounds inhibit 
mammalian cathepsin L, inhibition of the murine enzyme may be the cause of these side 
effects. While cysteine proteinases show many similarities, advances in the understanding 
of these enzymes is making it possible to exploit their small differences to create more 
specific inhibitors (Storer and Menard, 1996). ZLIII43A is 16 times more effective against 
trypanopain than against cathepsin L. Salvesen and Nagase (1989), however, suggest that 
in order to suppress the activity of a single proteinase in vivo, the selective inhibitor should 
have a Ki for the enzyme 1000-fold less than for any other enzyme in the mix, or a kass 
lOOO-fold greater than for any other proteinase in the mix. ZLIII43A clearly does not fit 
these criteria, but is nevertheless effective in vivo. Possibly chalcones are more able to 
enter trypanosomes than mammalian cells, so that the effective concentration of ZLIII43A 
is too low inside mammalian cells for cathepsin L inhibition to be toxic. T. cruzi selectively 
accumulates FMK-based inhibitors, leading McKerrow et al. (1995) to suggest that further 
study of the mechanisms used by parasites to endocytose small molecules from their 
surrounding medium may have benefits for drug design. Ideally, wholly specific inhibitors 
of cysteine proteinases should be used in vivo to prevent any side effects. To develop such 
inhibitors, the interactions between enzymes and their substrateslinhibitors that occur 
outside of the major sub sites should be studied (Storer and Menard, 1996). For example, 
the S' subsites oftrypanopain have not been characterised. 
Chalcones would be inexpensive to synthesise, and could thus potentially be of great use in 
the developing world. The major potential disadvantage of chalcones is their low water 
solubility, although attempts to improve this are being made. The in vivo half-life and oral 
bioavailability of chalcones remains to be tested. Various other classes of cysteine 
proteinase inhibitors have been recently described, and their effects on trypanopain and 
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T. b. brucei should be investigated. For example, a-keto amides reportedly inhibit calpains 
and cathepsin B (Li et aI., 1996), peptidyl acyloxymethanes (Krantz, 1994) and 
N, O-diacyl hydroxamates (Br6mme and Demuth, 1994) inhibit various cathepsins, while 
vinyl sulfones inhibit falcipain (Rosenthal et aI., 1996) and papain (Hanzlik and Thompson, 
1984). Vinyl sulfones have been shown to inhibit metabolism, growth and development of 
cultured P. falciparum (Rosenthal et aI. , 1996). Studies are presently under 'way to assess 





Trypanosomiasis has historically been of substantial economic and social importance in many 
parts of Africa, and continues to exert a significant effect on many parts of the continent today. 
Gutteridge (1985) remarked that none of the currently available anti-trypanosomal drugs is 
entirely satisfactory, since they generally lack oral activity, have undesirable side-effects and are 
unable to treat all stages of the disease. Additionally, while there are few reports of drug 
resistant human trypanosomes, resistant cattle strains limit the veterinary efficacy of the current 
drugs. This, together with the time and cost involved in controlling tsetse fly populations, has 
led to a search for novel means of disease therapy and prevention. However, while 
trypanosomes have been studied for many decades, there remains a general lack of 
understanding of the parasite metabolites responsible for the pathology of trypanosomiasis. 
This is illustrated by the fact that most of the anti-trypanosomal drugs currently in use were 
developed many decades ago and additionally, that their mode of action and target molecules 
remain speculative (Gutteridge, 1985). DFMO is the only drug developed in the last decade, 
and is also the best understood of the currently available treatments (McCann et aI. , 1981; 
Bacchi et aI., 1983; Fairlamb et aI. , 1987). 
The major lysosomal cysteine proteinases (trypanopains) oftrypanosomes have been suggested 
to contribute to the pathogenesis of trypanosomiasis by degrading host proteins in the 
bloodstream. At the time this study was undertaken, such theories were purely speculative, 
since the interactions between trypanopains and endogenous host cysteine proteinase inhibitors 
(cystatins) had not been reported. Additionally, while trypanopains were known to be major 
antigens in infected cattle (Authie et al., 1993), the effects of anti-trypanopain antibodies on 
trypanopain had not been investigated. Also, while the trypanopain-Tc and cruzipain had been 
purified from T congolense (Mbawa et aI., 1992) and T cruzi (Cazzulo et al., 1989; Murta et 
aI., 1990; Lima et aI., 1992) respectively and their kinetic properties extensively characterised, 
trypanopain-Tb from T b. brucei had not been purified to electrophoretic homogeneity or 
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similarly characterised. T b. bntcei is of considerable economic importance in Afiica as a cattle 
parasite, and also serves as an excellent model for the trypanosome species that infect humans. 
The aims of this study were thus initially to isolate trypanopain from T b. bntcei and 
subsequently to characterise the enzyme's kinetic properties and its interactions with host 
proteinase inhibitors and antibodies. 
8.2 Enzymatic characterisation 
This study reports the first isolation to electrophoretic homogeneity of trypanopain from 
mammalian bloodstream forms of T b. bntcei, using a combination of three-phase partitioning 
between ammonium sulfate and t-butanol, anion exchange chromatography on Q-resins and 
pepstatin A-Sepharose affinity chromatography. These methods had not been previously 
utilised for the purification of trypanopains. The purification was particularly challenging 
because of the extremely small amounts of starting material available and the low stability of the 
enzyme. A rapid, efficient means of purification was thus essential. As discussed in Chapter 3, 
purification of trypanopain relied heavily on the fact that this enzyme binds to Q-Sepharose at 
pH 5.5, while most other trypanosomal proteins do not. This indicates either that trypanopain 
has an unusually low pI or that regions of the enzyme remain strongly negatively charged below 
the enzyme's pI. 
Separation of trypanopain into three active peaks on Resource Q may indicate that the enzyme 
undergoes variable post-translational modifications. Alternatively, the different enzyme 
populations may consist of different gene products encoded by the different tandemly arranged 
genes (Mottram et a!. , 1989). This appears to be the situation with the major cysteine 
proteinases of T cntzi (Campetella et aI. , 1992; Eakin et aI. , 1992) and Leishmania (Souza et 
aI. , 1992; Mottram et aI., 1996). In the case of cruzipain, the different gene products vary 
slightly in their substrate specificity (Lima et al., 1994), possibly indicating that the gene 
products fulfil slightly different roles in the organism. Preliminary kinetic analysis of the three 
Resource Q peaks revealed no such variation in trypanopain specificity, but it remains possible 
that such variation would be revealed by a wider investigation involving more substrates. The 
separation of trypanopain into three peaks must reflect some underlying variability in 
trypanopain and further analysis of the translation of trypanopain genes is required to unravel 
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the cause and significance of this chromatographic separation and to better understand the 
reasons why trypanopain is encoded by multiple genes. 
Since Resource Q columns were not cost-effective, pepstatin A-Sepharose was used as the final 
purification step in later purifications. While it is unusual that an aspartic proteinase inhibitor 
should inhibit a cysteine proteinase, such inhibition has been previously reported for trypanopain 
from T. b. rhodesiense (pamer et aI. , 1989) and trypanopain-Tc (Mbawa et al., 1992). 
Pepstatin A was shown to be a competitive inhibitor of trypanopain, suggesting that it acts as a 
substrate analogue. 
Only 30 flg of the purified trypanopain over 4 injections was required to elicit high titre 
antibodies in a chicken. This is much less than is nonnally considered necessary to evoke an 
effective immune response (Thorpe, 1994), suggesting that trypanopain is highly immunogenic 
in chickens. This is of particular significance where the immunogen is unstable in its purified 
fonn or starting material is limited, as is commonly the case with parasite enzymes. Western 
blots using these antibodies confinned a previous report by Pamer et al. (1991) that 
anti-trypanopain antibodies recognise three bands in lysed T. b. bntcei. Pamer et al. (1991) 
suggested from analysis of the trypanopain gene coding region that these are likely to be 
processing intennediates of the enzyme, but pulse-chase studies are obviously needed to 
confinn this suggestion. 
Trypanopain was shown to be a fairly typical cysteine proteinase; active only in the presence of 
reducing agents and inhibited by E-64, cystatins and alkylating agents. Previous 
characterisations of trypanopain' s kinetic properties were all carried out on partially purified 
enzyme or lysed T. b. brucei (Boutignon et al., 1990; Robertson et aI., 1990; Pamer et aI. , 
1991; Huet et aI. , 1992), so this study represents the most reliable reported ' characterisations. 
The enzyme was found to be optimally active against Z-Phe-Arg-AMC between pH 6.5 and 
8.0, and against the proteinaceous substrate 14C-gelatin at pH 5.5. Since a pH optimum 
determined using a proteinaceous substrate is more likely to be physiologically relevant than 
that optimum determined using a synthetic substrate, it is considered likely that the in vivo pH 
optimum of trypanopain is approximately pH 5.5. Across the pH range, trypanopain was more 
stable in the absence of cysteine than in its presence, suggesting that the active enzyme 
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undergoes autocatalysis. Trypanopain has cathepsin L-like specificity for synthetic substrates, 
with Z-Phe-Arg-AMC being by far the most favoured of the tested synthetic substrates. 
Substrates with basic residues (Arg or Lys) in PI and hydrophobic residues (phe and Leu) in P2 
were most rapidly hydrolysed. Hydrophobic residues (e.g. Val) were preferred over small, 
uncharged residues (e.g. Ala) in P3. Additionally, acidic residues were unacceptable in P 4· 
Trypanopain was thus shown to be kinetically similar to trypanopain-Tc (Mbawa et al., 1992) 
and cruzipain (Cazzulo et aI. , 1989; Murta et aI. , 1990; Lima et aI. , 1992). 
Trypanopain was shown to be able to hydrolyse a number of mammalian proteins (e.g. BSA, 
IgG, fibrinogel\ albumin and gelatin) in vitro. Thus, if trypanopain remains active when it is 
released into the mammalian bloodstream (either actively or from dying parasites), then it is 
possible that the enzyme may contribute to disease pathogenesis by degrading host proteins. 
However, endogenous proteinase inhibitors (e.g. cystatins or kininogens) or anti-trypanopain 
antibodies may inhibit the enzyme in vivo. Consequently, the effects of both natural cysteine 
proteinase inhibitors (cystatins) and anti-trypanopain antibodies on enzyme activity were 
investigated in the present study. 
8.3 The control of trypanopain by inhibitors in the bloodstream 
Cystatin C and L-kininogen were both shown to strongly inhibit purified trypanopain in vitro. 
The binding constants for cystatin C and L-kininogen suggest that trypanopain is likely to be 
effectively inhibited in the host bloodstream and therefore unlikely to contribute to pathogenesis 
by the generalised digestion of host proteins. Indeed, no trypanopain-like activity was 
detectable in the blood of naturally-infected cattle or experimentally-infected rats, and 
in vivo-formed trypanopainlcystatin complexes were shown to be inactive against Z-Phe-Arg-
AMC. This study thus argues against the widely held contention amongst researchers in this 
field that trypanopains contribute to pathogenesis by degrading host proteins in the 
bloodstream. 
However, reports of the formation of active complexes between trypanopain and kininogen-like 
molecules (rIM) cast doubt on the conclusion that trypanopain is inhibited in all situations 
(Lonsdale-Eccles et aI. , 1995). The present study showed that L-kininogen enhances hydrolysis 
of Z-Phe-Arg-AMC by live T b. brucei by 20-40% in vitro. Thus, the possibility that active 
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trypanopainlcystatin complexes fonn under certain undefined conditions in vivo cannot be 
excluded. 
This study has shown that anti-trypanopain antibodies can inhibit trypanopain digestion of 
Z-Phe-Arg-AMC and FITC-albumin. While trypanopain-Tc and cruzipain have been reported 
as major antigens in infected cattle (de Souza et aI. , 1990; Murta et aI., 1990; Authie et aI., 
1993; Gonzruez et aI. , 1996), this is the first investigation of the effects of anti-trypanopain 
antibodies on enzyme activity. If similar antibody inhibition of trypanopain occurs in vivo in 
infected hosts, then degradation of host proteins could be limited and pathology reduced. It is 
also possible that inhibitory anti-trypanopain antibodies could exert a protective effect by 
opsonising trypanopain and thus mediating more rapid clearance of the enzyme from the blood. 
Either possibility is supported by the observed correlation between the production of 
anti-trypanopain IgG by certain breeds of cattle and their tolerance to trypanosome infection 
(Authie et at., 1993). 
However, the present study has shown that some anti-trypanopain antibodies can also enhance 
trypanopain activity against Z-Phe-Arg-AMC and 14C-gelatin. The presence of such activity-
enhancing antibodies in vivo may contribute to a complex interplay between enhanced host 
protein degradation and enhanced enzyme clearance by opsonisation and inhibition of enzyme 
activity. Since antibody modulation of trypanopain activity varies depending on the substrate 
used, and since the in vivo substrates of trypanopain remain unknown, it is difficult to predict 
the effects of these antibodies on in vivo trypanopain activity. However, it should be possible to 
investigate the effects of these antibodies on disease parameters (e.g . parasitaemia, anaemia) in 
a natural infection directly by passive immunisation of infected animals (e.g. mice) with these 
antibodies. 
Since it appears that trypanopain is effectively controlled by cystatins m the mammalian 
bloodstream under nonnal circumstances, the correlation between disease resistance and 
anti-trypanopain antibody production is puzzling. While the correlation does not necessarily 
imply a causal relationship, anti-trypanopain antibodies may be protective for reasons other than 
direct inhibition of the enzyme. As shown in this study, trypanopain is highly immunogenic in 
chickens. Trypanopain peptides are also in1munogenic in chickens and rabbits. Trypanopain 
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may thus elicit high titre antibodies that protect the host by alerting the immune system to the 
presence of the parasites in the blood. To investigate the protective effects of trypanopain 
directly, it would be necessary to immunise a susceptible host with trypanopain and then 
challenge the immunised animal with a trypanosome infection. Such an experiment was beyond 
the scope of the present study, since it requires large amounts of trypanopain, and would thus 
require expression of recombinant enzyme. 
8.4 Trypanocidal activity of trypanopain inhibitors 
Numerous parasites, including trypanosomes, have been shown to be sensitive to cysteine 
proteinase inhibitors, eliciting interest in these inhibitors as potential chemotherapeutic agents 
(Rosenthal et at., 1988; Ashall et at., 1990; Mbawa et at. , 1992; Wasilewski et at. , 1996; Irvine 
et al., 1997). With this in mind, the effects of cysteine proteinase inhibitors on T. b. brucei were 
investigated. Various DMK, FMK and CMK were shown to be effective inhibitors of the 
purified enzyme and additionally to be trypanocidal for cultured bloodstream forms of 
T. b. brucei. This study also showed for the first time that these inhibitors can associate with 
trypanopains at rates similar to those reported for mammalian enzymes (Shaw, 1994), and not 
only at the slower rates previously reported for cruzipain (Mierelles et al., 1992; Franke de 
Cazzulo et al., 1994). The higher rates of association observed in this study are attributed to 
the fact that second order conditions were used in the present study, while first order conditions 
were used in previous cruzipain studies. Labelling of lysed and live T. b. brucei with biotin-
labelled derivatives of these inhibitors showed that trypanopain is the principal intracellular 
target of these inhibitors. 
Salvesen and Nagase (1989) suggested that, in general, it is preferable to use a reversible 
inhibitor such as a chalcone in vivo rather than an irreversible one such as a CMK, DMK or 
FMK. An irreversible inhibitor will eventually inhibit proteinases it reacts with slowly, whereas 
a reversible inhibitor will never decrease the activity of an untargeted proteinase when that 
inhibitor is at a concentration above the Ki for the reaction (Salvesen and Nagase, 1989). In an 
attempt to develop less toxic cysteine proteinase inhibitors with greater bio-stability, the 
trypanocidal effects of chalcones were investigated. These reversible cysteine proteinase 
inhibitors were shown to inhibit purified trypanopain and to be trypanocidal for cultured 
T. b. brucei. Most significantly, these inhibitors protected mice from a lethal dose of 
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T b. brucei when given at the time of infection and a single dose given 3 hours after infection 
prolonged the lives of infected mice. This suggests that a new class of anti-trypanosomal agents 
could be developed based on trypanopain inhibitors. 
Chalcones do effectively inhibit mammalian cathepsin L, so their limited toxicity in the murine 
model is surprising. Predicted cross-reactivity with host cathepsins has been one of the 
predicted major stumbling blocks to the therapeutic use of cysteine proteinase inhibitors. The 
limited toxicity observed in the present study may suggest that trypanosomes accumulate the 
drug more actively or selectively than mammalian cells. Alternatively, the redundancy of 
mammalian cysteine proteinases may be such that inhibition of cathepsin L is not lethal to 
mammalian cells. 
Various other reports have suggested that cysteine proteinase inhibitors are potential treatments 
for parasitic diseases (Rosenthal et aI. , 1993; Wasilewski et aI. , 1996). While this study 
presents much circumstantial evidence that trypanopain is essential for T b. brucei viability, 
none of the evidence is conclusive. DMK and FMK react with some serine proteinases 
(Rasnick, 1996) and while the biotinylated inhibitors used in the present study bind 
predominantly to trypanopain, it is possible that their trypanocidal activity is a result of binding 
to a minor (but crucial) enzyme present at too low a level to be detected on such blots. 
Additionally, while chalcones were designed to inhibit cysteine proteinases, their actual 
specificity has not been directly investigated. The highly trypanocidal effect of the chalcone 
MC 161 , which is a poor trypanopain inhibitor, may indicate that chalcones have trypanosomal 
targets other than trypanopain. It is thus possible that the trypanocidal effects of these inhibitors 
are not a function of trypanopain inhibition, but rather of interaction with some other molecule. 
To confirm that trypanopain is essential for the viability of T b. brucei, a gene knockout 
trypanosome should be produced. Gene knockout of the cysteine proteinase of Streptococcus 
pyogenes (Lukomski et aI., 1997) and L. mexicana (Mottram et aI. , 1996) confirmed that these 
enzymes are important virulence factors, thus validating them as drug targets. Thus, similar 
studies on trypanopain are appropriate. 
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8.5 Future directions 
Most of the currently available cysteine proteinase inhibitors all bind only to the S sites of the 
susceptible enzyme rather than to the S' sites. Inhibitors binding to the S' as well as the S 
sub-sites are likely to be effective at much lower concentrations than the cur:ently available 
inhibitors. Additionally, their increased specificity should reduce cross-reaction with host 
proteinases, making them less toxic to mammalian cells. A better understanding of the S' 
subsite specificity of trypanopain would enable the rational design of more specific, less toxic 
inhibitors by exploiting the differences between parasite and host cysteine proteinases 
(Robertson et aI. , 1996). With this is mind, the S' sub sites of trypanopain were investigated 
using the method of Schellenberger et al. (1993). Nucleophilic peptides of the general structure 
X-Ala-Ala-Ala (where X represents each of the 20 natural amino acids) act as replacements for 
H20 in the final step of enzyme catalysis, with those peptides that bind best to the S' sites acting 
as better nucleophiles. HPLC is used to assess the rate of disappearance of each peptide from a 
mixture of such peptides, with this rate reflecting each peptide' s success as a nucleophile and 
thus its success at binding the enzyme active site. 
However, initial experiments suggested that none of the peptides were consumed over test 
periods of up to 16 h. A similar lack of utilisation was observed using the standard enzymes 
papain and cathepsin L. Variation ofHPLC conditions, substrates for binding to the S sub sites. 
assay buffers, enzyme and peptide concentrations was unsuccessful. More recently. 
considerable success has been reported using internally quenched substrates (Le Bonniec et al.. 
1996), and it is likely that these would also prove successful for trypanopain. 
Various new cysteine proteinase inhibitors have recently been reported, including a-keto 
amides (Li et al., 1996), peptidyl acyloxymethanes (Krantz, 1994), N, O-diacyl hydroxamates 
(Brbmme and Demuth, 1994) and vinyl sulfones (Hanzlik and Thompson, 1984; Rosenthal et 
aI. , 1996). These new families of inhibitors should be evaluated against T. b. brncei in the same 
manner as cha1cones have been evaluated in this study. Of these, vinyl sulfones seem to be the 
most promising, as they have shown in vitro antimalarial activity (Rosenthal et aI., 1996). 
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People living in areas where trypanosomiasis is common traditionally use various plants to treat 
infected people and animals. Studies have shown that many of these plants do contain 
anti-trypanosomal agents (Frieburghaus et al., 1996; Sepulveda-Boza and Cassels, 1996) and 
preliminary studies in this laboratory suggest that the indigenous plants Ehretia rigida and 
Albizza adanthafolia have anti-trypanosomal activity in vitro. Further investigation of these 
plants could uncover novel trypanosomal targets and may lead to the development of new 
anti-trypanosomal drugs. 
In conclusion, this study has shown that trypanopain is unlikely to remain active in the 
mammalian bloodstream, and so is unlikely to contribute to pathogenesis by degrading host 
proteins. However, the enzyme does appear to be essential for parasite viability. In addition to 
killing parasites in vitro, trypanopain inhibitors seem to be active in vivo, since they prolong the 
lives of infected mice. Thus trypanopain appears to be a potentially suitable target for new 
anti-trypanosomal agents. Further investigation of trypanopain substrate specificity will enable 
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Abstract 
Anti-peptide antibodies were produced against the cysteine proteinase trypanopain-Th from Trypanosoma brucei brucei 
and the effects of these antibodies on enzyme activity against carboxybenzoyl (Z)-Phe-Arg-aminomethylcoumarin (AMC) 
investigated. A peptide was synthesised corresponding to a region of the trypanopain-Tb active site around the active site 
histidine so that the resulting anti-peptide antibodies specifically targeted the active site of the enzyme. Such antibodies were 
considered more likely to modulate enzyme activity compared with antibodies directed against other regions of the enzyme. 
Trypanopain-Tb activity was modulated by rabbit and chicken antibodies produced against both the free and conjugated 
peptide. Rabbit anti-peptide antibodies enhanced trypanopain-Tb activity by up to 64% at 500 p,g/ml relative to 
non-immune antibodies. Chicken antibodies on the other hand , both enhanced (by up to 176% at 500 mg/mO and inhibited 
(by up to 85% at 250 mg/m!) trypanopain-Th activity against Z-Phe-Arg-AMC. The nature of the antibody effect depended 
on the stage during the immunisation protocol at which the antibodies were produced. Chicken antibodies also modulated 
trypanopain-Tb activity in Iysates of T.b. brucei, while rabbit antibodies were only effective against the purified enzyme. 
Anti-trypanopain-Th peptide antibodies were thus shown to have the potential to affect trypanopain-Tb activity. 
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1. Introduction 
Trypanosoma brucei brucei is the causative agent 
of bovine and human trypanosomiasis, called nagana 
and sleeping sickness, respectively. Both of these 
diseases are of great economic importance in regions 
of Africa where the disease vector (the tsetse fly) 
occurs. Currently available treatments are limited in 
their efficacy by their toxicity as well as emerging 
parasite resistance. Various aspects of the parasite's 
0162-3109/97/$17.00 Copyright © 1997 Elsevier Science B.V. All rights reserved. 
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metabolism are thus under study as potential future 
points for chemotherapeutic intervention. The major 
lysosomal cysteine proteinases of T. congolense and 
T. cruzi (called trypanopain-Tc and cruzipain, re-
spectively) have been identified as major antigens 
recognised in cattle and human infections (de Souza 
et a!., 1990; Authie et a!., 1993) and it is thus 
considered likely that trypanopain-Tb from T.h. bru-
cei is also highly immunogenic in natural infections. 
While previous studies have indicated that try-
panopain-Tb is unlikely to remain active in the host 
bloodstream (Troeberg et aI., 1996), cattle breeds 
resistant to trypanosomiasis produce anti-trypanopain 
IgGl, while susceptible breeds do not. This correla-
tion between trypanotolerance and the production of 
anti-trypanopain-Tb antibodies suggests that anti-
trypanopain antibodies may help protect the infected 
host (Authie et al.. 1993). We thus sought to investi-
gate the effects of anti-trypanopain-Tb antibodies on 
enzyme activity. We elected to produce antibodies 
against the trypanopain-Tb active site because of the 
increased possibility that antibodies against this re-
gion would modulate enzyme activity compared to 
antibodies directed against other regions of the en-
zyme. 
Production of antibodies against a protein of inter-
est can be accomplished in vaJious ways, to produce 
antibodies with differing specificities. For the pur-
poses of this study, antibodies able to recognise the 
enzyme active site in its native form (to assess the 
effects of the antibodies on activity) and also in its 
partially denatured form (for use in ELISAs) were 
required. The broad specificity of polyclonal anti-
protein antibodies excluded them as potential tools 
for specifically targeting the trypanopain-Tb active 
site. Conversely, the absolute specificity of mono-
clonal antibodies can limit their versatility. Anti-
peptide antibodies have advantages over both mono-
clonal and traditional polyc1onal antibodies which 
made them especially suited to the requirements of 
this study. Firstly, since anti-peptide antibodies are 
all directed against a single peptide, they have speci-
ficity more similar to monoclonal antibodies than to 
anti-protein polyclonal antibodies (Lerner, 1984). The 
specificity of such anti-peptide antibodies for the 
target protein arises from the fact that a sequence of 
ten or more residues is likely to be unique to a 
particular protein. Secondly, since several B-cell 
clones are stimulated by the peptide, the individual 
antibodies all have different specificities in that they 
bind to different, overlapping regions of the peptide. 
These antibodies are thus highly versatile in that they 
are able to specifically recognise the target sequence 
in many different conformations (e.g. both the native 
and denatured forms) . This combined versatility and 
specificity of anti-peptide antibodies led us to pro-
duce anti-trypanopain-Tb antibodies by imrnunising 
rabbits and chickens with a peptide immunogen. 
Here we describe the selection of a peptide corre-
sponding to a sequence in the active site of try-
panopain-Tb and the subsequent production of anti-
peptide antibodies in chickens and rabbits. The effect 
of the anti-peptide antibodies on trypanopain-Tb ac-
tivity was investigated using the fluorometric peptide 
substrate Z-Phe-Arg-AMC, previously found to be 
an appropriate synthetic substrate for trypanopain-Tb 
(Troeberg et a!. , 1996). 
2. Materials and methods 
2.1. Choosing a peptide frolll the active site 
The choice of an immunogenic peptide from the 
trypanopain-Tb active site was based on identifica-
tion of surface-located regions . In the absence of a 
three dimensional structure for trypanopain-Tb, the 
known three dimensional structure of papain (Drenth 
et aI. , 197 I), which is 3S !Jc similar to that of try-
panopain-Tb (Mottram et a!.. 1989) was used for the 
prediction of trypanopain B-cell epitopes. To in-
crease the likelihood of immunogenicity, epitope 
prediction algorithms, such as hydrophilicity, hy-
drophobicity, accessibility and antigenicity plots 
(Hopp and Woods, 1981 , Kyte and Doolittle, 1982; 
Van Regenmortel, 1986) were also used. Such a 
combination of methods has successfully identified 
an immunogenic peptide from the active site of the 
homologous mammalian proteinase, cathepsin L 
(Coetzer et aI., 199 I). 
In light of the success of the previous study by 
Coetzer et al. (199 I), a peptide analogous to that 
chosen from cathepsin L was chosen for the current 
study. The 16-residue peptide chosen corresponds 
with residues 274 to 289 in the primary sequence of 
trypanopain-Tb (Mottram et aI., 1989) and includes 
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the active site histidine residue, increasing the possi-
bility that antibodies would inhibit enzyme activity. 
The sequence of the chosen peptide (residues 274-
289, Mr = 1461.93) in trypanopain-Tb is ILTSCT-
SKQLDHGVL, where H represents the active site 
histidine. The corresponding peptide is surface-
located in papain and contains local peaks of hydro-
philicity, accessibility, antigenicity and flexibility in 
trypanopain-Tb, as determined using the software 
programme Predict7 (Ciirrnenes et aI., 1989). Modi-
fications were made to the original sequence for the 
synthesis of the peptide by the Peptide Synthesis 
Core Facility at the University of Georgia, GA, 
USA, namely: (a) an N-terrninal cysteine was added 
to allow coupling of the peptide to a carrier molecule 
via a thioether bond; (b) the internal cysteine residue 
was synthesised as an a-amino butyric acid residue 
to prevent dimerisation of peptides via disulphide 
bonds (Muller, 1988) and (c) the C-terrninal end was 
synthesised as an amide, mimicking an uncharged 
peptide bond, thereby potentially increasing cross-re-
activity with whole trypanopain-Tb. 
2.2. Peptide conjugation and immllnisariolls 
The selected peptide was conjugated to carrier 
proteins by means of meta-maleimidobenzoyl N-hy-
droxysuccinimide ester as described by Kitagawa 
and Aikawa (1976), using the modifications of Liu et 
al. (1979). 
Two rabbits and two chickens were immunised 
with free peptide (200 f.Lg each, dissolved in heat-
sterilised 100 mM sodium phosphate buffer, pH 6.0) 
and two rabbits and two chickens with peptide-
ovalbumin conjugate (200 j.Lg each of conjugated 
peptide, assuming a 40% coupling efficiency (Muller, 
1988)). Freund's complete adjuvant (FCA) was used 
for all immunisations with the free peptide in rabbits 
and for the first immunisation with the conjugated 
peptide in rabbits and chickens (Muller, 1988). Fre-
und 's incomplete adjuvant (PIA) was used for subse-
quent immunisations of rabbits and chickens with the 
conjugated peptide. In chickens, the free peptide was 
administered alternately in FCA and PIA. Rabbits 
were injected subcutaneously, at 4-6 sites on either 
side of the spine at weeks 0, 2, 6 and 10. Blood was 
collected from the ear vein 3, 8 and 12 weeks after 
the initial immunisation. Chickens were injected in-
tramuscularly at 4 to 6 sites on either side of the 
sternum at weeks 0, 1, 2, 6 and 10 and eggs col-
lected from the start of the immunisation protocol. 
2.3. Isolation of antibodies 
IgY was isolated from egg yolk by polyethylene 
glycol precipitation, as described by Polson et al. 
(1985). Rabbit IgG was similarly isolated from rabbit 
serum. 
2.4. ELISAs 
The production of anti-peptide antibodies by ex-
perimental animals was assessed using an enzyme-
linked immunosorbent assay (ELISA) as described 
by Coetzer et al. (1991). 
To investigate the cross-reactivity between anti-
peptide antibodies and whole trypanopain-Tb, try-
panopain-Tb (purified as described by Troeberg et 
aI., 1996) was coated (Nunc PolySorb, 16 h at 4°C, 
titrated between 28 and 0.2 ng per well in 40 mM 
carbonate buffer, pH 6.0). The remainder of the 
ELISA was carried out essentially as described by 
Coetzer et al. (I 991) except that a fixed concentra-
tion of primary antibody was applied (SO j.Lg/ ml , in 
0.5% (m/v) BSA-PBS, 0.1% (v/v) Tween-20, 2 h 
at 3rC), 3,3',5 ,5'-tetramethyI benzidine 
(TMB)/H 2 0 2 was used as HRPO-substrate and 1 M 
H 2 S04 added to stop the HRPO reaction. 
The recognition of cathepsin L by anti-
trypanopain-Tb peptide antibodies was investigated 
by coating sheep cathepsin L (Nunc MaxiSorb, 16 h 
at 4°C, I j.Lg/ mJ in 40 mM carbonate buffer, pH 
6.0). Test antibodies were titrated between 250 and 
0.1 j.Lg / ml in 0.5% BSA-PBS (2 h at 37°C). The 
remainder of the ELISA was carried out as described 
above for the trypanopain-cross reactivity ELISA. 
2.5. Effect of anti-peptide antibodies on trypanopain-
Tb activity against Z-Phe-Arg-AMC 
The effects of anti-peptide antibodies on enzyme 
activity against Z-Phe-Arg-AMC were investigated 
as described by Coetzer et al. (I 991). Trypanopain-Tb 
(1.5 ng, purified or present in lysates of T.b. bruceO 
was incubated with the antibody under study before 
assaying trypanopain-Tb activity (Troeberg et aI., 
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1996). Enhancement or inhibition of enzyme activity 
was expressed as a percentage of the activity de-
tected after incubation with the same concentration 
of non-immune antibody. 
2.6. Inhibition of ami-peptide antibody effect by 
addition of free peptide 
To confirm the specificity of the anti-peptide 
antibody effects on enzyme activity, the above exper-
iments were repeated in the presence of the free 
trypanopain-Tb peptide. Free peptide should compete 
with the enzyme for binding to the antibody and so 
diminish the effect of the antibodies on trypanopain-
Tb activity. Peptide was dissolved in 0.1 % (m/ v) 
Brij 35 to give 10,000: 1 to 1:1 molar ratios of 
peptide:enzyme. The peptide solution (100 fLl) was 
incubated with antibody (500 fLI, final concentration 
500 fLg / ml , IS min at 37°C). Trypanopain-Tb was 
added (15 min. 37°C) and activity against Z-Phe-
Arg-AMC detennined as before. A non-related pep-
tide (polY-L-glutamic acid) was added in parallel 
experiments to further confirm the specificity of the 
interaction. 
3. Results 
3.1. Determination of anti-peptide antibody titre in 
rabbits alld chickens 
Both the free and the conjugated trypanopain-Tb 
peptide were immunogenic in rabbits and chickens. 
High titre anti-peptide antibodies were produced 
against the conjugated peptide within 3 weeks of the 
initial immunisation (Fig. 1), while similarly high 
titre antibodies were only produced against the free 
peptide 8 weeks after immunisation (Fig. 1). By 8 
weeks post-immunisation, the titre of antibodies 
against the two forms of immunogen was compara-
ble. Anti-peptide antibody titres in rabbits and chick-
ens against corresponding immunogens were similar, 
as were titres of individual animals and species. 
3.2. Recognition of whole trypanopain-Tb and 
cathepsin L by anti-peptide antibodies 
In addition to recognising the free trypanopain-Tb 
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Fig. 1. Titre of rabbit antibodies produced against the free (A) and 
conjugated (B) trypanopain-Tb peptide at various weeks post-im-
munisation. Free peptide (5 j.tg jml) was coated for 16 h at 4°C in 
PBS . Non-immune antibodies (e ) and antibodies from week 3 
(.), week 8 (0) and week 12 (,,,) post-immunisation were 
titrated between 250 j.tg j ml and 0.1 f.Lg antibody j m!. Sheep 
anti-rabbit-HRPO was used as secondary antibody with 
ABTSjH 10 2 as substrate. 
trypanopain-Tb in an ELISA (Fig. 2). Antibodies 
against both forms of the immunogen (free and 
conjugated peptide) and from both species (rabbit 
and chicken) recognised the whole enzyme to a 
comparable extent, with titres below 31 fLg anti-
body / m!. Similarly. both chicken and rabbit anti-free 
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Fig. 2. ELISA showing recognition of whole trypanopain-Tb by 
chicken anti-free peptide and anti-conjugated peptide antibodies. 
Trypanopain-Tb (serial doubling dilutions from I j.tg/ ml) was 
coated for 16 h at .. oC in 40 mM carbonate buffer. pH 6.0. A fixed 
concentration of test antibody (50 j.tg antibody j m!) was then 
applied. Symbols represent non-immune antibodies (e ), anti-free 
peptide antibodies from chicken I ( . ) and II (0) and anti-con-
jugated peptide antibodies from chicken III (D.). Rabbit anti-
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Fig. 3. Cross-reactivity between rabbit anti-trypanopain-Tb anti-
peptide antibodies and sheep cathepsin L in an ELISA. Sheep 
cathepsin L (I J.Lg / m!) was coated for 16 h at 4°C in 40 mM 
carbonate buffer, pH 6.0. Rabbit non-immune antibodies ( . ), 
anti-free peptide antibodies from rabbits I (0) and II (e ) and 
anti -conjugated peptide antibodies from rabbits III ( A ) and IV 
( . ) were titrated from 250 J.Lg / ml to 2 J.Lg/ mJ. Sheep anti-rab-
bit-HRPO secondary antibodies and TMB / H20 2 were used for 
detection. 
cathepsin L in an ELISA (Fig. 3), albeit weakly 
when compared to recognition by the non-immune 
antibody. 
3.3. Effect of anti-peptide antibodies on trypanopain-
Tb activity against Z-Phe-Arg-AMC 
Rabbit antibodies directed against both the free 
and conjugated peptide enhanced trypanopain-Tb hy-
drolysis of Z-Phe-Arg-AMC relative to non-immune 
antibodies (Fig. 4A). Antibody preparations directed 
against the free peptide activated the enzyme slightly 
more (by 64% at 500 }.Lg antibody /ml decreasing to 
19% at 31 }.Lg/ m!) than those directed against the 
conjugated peptide (by 49% at 500 }.Lg antibody /ml 
decreasing to 16% at 31 }.Lg/m!). 
In contrast with rabbit antibodies, the effects of 
chicken antibodies on trypanopain-Tb hydrolysis of 
Z-Phe-Arg-AMC were more complex. Individual 
chickens produced both activity-enhancing and activ-
ity-inhibiting antibodies at different stages during 
'their immune response. This effect was observed 
both in chickens immunised with the free peptide 
and those immunised with the conjugated peptide. 
Up to 176% activation (by 500 }.Lg/ml week 8 
anti-free peptide antibodies) and 85% inhibition (by 
250 }.Lg/ml week 10 anti-conjugate antibodies) was 
observed (Fig. 5). Antibodies produced soon after 
immunisation/boosting appear~d to enhance activity 
while those produced a few weeks later appeared to 
be inhibitory. 
3.4. Incubation with free peptide reduced antibody 
effect on trypanopain-Tb acticity 
Pre-incubation of anti-peptide antibodies with the 
trypanopain-Tb peptide diminished the effect these 
antibodies subsequently had on trypanopain-Tb hy-
drolysis of Z-Phe-Arg-AMC. For example, week 8 
chicken anti-free peptide antibodies alone enhanced 
trypanopain-Tb activity by 276% at 500 mg/ml, but 
in the presence of a 10,000: 1 molar ratio of 
peptide:enzyme, only 46% enhancement of try-
panopain-Tb activity was observed, which represents 
an 83% reduction in the antibody effect (Table 1). 
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Fig. 4. Anti-peptide antibody-mediated enhancement of try-
panopain-Tb activity. A: Effect of conjugation on anti-peptide 
antibody enhancement of activity: Trypanopain-Tb (I.5 ng) was 
incubated with rabbit anti-peptide antibodies (31.25 to 1000 J.Lg 
antibody 1m!) at pH 8.0 (15 min. 3rC) and trypanopain-Tb 
activity against Z-Phe-Arg-AMC then determined. Enhancement 
mediated by antibodies raised against the free peptide (e ) and the 
conjugated peptide (0) are expressed relative to enzyme activity 
in the presence of the same concentration of non-immune antibod-
ies. B: Antibody-mediated enhancement of activity of purified 
trypanopain-Tb and T.b. bruce lysates. Z-Phe-Arg-AMC-hy-
droJysing activity in lysates of T.b. bTilcei (e ) and by purified 
trypanopain-Tb (0) was enhanced by the addition of chicken 
anti-free peptide antibodies (week 8, 1000 to 31.25 J.Lg 
antibody 1m!). 
300 L Troeberg et al. / lmmllnopharmacology 36 (1997) 295-303 
300 













3 9 10 11 12 20 
Weeks post-immunisation 
Fig. 5. Modulation of trypanopain-Th hydrolysis of Z-Phe-Arg-
AMC by chicken anti-free peptide antibodies. Trypanopain-Tb 
(1.5 ng) was incubated with chicken anti-free peptide antibodies 
(500 JLg/ mi) at pH 8.0 (15 min, 37"C). Enzyme activity against 
Z-Phe-Arg-AMC was then determined. Activity is expressed rela-
tive to that observed after incubation with non-immune antibodies 
(500 JLg / mi) with % enhancement of activ ity expressed as posi-
tive values and % inhibition of activity expressed as negative 
values . Chickens were immunised at weeks O. 1.2. 6, 10 and 20 
(indicated by arrows). 
In contrast with chicken anti-free peptide antibod-
ies produced in week 8, antibodies produced during 
week 10 by the same chicken inhibited trypanopain-
Tb activity by 80%. Pre-incubation of these antibod-
ies with the free trypanopain-Tb peptide reduced the 
inhibition observed to the extent that at 10,000: 1 
Table I 
molar ratio of peptide:enzyme, no inhibition was 
seen (Table 1). This represents a 100% decrease in 
the antibody effect by addition of free peptide. 
Addition of the free peptide to rabbit activity-en-
hancing anti-peptide antibodies produced a similar 
reduction in the antibody effect (Table 1). Addition 
of a non-related peptide (polY-L-gfutamic acid) did 
not alter antibody effects on enzyme activity (results 
not shown). 
3.5. Effect of anti-peptide antibodies on trypanopain-
Tb activity in Tb. brucei lysates 
Chicken anti-peptide antibodies modulated try-
panopain-Tb activity in lysates at levels comparable 
to those seen with the purified enzyme (Fig. 4B). For 
example, chicken antibodies that enhanced activity 
of the purified enzyme (anti-free peptide week 8) 
also enhanced Z-Phe-Arg-AMC hydrolysis in crude 
lysates of Tb. brucei. Comparable enhancement of 
the purified enzyme and of enzyme activity in lysates 
was observed at I and 0.5 mg antibody jm!. BelO\v 
this concentration, lower enhancement was seen in 
lysates than with the purified enzyme at equal anti-
body concentrations. 
Chicken anti-conjugated peptide antibodies (week 
10) that inhibited pure trypanopain-Tb also inhibited 
Z-Phe-Arg-AMC hydrolysis in Tb. brllcei lysates. 
For example, up to 82% inhibition was observed 
with the purified enzyme at 500 /-Lg antibody jml , 
while up to 70% inhibition was seen in lysates at the 
Effects of pre-incubation of rabbit (IgG) and chicken (IgY) antibodies with the free trypanopain-Tb peptide on activity against 
Z-Phe-Arg-AMC 
Peptide:enzyme ratio 
No peptide 1:1 100:1 1000:1 10000:1 
Chicken activity-enhancing antibodies 
% Enhancement of activity 276 131 99 73 46 
% Reduction of enhancement by peptide 0 59 64 74 83 
Chicken activity-inhibiting antibodies 
% Inhibition of activity 80 59 54 56 0 
% Reduction of inhibition by peptide 0 26 33 31 100 
Rabbit activity-enhancing antibodies 
% Enhancement of activity 64 57 48 28 15 
% Reduction of enhancement by peptide 0 11 25 56 77 
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same antibody concentration. However, rabbit anti-
free and anti-conjugated peptide antibodies that en-
hanced the activity of pure trypanopain-Tb, mediated 
no such enhancement in Iysates. Even at high con-
centrations of antibody (1 mg/ml) no enhancement 
of activity was detectable. 
4. Discussion 
4.1. 1mmunogenicity of peptide and antibody produc-
tion 
The trypanopain-Tb peptide was found to be 
equally immunogenic in rabbits and chickens. By 8 
weeks post-immunisation comparably high titre anti-
bodies were produced against the conjugated and 
free peptide. The free peptide was thus clearly im-
munogenic in its own right, in agreement with previ-
ous reports regarding similar peptides by Coetzer 
(1993). 
In addition to recognising the free peptide, all the 
anti-peptide antibodies recognised whole try-
panopain-Tb in an ELISA. This shows that :it least a 
proportion of the conformations adopted by the highly 
mobile peptide in solution mimic those that occur in 
the corresponding constrained region of the parent 
proteir. Anti-conjugate and anti-free peptide antibod-
ies cross-reacted equally well with trypanopain-Tb, 
showing that conjugation of the peptide to a carrier 
protein had no discernible effect on the degree of 
cross-reactivity with the parent molecule. Such 
cross-reactivity between anti-peptide antibodies and 
their corresponding protein has been previously re-
ported, for example, cathepsin Land D (Coetzer et 
aI., 1991) and cytochromeP-450IA2 (Edwards et aI., 
1990), but absence of cross-reactivity has also been 
found e.g. for cathepsin B (Coetzer et aI., 1991). 
Anti-trypanopain-Tb peptide antibodies not only 
recognised whole trypanopain-Tb in an ELISA, but 
also cross-reacted weakly with whole cathepsin L in 
an ELISA. This is thought to be a reflection of the 
homology between the peptide from the parasite 
proteinase and the corresponding region of the active 
site of the mammalian host proteinase, cathepsin L 
(Ritonja et aI., 1996). The effect of anti-trypanopain-
Tb antibodies on cathepsin L activity against protein 
substrates is being investigated. 
4.2. Effects of anti-peptide antibodies on try-
panopain-Tb hydrolysis of Z-Phe-Arg-AMC 
Previous studies have shown that anti-enzyme 
antibodies can enhance or inhibit enzyme activity, 
depending on the enzyme under study, the region 
targeted by the antibody and the substrate used to 
assess the antibody effects (Amon and Shapira, 1967; 
Dingle et aI., 1971; Richmond, 1977; Edwards et aI., 
1990; Dennison and Pike, 1991; Coetzer et aI., 1992). 
The anti-peptide antibodies produced in the present 
study affected trypanopain-Tb activity, showing that 
they do recognise and bind to native trypanopain-Tb 
in addition to recognising the partially denatured 
form present on ELISA plates. However, the effects 
on trypanopain-Tb hydrolysis of Z-Phe-Arg-AMC 
were varied. 
All of the rabbit anti-free and anti-conjugated 
peptide antibodies produced enhanced trypanopain-
Tb hydrolysis of Z-Phe-Arg-AMC. Such immuno-
enhancement of enzyme activity is thought to occur 
by antibody induction of a more active enzyme 
conformation (Richmond, 1977). Rabbit antibodies 
directed against the free peptide enhanced enzyme 
activity slightly more than those directed against the 
conjugated peptide, suggesting that the titre of anti-
bodies recognising the native form of trypanopain-Tb 
is slightly higher in anti-free peptide antibody prepa-
rations than in those directed against the conjugated 
peptide. A similar observation was made for anti-
cathepsin H peptide antibodies where anti-free pep-
tide antibodies decreased enzyme activity to a greater 
extent than their conjugated counterpartS (Coetzer. 
1993). 
The effects of chicken antibodies on trypanopain-
Tb were more varied, with individual chickens pro-
ducing activity-enhancing and activity-inhibiting an-
tibodies at different stages in their immune response. 
Antibodies produced shortly after each immunisation 
appear to enhance trypanopain-Tb activity, while 
those produced a few weeks later appear inhibitory. 
Since Z-Phe-Arg-AMC is a small substrate, it is 
considered likely that antibody binding induces a 
less active enzyme conformation, rather than steri-
cally hindering substrate binding. 
The production of both activity-enhancing and 
-inhibiting antibodies during the immunisation of a 
single test animal is thought to be a function of the 
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polyclonal nature of the evoked antibody response. 
Since a peptide can adopt numerous conformations 
in solution, some may elicit activity-enhancing anti-
bodies and some activity-inhibiting antibodies. The 
varied effects of antibodies observed in this study 
could thus reflect different B-cell clones being domi-
nant at different stages in the immune response. 
The effects of these antibodies on trypanopain-Tb 
activity were shown to be specific by the fact that 
pre-incubation of the antibodies with their target 
peptide reduced antibody effects on trypanopain-Th, 
while pre-incubation with an unrelated peptide (poly-
L-glutamic acid) had no such effect. Complete aboli-
tion of the antibody effects was not seen in these 
assays, possibly as a consequence of the high dilu-
tion of antibody and enzyme required by this sensi-
tive fluorometric assay. 
4.3. Effects in lysates 
Anti-peptide antibodies were added to lysates of 
T.b. brucei to assess the potential effects of other 
trypanosomal factors on interactions of these anti-
bodies with trypanopain-Tb. Chicken anti-peptide an-
tibodies had the same effect in lysates as with the 
purified enzyme i.e. some antibodies mediated inhi-
bition and others enhancement of trypanopain-Tb 
hydrolysis of Z-Phe-Arg-AMC. The degree of en-
hancement/inhibition observed with the purified en-
zyme and enzyme activity in lysates was compara-
ble, suggesting that these antibodies have the poten-
tial to modulate trypanopain-Tb activity in vivo. In 
contrast, rabbit antibodies which substantially acti-
vated the purified enzyme, had no effect in lysates 
even at 1 mg antibody jm!. This suggests that the 
interaction between this antibody and trypanopain-Tb 
is reduced by some factor in trypanosome lysates 
which does not affect interactions with chicken anti-
bodies. 
Depending on the epitope against which antibod-
ies are raised, the host species and the substrate used 
to assess the effects of the antibodies on enzyme 
activity, some anti-trypanopain antibodies are thus 
able to modulate trypanopain activity in vitro. The 
physiological importance of such modulation is un-
clear, because it is highly unlikely that trypanopain-
Tb remains active in the mammalian bloodstream 
since it is effectively inhibited by cystatins (Troeberg 
et aI., 1996). Additionally, no trypanopain-Th-like 
activity is detectable in the bloodstream of infected 
rats (Troeberg et aI., 1996). While Lonsdale-Eccles 
et al. (1995) reported that a kininogen-like moiety 
increases trypanopain-Th activity ' in gelatin SDS-
PAGE analyses, the in vivo occurrence of such 
interactions is unclear. Assuming that trypanopain-Tb 
is effectively controlled in the host bloodstream, the 
correlation between production of anti-trypanopain 
antibodies and tolerance to trypanosomiasis in cer-
tain cattle breeds (Authie et aI., 1993) is puzzling. 
While this correlation may just be a function of a 
more surveillant immune system in tolerant breeds, it 
is tempting to speculate that the anti-trypanopain 
antibodies are more directly protective. Experiments 
are currently under way to assess the in vivo effects 
of anti-trypanopain peptide antibodies more directly, 
by determining their effects on trypanopain-Tb hy-
drolysis of proteins and their effects on try-
panosomes in cell culture. 
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Proteases from Trypanosoma brucei brucei 
Purification, characterisation and interactions with host regulatory molecules 
Linda TROEBERG, Robert N. PIKE, Rory E. MORTY, Ronald K. BERRY. Theresa H. T. COETZER and John D. LONSDALE-ECCLES 
Department of Biochemistry. University of Natal, Scottsville, South Africa 
(Recei\'ed 16 February 1996) - EJB 960225/4 
African trypanosomes contain proteases that may be released into the bloodstream of their infected 
hosts. This paper describes a novel, combined isolation of a cysteine proteinase (called trypanopain-Tb) 
and a serine oligopeptidase (which we call oligopeptidase-Tb) from Trypanosoma brllcei brucei, as well 
as a comparison of the activities of these two enzymes against several host regulatory molecules. 
The enzymes differed in various respects. Firstly, purified trypanopain-Tb was shown to readily cleave 
proteins such as gelatin maximally at acidic pH. In contrast. oligopeptidase-Tb, which is optimally active 
at alkaline pH. did not hydrolyse proteins larger than 4 kDa. However, it readily hydrolysed various 
polypeptides. including neurotensin and atrial natriuretic factor. 
The interaction of the two enzymes with mammalian protease inhibitors also differed. Cystatins and 
o2-macroglobulin effectively inhibited trypanopain-Tb, with the Ki values for cystatin C and low-molecu-
lar-mass kininogen (= 10- 11 M) predicting that trypanopain-Tb is likely to be effectively controlled by 
these inhibitors if released into the host bloodstream. In contrast, oligopeptidase-Tb was not inhibited by 
serpins or G2-macroglobulin, suggesting that it may remain active if released into the host bloodstream. 
In support of these ill dlro results. the blood of trypanosome-infected rats displayed no trypanopain-Tb-
like activity. but exhibited high oligopeptidase-Tb-like acti\·ity. Thus , while trypanopain-Tb seems likely 
to be confined to an intracellular role within the parasite. oligopeptidase-Tb has the potential to remain 
active in the host bloodstream and so contribute directly to pathogenesis. 
Keywords: Tr .• panosom{{ brucei; cysteine proteinase : oligopeptidase; cystatin. 
African trypanosomes are protozoan parasites which cause 
the diseases nagana and sleeping sickness in cattle and humans, 
respectively. These diseases are characterised by intermittent fe-
ver. progressive anaemia, general loss of condition and, ulti-
mately. the death of the infected host. Nagana is still of great 
economic importance in Africa. where it prevents livestock 
farming in many areas, and certain parts of Africa are experienc-
ing a large resurgence in human trypanosomiasis (Walgate, 
199·h While the parasite's major lysosomal cysteine proteinase 
(trypanopain) is considered . a potentially important factor in the 
development of the disease (Authie et aI., 1993 ; Russo et al.. 
199-1). the role of a cytoplasmic serine oligopeptidase (which we 
call oligopeptidase-Tb. OP-Tb) has not yet been explored. 
Trypanopain is lysosomally located (Mbawa et aI., 1991) 
and. as such, is likely to be centrally involved in intracellular 
digestive and catabolic proteolysis. Additionally, the enzyme is 
proposed to help the parasite escape opsonisation by degrading 
internalised antibody-variant surface glycoprotein complexes 
(Russo et aI., 1994). Enzyme released into the host bloodstream 
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has also been proposed to contribute to pathogenesis more di-
rectly by degrading various host proteins. Also. since trypanotol-
erant cattle infected with Trypanosoma congoiellse produce anti-
bodies to trypanopain-Tc, while susceptible cattle do not. im-
mune targeting of the enzyme may help protect infected hosts 
(Authie et al.. 1993). While the cDNA of trypanopain-Tb from 
Trypallosoll/a iJrucei brucei has been sequenced (Mottram et al.. 
1989). no purification of the enzyme to electrophoretic homo-
geneity. or characterisation of its basic enzymatic properties. has 
been reported. The interactions of trypanopain-Tb with mamma-
lian cysteine proteinase inhibitors and other host regulatorv mol-
ecules also have not been reported before. - -
While OP-Tb has previously been partially purified from T 
iJ. brtlcei (Huet et aI., 1992 ; Kornblatt et al.. 1991) and Tly/wl/o-
soma crll~i (Ashall, 1990). the role of this enzyme in pathogene-
sis has not been investigated. Previous data indicates that the 
enzyme is a serine protease. but its sensitivity to reagents which 
modify cysteine residues suggests that reduction of a cysteine 
residue is required for full enzyme activity (Kornblatt et al.. 
1991). The enzyme also appears to be restricted in its action. 
cleaving only small peptide substrates. Both these facets of the 
enzyme's activity require further investigation. 
Here we report the joint purification of trypanopain-Tb and 
OP-Tb from T. b. brtlcei, the effects of various potential ill \'im 
inhibitors on the enzymes and the action of the enzymes on po-
tentially relevant host peptide and protein substrates. 
MATERIALS AND METHODS 
Materials. HiLoadnl Q-Sepharose and HiTrapTM Blue Se-
pharose were from Pharmacia. DEAE-cellulose was from What-
Troeberg et al. (ElII: 1. Biochelll. 238) 729 
man. 4-(2-Aminoethyl)-benzenesulfonyl fluoride (H~NEtPh­
SO~F), BSA and a~-macroglobulin (al-M) were from Boehringer 
Mannheim. Chymostatin. leupeptin and antipain were from 
Cambridge Research Chemicals (UK) and di-isopropyl 
fluorophosphate ( iPr~P-F) was from Fluka. [1-'"ClAcetic anhy-
dride was from Amersham. All other inhibitors, benzyloxycar-
bonyl phenylanlanyl-arginyl-aminomethyl coumarin (Z-Phe-
Arg-NHMec), Z-Arg-Arg-NHMec, pepstatin-A -Sepharose , 
POlY-(L-lysine)-Sepharose, fibrinogen , rabbit IgG, PercoW" and 
Sephacryl S-100 HR were from Sigma. The C18 HPLC column 
was from Vydac . Sheep stefin B was purified as described by 
Pike et al. (1992). Human recombinant stefin A was from Cal-
Biochem and human low-molecular-mass kininogen (L-kinino-
gen) was purified from human plasma as described by Gounaris 
et al. (1984). Recombinant human L-kininogen domain 3 was a 
gift from Dr Ennes Auerswald (Ludwig-Maximilians-Universita t 
Mlinchen) human cystatin C was a gift from Dr Magnus Abra-
hamson (Universi ty of Lund, Malmo General Hospital) and ser-
pins were a gift from Dr Jan Potempa (Jagiellonian University. 
Cracow). 
Growth and purification of trypanosomes. T. b. brucei 
(c lone ILTat 1.1) was grown in rats and purified from the in-
fected blood by a combination of PercoW~1 gradient centrifuga-
tion (Grab and Bwayo. 1982) and anion-exchange chromatogra-
phy on DEAE-cellu lose (Lanham and Godfrey, 1970). Purified 
trypanosomes were stored at -70°C until used. 
EIl::Yllle ({lid proteill ({ssm'S. Trypanopain-Tb activity against 
5 pM Z-Phe-Arg-NHMec at 3rC was initially measured as de-
sc ribed by Barrett and Kirschke (198 1) using an assay buffer of 
170 mM sodium acetate. 30 mM acetic acid , 2 mM Na~EDTA. 
3 mM dithiothreitol. pH 5.5. Following enzyme characterisation. 
the assay buffer was amended to 200 mM sodium phosphate 
pH 7.0 containing 30 mM cysteine and 2 mM Na~EDTA. OP-
Tb was similarly assayed against 5 ~lM Z-Arg-Arg-NHMec in 
100 mM Tris/HCl , 10 mM dithiothreitol. pH 8.0 (Kornblatt et 
al.. 1992). 
Protein assays were conducted according to the methods of 
Bradford as modified by Read and Northcote (1981) and Smith 
et al. (1985) . 
Isolation of trypanopain-Tb and OP-Tb. Trypanosomes 
(=5.5x 10 0 parasites) were thawed and lysed by addition of 
O.! 'Ie (by vol.) Triton X-100 (final concentration). Three-phase 
partitioning (Pike and Denni so n. 1989) was performed on the 
lysa te. with all enzyme activity precipitating between 10-25 lk 
(mass/vol. of the total volume) ammonium sulfate (results not 
shown). The pellet \\'as redissolved in buffer A (20 mM sodium 
acetate, 1 mM Na,EDTA. pH 5.5) and loaded onto HiLoadT " Q-
Sepharose (26x 110 mm. tlow rate I mI· min - I) equilibrated in 
buffer A with 100 mM NaC I. After elution of the unbound mate-
rial (which contained OP-Tb and was retained for OP-Tb purifi-
cation) , a linear gradient of 0.1 - I M NaCI in buffer A was ap-
plied over five column volumes. Fractions active against Z-Phe-
Arg-NHMec , but inactive against Z-Arg-Arg-NHMec and there-
fore identified as containing trypanopain-Tb, were pooled and 
dialysed against buffer A. Since preliminary studies had iden-
tified pepstatin A as a weak inhibitor of trypanopain-Tb. this 
inhibitor was considered to be a potential affinity chromatogra-
ph y ligand. Active samples were therefore loaded onto pep-
statin-A-Sepharose (13Xl0 mm, flow rate 0.26 ml . min - I) 
equilibrated in buffer A containing 500 mM NaCI. Following 
elution of the unbound material. trypanopain-Tb was eluted with 
5 % (mass/vol.) Brij-35 in buffer A with 500 mM NaCI. Frac-
tions active against Z-Phe-Arg-NHMec were applied to Hi-
Trapnl Blue Sepharose (9X23 mm, flow rate 1 ml . min-I) 
equilibrated in 50 mM Tris/HCI pH .8.0 to remove suspected al-
bumin contamination. Active fractions were concentrated and 
stored at -20°C mixed with glycerol (I : 1). The purity of the 
enzyme was analysed by tricine/SDS/PAGE (Shagger and von 
Jagow. 1987). 
The unbound material from HiLoadnl Q-Sepharose was 
active against Z-Arg-Arg-NHMec and Z-Phe-Arg-NHMec. but 
insensitive to L-trans-epoxysuccinyl-Ieucylamido (4-guanidino) 
butane (E-64), indicating that it contained OP-Tb (Koll1blatt et 
al.. 1992). This fraction was dialysed against buffer B (50 m~[ 
Tris/HCI, I mM dithiothreito!. pH 8.0) and applied to p-amino-
benzamidine-Sepharose (I5x50 mm. flow rate 0.3 ml . min-I). 
After the elution of unbound materia!. bound OP-Tb was eluted 
with a step gradient of 250 mM NaCI in buffer B. Following 
dialysis against buffer B. the sample was applied to HiLoadT ::' 
Q-Sepharose equilibrated in buffer B containing 100 mM NaC!. 
and a five-column-volume gradient of 0.1-1 M NaCI applied . 
The active fractions were diluted four-fold in buffer B and ap-
plied to poly-(L-Iysine)-Sepharose (55 X 15 mm, flow rate 1 ml 
. min-I) equilibrated in buffer B containing 100 mM Nael. A 
10-column-volume gradient of 0.1 - 1.5 M NaCI in buffer B was 
applied to elute the bound material. Active fractions were con-
centrated and appJied in buffer B to a Sephacryl S-100 HR gel 
filtration column (l5X850 mm. tlow rate 10 mi· h - I). 
Following analysis of enzyme purity by tricine/SDS/PAGE. the 
purified enzyme was concentrated and stored at 
-20 °C mixed with g lycerol (1 : 1). 
Characterisation of enzymes. The activity of trypanopain-
Tb and OP-Tb in the presence of various inhibitors was im'es ti-
gated by incubating the enzymes with each inhibitor for 15 min 
at 37 °C before assaying residual acti\'ity against Z-Phe-Arg-
NHMec or Z-Arg-Arg-NH\lec . respec ti ve ly. as described abO\e. 
OP-Tb experiments were conducted in the presence of either 
10 mM dithiothreitol (indicated as + dithiothreitol in Table 2) or 
in res idual dithiothreirol remaining from puri f ication (=-10 p\ 1 
dithiothreitol. indicated as - dithiothreitol in Table 2) . Since 
chloromethanes and alkylating agents are inactivated by reduc-
ing agents. care was taken to minimi se the re lative amount of 
reducing agents used with these inhibitors. Concentrated en-
zymes were thus acti va ted (10 min at 37°C in 30 mM cysteine 
for trypanopain-Tb: 10 ml\ 1 dithiothreitol for OP-Tb). before be-
ing diluted to the required \\'o rking concentration in assay buffer 
containing inhibitor (final reducing agent concentrations o f 
3 mM cysteine for trypanopain-Tb. 1 mM dithiothreito l for 
OP-Tb). 
The effects of \'arious reducing agents on trypanopain-Tb 
and OP-Tb activity \\ere investigated by adding dithiothreitol. 
cysteine . HCI. reduced glutathione or 2-mercaptoethanol (1-
100 mM for trypanopain-Tb and 1-25 mM for OP-Tb) to the 
relevant assay buffer. The pH profile of each enzyme against 
synthet ic substrates was inyestigated by substi tuting assay buffer 
with constant-ionic-strength acetate/MeslTris buffers ( 100111\ 1 
acetate, 200!TIM Tris. 100 mM Mes. 4!TIM Na~EDT.-\) of 
pH 4.0-9.0 (Ellis and Morri son. 1982). Trypanopain-Tb hydrol-
ysis of ['"Clgelatin at \'arious pH values was assessed using ace-
tate/MeslTris buffers as described above. with the ['"C]gelatin 
prepared using [I-'"C]acetic anhydride as described by Cawston 
and Barrett ( 1979). The pH stability of the enzymes was deter-
mined by incubating the enzymes in acetate/MeslTris buffers 
(25 mM acetate, 50 mM Tris. 25 mM Mes, 1 mM Na,EDTA) for 
I hat 3rC before addition of a pH-7.0 assay buffer and Z-Phe-
Arg-NHMec for trypanopain-Tb. or pH-8.0 assay buffer and Z-
Arg-Arg-NHMec for OP-Tb. The initial incubation was done 
either i; the presence or absence of reducing agents (30 mM 
cysteine for trypanopain-Tb and 10 mM dithiothreitol for OP-
Tb). 
Following determination of the concentration of active trypa-
nopain-Tb by titration with E-64 (Barrett and Kirschke. 1981). 
730 Troeberg et al. (Eur: 1. Biochem. 238) 
trypanopain-Tb (0.05 pmol) was incubated . with readily hy-
drolysed synthetic substrates (25-100 JlM) for 10 min at 37°C 
in continuous assays, or with poorly hydrolysed synthetic sub-
strates for 4 h at 37°C in stopped time assays. Knu V max and koa• 
were determined from the direct linear plot (Eisen thai and Cor-
nish-Bowden, 1974) using the software package Hyper 1.01 (© 
1992-1993, J. S. Easterby, UK). 
Digestion of protein and peptide substrates by trypano-
pain-Tb and OP-Tb. Fibrinogen, BSA and rabbit IgG were di-
gested with trypanopain-Tb at 3rC over 1 h at various molar 
ratios of enzyme/substrate in 100 mM TrislHCl, 30 mM cyste-
ine, pH 7.4. After the reactions were stopped by the addition of 
1 mM E-64, samples were boiled in reducing treatment buffer 
and analysed by electrophoresis on 10% tricine gels (Shagger 
and von Jagow, 1987). Trypanopain-Tb digestion of serpins was 
analysed at 37°C at 1:100 and 1:10 molar ratios of enzyme/ 
inhibitor in 25 mM Tris, 10 mM cysteine, pH 7.4. Reactions 
were stopped by the addition of 20 JlM E-64. To determine the 
extent of serpin degradation, remaining inhibition of trypsin or 
chymotrypsin was determined (Potempa et aI., 1986) and the 
degradation products analysed by tricine/SDS/PAGE. 
OP-Tb was incubated with oligopeptide substrates at various 
molar ratios of enzyme/substrate in 0.1 M TrislHCI, 10 mM di-
thiothreitol, pH 8.0 for 1-16 h at 3rC, after which the reaction 
was stopped by acidification with an equal volume of 5 % (by 
vol.) trifluoroacetic acid. The samples were placed on ice until 
analysed by HPLC on a C 18 column (flow rate 1 ml . 
min-I) using a gradient of 10-90 % (by vol.) acetonitrile in 
water containing 0.1 % (by vol.) tritluoroacetic acid. 
Associarion with cystatins alld Gl-M. The kinetics of trypa-
nopain-Tb inhibition by various cystatins were determined as 
described by Salvesen and Nagase (1992) with data treatment 
as described by Henderson (1972). Trypanopain-Tb and OP-Tb 
association with Gl-M was assessed by comparing the elution 
volumes from Sephacryl S-IOO (for trypanopain-Tb) and Seph-
acryl S-200 (for OP-Tb) (both 15 X300 mm, flow rate 10 cm . 
h - I, equilibrated with 50 mM Tris/HCI pH 8.0 containing 1 mM 
dithiothreitol for OP-Tb only) of each enzyme alone with that 
for each enzyme previously incubated with bovine Gl-M ("" 1 : 1 
molar ratio, Mason, 1989). 
Measurement of enzyme activity in the blood of infected 
rats. The blood of trypanosome-infected rats was harvested by 
cardiac puncture at peak parasitaemia, and centrifuged (3000Xg, 
25 min. 4°C). The supernatant was microscopically confirmed 
to be free of both parasites and blood cells, and then assayed 
against Z-Phe-Arg-NHMec and Z-Arg-Arg-NHMec in the pres-
ence of various inhibitors. Since OP-Tb, rat plasma kallikrein 
and trypanopain-Tb all hydrolyse Z-Phe-Arg-NHMec, soybean 
trypsin inhibitor (SBT!, 20 11M), H1NEtPhS01F (1.85 mM) and 
E-64 (1.7 mM) were used to discriminate between the activities 
of the three enzymes. SBT! inhibits blood plasma kallikrein 
(Coleman and Bagdasarian, 1976) but not OP-Tb, while 
H1NEtPhS02F inhibits both kallikrein and OP-Tb, so these in-
hibitors were used to discriminate between the two activities. 
Hydrolysis of Z-Arg-Arg-NHMec in the presence of these inhib-
itors was add itionally investigated to confirm the presence of 
OP-Tb. 
RESULTS 
Proteinase isolation. As far as we are aware, this is the first 
time trypanopain-Tb and OP-Tb have been completely and de-
monstrably purified from T b. brucei (Fig. 1). Three-phase parti-
tioning proved to be a very efficient crude purification method, 
removing large quantities of extraneous trypanosomal proteins 
kDa A 8 C D kDa 
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Fig. I. Silver-stained tricine/SDSIPAGE of trypanopain-Tb and OP-
Tb. OP-Tb (lane B, 250 ng) and trypanopain-Tb (lane C, 250 ng) were 
treated with non-reducing buffer and electrophoresed on a 10% tricinel 
SDSIPAGE gel prior to silver staining (Blum et aI., 1987). Molecular 
mass markers, shown in lanes A and 0 , are phosphorylase b (94 kDa). 
BSA (68 kDa), ovalbumin (43 kDa), carbonic anhydrase (30 kDa), SBTI 
(20 kDa) and a-lactalbumin (14.4 kDa). 
(Table 1). Additionally, the salt remaining from this procedure 
reduced the amount of protein binding to HiLoadT~ Q-Sepharose 
at pH 5.5, and thus increased the efficiency of this step for trypa-
nopain-Tb purification. This initial chromatography step on Hi-
Load™ Q-Sepharose also separated OP-Tb from trypanopain-Tb 
(Fig. 2), taking advantage of the unusual affinity of trypanopain-
Tb for this anion exchanger at pH 5.5 and making it possible 
for the two enzymes to be purified from the same trypanosome 
preparation. The current method is thus more economical and 
convenient than previously reported approaches. 
Various affinity chromatography resins were tested for the 
purification of trypanopain-Tb. The high affinity with which in-
hibitors, such as stefin B and chicken egg white cystatin, bound 
trypanopain-Tb rendered these ligands unsuitable for affinity 
chromatography purposes. While pepstatin A typically inhibits 
aspartic proteinases, it surprisingly also inhibits trypanopain-Tb 
weakly (Pamer et ai., 1989) and was thus considered a poten-
tially suitable affinity chromatography ligand. Pepstatin-A-
Sepharose chromatography proved to be a very successfu l purifi-
cation step, with electrophoresis of the column eluate showing 
that trypanopain-Tb was contaminated only by a 68-kDa protein. 
suspected to be rat serum albumin. This contaminant was suc-
cessfully removed by HiTrap nl Blue Sepharose. The speed of 
the trypanopain-Tb purification procedure was found to be criti-
cal for maintenance of enzyme activity, with activity irreversibly 
lost if more than one day was taken for purification. 
Two affinity chromatography steps were used in the purifica-
tion of OP-TlJ,-rramely p-aminobenzamidine-Sepharose and 
POlY-(L-lysine) - Sepharose chromatography. Since benzamidine 
is a fairly weak inhibitor of OP-Tb (62 % inhibition , Table 2). 
OP-Tb could be eluted from this column using fairly low salt 
concentrations (250 mM NaCI). POlY-(L-lysine)-Sepharose, on 
the other hand, bound OP-Tb more strongly. with approximately 
450 mM NaCI required to elute the enzyme. While p-amino-
benzamidine-Sepharose was particularly effective in removing 
large quantities of contaminating protein (increasing the specific 
activity 30-fold, Table I), poIY-(L-lysine)-Sepharose was essen-
tial for removing persistent contamination by a 68-kDa protein , 
shown by amino acid analysis to be rat albumin, as well as other 
minor contaminants. 
Trypanopain-Tb characterisation. Trypanopain-Tb actlVlty 
against Z-Phe-Arg-NHMec was optimal across a plateau be-
tween pH 5.5 and 8.0 (Fig. 3). The enzyme was optimally stable 
between pH 4.0 and 7.0 in the presence of cysteine, and between 
pH 4.0 and 8.0 in the absence of cysteine. At all pH values 
tested, more trypanopain-Tb activity was maintained after a I-h 
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Table 1. Purification table for the isolation of trypanopain-Tb and OP-Tb from T. b. brucei 
Enzyme Fraction Total 
protein 
mg 
Trypanopain-Tb Lysate 213 
Three-phase partitioning 9 
HiLoadnl Q-Sepharose 0.2 
Pepstatin-A - Sepharose 0.04 
HiTrapnl Blue Sepharose 0.01 
OP-Tb Lysate 213 
Three-phase partitioning 9 
HiLoadnl Q-Sepharose (pH 5.5) 8.6 
p-Aminobenzamidine-Sepharose 0.211 
HiLoadnl Q-Sepharose (pH 8) 0.134 
Poly(L-lysine) - Sepharose 0.104 
Sephacryl S-1 00 0.068 
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Fig. 2. Elution profile of HiLoadT>1 Q-Sepharose showing separation 
of trypanopain-Tb and OP-Tb. HiLoad '" Q-Sepharose (26X 110 111m. 
flow rate I ml . min· ') was equilibrated in loading buffer ( 100 mM NaCI 
in 20 mM sodium acetate. I 111M Na,EDTA. 100 mM NaC!. 0.02 '7c 
(mass/vol.) NaN ... pH 5.5). Thl! 10-25 '7r (NH.),SO. fraction of the 
three-phase partitioning was loaded onto the column and the bound ma-
terial eluted with a five-column-\'olume gradient of 0.1-1 M NaCI. 
While OP-Tb fractions (unbound) were active against both Z-Phe-Arg-
NHMec and Z-Arg-Arg-NHMec. trypanopai n-Tb-containing fractions 
(bound) were active against on ly Z-Phe-Arg-NHMec. 
incubation in the absence of cysteine than in its presence, indi-
cating that the active enzyme undergoes some autocatalysis. Try-
panopain-Tb was active against ['"C]gelatin over a far narrower 
and more acidic pH range than against Z-Phe-Arg-NHMec, with 
hydrolysis being optimal at pH 5.7 (Fig. 3). While activity de-
creased sharply on either side of this pH, trypanopain-Tb was 
still 44% active at pH 7.4, suggesting that it would be active 
under physiological pH conditions. 
Trypanopain-Tb was only active in the presence of reducing 
agents, thus displaying typical cysteine proteinase latency. Cys-
teine . HCI was the most effective of the reducing agents tested, 
with an optimal final concentration of 30 mM. Dithiothreitol was 
maximally effective at 20 mM, with 2-mercaptoethanol reaching 
optimum efficiency at much .higher concentrations (250 mM). 
Reduced glutathione was a comparatively poor activator. All 
subsequent trypanopain-Tb assays against Z-Phe-Arg-NHMec 
were thus performed at pH 7.0 (in the middle of the optimal 
Total Specific Purification Yield 
activity activity 
pmols . s·' pmol . s·' . mg - I -fold % 
4562 22 1 100 
1144 127 6 25 
397 1985 90 9 
252 6300 286 5 .5 
245 24500 1114 5.3 
3245 15 1 100 
2044 227 15 63 
1947 226 15 60 
1429 6773 452 44 
1428 10 657 710 44 
941 9048 603 29 
909 13368 891 28 
Table 2. Effects of various inhibitors on trypanopain-Tb activity 
against Z-Phe-Arg-NHMec and OP-Tb activity against Z-Arg-Ari-
NHMec at 37°C. Enzymes were incubated with each inhibitor for 
15 min at 37"C and then assayed as usual. OP-Tb experiments were 
conducted in the presence of either 10 mM dithiothreitol (indicated as 
+ dithiothreitol) or in residual dithiothreitol remaining from purificat ion 
("" 40 ~IM dithiothreitol. indicated as - dithiothreitol). Where different 
concentrations of inhibitor were used for op· Tb and trypanopain-Tb. the 
concentrations for trypanopain-Tb are given first. lAA . iodoacetate: 









































Trypano- OP-Tb activity 
pain-Tb 
- dithio- + dithio-
threitol threitol 
% of control 
0 70 85 
0 8 59 
0 21 16 
0 90 67 
100 18~ 100 
100 0 , 
100 14 9 
100 100 95 
0 5 5 
0 78 89 
0 3 2 
0 8 8 
3S 37 
nd 33 38 
Ill] 56 36 
100 100 100 
100 154 103 
78 100 100 
pH range) using 200 mM sodium phosphate containing 30 mM 
cysteine and 2 mM Na 2EDTA (fi nal concentrations). 
Typical cysteine proteinase inhibitors (including E-64 and 
iodoacetate) inhibited trypanopain-Tb completely, while typical 
serine and metalloproteinases inhibitors such as iPr2P-F and 
EDTA, respectively, had no effect on enzyme activity (Table 2). 
Leupeptin, anti pain and chymostatin were all effective inhibitors 
of the enzyme (99-100% inhibition). Interestingly, pepstatin A 
(22 % inhibition) also inhibited trypanopain-Tb. 
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Fig.3. pH profile of trypanopain-Tb and OP-Tb activity at 37°C. 
Enzym<! activ ity at various pH valu<!s was assessed using constant-ionic-
strength acetate/Mesrrri s buff<!rs (E llis and Morrison. 1982) of pH -to-
9.0. (A) Trypanopain-Tb (1.5 ng) activity against 5 ~IM Z-Ph<!-Arg-
NHMec (-+ -) and ['~C]-gelatin (-0-) ; (B) OP-Tb (2 ng) acti\'ity 
against 5 ~IM Z-Arg-Arg-NHM<!c in the pr<!sence ce) or absence C'f ) of 
10 mM dithiothreitol. 
Table 3. Kinet ic constants for trypanopain-Tb hydrolysis of various 
NHMec substrates. Values are calcl1lated from 10-min or 4-h stopped-
time assays. Constants were calculated at 3rC us ing the direct linear 
plot (Eisenthal and Cornish-Bowden. 1974). No hydrolysis occurred in 
4 h with Suc-Ala-Ala-Phe-NHMec. Glu-Gly-Gly-Phe-NHMec. Z-Gly-
Pro-NHMec. Gly-NHMec. Leu-NHMec. Ac-Ala-Ala-Tyr-NHMec. Ac-
Ala-Ala-Pro-Ala-NHMec. Z-Pro-Arg-NHMec. Glu-Gly-Arg-NHMec. Z-
Gly-Gly-Arg-NHMec. Boc-Val-Gly-Arg-NHMec. Boc-Leu-Gly-Arg-
NHM<!c. Boc-lIe-Glu-Gly-Arg-NHMec. Z-Arg-NHMec, Z-Ala-Arg-
Arg-NHylec or Arg-NHM<!c. 
Substrat<! Tim<! K", k"" k,jK", 
~IM s -I s- ' pM - ' 
Z-Arg-Arg-NHMec .+11 12 0.126 0.01 
Z-Phe-Arg-NHMec 10 min 1.2 13.4 11.3 
Pro-Ph<!-Arg-NHMec 10 min 4.2 4.2 I 
Val-Leu-Lys-NHMec 10 min 25 8.2 0.3 
Ala-Leu-Lys-NHMec 10 min 27 6.5 0.24 
Suc-Ala-Phe-Lys-NHMec 10 min 42 0.006 0.002 
Ala-Ph<!-Lys-NHMec 10 min 28 5.2 0.19 
Sue-Leu-Tyr-NHMec 4h 54 0.05 0.001 
MeOSuc-Asp-Tyr-Met-NHMec .+h 68 0.09 0.001 
MeOSuc-Gly-Trp-Met-NHMec 4h 4 0.04 0.011 
Trypanopain-Tb degradation of synthetic substrates and 
proteins. Of the synthetic substrates tested, Z-Phe-Arg-NHMec 
was most readily cleaved by trypanopain-Tb, with a K", of 
1.2 ).1M and ke,,, of 13.4 s-' (Table 3). Pro-Phe-Arg-NHMec was 
also readily hydrolysed. All other substrates tested, including Z-
Arg-Arg-NHMec used to monitor OP-Tb isolation, were com-
paratively poorly hydrolysed. 
Trypanopain-Tb hydrolysed fibrinogen, BSA and rabbit IgG 
at physiological pH. At a 1 : 100 molar ratio of enzyme/substrate, 
both the a and f3 chains of fibrinogen were substantially de-
graded within 15 min at pH 7.4, while the }' chain remained re-
sistant over the test period (\ h). However, at a 1: 1000 molar 
ratio of enzyme/substrate, no degradation occurred. Trypano-
pain-Tb also readily degraded BSA (1: 500 and 1: 1000 molar 
ratio) and IgG (1: 100 and I: I 000 molar ratio) within 15 min, 
hydrolysing the latter predominantly in t~e heavy-chain region. 
Characterisation of OP-Th_ OP-Tb activity was substantially 
increased by the presence of reducing agents; dithiothreitol was 
the most effective, increasing activity 10-fold at 25 mM and 6-
fold at I mM. Cysteine was almost as effective as dithiothreitol 
at lower concentrations, but activity was lowered at concentra-
tions above 5 mM. Glutathione was about half as effective as 
dithiothreitol. 
Irrespective of the presence or absence of reducing agents. 
OP-Tb was found to be most active between pH 8 and 9.5 at 
25°C (Fig. 3). In contrast, the pH stability of the purified en-
zyme was slightly affected by the presence of a reducing agent, 
with the enzyme being most stable in the absence of dithiothrei-
tol in the pH range 6-7.5 and in the presence of dithiothreitol 
at pH 8-9. These differences, however. were all ranged between 
80-100% activity and it was only below pH 6 and above pH 9 
that stability decreased significantly. 
The serine proteinase inhibitors iPrf-F and H~NEtPhSO:F 
completely inhibited OP-Tb, supporting the hypothesis that OP-
Tb is a serine protease (Table 2). Leupeptin and anti pain were 
very effective inhibitors of OP-Tb, as was tosyllysylchlorometh-
ane (TosLysCH2CI). Howe\·er. a basic residue was required for 
the chloromethane to be active, as shown by the lack of inhibi-
tion tosylphenylalanylchloromethane (TosPheCH~CI). The en-
zyme was not inhibited by phenylmethylsulfonyl fluoride 
(PhMeS02F) or Z-Phe-Phe-CHN~. Benzamidine waS found to be 
a weak inhibitor of the enzyme, possibly explaining the success 
of p-aminobenzamidine - Sepharose affinity chromatography as 
a step in the isolation of OP-Tb. EDTA increased OP-Tb activ-
ity, indicating that the enzyme is not stab ili sed by divalent cat-
ions. While E-64 had no effect on activity. iodoacetate. 
iodoacetamide and N-ethylmaleimide. which modify cysteine 
residues, all reduced OP-Tb activity to various degrees (Ta-
ble 2). 
Cleavage of protein and peptide subsh'ates by OP-Th. OP-
Tb did not hydrolyse tibrinogen, BSA. ovalbumin, carbonic an-
hydrase, SBTI, lysozyme, cystatin C or cytochrome c at pH 8.0. 
Therefore, as speculated by Kornblatt et al. ( 1992), the enzyme 
appears to be an oligopeptidase rather than a proteinase. We thus 
examined a range of substrates of increasing molecular mass in 
order to characterise the minimum size of substrates excluded 
from the active site of the enzyme. Since OP-Tb cleaves most 
efficiently after arginine residues (Kornblatt et aI., 1992), only 
pep tides containing such residues were tested. Where possible. 
peptides containing two consecutive basic residues were chosen 
to increase the likelihood of hydrolysis. Additionally, peptides 
with regulatory roles in the host system were chosen in order to 
shed light on the potential physiological relevance of OP-Tb. 
OP-Tb was found to completely cleave reduced [Arg"Jvaso-
pressin (1084.2 Da, CYFQNCPRG) and [Lys"Jvasopressin 
(1056.2 Da; CYFQNCPKG; 1: 100 molar ratios) in 4 h, while 
the oxidised forms of these peptides remained uncleaved after 
16 h. Neurotensin (1672.9 Da, ELYENKPRRPYIL) was also 
completely hydrolysed in 4 h at a 1 : 500 molar ratio of enzyme/ 
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Table 4. Equilibrium constant for inhibition, association and dissoci-
ation rate constants for cystatin inhibition of trypanopain-Tb 
(0.05 nM) at 30e. Note that the associations of cys tatin C and L-kinino-
gen domain 3 with trypanopain-Tb was too rapid for accurate measure-
ment and the value given is an estimate. 
Inhibitor 
Human stefin A 
Sheep stefin B 













M- I . S-I S-I 
2".13X 10' 9.6 X 10--
6.9 X 10' 2.8 X 10--
== 1.7 X 10' !.7 X 10 --
2.5 X 10' 8.8 X 10- ' 
== 1.1 X 10' 4.8 X 10--
peptide. The point of cleavage in thi s instance was determined 
to be after the second arginine residue in the sequence. re inforc-
ing the specificity of OP-Tb for two consecutive basic residues 
in a given sequence. Atrial natriuretic factor (3080.5 Da. 
SLRRSSCFGGRMDRIGAQSGLGCNSFRY) was effectively 
cleaved at a 1: 100 molar ratio. with the reduced form of the 
peptide undergoing more cleavage than the oxidi sed form. The 
importance of the state of substrate reduction sugges ts that sub-
strate conformation is critical for OP-Tb activity. Peptides such 
as angiotensin I (1 296.5 Da. DRVYIHPFHL). substance P 
( 13-+7 .6 Da. RPKPQQFFGLM ) and ox idised insulin S chain 
(3-+95 .9 Da. FVNQHLCGSHLVEALYLVCGERGFFYTPKA: 
1: 100 molar ratios) were not cleaved after 16 h, poss ibly due to 
the particular amino acid residues surrounding the basic residues 
present in these peptides (Kornblatt et al.. 1992), although it is 
possible that a size restriction was the reason for non-c leavage 
of the insulin S chai n. Pancreatic polypeptide (4 18 1.7 Da) and 
growth-hormone-releasing factor (5039.7 Da) were also not 
cleaved, poss ibly due to the sizes of these peptides. OP-Tb thus 
does not appear to cleave peptides larger than 4 kDa. Further 
im'esti gation of peptides between 3 -4 kDa which con tain suit-
able consecutive basic residues is needed to clarify the exclusion 
limit more finely. 
Interaction of trypanopain-Tb and OP-Tb with host protein-
ase inhibitors. /.:"" and pred icted /.:"". values for trypanopain-Tb 
association with various cystatins were in the 10'-10' M- I . S- I 
and 10- - S - I range, respectively. while K, values were in the 
10- 11 M range (Table 4). Cystatin C and L-kininogen were the 
most effective inhibitors. Interestingly, very little ditference was 
observed between the inhibition by whole L-kininogen and by 
domain 3 of the molecule . suggesting that thi s domain is likel y 
to be predominantly responsible for the inhibition observed wi th 
the whole molecule . Assuming a plasma concen tration of 
7.5 pM for L-kininogen and 80 nM for cystatin C (Abrahamson. 
1993), trypanopain-Tb would be expected to assoc iate very 
rapidly with these inhibitors: the half-life (Sieth, 1980) of the 
enzyme in the presence of L-kininogen can be calculated as 
0.006 s and with cystatin C, 0.08 s. The inhibitor-enzyme com-
plexes can also be predicted to dissociate slowly, with a half-life 
of 131 min for L-kininogen and 67 min for cystatin C. Trypano-
pain-Tb is thus likely to be inhibited effectively by cystatin C 
and (especially) L-kininogen in vivo. Additionally, trypanopain-
Tb bound to a,-M (= 1: I molar ratio) and is thus also likely to 
be effectively controlled by this inhibitor ill vivo. 
Trypanopain-Tb was found to cleave the serpin inhibitor 
antithrombin III, but only at enzymelinhibitor ratios of 1: 10, so 
it is unlikely that such hydrolysis would occur ill vi l'o. Trypano-
Table 5. Effect of inhibitors on Z-Phe-Arg-NHMec and Z-Aro-Aro-
NHMec activity in the blood of rats infected with T. b. bruc:i. The 
blood of infected rats was assayed against synthet ic substrates in the 
absence or presence of various inhibitors for 30 min at 37 °C. Values are 
in arbitrary units. 
Substrate Rats Total activity with 
no in- E-64 SBTI H,NEt 
hibitors PhSO,F 
(1.67 mM) (20 ~lM) (1.85 mM) 
Z-Phe-Arg- infected 1521 1585 1573 297 
NHMec uninfected 234 177 193 193 
Z-Arg-Arg- infected 22-l-l 2372 228-l 97 
NHMec uninfected 10-l 97 74 55 
pain-Tb did not cleave other serpi ns, such as ai -proteinase inhib-
itor, a ,-antichymotrypsi n and a,-a ntiplasmi n. 
OP-Tb did not interact with any of the tested host system 
inhibitors. including serpins. cystatins and a,-M, presumably due 
to the limited interacti on of the active si te with higher-molecu-
lar-mass proteins in general. 
Measurement of enzyme activity in infected rat blood. High 
leve ls of activity against both Z-Phe-Arg-NHMec and Z-Arg-
Arg-NHMec were detected in the blood of infected rats. while 
little ac ti yity was detectable in the blood of contro l. uninfected 
animals (Table 5). This activ ity was insensitive to E-6-+ and 
SSTI , but enti rely elimi nated by H,NEtPhSO,F. OP-Tb is thus 
likely to be predominantly responsible for the hydrolysis ob-
served. suggesting that OP-Tb may be released into the blood-
stream of infected rats. Secondly. this stud y suppo rts the conclu -
sion arri\'ed at from ill "ilro stud ies with the purifi ed enzymes. 
namely th at while trypanopain-Tb is likely to be effectively con-
trolled in the bloodstream. OP-Tb seems to remain active. 
DISCUSSION 
Isolation of trypanopain-Tb and OP-Tb. A cysteine protein -
ase has prev iously been isolated from T c(J/Igo/ellse (MbU\\'a et 
al. . 1992) but we have no\\' purified one from T b. brucei. OP-
Tb from T b. brucei has been partially purified and charac teri sed 
(Kornblatt et aI. , 1992 ). but here \\'e report the purificati on of 
the enzyme to homogenei ty as \vel l as a more complete charac-
terisation of certain aspects of its ac tivity. The linked isolation 
of these proteinases as re ported here ha. the added advantage of 
max imi sing the yield of both enzymes from a single parasite 
preparation . 
Characterisation of trypanopain-Tb. Trypanopain-Tb was 
shown to be a fairly typical cysteine proteinase, similar to trypa-
nopain-Tc from T cOllgo/ellse (M bawa et al.. 1992) and cruzi-
pain from T cruz.i (Cazzula et aI. , 1989). Interestingly, the aspar-
tic proteinase inhibitor pepstatin A inhibits trypanopain-Tb 
slightly (Table 2 ; Pamer et aI., 1989). In contrast, pepstatin A 
inhibits trypanopain-Tc by onl y 9.7 % (M bawa et aI., 1992) and 
does not affect cruzipain (Murta et aI., 1990; Cazzulo et aI., 
1989) . Pepstatin A appears to be a competitive inhibitor of try-
panopain-Tb (data not shown), and may act as a substrate ana-
logue. This unusual inhibition was successfully exploited in the 
puritication of trypanopain-Tb, using pepstatin-A -Sepharose. 
Trypanopain-Tb was only active in the presence of reducing 
agents, and appe2red to be quite similar to cathepsin L (Den-
ni son et aI., 1992) in its requirement of fairly high concentra-
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tions of reducing agent for optimal activity. It was shown to 
have cathepsin-L-like specificity for synthetic substrates, hy-
drolysing Z-Phe-Arg-NHMec and Pro-Phe-Arg-NHMec most 
rapidly of the substrates tested. Generally, only substrates with 
basic residues such as Arg or Lys in P, and hydrophobic residues 
such as Phe or Leu in P2 were hydrolysed (Table 3). The pres-
ence of an acidic residue in p. appeared to be unacceptable. 
Similar specificity has been reported for trypanopain-Tc (Mbawa 
et aI. , 1992), cruzipain (Cazzulo et aI., 1990) and mammalian 
cathepsin L (Barrett and Kirschke, 1981 ; Dufour and Ribadeau-
Dumas, 1988). Minimal hydrolysis of Z-Arg-Arg-NHMec was 
observed in the current study (4-h incubation required to demon-
strate hydrolysis), allowing this substrate to be used for monitor-
ine: OP-Tb isolation. This contradicts a previous report by Pamer 
et ~ al. (1991) that trypanopain-Tb cleaves Z-Arg-Arg-NHMec 
readily, with a K", of 3.2 pM, although it must be noted that 
only partially purified trypanopain-Tb was used in their study. 
Trypanopain-Tc does not hydrolyse Z-Arg-Arg-NHMec (Mbawa 
et al.. 1992), while cruzipain cleaves it poorly (K", 41 pM; Lima 
et al.. 1992). 
Of the serpins tested, only antithrombin III was cleaved by 
trypanopain-Tb. Interestingly, cathepsin L, which has been 
found to be one of the closest mammalian analogues to trypano-
pain-Tb (Mottram et al.. 1989), cleaves ai-proteinase inhibitor 
very effectively (Johnson et aI., 1986). Cathepsin L also cleaved 
antithrombin III and a,-antiplasmin very effectively at much 
lower enzyme/substrate ratios than did trypanopain-Tb (data not 
shown). This indicates that these two enzymes. while very simi-
lar in substrate specificity, are not always comparable. 
Effect of host proteinase inhibitors on trypanopain-Tb. It has 
been postulated that if released into the host bloodstream. trypa-
nopain-Tb could contribute to pathogenesis by degrading vari-
ous host proteins. For this to occur, the enzyme would have to 
remain active in the presence of host proteinase inhibitors such 
as cystatins, kininogens and Cl,-M. Trypanopain-Tb is, however. 
effectively inhibited by kininogens, various cystatins and a,-M 
ill I'itro (Table 4) . The physiological concentrations of cystatin 
C and L-kininogen are more than 10 times K;, so these inhibitors 
are likely to inhibit any trypanopain-Tb secreted or released by 
trypanosomes ill vivo (Bieth, 1980). Interestingly, the most abun-
dant cysteine proteinase inhibitors in blood are also the most 
effective ill vitro inhibitors of the purified enzyme. Since cysta-
tins are relatively conserved between species (Barrett et al.. 
1986) and the trypanosomal cysteine proteinases sequenced to 
date are highly similar to each other (Mottram et aI., 1989; 
Pamer et aI., 1990; Eakin et aI., 1992: Fish et a!.. 1995). this ill 
I'it/,o approach implies that trypanopains from various trypano-
some species are likely to be effectively inhibited by cystatins 
in the bloodstream of a variety of mammalian hosts. This con-
clusion is supported by Nwagwu et al. (1988), who showed that 
addition of rat serum to isolated parasites inhibited a trypano-
pain-Tb-like activity. Additionally, the Z-Phe-Arg-NHMec ac-
tivity detected in the blood of infected rats in the present study 
was not E-64-inhibitable (Table 5), suggesting that there are not 
significant concentrations of active trypanopain-Tb in the blood 
of infected animals. Thus while trypanopain-Tb readily degrades 
IgG and BSA in vitro, it appears that this is unlikely to occur in 
the host bloodstream. 
In apparent conflict with this conclusion, Lonsdale-Eccles et 
al. (1995) reported that a kininogen-like molecule from rat se-
rum enhances trypanopain-Tb activity in fibrinogen zymograms 
of T b, brucei Iysates. This molecule (called rat trypanopain 
modulator, rTM) cross-reacts to some extent with anti-(human 
kininogen) antibodies and has many other features in common 
with kininogens, such as its size. (68 kDa), its acid and heat sta-
biJity, and the presence of 15-kDa proteinase-sensitive domains. 
Additionally, L-kininogen was shown to enhance trypanopain 
activity on fibrinogen zymograms in a similar manner to rTM. 
The current study, however, clearly indicates that purified human 
L-kininogen is an effective inhibitor of purified trypanopain-Tb 
with a K; of 0.0035 nM. Pike et a!. (1992) reported a similar 
apparent contradiction in the interaction between a cysteine pro-
teinase and its putative inhibitor. While purified stefin B inhib-
ited purified cathepsin L as expected, active covalent complexes 
of the enzyme and inhibitor were shown to form under certain 
circumstances. An unidentified factor. Which may be absent ill 
vitro studies using purified components, may contribute to the 
formation of these active complexes ill vivo. It is possible that 
this putative factor modifies the interaction between trypano-
pain-Tb and L-kininogen ill vil'o. resulting in the formation of 
active complexes as reported by Lonsdale-Eccles et al. (1995). 
Such an interaction may therefore interfere with effective control 
of trypanopain in the host bloodstream. 
Effect of reducing agents and cysteine proteinase inhibitors 
on OP-Tb. Because OP-Tb is inhibited by iPr,P-F and 
H,NEtPhS02F, it is likely to be a serine protease. However, the 
enzyme is not inhibited by some other serine protease inhibitors. 
namely PhMeS02F and SBTI. The lack of inhibition by PhMe-
SO,F is not entirely unexpected in view of the subsite specificity 
of the enzyme as discussed by Kornblatt et al. (1992) . SBTI 
(20.1 kDa), on the other hand, is probably ineffective because it 
is too large to gain complete access to the active site of the 
enzyme. 
Additionally, previous work on this enzyme (Kornblatt et al .. 
1992) and a similar enzyme from T Cl'1I;:.i (Ashall, 1990: Ashall 
et aI. , 1990) indicated that some compounds which are generally 
considered to be cysteine protease inhibitors reduce OP-Tb ac-
tivity. Here we have been able to delineate more clearly the 
effect of various cysteine protease inhibitors on this enzyme. 
While OP-Tb is unaffected by the common cysteine protease 
inhibitor E-64, the enzyme is inactivated by compounds such as 
iodoacetate, iodoacetamide and N-ethylmaleimide, that cova-
lently modify cysteine residues. It is interesting to note that these 
three compounds act in rather contrasting manners, depending 
on the presence or absence of dithiothreitol , possibly reflecting 
the particular micro-environment of the cysteine residue in-
volved (Table 2). This data. together \\'ith the fact that OP-Tb is 
activated by reducing agents, suggests that the enzyme contains 
a cysteine residue which must be reduced and available for ma.'\-
imum activity and thus involved in the: control of OP-Tb acti\'ity. 
This may provide an alternative means of controlling this en-
zyme ill I'ivo, which would be of particular importance in light 
of the insensitivity of OP-Tb to more typical means of control 
by host inhibitors, including serpins and a,-M. 
Hydrolysis of peptides by OP-Tb. OP-Tb successfully cleaved 
reduced [Arg"Jvasopressill. [Lys"Jvasopressin, neurotensin and 
atrial natriuretic factor, but was found to be inactive against sub-
strates of more than 4 kDa. The enzyme is likely to cleave only 
small peptides ill vivo. The fact that atrial natriuretic factor. 
[ArtJvasopressin and [Lys"Jvasopressin were more readily 
cleaved when reduced suggests that access to the OP-Tb active 
site is probably dependent on conformation as well as size. A 
similar enzyme from T cruzi was found to be vital for the infec-
tivity of this organism, since it cleaves and activates a cyto-
plasmic factor involved in a calcium signalling mechanism 
which mediates the entry of trypanosomes into cells (Burleigh 
and Andrews, 1995). While a similar function for OP-Tb is un-
likely since African trypanosomes are not intracellular parasites. 
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OP-Tb may playa role in the activation of other hormone-like 
peptides in T b. brucei. 
OP-Tb was not inhibited by any mammalian protein protein-
ase inhibitor used in this study. In view of the restricted access 
to the active site of the proteinase, this is not entirely unex-
pected. Upon release of this enzyme from the parasite, as we 
have shown is likely to occur during infections, the enzyme will 
thus be free to act upon small regulatory molecules in its imme-
diate environment. The demonstration here that the enzyme is 
able to cleave native neurotensin and atrial natriuretic factor. 
which have diverse roles in the complex mechanisms of control 
over bodily functions, means that this enzyme has the potential 
to seriously disrupt control mechanisms of the host system. 
Symptoms of sleeping sickness are difficult to define in general 
terms, but altered blood volume, and eventual disruption of neu-
rological systems, is not inconsistent with the general symptoms 
found (Tizard et aI., 1978) ; thus inappropriate cleavage of regu-
latory molecules by OP-Tb may have profound implications for 
the host. It will be of interest to determine the level s of various 
hormones in hosts infected by T b. brucei in order to investie:ate 
thi s poss ibility more directly. -
In conclusion, this study suggests that OP-Tb is more likel y 
than trypanopain-Tb to have an extracellular, pathological role 
in African trypanosomiasis, making OP-Tb an attractive target 
for future studies in drug design. 
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Trypanosomatid cysteine protease activity may be enhanced by a 
kininogen-like moiety from host serum 
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African trypanosomes contain cysteine proteases (trypanopains) 
the activity of which can be measured by ill vitro digestion of 
fibrinogen , after electrophoresis in fibrinogen-containing SDS/ 
polyacrylamide gels. When assessed by this procedure, trypano-
pain from Trypanosoma brucei (trypanopain-Tb) is estimated to 
have a molecular mass of 28 kDa. However, two additional 
bands oftrypanopain activity (87 kDa and IDS kDa) are observed 
if serum is added to the trypanopain before electrophoresis . 
Formation of the 87 and 105 kDa bands is frequently ac-
companied by a reduction in the intensity of the 28 kDa activity 
which suggests that the extra .bands are complexes of the 28 kDa 
trypanopain-Tb and a molecule from rat serum called rat 
trypanopain moledulator (rTM). The rTM-induced activation of 
cysteine proteases is not restricted to T. brucei as it is also 
observed with proteases from other protozoan parasites such 
as bloodstream forms of Tr.lpanosol17a cOllgolense and the 
mammalian-infective in vitro-derived promastigote forms of 
Leishmania donovani and Leishmania major. The physical proper-
ties of rTM resemble those of the kininogen family of cysteine 
INTRODUCTIO N 
Bloodstream and meta cyclic forms of African trypanosomes 
such as Trypanosoma brucei and Trypanosoma congolense endo-
cytose exogenous proteins through their flagellar pockets. These 
molecules are then de livered , via a complex endosomal network, 
into the Iysosomes of the parasites (Langreth and Balber. 1975 ; 
Webster and Grab, 1988 ; Webster. 1989) where they are assumed 
to be hydrolysed by proteases (Lonsdale-Eccles and Grab, 1987a ; 
Mbawa et aI. , 1992). Although the function of the proteases has 
not been clearly defined , they may playa role in parasite evasion 
of the host immune system. For example, bloodstream forms of 
T. brLlcei that were incubated with antibodies specific for the 
variant surface glycoprotein were shown to endocytose and 
degrade the immunoglobulins (Lonsdale-Eccles et aI. , 1993; 
Russo et aI. , 1993) . However, when the parasites were incubated 
in the presence of protease inhibitors, there was a massive 
accumulation of IgG within the endosomal/ lysosomal system of 
the parasites. Procycl ic forms of T. brucei, which do not possess 
a variant surface glycoprotein, have minimal or no lysosomal 
cysteine protease activity (Lonsdale-Eccles and 'Mpimbaza, 1986; 
Pamer et aI., 1989 ; Mbawa et a I. , 199Ib). 
protease inhibitors . rTM is an acidic (pI 4.7) heat-stable 68 kDa 
glycoprotein with IS kDa protease-susceptible domains. This 
resemblance between rTM and kininogens was confirmed by the 
positive, albeit weak, immunoreactivity between anti-(human 
low-molecular-ma~s kininogen) antibody and rTM as well as 
anti-rTM antibody and human low-molecular-mass kininogen. 
Furthermore, commercial preparations of human-Iow-mol-
ecular-mass kininogen and chicken egg white cystatin mimicked 
rTM by forming extra bands of proteolytic activity in the 
presence of trypanopain-Tb. In some instances, low-m0Iecular-
mass kininogen was also observed to increase the rate 
of hydrolysis of 7-(benzyloxycarbonyl-phenylalanyl-arginyl-
amido)-4-methylcoumarin by live T. brllcei. Although this effect 
was rather erratic, in no instance was significant inhibition 
observed when this putative cysteine protease inhibitor was used 
under these conditions . The ac ti\'ation of parasite cysteine 
proteases by commonly accepted cysteine protease inhibitors is 
unexpected and may have important pathological repercussions. 
Lysosomal cysteine proteases have been found in a wide 
variety of protozoans (e .g. North et al.. 1983 ; Bontempi et aI. , 
1984, 1989 ; Grab et aI., 1987 ; Lonsdale-Eccles and Grab, 1987a ; 
Cazzulo et aI., 1989; Mbawa et al.. 1991 a) and the importance of 
these proteases to protozoan viability has been established in a 
number of systems. For example, specific inhibitors of lysosomal 
cysteine proteases kill American and African trypanosomes 
(Ashall et aI., 1990; Mbawa et al.. 1992) and block the de-
velopment of Plasmodium Jalciparlll1l (Rosenthal et aI., 1989: 
Rockett et aI., 1990). The molecular-mass values of the cysteine 
protease from T. bruce; (trypanopain-Tb) and T. cOllgo/ellse 
(trypanopain-Tc) are about 28 and 32 kDa respectively. How-
ever, the molecular-mass values of crude trypanopain prepara-
tions have proved to be variable when analysed by either contact 
print zymography (Rautenberg et aI. , 1982) or electrophoresis in 
substrate-containing (e.g. fibrinogen) SDS/ polyacrylamide gels 
[Fbg/ SDS/ PAGE (Lonsdale-Eccles and Mpimbaza, 1986)]. 
Some of this variability may be caused by the presence of 
molecules derived from host plasma or serum in the parasite 
preparations. Indeed , the pattern obtained varies according to 
the animal species from which the serum is obtained (Lonsdale-
Eccles and Grab, 1987a). As well as changing the zymographic 
Abbreviations used : Trypanopain-Tb, lysosomal cysteine protease from Trypanosoma brucei : trypanopain-Tc, lysosomal cysteine protease 
from Trypanosoma congolense; Fbg/SOS/PAGE, SOS/PAGE on fibrinogen-containing gels; rTM, rat trypanopain modulator; Z-Phe-Arg-NH-Mec, 
7 -(benzyloxyca rbonyl-phenyla I a nyl-a rg inyl-amido) -4-methylcou m ari n ; E64, Ira ns-epoxysuccinyl-L -Ieucyla m id 0-( 4-g u anid i no) bu tane. 
§ Present address: P.O. Box 5170, Kampala, Uganda. 
II Present address : Veterinary Department, University of Zambia, P.O. Box 32379, Lusaka, Zambia. 
" Present address : Tulane Regional Primate Center, Tulane University, 18703 Three Rivers Road, Covington, LA 70112, U.S.A. 
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molecular-mass patterns, the addition of serum to the trypano-
some Iysates causes an apparen t increase in the total amount of 
proteolysis when the mixture is analysed by Fbg/ SDS/PAGE. 
Here we describe the isolation and partial characterization of a 
serum-derived molecule that actuates this modulation oftrypano-
pains . 
' . 
MATERIALS AND METHODS 
Materials 
Dithiothreitol, fibrinogen, Mes. Hepes, BSA, cystatin, trypsin. 
and phospholipase C were obtained from Sigma Chemical Co. 
Glycosidases were from Seikagaku Fine Biochemicals and kini-
no gens from Protogen AG. Methanol, acetic acid and glycine 
were purchased from BDH Chemical Co. Tris (hydroxymethyl)-
aminomethane and Coomassie ' Brilliant Blue were from E. 
Merck. SDS and poly(ethylene glycol) were obtained from 
Serva. Ampholytes were from LKB-Produktor AB and Seph-
acryl S-200 and the molecular-mass markers (phosphorylase b, 
94 kDa; BSA, 67 kDa; ovalbumin , 43 kDa ; carbonic anhydrase, 
30 kDa; soya-bean- trypsin inhibitor, 2.1.1 kDa; a- lactalbumin. 
14.4 kDa) were from Pharmacia Fine Chemicals Co. Matrix Gel 
Blue A (lot JD-1462) was purchased from Amicon Corp. Linoleic 
acid and DE-53 (DEAE-cellulose) were obta ined from Aldrich 
Chemical Co. and Whatman respectively. [7-14C]Phenylglyoxal 
(855 MBq/ mmol) was fr9m Amersham. Human high- and low-
molecular-mass kininogens and ai1ti-(human low-molecular-
mass kininogen) an tibodies were purchased from Protogen 
AG or Calbiochem-Novabiochem AG. 7-(Benzyloxycarbonyl-
phen ylalan y l-arginyl-amido )-4-methy lcoumari n (Z-Phe-Arg-
NH-Mec), leupeptin and lrans-epoxysuccinyl-L-Ieucylamido-( 4-
guanidino)butane (E64) were from Cambridge Research Bio-
chemicals. 
. Sample preparation and analysis 
Bloodstream forms of the African trypanosomes T. brucei, MITat 
1.2, and T. congo/ense, clone IL 3000 (Fish et al. , 1989), were 
grown in lethally irrad iated randomly br,ed Sprague-Dawley rats 
(600-900 rad). The parasites were isolated on the day 3 after 
infection and purified by centrifugation through Percoll (Grab 
and Bwayo, 1982) and by DEAE-cellulose chromatography in 
PBS/ gluocose buffer, pH 8.0 [prepared as described by Lanham 
and Godfrey (1970)] containing 100 I,M hypoxanthine (Lons-
dale-Eccles and Grab, 1987b). After elution from the DEAE-
cellulose. the parasites were washed three times wi th the hypo-
xanthine-containing PBS/ glucose, pH 8.0, suspended in the 
same buffer and stored in I ml portions of 2 x 108 parasites/ ml at 
-70°C. 
Leishmania donovani (NLB-065) and Leishmania major (NlB-
144) promastigotes were grown by in vitro cu lture in Schneider's 
Drosophila medium (Gibco laboratories) (Chi lds et al.. 1978) 
and medium 199 (Flow Laboratories) (Hendricks et al., 1978) 
respectively. The parasites were harvested at the stationary phase 
of growth, washed three times in PBS/ glucose and resuspended 
at a final concentration between 5 x 108 and 1 x 109 parasites/ ml 
and either used directly or stored at - 70°C until requi red . 
Proteolytic activity in the parasite lysates was detected by 
Fbg/SDS/PAGE (Lonsdale-Eccles and Mpimbaza, 1986) . 
Analysis of rat trypanopain modulator (rTM) during its purifica-
tion was performed by mixing the rTM-containing samples 
(20-100 It!) with a trypanosome lysate (4 x 106 trypanosomes in 
20 pi) and subjecting the mixture to Fbg/SDS/ PAGE. The 
molecular masses of the active bands were determined from a 
calibration curve of relative mobility against log (molecular 
mass) prepared using Bio-Rad molecular-mass markers as stand-
ards. To test serum albumin, kininogens and cystatin for their 
ability to modulate trypanopain activity, 201'1 containing 4 x 106 
trypanosomes mixed with 20 pi of the protein (1.05 mg/ml) was 
analysed by Fbg/SDS/PAGE. In the case of the Leishmania 
samples, 20 pI of 5.2 x 106 promastigotes/ml was used. After 
electrophoresis (40 rnA per gel at 12°C) of the mixtures. the 
Fbg/SDS/polyacrylamide gels (1.5 x 135 mm x 145 mm) were 
rinsed in distilled water for 15 min . followed by overnight 
incubation in a shaking water bath (37°C) in a buffer mixture 
containing I mM dithiothreitol. 50 mM each of Mes, Hepes and 
citric acid (pH 6.0). The gels were stained in 0.1 o ,~ (w I v) 
Coomassie Brilliant Blue R250 in methanol/acetic acid / \vater 
(3 : I : 6, by vol.) and destained in the same solution without 
Coomassie Brilliant Blue. Quantitative analysis of the gels was 
performed using a Molecular Dynamics personal densitometer. 
Purification of rTM 
Rat serum (1 ml) was added to a 5 ml packed volume of Matrex 
Gel Blue A or Matrex Gel Green A that had been prewashed in 
50 mM Tris / HCl, pH 8.0, and then resuspended in 5 ml of the 
same buffer. The serum and beads (total volume II ml) were 
mixed on a rotary mixer at 4°C for 2 h to remove serum 
albumin. Samples were then centrifuged in a bench Minifuge set 
at 4 °C for 20 min at 3000 g. The supernatant was used im-
mediately or stored at -20 °C until required. 
A total of 15 ml of Matrex Gel Blue A-treated serum super-
natant was applied to a column of DE-53 DEAE-cellulose 
(65 ml) equilibrated in 50 mM Tris / HCl buffer, pH 8.0. The 
column was washed with 250 ml of the same buffer. A 200 ml 
linear gradient (0-500 mM NaCI in 50 mM Tris/ HCl. pH 8.0) 
was then applied to the column to fractionate proteins bound to 
the column . The chromatographic fractions were analysed for 
protein by SDS/ PAGE (Laemmli. 1970), and rTM was analysed 
by Fbg/ SDS/ PAGE (Lonsdale-Eccles and Mpimbaza. 1986) . 
Fractions containing rTM activity were pooled and dialysed 
against water (2 x 2 litres for 4 h each). 
The pooled and dialysed fractions from the DE-53 columns 
were subjected to isoelectric focusing in I ° '0 (v I v) ampholytes 
(pH range 3.5-10) in a 5- 50 0 0 (w/ v) sucrose gradient for 18 h at 
4 °C and 20 W constant pO\\'cr (final voltage 2000 V). The 
fractions containing rTM were pooled. dialysed against 4 x :: 
litres of 10 mM Tris / HCI buffer. pH 8.0, over 8 h. lyophilized 
and reconstituted in double-distilled deionized water (to give a 
final concentration ofTris/ HCI of 50 mM). The pooled material 
was loaded on to a Sephacryl S-200 gel-filtration column 
(100 cm x 1.6 cm, equilibrated in 100 mM Tris / HCl buffer. 
pH 8.0) and the sample was eluted with the same buffer. Fractions 
containing rTM were concentrated by lyophilization, recon-
stituted in 10 ml of water, dialysed agains t water (4 litres for 
4 h) and stored at - 70°C. The purified rTM was used to prepare 
anti-rTM in rabbits (Harlow and lane, 1988). 
Characterization of rTM 
Reduced and unreduced samples of rTM were analysed by 
SDS/ PAGE using the discontinuous buffer system described by 
Laemmli (1970). The gels were stained with O. I % Coomassle 
Brilliant Blue R250 in methanol/acetic acid/water (3: I : 6, by 
vol.), and then destained in the same solution wi thout Coomassie 
Brilliant Blue. 
Enzymic digestion of rTM was performed by incubating 
7.5 pg of rTM with trypsin, glycosidase or phospholipase C 
(0. 1 pg each) for I hat 37°C in a total volume of 10 It! of 25 m?-'l 
Tris/HCl, pH 8.0, before boiling for 5 min to inactivate the 
:nzymes. The samples were cooled to room te!11perature, added 
:0 a lysate of 4 x 106 trypanosomes/ml and subjected to Fbg/ 
SDS/PAGE. Samples of purified rTM (7.5""g in 5/d) were also 
dded to various concentrations of linoleic acid (0-750 liM). The 
ixtures were incubated for approx. I min and then Iysates of 
.rypanosomes, in sample buffer, were added before the samples 
){ere analysed by Fbg/SDS/PAGE. The areas corresponding to 
he hioh-molecular-mass bands were scanned using the LKB 
aser d~nsitometer. For Western-blot analysis, samples of purified 
rTM human low molecular-mass kininogen and human high-
mole~ular-mass kinogen were subjected to SDS/PAGE before 
Immunoblotting (Harlow and Lane, 1988). 
Arginine residues on the purified rTM were radiolabelled by 
treatment with [7-uC]phenylglyoxal by the procedure of Taka-
hashi (1968). To 100 pg of rTM in 200 pi of 50 mM Tris / HCl, 
pH 8.0, was added 2.16 pmol (50/lCi) of [7-14C]phenylglyoxal 
for 90 min at room temperature. The reaction by-products from 
the above were separated from radiolabelled rTM by chromato-
graphy through Sephadex G-25 (medium grade) equilibrated in 
PBS. The radiolabelled rTM was stored at -70°C until required. 
Z-Phe-Arg-NH-Mec hydrolysis by live T. brucei 
T. brllcei (1.8 x 106 parasites/ml; stored on ice until required) 
were incubated at 25°C and 37 °C with the fluorogenic trypano-
pain substrate Z-Phe-Arg-NH-Mec (5 pM) in PBS/glucose. 
pH 7.4 (Lanham and Godfrey. 1970) containing 100 pM hypo-
xanthine . Z-Phe-Arg-NH-Mec. which is an excellent substrate 
for trypanopains (Mbawa et a1.. 1991 b, 1992), permits the ill silll 
assessment of the effect of various inhibitors on trypanosomal -
proteases without the need to purify reaction products from the 
parasites. Hydrolysis of Z-Phe-Arg-NH-Mec was monitored 
continuously for up to 5 min on an Hitachi F-200 spectro-
fluorimeter (excitatiQn wavelength 370 nm; emission wavelength 
460 nm) in the presence and absence of E64 (0.1 mg/ ml), 
leupeptin (0.1 mg/ ml) or low-molecular-mass kininogen 
(0 .1 mg/ml) . 
RESULTS 
Lysates of T. brucei contain lysosomal cysteine protease activity. 
called trypanopain-Tb, which has a molecular mass of 28 kDa 
when analysed by Fbg/ SDS/ PAGE. The addition of a trace 
(0.0 I 00) of heated (boiled for 5 min at 93°C; altitude 1800 m) or 
unheated rat plasma or serum to such a lysate of T. brllcei results 
in the generation of two (87 kDa and 105 kDa) or more extra 
bands of proteolytic activity when analysed by Fbg/ SDS/PAGE 
(not shown). Simila r results are obtained with serum from 
different animal species, although the apparent molecular masses 
of the additional band(s) of activity vary according to the 
particular animal species studied (Lonsdale-Eccles and Grab, 
1987a). When the trypanosome Iysates are boiled, no activity is 
observed in either the presence or absence of added serum. Thus 
rat serum contains a heat-stable molecule (rTM) that seems to 
alter the apparent molecular mass and activity of T. brllcei 
proteolytic activity. 
The initial steps of the purification of rTM involved the 
removal of serum albumin by chromatography on Amicon 
Matrex Gel Blue A; rTM does not bind to Amicon Matrex Gel 
Blue A whereas serum albumin does (Fulton, 1980). Further 
purification of rTM was then accomplished by a combination of 
gel-filtration and ion-exchange column chromatography and 
isoelectric focusing. 
Fgb/SDS/PAGE of the fractions obtained from Sephacryl 
S-200 chromatography of rTM showed that rTM was eluted 
slightly before a 68 kDa molecule that might be serum albumin 
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Figure 1 Chromatography of rTM on Sephacryl S-200 
A column of Sephacryl S·200 was equilibrated and run in 100 mM Tris/HCI (pH 8.0: 4°C). 
Fractions of volume 5 ml were collected and 50 III samples assayed with 20 III of Iysates of 
2 x 108 trypanosomes/ml by Fbg/SDS/PAGE. The fraction number is indicated at the bottom 
of the Figure. The peak of rTM activity. frac;ion 48. corresponded to a molecular mass of 
120 kDa. 
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Figure 2 Chromatography of rTM on DE-53 cellulose 
After equilibration in 50 mM Tris/HCI (pH 8J ). a 16 cm x 2.5 cm column of DE·53 cellulose 
was loaded with rTM. The column was wasr:ed with 4 bed vol. of 50 mM TrislHCI. and then 
a 200 ml gradient of 0-500 mM NaCI in 50 "M Tris/HCI was applied. Fractions (2.5 ml) lVere 
collected and assayed by Fbg/SDS/PAGE as described in the Materials and methods section. 
The destained areas of the gel. corresponding to the peaks of proteolytic activity. were measured 
by densitometric scanning. Areas lacking rTM activity were not scanned. O. 87 kDa activity 
band; <>. 105 kDa activity band; •. 87 kDc + 1 05 kDa activity. rTM was eluted between 110 
and 160 mM NaCI. 
(Figure I) . The peak ofrTM activity from the Sephacryl column 
corresponded to a molecular mass of 120 kDa and may be a 
dimer of an approx. 70 kDa molecule. Figure I also illustrates 
the dramatic enhancement of proteolytic activity that can occur 
in the presence of rTM. 
A fairly broad peak of rTM was eluted from DE-53 cellulose 
at approx. 140 mM NaCI (Figure 2). A trace amount of an 
approx. 70 kDa protein, which may be serum albumin, was also 
eluted from the same column slightly after the peak of rTM 
activity at about 150 mM NaCI (not shown). Fbg/SDS/PAGE 
of rTM that had been purified by isoelectric focusing indicated 
that it has a pI of approx. 4.7 (not shown). SDS/PAGE shows 
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Figure 3 Coomassie-sta ined SDS/polyacrylamide gel of purified rTM 
Lane 1. reduced rTM (7.5/19 of rTM /lane : t e sampfe was boiled in sample bufier for aDorox. 
3 min)' lane 2. non·reduced unbOlled rTM' 2ne 3. molecular·mass standards : lane J . :u'lfled 
rat se'um albumin. 
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Figure 4 Dose-response of rTM with trypanosome lysate 
Increasing volumes of rTM (2.6 M Imi) were added to 20 I" conlaining 4 x 106 lrypanosomes. 
The mixtures were then subjected to Fbg/SOS/PAGE. The gel was stained and destalned with 
Coomassie Brill iant Blue and photographed to obtain a negative image. The negative was then 
scanned and the relative amounts of enzyme activity in each band determined. /::" , 87 kOa band 
of activity, '\1, 105 kOa band of act ivity, 0 . 37 + 105 kOa band of activity: . , 28 kOa band 
of activity. 
that the mo lecular mass of rTM is very similar to tha t of bovine 
and rat serum albumin (Figure 3). Reduction and boiling 
increases the apparent molecular mass of purified rTM when 
a na lysed by SDS/PAGE but provides no evidence for the 
presence of different subunits that may be held together by 
dis ul phide bridges . 
The addition of increasing amounts (volumes) of rTM to 
trypanopain-Tb results in saturable increases in higher-mol-
ecular-mass proteolytic activity accompanied by a decrease in the 
28 kDa band. In the dose-response curve (Figure 4), the 87 kDa 
band is more prominent than the 105 kDa band at high doses of 
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Figure 5 Effect of enzymes on rTM 
Purified rTM (51'1 ; 7.5/19) was incubated for 1 h at 37 °C before Fbg/SOS/ PAGE with the 
enzymes indicated. Lane 1, trypanosome lysate alone ; lane 2, trypanosome lysate + purified 
rTM ; lane 3. trypanosome lysate + rTM treated with trYPsin (5 II I of 0.01 ·0. w/v) : lane 4. 
trypanosome lysate + rTM treated with glycosidase·S (5 II I of 0.01 %, w/v; 1 h; 37 °C); lane 
5, trypanosome fysate + rTM treated with phospholipase C (5 III of 0.01 ·0. w/v). 
rTM. whereas at low d oses the re\'erse appl ies . Although the 
observation of activation is reproducible. precise quantificati o n 
of the enhancement of the trypanopain proteolytic activity in the 
presence of rTM has not yet been achie\'ed despite the kno\\'ledge 
that the den sitometric readings are proportiona l to the amount 
of acti\'i ty applied to the gel (Lo nsdale-Eccles and Mpimbaza . 
1986). This is because of the variation tha t occurs between 
ditTerent preparations ofrTM a nd parasite extracts. Nevertheless. 
extrapolation of an in ve rse plo t ofa similar experiment. in which 
less than Io n 0 diminution of the :::!8 k Da band \Vas obsen·ed. 
suggested that the acti\"ation may approach 20-fold . This is fi\"e -
fo ld greater than that repo rted for the cysta tin acti\"ation of 
ca th epsin L (Dennison et al.. 199:::!) but is sim ilar to the 24-fo ld 
acti vation of papain by a protein in blood (Senthilmohan a nd 
Topping. 1994) and the 28-fold increase in proteolytic activity of 
an £I1{(1l11ot'bu hislO!.rlicu cysteine protease when relea sed into 
serum-containing medium (Avila and Calderon. 1993). 
The ability of trypsin o r a mixture of glycosidases to cause 
partial breakdown of the active pro tein with the high molecul a r 
ma ss (Figure 5) suggests that the activator is a glycoprotein . 
When the high-molecular-mass bands were excised and subjected 
again to Fbg/ SDS/ PAGE. several additional discrete bands of 
activity were found between about 105 kDa and 30 kDa (Table 
I) . Thus the rTM-enzyme complex appears to undergo self-
catalysed limited proteolysis. If. as suggested above. the high-
molecular-mass bands of activity are composed of a complex of 
the trypanopain and rTM. then the apparent molecular-mass 
values of the fragmentation products appear to co rrespond to 
cleavages at about 14- 15 kDa intervals in the complex . 
In order to assess the nature of the r.T M-trypanopain 
complex, rTM was treated with radiola belled phenylglycoxa l 
which modifies arginine residues. The specific radioactivity 
of the [7- 1~C]phenylglyoxal-Iabelled protein was greater than 
7400 d.p .m'/llg of protein . However. the treatment of rTM with 
this reagent had no obvious inhibitory or enhancing effect on the 
interaction of rTM with trypanopain-Tb (no t shown). In con-
trast. hydrophobic interactions would appear to be an important 
componen t of the complex-forma tion. Lino leic acid, when added 
to a final concentration of 500 11M. completely preven ted the 
forma tion of the high-molecular-mass bands of act ivity. A 50 0 0 
Table 1 Molecular masses of trypanopain-rTM complexes and auto-
digestion products 
The value ex is obtained by subtracting the molecular mass of the native cysleine protease 
(28 kOa for trypanopain-Tb and 32 kOa for trypanopain-Tc) from the observed molecular mass of 
the proteolytically active fragments. The integer (j!) corresponds to a hypothetical repetitive 
domain structure that could accommodate the observed molecular mass. Numbers In 

















































Figure 6 Cystatin and kininogen interaction with trypanopain-Tb 
Chicken cystatin and human kininogen were subiected to Fbg/SDS/PAGE in the presence and 
absence of trypanopain-Tb. Lane 1, cystatin alone; lane 2, cystatin + Irypanopain·Tb; lane 3, 
low·molecular -mass kininogen alone ; lane 4, low-molecular· mass kininogen + trypanopain· Tb ; 
lane 5, rat serum alone; lane 6, rat serum + trypanopain·Tb; lane 7, human serum alone ; lane 
8, human serum + trypanopain-Tb. 
inhibition of the production of the high-molecular-mass bands, 
as assessed by a 50 0 '0 reduction in the areas of the scanned 
bands, occurred between 100 and 250 ItM linoleic acid. SDS also 
completely inhibited the formation of the 87 and 105 kDa bands 
of activity when used at 0.25 % (8.7 mM). This is just above its 
critical micelle concentration of 8.2 mM (Helenius and Simons, 
1975). However, when used at the concentrations employed in 
SDS/PAGE (350 ,uM), SDS does not prevent the interaction. 
The ability of rTM to interact with cysteine proteases, coupled 
with its acidic isoelectric point and approx. 70 kDa molecular 
mass, suggested to us that it might be a kininogen-like molecule. 
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Figure 7 Western-blot analysis of rTM and kininogens 
Purilied rTM (lane 1), human-Iow·molecular·mass kininogen (lane 2) and human high· 
molecular·mass kininogen (lane 3) were subjected 10 SOS/PAGE and Western blotting with anti· 
rTM (a) and anti·(human low·molecular·mass kininogen) antibodies (b). (c) Negative control 
serum blot. Lane M, molecular-mass markers. The arrowhead indicales the position of rTM. 
Strong reactivity is observed in this poSition using anti·rTM and a weak but positive reaction 
with anti-(human low-molecular-mass kininogen). 
We therefore investigated whether kininogen and/or cystatin 
cause similar activation. Both did so (Figure 6). The molecular 
mass of the additional bands from the kininogen were in the 
same range as that of rTM whereas that of cystatin, as expected. 
was considerably smaller. Serum albumins also have similar 
molecular masses (Figure 3) and isoelectric points to low-
molecular-mass kininogens. but neither rat serum albumin (see 
Figure 8) nor BSA (not shown) caused formation of the additional 
bands of Fbg/ SDS/PAGE-detectable activity. [Interestingly, a 
commercial preparation of high-molecular-mass kininogen was 
observed to contain endogenous leupeptin-inhibitable Fbgl 
SDS/PAGE-detectable activity (results not shown) which pre-
cluded its use for ' the analysis of rTM-like activity.] Further 
indication that rTM may be a kininogen-like molecule was 
provided by Western-blot analysis using anti-(human low-mol-
ecular-mass) and anti-rTM antibodies (Figure 7). As might be 
expected, the cross-reactivity between the different species was 
rather weak. Nevertheless, anti-rTM antibody reacted with a 
commercial human kininogen preparation to give two weak 
bands, and anti-(human low-molecular-mass kininogen) anti-
body produced a single 68 kDa cross-reactive band against the 
purified rTM. 
Very variable results were obtained with live parasites . Sus-
pensions of live T. brucei hydrolyse the fluorogenic peptide Z-
Phe Arg-NH-Mec (see also Lonsdale-Eccles et aI., 1989). In the 
presence of leupeptin the hydrolysis of Z-Phe Arg-NH-Mec by 
live T. brucei was inhibited by almost 100 %. In contrast, in the 
presence of E64 only about 50 % of the activity was inhibited. 
This difference probably reflects the presence of two predominant 
but distinct typanosomal enzymes that hydrolyse Z-Phe-Arg-
NH-Mec; leupeptin inhibits both enzymes but E64 only the 
cysteine protease (Lonsdale-Eccles, 1991). In our preliminary 
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Figure 8 Effect of rTM on purified trypanopain-Tc 
Trypanopain-Tc was purified rapidly on a column of cyslatin-Sepharose as described by Mbawa 
et a\. (1991a), and subjected to Fbg/SDS/PAGE in the presence of rTM. Lane 1, molecular-
mass markers; lane 2, trypanopain-Tc alone; lane 3, trypanopain· Tc + commercial rat serum 
albumin; lane 4, trypanopain-Tc+rTM; lane 5, commercial rat serum albumin; lane 6, rTM 
alone. 
experiments we observed an approx. 200 0 0 increase in the rate of 
hyd rolysis ofZ-Phe-Arg-NH-Mec by the parasites in the presence 
of low-molecular-mass kininogen. Unfortunately, subsequent 
a ttempts to reproduce this effect showed minimal ac ti vation 
(approx. 10-20 %) or no significant activation. It should be 
noted, however, that we saw no significant inhibition of the 
hydrolysis of Z-Phe-Arg-NH-Mec by live parasites at 37°C 
when using this putative cys teine protease inhibitor. The varia-
bility in activation is similar to the variability observed using the 
Fbg/SDS/PAGE procedure with d iffering purified rTM and/or 
trypanopain sources. 
In order to determine whether the protease-activating effect of 
rTM is restricted to bloodstream forms of T. brucei, bloodstream 
forms of T. congo/ense were also assayed for interaction with 
rTM (Figure 8). A trypanopain-Tc preparation was prepared 
from T. congo/ense by ra pid affin ity chromatography on cystatin-
Sepharose (Mbawa et a I. , 1991a). This result shows that ac-
tivation can occur with purified as well as crude preparations of 
trypanosoma I enzymes. The result also shows that rTM can 
interact with a cysteine protease of a different species of African 
trypanosome. 
The formation of similar additional bands of high-molecular-
mass activity was observed when rTM was added to Iysates of 
stationary-phase (metacyclic) promastigote forms of either L. 
donovani or L. major (Figure 9). Because Leishmania are human 
infective parasites, we investigated whether human serum could 
mimic rTM by generating additional bands of proteolytic activity. 
Human serum alone exhibited no proteolytic activity (Figure 9, 
lane 7), but formed two extra bands of higher-molecular-mass 
proteolytic activity when added to Leishmania extracts (Figure 9, 
lane 8). Thus human serum must contain a similar molecule to 
rTM that can modulate the proteolytic activity of the L. major 
parasites. 
The protease profiles of L. major promastigotes, like those of 
Leishmania mexican a (Robertson and Coombs, 1990 ; Combs et 
a!., 1991), were considerably more complex than those of L. 
donovani or the African trypanosomes. We have not specifically 
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Figure 9 Effect of rTM and human serum on Leishmania sp 
Lysates of L. donovan; and L. major were subjected to Fbg/SDS/PAGE in the absence of rTM 
(lanes 1, 3 and 5) and in its presence (lanes 2, 4 and 6). Lane 7 shows human serum alone 
and lane 8 human serum in the presence of L. major. The Leishmania samples in lanes 1-4 
and 8 were freshly prepared whereas those in lanes 5 and 6 were stored frozen at - 70°C 
for several days. Lanes 1 and 2. L. donovan; (7.6 x 106 parasites/ml); lane 3 and 4, L. major 
(1.7 x 106 parasites/ml); lanes 5. 6 and 8. L. major (1 0.3 x 106 parasites/mil. The arrowheads 
indicate the positions of the add itional bands of activity in the presence of rTM or human serum 
and the arrow indicates the induction of an approx. 60 kDa band of activity observed in L. major 
after storage. The dashes on the left of each panel indicate the positions of the 94, 67. 43 ano 
30 kDa molecular-mass markers from top to bottom respectively. 
characterized each of the bands of proteolytic activity from the 
Leishmania and so one or more of these bands of activity may be 
related to the surface metalloprotease of these parasites. H ow-
ever, over 90 % of the protease activity in Leishmania is at-
tributable to cysteine proteases (Coombs et aI., 1991) and studies 
on the metalloproteases from L. major, Leishmania ama:::onellsis 
and L. mexican a show that these proteases are optimally acti\'e 
a t neutral to basic pH and that the metalloprotease from L. 
ama:::onellsis is not able to digest fibrinogen at acid pH after 
SDS/PAGE (Etges et aI. , 1986; Chaudhuri et aI., 1989; Ip et al.. 
1990). Thus, although we cannot unequivally eliminate the 
possibility that some of the bands of activity may be metallo-
protease, this seems unlikely, particularly in view of the acid ic 
pH in which our assays are performed. 
After storage of L. major at - 70°C for 24 h or more, enhanced 
proteolytic activity was observed at an approx. molecular mass 
of 60 kDa that was only moderately apparent in the freshly 
prepared sample (compare lanes 3 and 4 with lanes 5 and 6 
respectively of Figure 9). Indeed , the stored sample had to be 
diluted about 6-fold in order to obtain similar levels of proteolytic 
ac ti vity to those obse rved before storage. The extra activitymay 
result from activation of the zymogen-like precursors, predicted 
from cDNA sequence analysis of the structure of several pro to-
zoan cysteine proteases [reviewed in Coombs et a!. (1991)], but 
this remains to be shown . 
DISCUSSION 
African trypanosomal cysteine proteases have molecular-ma~s 
values of approx. 30 kDa when assayed by Fbg/SDS/PAGE I.n 
the absence of serum. However, -if a trace amount of serum IS 
added to the trypanosome lysates, there is an increase in total 
proteolytic activity that can be correlated with ~h~ formatIOn of 
additional high-molecular-mass bands of activity (Lonsdale-
Eccles and Grab, 1987a). The appearance of the additional high-
molecular-mass bands of activity (87 and 105 kDa) frequently 
occurs with a concomitant decrease in the amount of the 30 kDa 
band which suggests that the additional enzyme activity is 
formed by the binding of the rTM to the 30 kDa trypanopain, 
presumably by causing the trypanopain to change its con-
formation into a more active and/or stable form. The mechanism 
by which this proteolytic activity is increased is not clear as it 
may be an allosteric process that resembles the activation of 
intracellular proteases by ATP, fatty acid or a Ca2+-dependent 
protease regula tor (De Martino and Goldberg, 1979; De Martino 
and Blumenthal, 1982; Dahlmann et al. 1985). Nor have we 
eliminated the possibility that rTM may enhance the minimal 
endogenous activity found in some zymogens (Lonsdale-Eccles 
et aI., 1978) but, in such a case, the rTM preparation must also 
cause the inhibition of the 30 kDa enzyme. This seems unlikely, 
particularly in view of the recent report of the activation of 
papain by a molecule in blood (Senthilmohan and Topping, 
1994). 
Interaction between rTM and trypanopains appears to reduce 
the pH optimum of the enzyme activity from about pH 5.3 to 
about pH 4.8 (Lonsdale-Eccles and Mpimbaza, 1986). This lower 
value is close to the intralysosomal pH (4.2) reported for an 
African trypanosome (Mbawa et aI., 1992) and may result in 
enhanced lysosomal proteolytic activity in vivo. 
The ability of rTM to form an rTM-trypanopain complex is 
dependent on the handling of the various preparations. High-
molecular-mass bands of activity were not seen with highly 
purified enzyme that had been isolated from Iysates of T. brucei 
by slow conventional chromatography on DE-52 cellulose and 
Sephacryl S-200. Similarly, repeated freezing and thawing of the 
trypanosome Iysates also results in a diminished capacity to 
generate the high-molecular-mass bands of activity . However, 
when the cysteine protease from T. congolense was purified 
rapidly by affinity chromatography, complex-formation was 
observed with the pure enzyme, although the activities of the 
high-molecular-mass bands were weak. Similar erratic activation 
was observed with live parasites. The reason for such variability, 
which has made it difficult to quantify the extent of activation, is 
not known and will be the subject of future study. Possibly the 
domain to which the rTM binds is very susceptible to (self) 
proteolysis. Limited proteolysis may also explain why the 
105 kDa band is frequently less intense than the 87 kDa band. 
Early work on the cysteine proteases of African trypanosomes 
led to the suggestion that trypanopains may be composed of 
several 14-15 kDa structural domains (Lonsdale-Eccles, 1985) 
but subsequent sequence studies provided no support for such a 
repetitive structure within the proteases themselves (Mottram et 
aI., 1989; Pamer et aI., 1990). It now seems likely that the early 
studies were performed on enzyme-rTM complexes and so the 
repetitive structural motifs may be present in the rTM itself 
rather than in the enzyme. These domains could be analogous to 
the similar-sized cystatin-like domains of kininogens (Ohkubo et 
aI., 1984 ; Muller-Esterl et aI., 1985) with the cleavages occurring 
in the 'hyperfrangible regions I and II' (Vogel et aI., 1988) 
between domains I and 2 and domains 2 and 3 (Salvesen et aI., 
1986). The association of the enzyme with fragments obtained by 
cleavage at each of these sites would be sufficient to explain the 
autodigestion products seen with rTM and trypanopain-Tb 
(Table 1). 
Although the idea that a cysteine protease inhibitor may 
interact with its target enzyme to form an active complex seems 
counterintuitive, it should be born in mind that not all cysteine 
proteases (e.g. bromelain) are inhibited by kininogens (Barrett et 
aI., 1986). Furthermore, purified chicken cystatin and human 
kininogen react in a similar manner with trypanopain to form 
Trypanopain modulation by kininogen-like molecules 555 
active complexes like those seen with trypanopain and rTM. The 
cross-reactivity between anti-(human kininogen) and rTM, and 
between anti-rTM and human kininogen, lends credence to the 
idea that rTM contains amino acid sequence domains that are 
common to those in human kininogen. Also the active inhibitor-
protease complexes are similar to those observed with cystatin 
(or stefin B) and cathepsin L (Pike et ai., 1992; Dennison et aI., 
1992). The similarity between rTM and kininogens is also 
supported by the observations that ai-cyst<;ine protease inhibitor, 
T-kininogen and thiostatin (Esnard and Gauthier, 1983; Enjyoji 
et aI., 1988 ; Rusiniak et aI., 1991) are single-chain glycoproteins 
with similar molecular masses (68 kDa) and similar pIs (PI 4.75) 
to rTM, and the carbohydrate moiety is as important for the 
interaction between thiostatin and papain as it is for the 
interaction between trypanopain-Tb and rTM. 
The results in this study are based primarily on SDS/PAGE 
analyses and so the phenomena may be artifacts, a consequence 
of the proteins interacting under partially denaturing conditions. 
Nevertheless, we have seen that, in the presence of live T. brucei, 
hydrolysis of the small substrate Z-Phe-Arg-NH-Mec may also 
be enhanced by kininogen, albeit erratically. Furthermore, recent 
studies with cystatin or kininogen showed that proteolytically 
active complex-formation is possible between those inhibitors 
and cathepsin L in the absence of SDS (Dennison et aI., 1992; 
Pike et aI., 1992; Dennehy et aI., 1994). 
An activator of trypanopains has been observed in the serum 
of several mammalian species (Lonsdale-Eccles and Grab, 
1987a), and rat TM enhances the in vitro activity of cysteine 
proteases in T. brucei, T. congolense, L. major and L. donovani. 
However, we have been unable to demonstrate any reactivity 
between rTM and the cysteine protease activities in rat skin or 
liver, the proteolytic activity of which is 100-200-fold lower than 
that present in the trypansomes (1. D. Lonsdale-Eccles and 
G. W. N. Mpimbaza, unpublished work). The activation or 
stabilization of the trypanosoma tid cysteine proteases by 
mammalian kininogen-like cysteine protease inhibitors may have 
profound implications with respect to disease pathology as a 
consequence of the inappropriate control of these proteases 
when they are released into the hot bloodstream and tissues 
(Nwagwu et ai., 1988; Authie et aI., 1992) .. It has been proposed 
that these cysteine protease inhibitors contribute to the body's 
defence against foreign organisms that invade by using cysteine 
proteases (Green et aI., 1984), and yet our observations suggest 
that this may not always be the case. Recently, papain was 
reported to be activated 24-fold by a molecule in blood 
(Senthilmohan and Topping, 1994), and Avila and Calderon 
(1993) have reported that the proteolytic activity of a cysteine 
protease of E. histolytica was increased 28-fold when released 
into medium containing 15 % bovine serum. Despite the strong 
inhibition of some cysteine proteases by the cystatin/kininogen 
family of proteins [e.g. the inhibition of papain by the acute-
phase reactant ai-cysteine proteinase inhibitor; K, = 5 X 10-11 M 
(Esnard and Gauthier, 1993»), these reports and our observations 
strengthen the argument that a reassessment of the regulation of 
cysteine protease activity in blood is probably in order. 
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